<body style="font: 10pt Times New Roman, Times, Serif"> <document>  <type>   10-K   <sequence>    1    <filename>     form10-k.htm     <text>      <title>      </title>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <!-- Field: Rule-Page -->      <div style="width: 100%">       <div style="font-size: 1pt; border-top: Black 4pt solid; border-bottom: Black 1.5pt solid">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </div>      </div>      <!-- Field: /Rule-Page -->      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">       <font style="font-family: Times New Roman, Times, Serif; font-size: 18pt">        <b>         UNITEDSTATES        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">       <font style="font-family: Times New Roman, Times, Serif; font-size: 18pt">        <b>         SECURITIESAND EXCHANGE COMMISSION        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">       <font style="font-family: Times New Roman, Times, Serif; font-size: 12pt">        <b>         Washington,D.C. 20549        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">       <font style="font-family: Times New Roman, Times, Serif; font-size: 18pt">        <b>         FORM10-K        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <b>         (MarkOne)        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <b>         [X]ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <b>         Forthe fiscal year ended July 31, 2020        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <b>         OR        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <b>         [  ]TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <b>         Forthe transition period from _________ to _________.        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <b>         Commissionfile number 000-54318        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">       <font style="font-family: Times New Roman, Times, Serif; font-size: 18pt">        <b>         ONCOSECMEDICAL INCORPORATED        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        (Exactname of registrant as specified in its charter)       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">       <tbody>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; width: 49%; text-align: center">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           <b>            Nevada           </b>          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; width: 2%; text-align: center">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; width: 49%; text-align: center">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           <b>            98-0573252           </b>          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           (State    or other jurisdiction of           <br/>           incorporation or organization)          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="text-align: center; font: 10pt Times New Roman, Times, Serif">          <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            (I.R.S.                                         Employer           </font>          </p>          <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Identification        Number)           </font>          </p>         </td>        </tr>       </tbody>      </table>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">       <tbody>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; width: 49%; text-align: center">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           <b>            24    North Main Street           </b>          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; width: 2%; text-align: center">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; width: 49%; text-align: center">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           <b>            Pennington,    NJ           </b>          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           <b>            08534           </b>          </font>         </td>        </tr>       </tbody>      </table>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">       <tbody>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; width: 49%; text-align: center">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           <b>            3565    General Atomics Court, Suite 100           </b>          </font>         </td>         <td style="text-align: center; font: 10pt Times New Roman, Times, Serif; width: 2%">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="text-align: center; font: 10pt Times New Roman, Times, Serif; width: 49%">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           <b>            San    Diego, CA           </b>          </font>         </td>         <td style="text-align: center; font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           <b>            92121           </b>          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           (Address    of principal executive offices)          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           (Zip    Code)          </font>         </td>        </tr>       </tbody>      </table>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <b>         (855)662-6732        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        (Registrant’stelephone number, including area code)       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Securitiesregistered pursuant to Section 12(b) of the Act:       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">       <tbody>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 39%; text-align: center">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           <b>            Title    of Class           </b>          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; width: 2%; text-align: center">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 20%; text-align: center">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           <b>            Trading    Symbol           </b>          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; width: 2%; text-align: center">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 37%; text-align: center">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           <b>            Name    of Exchange on which Registered:           </b>          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           <b>            Common    Stock, par value $0.0001 per share           </b>          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           <b>            ONCS           </b>          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           <b>            Nasdaq    Capital Market           </b>          </font>         </td>        </tr>       </tbody>      </table>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Securitiesregistered pursuant to Section 12(g) of the Act:        <b>         None        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Indicateby check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Yes [  ]No [X]       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Indicateby check mark if the registrant is not required to file reports pursuant to Section 13 or 15(d) of the Act. Yes [  ]No [X]       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Indicateby check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities ExchangeAct of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports),and (2) has been subject to such filing requirements for the past 90 days. Yes [X] No [  ]       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Indicateby check mark whether the registrant has submitted electronically, if any, every Interactive Data File required to be submittedpursuant to Rule 405 of Regulation S-T (§229.405 of this chapter) during the preceding 12 months (or for such shorter periodthat the registrant was required to submit and post such files). Yes [X] No [  ]       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Indicateby check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reportingcompany, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,”“smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">       <tbody>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; width: 50%; text-align: center">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           Large    accelerated filer [  ]          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; width: 49%; text-align: center">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           Accelerated    filer [  ]          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           Non-accelerated    filer [X]          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           Smaller    reporting company [X]          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           Emerging    growth company [  ]          </font>         </td>        </tr>       </tbody>      </table>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Ifan emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period forcomplying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. [  ]       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Indicateby check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes [  ]No [X]       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Theaggregate market value of voting and non-voting common stock held by non-affiliates of the registrant as of January 31, 2020,the last business day of the registrant’s most recently completed second fiscal quarter, was approximately $17,729,615,computed by reference to the price at which the registrant’s common stock was last sold on such date, as reported by theNasdaq Capital Market. Shares of common stock held by the registrant’s officers and directors and holders of 10% or moreof the outstanding shares of the registrant’s common stock have been excluded from this calculation because such personsmay be deemed to be affiliates of the registrant; however, this determination of affiliate status is not, and shall not be considered,a determination of affiliate status for any other purpose.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Asof October 28, 2020, there were 27,688,354 outstanding shares of the Company’s common stock.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <b>         DOCUMENTSINCORPORATED BY REFERENCE        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Portionsof the registrant’s proxy statement for the 2020 Annual Meeting of Stockholders, which is expected to be filed with theU.S. Securities and Exchange Commission within 120 days after the end of the registrant’s fiscal year ended July 31, 2020,are incorporated by reference in Part III of this Annual Report on Form 10-K to the extent stated herein.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <!-- Field: Rule-Page -->      <div style="width: 100%">       <div style="font-size: 1pt; border-top: Black 1.5pt solid; border-bottom: Black 4pt solid">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </div>      </div>      <!-- Field: /Rule-Page -->      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <!-- Field: Page; Sequence: 1 -->      <div style="margin-bottom: 6pt; border-bottom: Black 1.5pt solid">       <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">        <tbody>         <tr style="vertical-align: top; text-align: left">          <td style="text-align: center; width: 100%">          </td>         </tr>        </tbody>       </table>      </div>      <div style="page-break-before: always; margin-top: 6pt">       <p style="margin: 0pt">       </p>      </div>      <!-- Field: /Page -->      <p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <b>         TABLEOF CONTENTS        </b>       </font>      </p>      <p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">       <tbody>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="border-bottom: black 1.5pt solid; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; text-align: center">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           Page          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; text-align: right">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif">           <a href="#b_001">            <font style="font-size: 10pt">             CAUTIONARY    NOTE REGARDING FORWARD-LOOKING STATEMENTS AND OTHER MATTERS            </font>           </a>          </font>         </td>         <td style="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; width: 58px; text-align: right">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           1          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; text-align: right">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif">           <a href="#b_002">            <font style="font-size: 10pt">             PART    I            </font>           </a>          </font>         </td>         <td style="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; text-align: right">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           3          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">         <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt">          <font style="font-family: Times New Roman, Times, Serif">           <a href="#b_003">            <font style="font-size: 10pt">             ITEM    1. BUSINESS            </font>           </a>          </font>         </td>         <td style="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; text-align: right">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           3          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">         <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt">          <font style="font-family: Times New Roman, Times, Serif">           <a href="#b_004">            <font style="font-size: 10pt">             ITEM    1A. RISK FACTORS            </font>           </a>          </font>         </td>         <td style="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; text-align: right">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           19          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">         <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt">          <font style="font-family: Times New Roman, Times, Serif">           <a href="#cj_001">            <font style="font-size: 10pt">             ITEM    1B. UNRESOLVED STAFF COMMENTS            </font>           </a>          </font>         </td>         <td style="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; text-align: right">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           51          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">         <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt">          <font style="font-family: Times New Roman, Times, Serif">           <a href="#cj_002">            <font style="font-size: 10pt">             ITEM    2. PROPERTIES            </font>           </a>          </font>         </td>         <td style="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; text-align: right">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           51          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">         <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt">          <font style="font-family: Times New Roman, Times, Serif">           <a href="#cj_003">            <font style="font-size: 10pt">             ITEM    3. LEGAL PROCEEDINGS            </font>           </a>          </font>         </td>         <td style="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; text-align: right">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           51          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">         <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt">          <font style="font-family: Times New Roman, Times, Serif">           <a href="#cj_004">            <font style="font-size: 10pt">             ITEM    4. MINE SAFETY DISCLOSURES            </font>           </a>          </font>         </td>         <td style="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; text-align: right">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           52          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; text-align: right">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif">           <a href="#cj_005">            <font style="font-size: 10pt">             PART    II            </font>           </a>          </font>         </td>         <td style="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; text-align: right">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           52          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">         <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif; padding-left: 10pt">          <font style="font-family: Times New Roman, Times, Serif">           <a href="#cj_006">            <font style="font-size: 10pt">             ITEM    5. MARKET FOR REGISTRANT’S COMMON EQUITY, RELATED STOCKHOLDER MATTERS AND ISSUER PURCHASES OF EQUITY SECURITIES            </font>           </a>          </font>         </td>         <td style="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; text-align: right">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           52          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">         <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt">          <font style="font-family: Times New Roman, Times, Serif">           <a href="#cj_007">            <font style="font-size: 10pt">             ITEM    6. SELECTED FINANCIAL DATA            </font>           </a>          </font>         </td>         <td style="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; text-align: right">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           52          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">         <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif; padding-left: 10pt">          <font style="font-family: Times New Roman, Times, Serif">           <a href="#cj_008">            <font style="font-size: 10pt">             ITEM    7. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS            </font>           </a>          </font>         </td>         <td style="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; text-align: right">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           53          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">         <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt">          <font style="font-family: Times New Roman, Times, Serif">           <a href="#cj_009">            <font style="font-size: 10pt">             ITEM    7A. QUANTITATIVE AND QUALITATIVE DISCLOSURE ABOUT MARKET RISK            </font>           </a>          </font>         </td>         <td style="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; text-align: right">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           60          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">         <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt">          <font style="font-family: Times New Roman, Times, Serif">           <a href="#cj_010">            <font style="font-size: 10pt">             ITEM    8. FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA            </font>           </a>          </font>         </td>         <td style="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; text-align: right">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           61          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">         <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif; padding-left: 10pt">          <font style="font-family: Times New Roman, Times, Serif">           <a href="#cj_011">            <font style="font-size: 10pt">             ITEM    9. CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL DISCLOSURE            </font>           </a>          </font>         </td>         <td style="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; text-align: right">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           61          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">         <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt">          <font style="font-family: Times New Roman, Times, Serif">           <a href="#cj_012">            <font style="font-size: 10pt">             ITEM    9A. CONTROLS AND PROCEDURES            </font>           </a>          </font>         </td>         <td style="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; text-align: right">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           61          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">         <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt">          <font style="font-family: Times New Roman, Times, Serif">           <a href="#cj_013">            <font style="font-size: 10pt">             ITEM    9B. OTHER INFORMATION            </font>           </a>          </font>         </td>         <td style="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; text-align: right">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           62          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; text-align: right">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif">           <a href="#cj_014">            <font style="font-size: 10pt">             PART    III            </font>           </a>          </font>         </td>         <td style="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; text-align: right">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           62          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">         <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt">          <font style="font-family: Times New Roman, Times, Serif">           <a href="#cj_015">            <font style="font-size: 10pt">             ITEM    10. DIRECTORS, EXECUTIVE OFFICERS AND CORPORATE GOVERNANCE            </font>           </a>          </font>         </td>         <td style="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; text-align: right">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           62          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">         <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt">          <font style="font-family: Times New Roman, Times, Serif">           <a href="#cj_016">            <font style="font-size: 10pt">             ITEM    11. EXECUTIVE COMPENSATION            </font>           </a>          </font>         </td>         <td style="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; text-align: right">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           62          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">         <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif; padding-left: 10pt">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           <a href="#cj_017">            ITEM    12. SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS           </a>          </font>         </td>         <td style="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; text-align: right">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           62          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">         <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt">          <font style="font-family: Times New Roman, Times, Serif">           <a href="#cj_018">            <font style="font-size: 10pt">             ITEM    13. CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS, AND DIRECTOR INDEPENDENCE            </font>           </a>          </font>         </td>         <td style="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; text-align: right">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           62          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">         <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt">          <font style="font-family: Times New Roman, Times, Serif">           <a href="#cj_019">            <font style="font-size: 10pt">             ITEM    14. PRINCIPAL ACCOUNTING FEES AND SERVICES            </font>           </a>          </font>         </td>         <td style="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; text-align: right">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           62          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; text-align: right">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif">           <a href="#cj_020">            <font style="font-size: 10pt">             PART    IV            </font>           </a>          </font>         </td>         <td style="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; text-align: right">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           63          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">         <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt">          <font style="font-family: Times New Roman, Times, Serif">           <a href="#cj_021">            <font style="font-size: 10pt">             ITEM    15. EXHIBITS, FINANCIAL STATEMENT SCHEDULES            </font>           </a>          </font>         </td>         <td style="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; text-align: right">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           63          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">         <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt">          <font style="font-family: Times New Roman, Times, Serif">           <a href="#v_01">            <font style="font-size: 10pt">             ITEM    16. FORM 10-K SUMMARY            </font>           </a>          </font>         </td>         <td style="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; text-align: right">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           64          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; text-align: right">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif">           <a href="#v_02">            <font style="font-size: 10pt">             SIGNATURES            </font>           </a>          </font>         </td>         <td style="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; text-align: right">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           65          </font>         </td>        </tr>       </tbody>      </table>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <!-- Field: Page; Sequence: 2; Options: NewSection; Value: 1 -->      <div style="margin-bottom: 6pt; border-bottom: Black 1.5pt solid">       <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">        <tbody>         <tr style="vertical-align: top; text-align: left">          <td style="text-align: center; width: 100%">           <!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->           i           <!-- Field: /Sequence -->          </td>         </tr>        </tbody>       </table>      </div>      <div style="page-break-before: always; margin-top: 6pt">       <p style="margin: 0pt">       </p>      </div>      <!-- Field: /Page -->      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">        <a name="b_001">        </a>        <b>         CAUTIONARYNOTE REGARDING FORWARD-LOOKING STATEMENTS AND OTHER MATTERS        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        ThisAnnual Report on Form 10-K contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933,as amended, or Securities Act, and Section 21E of the Securities Exchange Act of 1934, as amended, or Exchange Act. Forward-lookingstatements relate to future events or circumstances or our future performance and are based on our current assumptions, expectationsand beliefs about future developments and their potential effect on our business. All statements in this report that are not statementsof historical fact could be forward-looking statements. In some cases, you can identify forward-looking statements by terminologysuch as “may,” “should,” “expects,” “plans,” “intends,” “anticipates,”“believes,” “estimates,” “predicts,” “potential” or “continue” orthe negative of these terms or other comparable terminology. The forward-looking statements in this report include statementsabout, among other things: the status, progress and results of our clinical programs; our ability to obtain regulatory approvalsfor, and the level of market opportunity for, our product candidates; our business plans, strategies and objectives, includingplans to pursue collaboration, licensing or other similar arrangements or transactions; our expectations regarding our liquidityand performance, including our expense levels, sources of capital and ability to maintain our operations as a going concern; thecompetitive landscape of our industry; and general market, economic and political conditions.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Someof the factors that we believe could cause actual results to differ from those anticipated or predicted include:       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">      </p>      <table cellpadding="0" cellspacing="0" style="width: 100%; font: 11pt Calibri, Helvetica, Sans-Serif; border-collapse: collapse">       <tbody>        <tr style="vertical-align: top">         <td style="width: 0.5in">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td style="text-align: left; width: 0.5in; vertical-align: top">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           ●          </font>         </td>         <td style="text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           the success and    timing of our clinical trials, including safety and efficacy of our product candidates, patient accrual, unexpected or expected    safety events, and the usability of data generated from our trials;          </font>         </td>        </tr>        <tr style="vertical-align: top">         <td>          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td style="text-align: left; vertical-align: top">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td style="text-align: justify">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>        </tr>        <tr style="vertical-align: top">         <td>          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td style="text-align: left; vertical-align: top">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           ●          </font>         </td>         <td style="text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           the ability to achieve    the clinical and operational objectives set by management and the board;          </font>         </td>        </tr>        <tr style="vertical-align: top">         <td>          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td style="text-align: left; vertical-align: top">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td style="text-align: justify">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>        </tr>        <tr style="vertical-align: top">         <td>          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td style="text-align: left; vertical-align: top">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           ●          </font>         </td>         <td style="text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           our ability to successfully    file and obtain timely marketing approval from the U.S. Food and Drug Administration, or FDA, or comparable foreign regulatory    agency for one or more Biologics License Applications, or BLAs, or New Drug Applications, or NDAs;          </font>         </td>        </tr>        <tr style="vertical-align: top">         <td>          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td style="text-align: left; vertical-align: top">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td style="text-align: justify">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>        </tr>        <tr style="vertical-align: top">         <td>          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td style="text-align: left; vertical-align: top">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           ●          </font>         </td>         <td style="text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           our ability to obtain    and maintain marketing approval from regulatory agencies for our products in the U.S. and foreign countries;          </font>         </td>        </tr>        <tr style="vertical-align: top">         <td>          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td style="text-align: left; vertical-align: top">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td style="text-align: justify">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>        </tr>        <tr style="vertical-align: top">         <td>          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td style="text-align: left; vertical-align: top">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           ●          </font>         </td>         <td style="text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           our ability to adhere    to ongoing compliance requirements of all health authorities, in the U.S. and foreign countries;          </font>         </td>        </tr>        <tr style="vertical-align: top">         <td>          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td style="text-align: left; vertical-align: top">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td style="text-align: justify">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>        </tr>        <tr style="vertical-align: top">         <td>          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td style="text-align: left; vertical-align: top">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           ●          </font>         </td>         <td style="text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           our ability to obtain    and maintain adequate reimbursement for our products;          </font>         </td>        </tr>        <tr style="vertical-align: top">         <td>          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td style="text-align: left; vertical-align: top">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td style="text-align: justify">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>        </tr>        <tr style="vertical-align: top">         <td>          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td style="text-align: left; vertical-align: top">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           ●          </font>         </td>         <td style="text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           our ability to obtain    the desired labeling of our products under any regulatory approval we might receive;          </font>         </td>        </tr>        <tr style="vertical-align: top">         <td>          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td style="text-align: left; vertical-align: top">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td style="text-align: justify">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>        </tr>        <tr style="vertical-align: top">         <td>          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td style="text-align: left; vertical-align: top">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           ●          </font>         </td>         <td style="text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           our plans to develop    and commercialize our products;          </font>         </td>        </tr>        <tr style="vertical-align: top">         <td>          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td style="text-align: left; vertical-align: top">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td style="text-align: justify">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>        </tr>        <tr style="vertical-align: top">         <td>          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td style="text-align: left; vertical-align: top">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           ●          </font>         </td>         <td style="text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           the successful development    and implementation of sales and marketing campaigns;          </font>         </td>        </tr>        <tr style="vertical-align: top">         <td>          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td style="text-align: left; vertical-align: top">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td style="text-align: justify">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>        </tr>        <tr style="vertical-align: top">         <td>          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td style="text-align: left; vertical-align: top">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           ●          </font>         </td>         <td style="text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           the loss of key    scientific or management personnel;          </font>         </td>        </tr>        <tr style="vertical-align: top">         <td>          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td style="text-align: left; vertical-align: top">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td style="text-align: justify">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>        </tr>        <tr style="vertical-align: top">         <td>          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td style="text-align: left; vertical-align: top">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           ●          </font>         </td>         <td style="text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           the size and growth    of the potential markets for our product candidates and our ability to serve those markets;          </font>         </td>        </tr>        <tr style="vertical-align: top">         <td>          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td style="text-align: left; vertical-align: top">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td style="text-align: justify">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>        </tr>        <tr style="vertical-align: top">         <td>          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td style="text-align: left; vertical-align: top">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           ●          </font>         </td>         <td style="text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           our ability to successfully    compete in the potential markets for our product candidates, if commercialized;          </font>         </td>        </tr>        <tr style="vertical-align: top">         <td>          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td style="text-align: left; vertical-align: top">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td style="text-align: justify">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>        </tr>        <tr style="vertical-align: top">         <td>          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td style="text-align: left; vertical-align: top">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           ●          </font>         </td>         <td style="text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           regulatory developments    in the United States and foreign countries;          </font>         </td>        </tr>        <tr style="vertical-align: top">         <td>          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td style="text-align: left; vertical-align: top">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td style="text-align: justify">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>        </tr>        <tr style="vertical-align: top">         <td>          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td style="text-align: left; vertical-align: top">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           ●          </font>         </td>         <td style="text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           the rate and degree    of market acceptance of any of our product candidates;          </font>         </td>        </tr>       </tbody>      </table>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <!-- Field: Page; Sequence: 3; Options: NewSection; Value: 1 -->      <div style="margin-bottom: 6pt; border-bottom: Black 1.5pt solid">       <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">        <tbody>         <tr style="vertical-align: top; text-align: left">          <td style="text-align: center; width: 100%">           <!-- Field: Sequence; Type: Arabic; Name: PageNo -->           1           <!-- Field: /Sequence -->          </td>         </tr>        </tbody>       </table>      </div>      <div style="page-break-before: always; margin-top: 6pt">       <p style="margin: 0pt">       </p>      </div>      <!-- Field: /Page -->      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <table cellpadding="0" cellspacing="0" style="width: 100%; font: 11pt Calibri, Helvetica, Sans-Serif; border-collapse: collapse">       <tbody>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           ●          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           new    products, product candidates or new uses for existing products or technologies introduced or announced by our competitors    and the timing of these introductions or announcements;          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           ●          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           market    conditions in the pharmaceutical and biotechnology sectors;          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           ●          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           our    available cash and investments;          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           ●          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           the    accuracy of our estimates regarding expenses, future revenues, capital requirements and needs for additional financing;          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           ●          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           our    ability to obtain additional funding;          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           ●          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           our    ability to obtain and maintain intellectual property protection for our product candidates;          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           ●          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           our    ability to maintain license agreements for our licensed product candidates;          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           ●          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           the    success and timing of our preclinical studies, including those intended to support an Investigational New Drug, or IND, application;          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           ●          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           the    ability of our product candidates to successfully perform and advance in clinical trials;          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           ●          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           our    continued compliance with the listing requirements of the Nasdaq Capital Market;          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           ●          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           our    ability to obtain and maintain authorization from regulatory authorities for use of our product candidates for initiation    and conduct of clinical trials;          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           ●          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           our    ability to manufacture and supply our products, gain access to products we plan to use in combination studies and the performance    of and reliance on third-party manufacturers and suppliers;          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           ●          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           the    performance of our clinical research organizations, clinical trial sponsors, and clinical trial investigators; and          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           ●          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           our    ability to successfully implement our strategy.          </font>         </td>        </tr>       </tbody>      </table>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Forward-lookingstatements are only predictions and are not guarantees of future performance, and they are subject to known and unknown risks,uncertainties and other factors, including the risks described under “Risk Factors” in Part I, Item IA of this reportand similar discussions contained in the other documents we file from time to time with the Securities and Exchange Commission,or the “SEC.” Moreover, we operate in a rapidly evolving industry in which new risks and uncertainties continuouslyemerge, and it is not possible for us to predict all of the risks we may face or assess the impact of all uncertainties or otherfactors on our business or the extent to which any factor or combination of factors could cause actual results to differ fromour current expectations, assumptions or beliefs. In light of these risks, uncertainties and other factors, the forward-lookingevents and circumstances described in this report may not occur and our results, levels of activity, performance or achievementscould differ materially from those expressed in or implied by any forward-looking statements we make. As a result, you shouldnot place undue reliance on any of our forward-looking statements. Forward-looking statements speak only as of the date they aremade, and unless required to by law, we undertake no obligation to update or revise any forward-looking statement for any reason,including to reflect new information, future developments, actual results or changes in our expectations.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Wequalify all of our forward-looking statements by this cautionary note.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        ** * * *       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <i>        </i>       </font>      </p>      <!-- Field: Page; Sequence: 4; Value: 1 -->      <div style="margin-bottom: 6pt; border-bottom: Black 1.5pt solid">       <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">        <tbody>         <tr style="vertical-align: top; text-align: left">          <td style="text-align: center; width: 100%">           <!-- Field: Sequence; Type: Arabic; Name: PageNo -->           2           <!-- Field: /Sequence -->          </td>         </tr>        </tbody>       </table>      </div>      <div style="page-break-before: always; margin-top: 6pt">       <p style="margin: 0pt">       </p>      </div>      <!-- Field: /Page -->      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <i>        </i>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <i>         Unlessthe context indicates otherwise, all references to OncoSec, our Company, we, us and our in this report refer to OncoSec MedicalIncorporated and its subsidiary.        </i>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <i>         Weown registered trademark rights in the United States to ImmunoPulse®, and we have filed applications in the United Statesand in certain foreign jurisdictions to register trademark rights to ImmunoPulse and OncoSec. Other service marks, trademarksor trade names used in this report are the property of their respective owners. We do not use the ® or ™ symbol in eachinstance in which one of our registered or common law trademarks appears in this report, but this should not be construed as anyindication that we will not assert our rights thereto to the fullest extent permissible under applicable law.        </i>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <i>         Wemake available, free of charge, on our website, www.oncosec.com, our reports on Forms 10-K, 10-Q, 8-K and amendments thereto,as soon as reasonably practical after we file such materials with the SEC. Any information that we include on or link to our websiteis not, and should not be considered, part of this report.        </i>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">        <b>        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">        <a name="b_002">        </a>        <b>         PARTI        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif">        <a name="b_003">        </a>        <font style="font-size: 10pt; text-transform: uppercase">         <b>          ITEM1. BUSINESS         </b>        </font>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <b>         Overview        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif">        Weare a late-stage biotechnology company focused on designing, developing and commercializing innovative therapies and proprietarymedical approaches to stimulate and to guide an anti-tumor immune response for the treatment of cancer. Our core technology platformImmunoPulse®is a drug-device therapeutic modality platform comprised of proprietary intratumoral electroporation (“EP”)delivery devices (the “OncoSec Medical System (OMS) Electroporation Device” or “OMS EP Device”).The OMS EP Device is designed to deliver plasmid DNA-encoded drugs directly into a solid tumor and promote an immunologicalresponse against cancer. The OMS EP Device can be adapted to treat different tumor types, and consists of an electricalpulse generator, a reusable handle and disposable applicators. Our lead product candidate is a DNA-encoded interleukin-12 (“IL-12”)called tavokinogene telseplasmid (“TAVO”). The OMS EP Device is used to deliver TAVO intratumorally, with theaim of reversing the immunosuppressive microenvironment in the treated tumor. The activation of the appropriate inflammatory responsecan drive a systemic anti-tumor response against untreated tumors in other parts of the body. In 2017, we received Fast TrackDesignation and Orphan Drug Designation from the U.S. Food and Drug Administration (“FDA”) for TAVO in metastaticmelanoma, which could qualify TAVO for expedited FDA review, a rolling Biologics License Application review and certain otherbenefits.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Ourcurrent focus is to pursue our study of TAVO in combination with Merck &amp; Co., Inc. (“Merck”) KEYTRUDA®(pembrolizumab) in melanoma and triple negative breast cancer (“TNBC”).       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif">        Our       </font>       <font style="font-family: Times New Roman, Times, Serif">        KEYNOTE-695 study targets melanoma patients who aredefinitive anti-PD-1 non-responders. In May 2017, we entered into a clinical trial collaboration and supply agreement with a subsidiaryof Merck in connection with the KEYNOTE-695 study. Pursuant to the terms of the agreement, both companies will bear theirown costs related to manufacturing and supply of their product, as well as be responsible for their own internal costs. We arethe study sponsor and are responsible for external costs. The KEYNOTE-695 study is currently enrolling and treating patients andwe plan to complete or nearly complete enrollment in the second half of 2020. This study is a registration-directed, Phase 2bopen-label, single-arm, multicenter study in the United States, Canada, Australia and Europe.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        InMay 2018, we entered into a second clinical trial collaboration and supply agreement with Merck with respect to a Phase 2 studyof TAVO in combination with KEYTRUDA® to evaluate the safety and efficacy of the combination in patients with inoperable locallyadvanced or metastatic TNBC, who have previously failed at least one systemic chemotherapy or immunotherapy. This study is referredto as KEYNOTE-890, Cohort 1. Pursuant to the terms of the agreement, both companies will bear their own costs related to manufacturingand supply of their product, as well as be responsible for their own internal costs. We are the study sponsor and are responsiblefor external costs. The KEYNOTE-890 study, Cohort 1 is currently treating patients. We completed enrollment in fourth quarter2019 and provided interim preliminary data from this study at the San Antonio Breast Cancer Symposium (“SABCS”) inDecember 2019. The study is a Phase 2 open-label, single-arm, multicenter study in the United States and Australia.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <!-- Field: Page; Sequence: 5; Value: 1 -->      <div style="margin-bottom: 6pt; border-bottom: Black 1.5pt solid">       <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">        <tbody>         <tr style="vertical-align: top; text-align: left">          <td style="text-align: center; width: 100%">           <!-- Field: Sequence; Type: Arabic; Name: PageNo -->           3           <!-- Field: /Sequence -->          </td>         </tr>        </tbody>       </table>      </div>      <div style="page-break-before: always; margin-top: 6pt">       <p style="margin: 0pt">       </p>      </div>      <!-- Field: /Page -->      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        InJune 2020, we amended our second clinical trial collaboration and supply agreement with Merck to include another Phase 2 studyof TAVO in combination with KEYTRUDA® plus chemotherapy to evaluate the safety and efficacy of the combination in patientswith inoperable locally advanced or metastatic triple negative breast cancer (“mTNBC”). This study is referredto as KEYNOTE-890, Cohort 2. Pursuant to the terms of the amended agreement, both companies will bear their own costs relatedto the manufacture and supply of their product, as well as be responsible for their own internal costs. We are the studysponsor and are responsible for external costs. The KEYNOTE-890, Cohort 2 study is currently expected to begin enrolling patientstowards the end of calendar year 2020 or the beginning of calendar year 2021. We expect to complete enrollment within fifteenmonths and provide interim preliminary data from this study at a future medical conference. The study is a Phase 2 open-label,single arm, multicenter study in the United States and Australia.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        InAugust 2020, we commenced an Investigator-Initiated Phase 2 study conducted by the H. Lee Moffitt Cancer Center and Research Instituteand the University of South Florida Morsani College of Medicine to evaluate TAVO™ as neoadjuvant treatment (administeredbefore surgery) in combination with intravenous OPDIVO® (nivolumab) in up to 33 patients with operable locally/regionallyadvanced melanoma. This Investigator-Initiated Phase 2 study has been designed to evaluate whether the addition of TAVO can increasethe published anti-tumor response observed with monotherapy OPDIVO®, an anti-PD-1 checkpoint inhibitor, in patients with locally/regionallyadvanced melanoma prior to surgical resection of tumors. This study is currently enrolling and expected to complete enrollmentwithin eighteen months. In April 2020, we announced that Providence Cancer Institute, a part of Providence St. Joseph Health (“Providence”),is pursuing a first-in-human Phase 1 clinical trial of OncoSec’s novel DNA-encodable, investigational vaccine, CORVax12,which is designed to act as a prophylactic vaccine to prevent COVID-19. CORVax12 consists of OncoSec’s existing productcandidate, TAVO™ (interleukin-12 or “IL-12” plasmid), in combination with an immunogenic component of the SARS-CoV-2virus recently developed by researchers at NIH’s National Institute of Allergy and Infectious Diseases (“NIAID”)and licensed to OncoSec on a non-exclusive basis.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Providenceinvestigators have filed an Investigator-Initiated Investigational New Drug Application (“IND”) with the UnitedStates Food and Drug Administration (“FDA”) and have designed a clinical trial protocol that will evaluatethe vaccination of healthy adult volunteers utilizing CORVax12 and an investigational low voltage generator technology if theFDA approves the IND. The trial will also include extensive immune monitoring.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        OncoSecwill supply TAVO and the low voltage electroporation device to Providence as part of this effort and does not anticipate any additionalcapital commitment at this time. Additionally, OncoSec will contribute manufacturing, preclinical, and prior clinical informationand data for TAVO, along with manufacturing data with respect to the generator, to support the FDA’s allowance ofthe IND. Providence will hold the IND, if approved by FDA, and perform the preclinical and clinical development work. Theanticipated work and clinical trials outlined above are subject to FDA allowance of the Investigator-Initiated IND filed by Providence.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        InMay 2019, we commenced an Investigator-Initiated Phase 1 clinical trial conducted by the University of California San FranciscoHelen Diller Family Comprehensive Cancer Center (“OMS-131”). This study targets patients with SCCHN and isa single-arm open-label clinical trial in which 35 evaluable patients will receive TAVO, KEYTRUDA® and epacadostat. OMS-131is currently enrolling and treating patients and is expected to complete enrollment within eighteen months.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Weintend to continue to pursue other ongoing or potential new trials and studies related to TAVO, in various tumor types. In addition,we are also developing our next-generation EP device and applicator, including advancements toward prototypes, pursuing discoveryresearch to identify other product candidates that, in addition to IL-12, can be encoded into propriety plasmid-DNA and deliveredintratumorally using EP. Specifically, we are developing a new, propriety technology to potentially treat liver, lung, bladder,pancreatic and other difficult to treat visceral lesions through the direct delivery of plasmid-based IL-12 with a new VisceralLesions Applicator (“VLA”).       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <!-- Field: Page; Sequence: 6; Value: 1 -->      <div style="margin-bottom: 6pt; border-bottom: Black 1.5pt solid">       <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">        <tbody>         <tr style="vertical-align: top; text-align: left">          <td style="text-align: center; width: 100%">           <!-- Field: Sequence; Type: Arabic; Name: PageNo -->           4           <!-- Field: /Sequence -->          </td>         </tr>        </tbody>       </table>      </div>      <div style="page-break-before: always; margin-top: 6pt">       <p style="margin: 0pt">       </p>      </div>      <!-- Field: /Page -->      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        TheVLA has been designed to work with low voltage EP generators, including but not limited to our proprietary APOLLO        <sup>         TM        </sup>        EP generator to leverage plasmid-optimized EP and enhance the depth of transfection of immunologically relevant genes intocells located in visceral organs. In early 2020, the Company had two poster presentations, one at the Society for InterventionalOncology (“SIO”) and one at the Society for Interventional Radiology (“SIR”), where it presented preclinicaldata on both the VLA and APOLLO generator. The poster at SIO was awarded “Best Technology Scientific Abstract”. Additionally,we have successfully completed several large animal studies and aim to use the VLA in our clinical trials in the secondhalf of 2021. By using our next-generation technology with the VLA, our goal is to reverse the immunosuppressive mechanismsof a tumor, as well as to expand our pipeline. We believe that the flexibility of our propriety plasmid-DNA technology allowsus to deliver other immunologically relevant molecules into the tumor microenvironment in addition to the delivery of plasmid-DNAencoding for IL-12. In June 2020, the Company had two poster presentations at the 2020 America Association for Cancer Research(“AACR”) where it presented pre-clinical data regarding its new anti-tumor product candidate, which will amplify thepower of intratumoral IL-12 through the addition of both CXCL9, a critical T cell chemokine, and anti-CD3, a membrane bound panT cell stimulator. These other immunologically relevant molecules may complement IL-12’s activity by limiting or enhancingkey pathways associated with tumor immune subversion.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Wehave established a collaboration with Emerge Health Pty (“Emerge”), the leading Australian company providing fullregistration, reimbursement, sales, marketing and distribution services of therapeutic products in Australia and New Zealand,to commercialize TAVO and have made it available under Australia’s Special Access Scheme (“SAS”) as of early2020. As a specialized Australian pharmaceutical company focused on the marketing and sales of high-quality medicines to the hospitalsector, Emerge has previously made numerous other products successfully available under Australia’s SAS.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <b>         CancerImmunotherapy Treatments: Background        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Manytraditional modalities for treating cancer have limited clinical efficacy and are frequently associated with significant negativeside effects. Immunotherapy, which has received significant attention in recent years, focuses on modulating theimmune system to treat cancer rather than directly killing the cancer cells. Systemic delivery of immune-modulating proteins,such as interleukin-2, interleukin-10, interleukin-12 or IL-2, IL-10 and IL-12, has shown early indications of efficacy,but with significant mechanism-based toxicity.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Recentattention has also focused on the development of monoclonal antibody drugs, which target critical “immune checkpoint”proteins and augment anti-tumor immunity. Therapies using monoclonal antibodies, such as anti-CTLA-4 (cytotoxic T-lymphocyte-associatedprotein-4), anti-PD-1 (program cell-death-1) and anti-PD-L1 (programmed death-ligand-1), are being developed for the treatmentof several cancers and have been approved for the treatment of multiple sold tumor cancers. Although these new immuno-oncologyagents have shown clinical benefit for patients with late-stage cancer across multiple tumor types, only a small subset of theoverall patient population responds to these therapies. Certain tumors are able to evade the immune system. We believe that whentumors do not have any immune cells inside (immune desert) or surrounding the tumor (immune excluded), immune checkpoint therapiesare less effective or ineffective. These tumors are sometimes referred to as “cold” tumors.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Webelieve that if we can convert an inactive, or “cold,” tumor with a low frequency of tumor infiltrating lymphocytes,or TILs, that limit the anti-tumor response and remove the interferon signature, into an active, or “hot,” tumor thatcan activate the anti-PD-1 or anti-PD-L1 pathway, then we can potentially increase the number of patients who respond to thesetherapies. We believe our TAVO platform addresses this objective, as it has the potential to reshape the tumor microenvironmentin patients with an immunologically cold tumor into a highly-inflamed tumor with a fully engaged PD-1 / PD-L1 axis. The immunologicalcomponents that enable this conversion relates to the intratumoral delivery of TAVO, which increases the density of TILs, andin the presence of an anti-PD-1 antibody, adaptive resistance can be neutralized allowing for the maximal T cell cytotoxicity.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <!-- Field: Page; Sequence: 7; Value: 1 -->      <div style="margin-bottom: 6pt; border-bottom: Black 1.5pt solid">       <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">        <tbody>         <tr style="vertical-align: top; text-align: left">          <td style="text-align: center; width: 100%">           <!-- Field: Sequence; Type: Arabic; Name: PageNo -->           5           <!-- Field: /Sequence -->          </td>         </tr>        </tbody>       </table>      </div>      <div style="page-break-before: always; margin-top: 6pt">       <p style="margin: 0pt">       </p>      </div>      <!-- Field: /Page -->      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Thereis a significant unmet medical need for patients who may not respond well to these therapies on their own. In particular, forpatients who have “cold” tumors and would be unlikely to respond to an immune checkpoint therapy alone, our focusis to develop a therapeutic that has the ability to directly modulate the microenvironment of the tumor by stimulating a localimmune reaction through the intratumoral delivery of IL-12 or other immune-modulating molecules. This immune cascade allows anti-tumorimmune cells to infiltrate the lesion, turning the tumor “hot” and ultimately generates a productive systemic immuneresponse. In doing so, we believe intratumoral delivery of immune-modulating molecules, such as IL-12, provides a strongbiological rationale for treatment in combination with immune checkpoint inhibitors, such as anti-PD-1 or anti-CTLA-4.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <b>         CLINICALPROGRAMS        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <b>         OurLead Product Candidate: TAVO        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Ourlead product candidate, TAVO, is a drug-device combination. The drug consists of a plasmid construct called tavokinogene telseplasmid,or TAVO, with plasmid DNA-encoded, IL-12, and is delivered into a tumor using our proprietary electroporation device. Our clinicaldata indicates that the in vivo gene transfer of plasmid DNA-encoded IL-12 using EP is well-tolerated and anti-tumor activityhas been observed after a single cycle of treatment. Importantly, regression in distant, non-injected/non-electroporated lesionshas also been observed (“abscopal effect”) in different solid cancers.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <b>         OurClinical Pipeline        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <b>        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <b>         MELANOMA        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Melanomais a deadly form of skin cancer with rapidly rising incidences both in the U.S. and internationally. The National Cancer Institute(“NCI”) Surveillance, Epidemiology and End Results (“SEER”) Program estimates that 96,480 new melanomacases were diagnosed in 2019, representing 5.5% of all new cancer cases in the U.S. Overall, the five-year survival rate for melanoma,regardless of disease stage, is high (92.2%); however, according to SEER 2019, for patients who present with metastatic diseaseand receive systemic treatment, the five-year survival rate is considerably lower at less than 25%. Despite recent advances intherapy, advanced metastatic melanoma continues to present a major and increasing burden with significant morbidity and mortality.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <b>         <i>          KEYNOTE-695Study (ongoing)         </i>        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        TheKEYNOTE-695 study is a Phase 2b, open-label, single-arm, multi-center study of TAVO in combination with an intravenous anti-PD-1antibody, Merck’s KEYTRUDA®, in patients with histological diagnosis of melanoma with progressive locally advanced ormetastatic disease defined as stage III/IV. KEYNOTE-695 study is evaluating approximately 100 patients and is currentlyenrolling and treating patients in the United States, Canada, and Australia across approximately 30 sites, and we plan to treatpatients in Europe.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        KEYNOTE-695enrollment criteria with respect to anti-PD-1 checkpoint failure is highly restrictive. In order to be considered an anti-PD-1checkpoint failure, all patients must have histological or cytological confirmed diagnosis of unresectable melanoma (Stage IIIor IV) with progressive locally advanced or metastatic diseases, be refractory to anti-PD-1 monoclonal antibodies, namely KEYTRUDA®(pembrolizumab) or OPDIVO® (nivolumab), as either monotherapy or in combination with other approved checkpoint inhibitorsor targeted therapies according to their approved label, and must have relapsed as documented disease progression within 12 weeksof the last dose of anti-PD-1 monoclonal antibodies according to RECIST v1.1, measured by radiologic assessment. Patients canhave no intervening therapies between failure of anti-PD-1 therapy and the TAVO / KEYTRUDA® combination treatment with theexception of approved BRAF/MEK inhibitor combinations. Patients that are BRAF eligible must receive and progress following BRAFtreatment. The primary endpoint of the study, by blinded independent central review, is to assess the objective response rate(“ORR”) based on RECIST v1.1.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <!-- Field: Page; Sequence: 8; Value: 1 -->      <div style="margin-bottom: 6pt; border-bottom: Black 1.5pt solid">       <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">        <tbody>         <tr style="vertical-align: top; text-align: left">          <td style="text-align: center; width: 100%">           <!-- Field: Sequence; Type: Arabic; Name: PageNo -->           6           <!-- Field: /Sequence -->          </td>         </tr>        </tbody>       </table>      </div>      <div style="page-break-before: always; margin-top: 6pt">       <p style="margin: 0pt">       </p>      </div>      <!-- Field: /Page -->      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        KEYNOTE-695is a registration directed clinical trial. In order to be eligible for accelerated approval, the TAVO / KEYTRUDA® combinationmust treat a serious condition and provide a meaningful advantage over available therapies. Prior to the commencement of the study,within the context of the Fast Track Designation request, the Company reviewed the patient inclusion and progression criteria,and other study requirements with FDA. In light of this review, we strictly defined the patient population to be enrolled in KEYNOTE-695to include only those patients who have definitively failed prior anti-PD-1 checkpoint therapy, as determined by the above-describedrigor, and who have exhausted all available FDA approved treatment options.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Wepreviously provided preliminary data updates at The Society for Immunotherapy of Cancer (“SITC”) Annual Meeting inNovember of 2018, at our Business Outlook in February 2019, and at several Company investor presentations in 2019 and 2020, whichwere made publicly available on the Company’s website. Further, interim data regarding the investigator assessment of tumorresponses for over 50 patients from this trial is planned to be presented at the Society for Cancer Immunotherapy (SITC) on andduring the week of November 9, 2020. We plan to complete or nearly complete enrollment in the KEYNOTE-695 study in the secondhalf of 2020. We are working on the commercial version of the OMS Electroporation Device currently being used in this trial sothat it complies with current regulatory standards, a prerequisite for FDA clearance. We anticipate using this version of theOMS Electroporation Device in this study in an expansion cohort of approximately 25 patients to enable our plan to file for acceleratedapproval. We are currently seeking FDA concurrence to use this updated version in the ongoing trial. Lastly, based on the outcomeof the study and feedback from FDA, we plan to file for accelerated approval with the FDA for this patient population in late2021 / early 2022.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <b>         <i>          OMS-102(completed)         </i>        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        OMS-102was an open-label, multi-center, Phase 2 trial of TAVO and KEYTRUDA® (pembrolizumab) in patients with advanced, metastaticmelanoma. In August 2015, we enrolled the first patient in our Phase 2 investigator-sponsored clinical trial led by the cliniciansat the University of California, San Francisco, or UCSF. Huntsman Cancer Institute in Utah was the second clinical site. The primaryendpoint of this study was to assess the anti-tumor efficacy of the combination of TAVO and KEYTRUDA® in patients with stageIII/IV metastatic melanoma whose tumors are characterized by low frequency of CD8        <sup>         +        </sup>        /PD-1        <sup>         +        </sup>        /CTLA-4        <sup>         +        </sup>        TILs (tumor infiltrating lymphocytes). The primary endpoint of the study was best overall response rate by RECIST of the combinationregimen. Recent data suggests that patients whose tumors are lacking TILs or CD8        <sup>         +        </sup>        T-cells at the tumor margin or generallyhave a low frequency of CD8        <sup>         +        </sup>        /PD-L1        <sup>         +        </sup>        /CTLA-4        <sup>         +        </sup>        TILs are unlikely to respond to anti-PD-1 therapiessuch as KEYTRUDA®, while tumors with a frequency of CTLA-4        <sup>         +        </sup>        /PD-L1        <sup>         +        </sup>        /CD8        <sup>         +        </sup>        &gt;20% in the tumorare likely to have a clinical benefit. Therapies, such as TAVO, that promote TIL generation and PD-L1 positivity play an importantrole in augmenting the clinical efficacy of the anti-PD1/PD-L1 agents.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Initialdata were presented in February 2017 at ASCO-SITC and the trial stopped enrolling patients in September 2017, allowing the Companyto progress on KEYNOTE-695. The final data was selected for prominence at SITC 2017 and was presented during the oral poster session.The overall response rate in the 22-patient population was 43% by RECIST v1.1. at week 24 (best overall response rate was 50%by clinical assessment), with one Grade-3 adverse event of cellulitis that resolved with antibiotics. Based on these results,we believe the combination of TAVO and KEYTRUDA® demonstrated efficacy in this low TIL metastatic melanoma patient populationand was well-tolerated. Further, long-term follow up has shown responses with significant durability, with all patients who experienceda response remaining in responding status. To date only one patient has required additional surgery to maintain remission. Datafrom this study was published in the Clinical Cancer Research journal in May 2020.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif">       </font>      </p>      <!-- Field: Page; Sequence: 9; Value: 1 -->      <div style="margin-bottom: 6pt; border-bottom: Black 1.5pt solid">       <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">        <tbody>         <tr style="vertical-align: top; text-align: left">          <td style="text-align: center; width: 100%">           <!-- Field: Sequence; Type: Arabic; Name: PageNo -->           7           <!-- Field: /Sequence -->          </td>         </tr>        </tbody>       </table>      </div>      <div style="page-break-before: always; margin-top: 6pt">       <p style="margin: 0pt">       </p>      </div>      <!-- Field: /Page -->      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <b>         <i>          OMS-100(completed)         </i>        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        OMS-100was an open-label Phase 2 trial of TAVO monotherapy in patients with metastatic melanoma. On December 5, 2014, we released top-linesix-month data from a Phase 2 repeat dose trial of TAVO in patients with stage III/IV metastatic melanoma. We presented finaldata at the Melanoma Bridge Conference in 2018. This study is now locked with the data collected at 6 clinical centers. Thirty(30) patients with stage III/IV melanoma received up to four cycles of TAVO delivered by EP on days one, five and eight of each12-week cycle. Of the 28 patients in the study who were evaluable, an objective response rate of 35.7% (10/28 patients) was observed.Five patients (17.9%) had a CR, 5 patients (17.9%) had a PR, 12 patients (42.9%) had SD. Of the distant untreated and assessedlesions that decreased in longest dimension by ≥ 30%, 17.4% (20/115) were assessed. Of the 26 patients with ≥ 1 assessedlesion, 12 patients (46.2%) had ≥ 1 assessed distant lesion with major regression (≥ 30%). Two patients were not evaluateddue to not having evaluable distant untreated lesions. Other clinical endpoints included objective response rate, local and distantlesion regression, duration of response, overall survival and safety. The results of this study demonstrated that multiple treatmentcycles of TAVO were well-tolerated, with no treatment-limiting toxicities. The majority of adverse events were localized to thetreatment site and were Grade-1 or -2 in severity.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Inorder to continue to acquire clinical and immune correlational data on melanoma patients treated with TAVO, the protocol of theOMS-I100 study was amended in February 2014 to enroll up to an additional 30 patients. Enrollment in OMS-I100 Addendum was completedin March 2016. The study is now completed and the Company presented final data at the Melanoma Bridge Conference held on November29 – December 1, 2018. The data was selected for an oral presentation and included new data demonstrating that local treatmentwith TAVO alone led to whole-body immune responses associated with regression of untreated lesions in almost half of the 50 patientstreated on the study. Final data from this study was published in the Annals of Oncology in March 2020.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Followingthis trial, a retrospective analysis of the patients who went on to receive an anti-PD-1/PD-L1 therapy was conducted. Resultsfrom this retrospective analysis suggested that TAVO primes and enhances response rates to PD-1/PD-L1 blockade. Specifically,of the 29 patients who completed TAVO, 14 subsequently received an anti-PD-1/PD-L1 treatment. Overall, five of these 14 patients(36%) experienced a complete response and four patients experienced a partial response (29%), for an overall response rate of65% (75% without intervening therapies). Two patients experienced stable disease (14%) and three patients experienced progressivedisease (21%). We believe this retrospective sequential data could suggest combinatorial potential of an immune-priming effectwith TAVO prior to anti-PD-1/PD-L1 therapy. Data from this retrospective analysis formed the clinical rationale for conductingOMS-I102.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif">        <b>         <i>          PHASE2 INVESTIGATOR-INITIATED NEOADJUVANT STUDY         </i>        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif">        InAugust 2020, we commenced an investigator-initiated Phase 2 study conducted by the H. Lee Moffitt Cancer Center and Research Instituteand the University of South Florida Morsani College of Medicine to evaluate TAVO™ as neoadjuvant treatment (administeredbefore surgery) in combination with intravenous OPDIVO®(nivolumab) in up to 33 patients with operable locally/regionally advancedmelanoma. This investigator-initiated Phase 2 study has been designed to evaluate whether the addition of TAVO can increase thepublished anti-tumor response observed with monotherapy OPDIVO®, an anti-PD-1 checkpoint inhibitor, in patients with locally/regionallyadvanced melanoma prior to surgical resection of tumors. This study is currently enrolling and expected to complete enrollmentwithin eighteen months.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <b>         <i>          TRIPLENEGATIVE BREAST CANCER (TNBC)         </i>        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Breastcancer is the most common cancer diagnosed among U.S. women and is the second leading cause of cancer-related deaths. Worldwide,approximately 170,000 new cases of TNBC are diagnosed each year, with TNBC representing one of the four main molecular subtypesof invasive breast cancer, accounting for approximately 10 -20% of all breast cancer, according to breastcancer.org. Accordingto the American Cancer Society, for patients who present with Stage 4 metastatic disease, the five-year survival rate is considerablylower at approximately 22%.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        TNBCfrequently affects younger women (less than 40 years old) and is characterized by higher relapse rates than estrogen receptorpositive breast cancers. TNBC is also associated with an increased risk of recurrence, both locally and in distant sites includingthe lungs and brain. Advanced TNBC remains a significant area of unmet medical need and there is no established standard-of-care.Chemotherapy is the current standard-of-care treatment in the adjuvant, neoadjuvant, and metastatic settings. Due to the lossof the tumor cell receptors, patients with TNBC do not benefit from hormonal therapy or treatments targeting the oncogenic HER2pathway. The standard of care for patients with recurrent and/or metastatic disease is cytotoxic chemotherapy, leading to a mediansurvival of approximately 13 months from the time of recurrence or diagnosis of distant metastases. Importantly, for patientswith metastatic TNBC, the traditional chemotherapeutic treatment approach has undergone limited advance in the last decades, andno regimen is specifically indicated in this unique patient population.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <!-- Field: Page; Sequence: 10; Value: 1 -->      <div style="margin-bottom: 6pt; border-bottom: Black 1.5pt solid">       <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">        <tbody>         <tr style="vertical-align: top; text-align: left">          <td style="text-align: center; width: 100%">           <!-- Field: Sequence; Type: Arabic; Name: PageNo -->           8           <!-- Field: /Sequence -->          </td>         </tr>        </tbody>       </table>      </div>      <div style="page-break-before: always; margin-top: 6pt">       <p style="margin: 0pt">       </p>      </div>      <!-- Field: /Page -->      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <b>         <i>          KEYNOTE-890study (ongoing)         </i>        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        KEYNOTE-890is a Phase 2, open-label, single-arm, multi-center study of TAVO in combination with an intravenous anti-PD-1 antibody, Merck’sKEYTRUDA®, in patients with histologically confirmed diagnosis of inoperable locally advanced or metastatic TNBC who havereceived at least one prior line of approved systemic chemotherapy or immunotherapy.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Incollaboration with Merck, we plan to complete treatment in KEYNOTE-890, Cohort 1 in 2020. We also plan to beginenrollment in Cohort 2 in the fourth quarter of calendar year 2020. We previously provided interim data from Cohort1 in December, 2019 on the first group of patients enrolled from this study at the San Antonio Breast Cancer Symposium(“SABCS”). Based on the outcome of the study and feedback from FDA, we amended the KEYNOTE-890 clinical protocol toinclude TAVO in combination with KEYTRUDA® plus chemotherapy to evaluate the safety and efficacy of the combination in patientswith inoperable locally advanced or metastatic triple negative breast cancer (“mTNBC”). The study is a Phase2 open-label, single-arm, multicenter study in the United States and Australia.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <b>         <i>          OMS-140(completed)         </i>        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        OMS-140is a Phase 2, monotherapy biomarker study in patients with advanced or metastatic TNBC. The study is being conducted at StanfordUniversity and is designed to assess whether TAVO increases TNBC tumor immunogenicity by driving a pro-inflammatory cascade thatleads to increases in cytotoxic TILs. The presence and number of TILs is thought to be a key requirement for promoting the anti-tumoractivity of anti-PD-1. By driving cytotoxic immune cells into the tumor, TAVO could be used in combination with checkpoint blockadetherapies, which have reported some, but limited, activity in TNBC.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Theprimary objective of the study is to evaluate the potential of TAVO to promote a pro-inflammatory molecular and histological signature,and the secondary objectives include the evaluation of safety and tolerability, evaluation of local ablation effect (%of necrosis), and description of other evidence of anti-tumor activity. The study has been subsequently amended to capturethe post-TAVO treatments and outcomes.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Preliminarydata was presented at the SABCS annual meeting in 2018 and enrollment in this trial (n=10) is now complete. The clinical observationsfrom this study prompted the Company to conduct KEYNOTE-890, which is currently underway.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <b>         <i>          SQUAMOUSCELL CARCINOMA HEAD &amp; NECK CANCER (SCCHN)         </i>        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <b>        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Headand neck cancer represent approximately 4% of all cancers in the U.S., and it is estimated over 65,000 patients will develop headand neck cancer this year with over 14,000 deaths.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <b>         <i>          OMS-131(ongoing)         </i>        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <b>        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        OMS-131is an investigator-initiated Phase 2 clinical trial conducted by the University of California San Francisco Helen Diller FamilyComprehensive Cancer Center. This study targets patients with SCCHN and is a single-arm open-label clinical trial in which 35evaluable patients will receive TAVO, KEYTRUDA® and epacadostat. OMS-131 is currently enrolling and treating patients.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        OMS-131,also referred to as the “TRIFECTA” study, was formed from the clinical observations from a 2017 pilot study of TAVOin head and neck cancer patients, which demonstrated clinical and biological results including evidence of synergy between TAVOand PD-1 antibodies in the disease.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <b>         <i>          ROSEWELLPARK COMPREHENSIVE CANCER CENTER         </i>        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <b>        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        TheCompany has an ongoing research collaboration with Roswell Park Comprehensive Cancer Center (“Roswell Park”)to evaluate the use of Roswell Park’s intravital microscopy (“IVM”) and TAVO        <sup>         PLUS        </sup>        (enhanced IL-12DNA-plasmid), in combination with our APOLLO™ EP generator in preclinical studies. The collaboration is led by Joseph Skitzki,MD, FACS, Associate Professor of Immunology, Associate Professor of Surgery and Chair of the Melanoma/Sarcoma Disease Site ResearchGroup at Roswell Park.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <!-- Field: Page; Sequence: 11; Value: 1 -->      <div style="margin-bottom: 6pt; border-bottom: Black 1.5pt solid">       <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">        <tbody>         <tr style="vertical-align: top; text-align: left">          <td style="text-align: center; width: 100%">           <!-- Field: Sequence; Type: Arabic; Name: PageNo -->           9           <!-- Field: /Sequence -->          </td>         </tr>        </tbody>       </table>      </div>      <div style="page-break-before: always; margin-top: 6pt">       <p style="margin: 0pt">       </p>      </div>      <!-- Field: /Page -->      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <b>         <i>          DUKEUNIVERSITY         </i>        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <b>        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        TheCompany has an ongoing research collaboration with Duke University’s Center for Applied Therapeutics (“DukeUniversity”) to evaluate TAVO        <sup>         PLUS        </sup>        in combination or sequenced with a HER2-plasmid vaccine administered our APOLLO™EP generator in preclinical studies. The research is led by Herbert Kim Lyerly, M.D., George Barth Geller Professor, Professorof Immunology, Surgery and Pathology at Duke University School of Medicine and a director on our board of directors. Weplan to present data from the pre-clinical trials completed in collaboration at SABCS and SITC in 2020.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <b>         OtherTrials and Studies        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Inaddition to the trials and studies described above, we have also pursued and closed Phase 2 clinical trials in patients with Merkelcell carcinoma and cutaneous T-cell lymphoma, although we do not have any active clinical programs related to these indicatorsat this time.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        InApril 2020, we announced that Providence Cancer Institute, a part of Providence St. Joseph Health (“Providence”),is pursuing a first-in-human Phase 1 clinical trial of OncoSec’s novel DNA-encodable, investigational vaccine, CORVax12,which is designed to act as a prophylactic vaccine to prevent COVID-19. CORVax12 consists of OncoSec’s existing productcandidate, TAVO™ (interleukin-12 or “IL-12” plasmid), in combination with an immunogenic component of the SARS-CoV-2virus recently developed by researchers at NIH’s National Institute of Allergy and Infectious Diseases (“NIAID”)and non-exclusively licensed to OncoSec on a non-commercial basis.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Providenceinvestigators have filed an Investigator-Initiated Investigational New Drug Application (“IND”) with the UnitedStates Food and Drug Administration (“FDA”) and have designed a clinical trial protocol that will evaluatethe vaccination of healthy adult volunteers utilizing CORVax12 and an investigational low voltage generator technology if FDAclears the IND. The trial will also include extensive immune monitoring.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        OncoSecwill supply TAVO and a low voltage electroporation device to Providence as part of this effort and does not anticipateany additional capital commitment at this time. Additionally, OncoSec will contribute manufacturing, preclinical, and prior clinicalinformation and data for TAVO, along with manufacturing data with respect to the generator, to support FDA’s allowance ofthe Providence IND. Providence will hold the IND, if cleared by FDA, and perform the preclinical and clinical development work.The anticipated work and clinical trials outlined above are subject to FDA allowance of the Investigator-Initiated IND filed byProvidence.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <b>         VisceralLesion Applicator        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <b>        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Weare developing our next-generation EP device and applicators, including advancements toward prototypes, pursuing discovery researchto identify other product candidates that, in addition to IL-12, can be encoded into propriety plasmid-DNA, delivered intratumorallyusing EP. Specifically, we are developing a new, propriety technology to potentially treat liver, lung, bladder, pancreatic andother difficult to treat visceral lesions through the direct delivery of plasmid-based IL-12 with a new Visceral Lesions Applicator(“VLA”).       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        TheVLA has been designed to work with low voltage EP generators including our new, APOLLO        <sup>         TM        </sup>        EP generator, which optimizesthe balance of lower voltage and longer pulse duration to significantly increase DNA-plasmid cellular transfection rates. Movingforward, we see significant opportunity to leverage this innovative technology to secure new partnerships that may allow us toexpand our capabilities and drive shareholder value.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Throughout2019 and 2020, we have successfully completed five large animal studies and aim to bring the VLA into the clinic during 2021.Preclinical data was presented in posters at the 2020 Society for Interventional Oncology (“SIO”) meeting, where itwas awarded “Best Technology Scientific Abstract”, and the 2020 Society for Interventional Radiology (“SIR”)meeting.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <!-- Field: Page; Sequence: 12; Value: 1 -->      <div style="margin-bottom: 6pt; border-bottom: Black 1.5pt solid">       <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">        <tbody>         <tr style="vertical-align: top; text-align: left">          <td style="text-align: center; width: 100%">           <!-- Field: Sequence; Type: Arabic; Name: PageNo -->           10           <!-- Field: /Sequence -->          </td>         </tr>        </tbody>       </table>      </div>      <div style="page-break-before: always; margin-top: 6pt">       <p style="margin: 0pt">       </p>      </div>      <!-- Field: /Page -->      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <b>         EmergeHealth Pty        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Wehave established a collaboration with Emerge Health Pty (“Emerge”), the leading Australian company providing fullregistration, reimbursement, sales, marketing and distribution services of therapeutic products in Australia and New Zealand,to commercialize TAVO and made it available under Australia’s Special Access Scheme (“SAS”) in early 2020. Asa specialized Australian pharmaceutical company focused on the marketing and sales of high-quality medicines to the hospital sector,Emerge has previously made numerous other products successfully available under Australia’s SAS.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <b>         OurOMS Electroporation Device        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Theeffectiveness of many drugs and DNA-based therapeutics is dependent upon their crossing the cell membrane. In the 1970s, it wasdiscovered that the brief application of high-intensity, pulsed electric fields to the cell resulted in a temporary and reversibleincrease in the permeability of the cell membrane, a mechanism known as “electroporation.”       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Thetransient, reversible nature of the electrical permeabilization of cell membranes and the resulting increase in intracellulardelivery of therapeutic agents is the underlying basis of our electroporation facilitated therapeutic approach. Our EP deliverysystem consists of an electrical generator, a reusable applicator handle and disposable tips. While the extent of membrane permeabilizationdepends on various electrical, physical, chemical, and biological parameters, research with EP delivery has demonstrated an improvementin cellular uptake of chemical molecules such as chemotherapeutic agents (e.g., bleomycin and cisplatin), and nucleic acids (e.g.,DNA and RNA).       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Multipleviral and non-viral delivery modalities have been developed to deliver nucleic acids into cells, however, many of these methodshave faced challenges related to the safe and efficient expression of the DNA-encoded biologic into the intended target cells.For example, viral mediated delivery technologies appear to be efficient at transfecting cells, but they have suffered from significantsafety issues related to the immunogenicity of the viral vector, shedding of the virus, and potential integration of the viralDNA into the host genome. Other non-viral delivery methods have employed the use of nanotechnology to coat the DNA with fat molecules,called lipids. Although these lipid nanoparticle technologies have been used extensively in the clinic to deliver DNA-encodedbiologic agents, few particles have been developed with the ability to specifically target cancer cells; instead, many of theseparticles naturally target the liver, which can lead to potential liver toxicities.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Likeviral vectors and lipid nanoparticle technologies, EP has been used extensively in the clinic to deliver multiple therapeuticagents, including DNA. However, unlike these other technologies, EP has not seen the same safety concerns. In fact, the use ofEP to deliver bleomycin intratumorally has been approved for use in Europe for cancers, such as basal cell carcinoma, and hasbeen accepted across many European countries, including the United Kingdom.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        OurOMS EP devices are designed to create favorable conditions to deliver plasmid DNA encoding immunotherapeutic cytokines directlyinto cells of the tumor microenvironment. The cytokine-encoding plasmid is first injected into the tumor. A needle-electrode arraythen delivers the electrical pulses produced in the pulse generator.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Ourlead product candidate, TAVO, consists of a plasmid construct encoding the proinflammatory cytokine IL-12 that is injected intothe tumor and delivered into the tumor cells through in vivo electroporation using our OMS EP device. We are also researchingother DNA-encoded, immunologically-active molecules, with an aim of developing additional immunotherapeutic drugs that, when deliveredusing our OMS EP device, may be capable of breaking the immune system’s tolerance to cancer.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <!-- Field: Page; Sequence: 13; Value: 1 -->      <div style="margin-bottom: 6pt; border-bottom: Black 1.5pt solid">       <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">        <tbody>         <tr style="vertical-align: top; text-align: left">          <td style="text-align: center; width: 100%">           <!-- Field: Sequence; Type: Arabic; Name: PageNo -->           11           <!-- Field: /Sequence -->          </td>         </tr>        </tbody>       </table>      </div>      <div style="page-break-before: always; margin-top: 6pt">       <p style="margin: 0pt">       </p>      </div>      <!-- Field: /Page -->      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <b>         Commercialization        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <i>         Strategy        </i>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Ourprimary focus is to continue our clinical development strategy for TAVO, including our planned and ongoing clinical trials discussedunder “Clinical Programs” above and potentially other trials we may pursue in the future.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Asa part of our commercialization strategy, we also regularly investigate and evaluate potential collaboration opportunities toidentify rational combinations with existing and emerging monoclonal antibody therapies and other drugs. For instance, we mayseek to collaborate with pharmaceutical or biotechnology companies to provide us with access to complementary technologies and/orgreater resources. In addition, we may seek to expand the applications of our technologies through strategic collaborations orother opportunities, such as in-licensing or strategic acquisitions, and we may seek to out-license our intellectual propertyto other companies to leverage our technologies for applications that we may not choose to internally and independently develop.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <i>        </i>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <i>         Manufacturingand Supply        </i>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Currently,we assemble and store certain components of our OMS Electroporation System, which is our proprietary delivery mechanism for ourTAVO product candidate, and we utilize the services of qualified contract manufacturers to make the remaining components of thissystem and for the manufacturing, testing, packaging and storage of our plasmid product candidate for clinical trials orother studies. The manufacture of our systems and product supplies requires significant expertise and capital investment, includingthe use of advanced manufacturing techniques and process controls. We do not own and have no plans to build our own clinical orcommercial Good Manufacturing Practices (“GMP”) manufacturing capabilities for any device, drug substance ordrug product. We expect to increase our reliance on third-party manufacturers.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Werely upon a small number of suppliers and manufacturers for our clinical activities. For manufacturing and distributing we useCryosite, PCI, Richter-Helm Biologics, VGXI, Baxter Oncology GmbH, SGS, Minnetronix and EG Medacys, which collectively accountfor approximately 90% of clinical materials and EP systems support and materials. We believe there are alternate sources of rawmaterial supply and finished goods manufacturing to satisfy our requirements, although transitioning to other vendors, if necessary,could result in significant delay or material additional costs. In addition, for combination trials, we typically rely exclusivelyon one supplier of the non-company-owned product used in the trial, such as our reliance upon Merck for the supply of KEYTRUDA®in the KEYNOTE-695 and KEYNOTE-890 studies.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Weare ISO 13485:2016 certified and comply with all appropriate standards and authorities for the assembly, manufacturing and activitieswe conduct, and we have established an audited quality management system for these activities. In addition, all contract manufacturersthat we use must comply with various requirements enforced by the FDA through its facilities inspection programs. See “Regulation”below for more information.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <b>         Competition        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Thebiotechnology industry is intensely competitive. This competitive environment stimulates an ongoing and extensive search for technologicalinnovation and necessitates effective and targeted marketing strategies to communicate the effectiveness, safety and value ofproducts to healthcare professionals in private practice and group practices and payors in managed care organizations, group purchasingorganizations, and Medicare and Medicaid services.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <!-- Field: Page; Sequence: 14; Value: 1 -->      <div style="margin-bottom: 6pt; border-bottom: Black 1.5pt solid">       <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">        <tbody>         <tr style="vertical-align: top; text-align: left">          <td style="text-align: center; width: 100%">           <!-- Field: Sequence; Type: Arabic; Name: PageNo -->           12           <!-- Field: /Sequence -->          </td>         </tr>        </tbody>       </table>      </div>      <div style="page-break-before: always; margin-top: 6pt">       <p style="margin: 0pt">       </p>      </div>      <!-- Field: /Page -->      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Weface competition from a number of sources, including large pharmaceutical companies, biotechnology companies, academic institutions,government agencies and private and public research institutions. We compete against all other developers of cancer treatments,including other immunotherapy treatments as well as other types of treatments for the cancer indications on which we are focused.In particular, a number of companies, some of which are large, well-established pharmaceutical companies, have development strategiessimilar to our current focus. These companies could include, among others, Bristol Myers-Squibb, Iovance Therapeutics, Syndax,Dynavax Technologies, Checkmate, Immunomedics and Idera Pharmaceuticals. In addition, we also compete with other clinical-stagebiotechnology companies for funding and support from healthcare and other investors and potential collaboration relationshipswith larger pharmaceutical or other companies, as well as for personnel with expertise in our industry. We are smaller and lesswell-funded than many of our competitors, and we have a shorter and less proven operating history and a less recognizable andestablished brand name than many of our competitors. In addition, some of our competitors have commercially available products,which provide them with operating revenue and other competitive advantages.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Ourcompetitors may obtain regulatory approval of their product candidates more rapidly than we can or may obtain more robust patentprotection or other intellectual property rights to protect their product candidates and technologies, which could limit or preventus from developing or commercializing our product candidates. If we are able to obtain regulatory approval of one or more of ourproduct candidates, we will face competition from approved products or products under development by larger companies that mayaddress our targeted indications. If we directly compete with these very large entities for the same markets and/or customers,their greater resources, brand recognition, sales and marketing experience and financial strength could prevent us from capturinga share of these markets or customers. Our competitors may also develop products that are more effective, more useful, bettertolerated, subject to fewer or less severe side effects, more widely prescribed, less costly or more widely accepted for otherreasons than any of our products that obtain regulatory approvals, and our competitors may also be more successful than us inmanufacturing, distributing and otherwise marketing their products.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Weexpect our product candidates, if approved and commercialized, to compete on the basis of, among other things, product efficacyand safety, time to market, price, coverage and reimbursement by third-party payors, extent of adverse side effects and convenienceof treatment procedures. We may not be able to effectively compete in any of these areas. Presently, we compete with other biotechnologycompanies for funding and support on the basis of our technology platforms and the potential value of our product candidates basedon the factors described above.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <b>         IntellectualProperty        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif">        Webelieve our success and ability to compete depends in large part on our ability to protect our proprietary rights and technologies,including obtaining and maintaining patent, trademark and trade secret protection of our product candidates and their respectivecomponents and underlying technologies, including devices, formulations, manufacturing methods and methods of treatment, and appropriatelysafeguarding unpatented proprietary rights, including trade secrets and know-how. As of October 2020, we owned 14 issued patents(3 U.S. and 11 foreign) and 58 pending patent applications (18 U.S. and 40 foreign). We are currently prosecuting pending patentapplications in various jurisdictions. One of our patent applications in the US, with claims directed to cytokine-based intratumoralimmunotherapies in combination with a checkpoint inhibitor, was issued on October 1, 2019. In April 2020, we received a decisionto grant for a European patent application with claims directed to an electroporation device having a central probe for administeringa therapeutic. Also in April 2020, we received a decision to grant for a European patent application with claims directed to electroporationof TAVO (IL-12)_in combination with a plasmid encoding an immune co-stimulator for use in the treatment of cancer. In addition,we have licensed intellectual property rights that allow us to use certain EP technology to deliver DNA-based cytokines as animmunotherapy, as well as catheter-based delivery devices. From these in-licensed portfolios, we have access to 78 issued U.S.and foreign issued patents (6 from USF, 14 from Gaeta Therapeutics, and 58 from Inovio Pharmaceuticals, Inc. (Inovio))and 14 U.S. and foreign pending patent applications (2 from USF, 4 from Gaeta Therapeutics, and 8 from Inovio). We expect to continueto file additional patent applications, if and when appropriate, as our research and development efforts continue. The majorityof the patents in our portfolio, including owned and in-licensed patents and fundamental patents directed toward our proprietarytechnology, expire between 2021 and 2040. We have previously obtained patent protection through an asset purchase agreement withInovio covering our original clinical electroporation device. The primary patents providing protection of this original devicehave expired. However, the Company has recently filed applications, in 2019 and 2020, on our next generation electroporation devicesand applicator handles and our next generation DNA-based cancer immunotherapeutics and will continue to file patent applicationsthis year.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <!-- Field: Page; Sequence: 15; Value: 1 -->      <div style="margin-bottom: 6pt; border-bottom: Black 1.5pt solid">       <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">        <tbody>         <tr style="vertical-align: top; text-align: left">          <td style="text-align: center; width: 100%">           <!-- Field: Sequence; Type: Arabic; Name: PageNo -->           13           <!-- Field: /Sequence -->          </td>         </tr>        </tbody>       </table>      </div>      <div style="page-break-before: always; margin-top: 6pt">       <p style="margin: 0pt">       </p>      </div>      <!-- Field: /Page -->      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Inaddition, we have entered into a cross-license agreement for certain electroporation technology with Inovio, including patentprotection for some of our clinical electroporation devices (some of which, as noted above, have recently expired or will soonexpire). Under the terms of the agreement, Inovio has granted us a non-exclusive, worldwide license under certain of its electroporationpatents, and in exchange, we have granted to Inovio an exclusive license to certain of our purchased technology in a limited fieldof use.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <b>         Regulation        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <b>         <i>          CommercializationApproval for our Product Candidates         </i>        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Biotechnologycompanies are subject to extensive, complex, costly and evolving government regulation relating to the ability to market and sellany therapeutic or medical device. In the United States, these regulations are principally enforced by the FDA and state governmentagencies. Outside the United States, these regulations are typically administered by various health authorities comparable tothe FDA in countries where products or product candidates are researched, tested, manufactured and/or marketed.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <i>         UnitedStates        </i>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <i>        </i>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <i>         General        </i>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Inthe United States, the federal Food, Drug and Cosmetic Act, or FDCA, other state statutes and regulations, many of which are administeredand enforced by the FDA, govern or influence, among other things, the research, development, testing, manufacturing, storage,record-keeping, approval, labeling, promotion, marketing, distribution, post-approval monitoring and reporting, sampling, importand export of product candidates such as ours. Under these regulations, we and our contract manufacturers may be subject to periodicinspection of our facilities, quality control and other procedures, and operations and/or the testing of our product candidatesduring and after the approval process for a product candidate, to confirm compliance with all applicable regulations, includingcurrent good manufacturing practices and other applicable requirements.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Possiblepenalties or other consequences for failure to comply with these regulatory requirements include, among others, observations,notices, citations and/or warning letters that could force us to modify our clinical programs or other activities; clinical holdson our ongoing clinical programs; adverse publicity from the FDA or others; the FDA’s suspension of its review of pendingapplications; fines; product recalls or seizures; total or partial suspension of production and/or distribution; labeling changes;withdrawal of previously granted product approvals; enforcement actions; injunctions and civil or criminal prosecution. Any suchsanctions, if imposed, could have a material adverse effect on our business, operating results and financial condition.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <i>         ApprovalProcess        </i>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Beforeany new drug, device or dosage form, including a new use of a previously approved drug or biologic, can be marketed in the UnitedStates, FDA approval is required. The process required by the FDA before a product may be marketed in the United States generallyinvolves, among other things:       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">       <tbody>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; width: 48px">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; width: 48px">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           ●          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           completion    of non-clinical testing;          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           ●          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           completion    of chemistry, manufacturing, and control testing, commonly known as CMC;          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           ●          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           submission    to the FDA of an investigational new drug application (“IND”) for human clinical testing, which must be    accepted and effective before human clinical trials may begin in the United States;          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           ●          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           performance    of adequate human clinical trials in accordance with good clinical practices to establish the safety and efficacy of the proposed    product for each intended use;          </font>         </td>        </tr>       </tbody>      </table>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <!-- Field: Page; Sequence: 16; Value: 1 -->      <div style="margin-bottom: 6pt; border-bottom: Black 1.5pt solid">       <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">        <tbody>         <tr style="vertical-align: top; text-align: left">          <td style="text-align: center; width: 100%">           <!-- Field: Sequence; Type: Arabic; Name: PageNo -->           14           <!-- Field: /Sequence -->          </td>         </tr>        </tbody>       </table>      </div>      <div style="page-break-before: always; margin-top: 6pt">       <p style="margin: 0pt">       </p>      </div>      <!-- Field: /Page -->      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">       <tbody>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; width: 48px">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; width: 48px">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           ●          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           for    a stand-alone medical device, submission to the FDA of a premarket approval application (“PMA”) or 510(k)    premarket notification, which the FDA must review and approve; and          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           ●          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           for    a therapeutic, submission to the FDA of a NDA or BLA which the FDA must review and approve.          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>       </tbody>      </table>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Thepre-clinical and clinical testing and approval process can take many years and requires substantial company time, effort and financialresources. The receipt and timing of approval, if any, is uncertain. The results of pre-clinical tests, together with certainmanufacturing information, analytical data and a proposed clinical trial protocol and other information, are submitted as partof an IND to the FDA. Once an IND is in effect, the protocol for each clinical trial to be conducted under the IND must be submittedto the FDA, which may or may not allow the trial to proceed. A separate submission to an existing IND must also be made for eachsuccessive clinical trial conducted during product development.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Clinicaltrials involve the administration of the investigational new drugs or biologics to human subjects under the supervision of qualifiedinvestigators in accordance with good clinical practice requirements. For purposes of an NDA or BLA submission and approval, humanclinical trials are typically conducted in the following sequential phases, which may overlap or be combined:       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">       <tbody>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; width: 48px">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; width: 48px">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           ●          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           <i>            Phase    1           </i>           : The product candidate is initially introduced to healthy human subjects or patients and tested for safety, dose tolerance,    absorption, metabolism, distribution and excretion and, if possible, to gain an early indication of its safety, tolerability    and effectiveness.          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           ●          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           <i>            Phase    2           </i>           : The product candidate is administered to a limited patient population to identify possible adverse effects and safety    risks, to preliminarily evaluate the efficacy of the product for specific targeted indications, and to determine dose tolerance    and optimal dosage. Multiple Phase 2 clinical trials may be conducted.          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           ●          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           <i>            Phase    3           </i>           : The product candidate is administered in an expanded patient population at multiple, geographically-dispersed clinical    trial sites, to obtain additional evidence of clinical efficacy and safety and to establish the overall risk-benefit relationship    of the product candidate.          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           ●          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           <i>            Phase    4           </i>           : In some cases, the FDA may condition approval of an NDA or BLA for a product candidate on the sponsor’s agreement    to conduct additional post-approval clinical trials to further assess the safety and efficacy of the drug or biologic.          </font>         </td>        </tr>       </tbody>      </table>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Theresults of product development, pre-clinical studies and clinical trials are submitted to the FDA as part of an NDA or BLA requestingapproval to market the product. NDAs or BLAs must also contain extensive information relating to the product’s pharmacology,chemistry, manufacture, controls, and proposed labeling, among other things.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Oncethe NDA or BLA submission has been accepted, the FDA begins an in-depth substantive review. Pursuant to the FDA’s performancegoals, NDA and BLA standard reviews are to be completed within 10 months, subject to extensions by the FDA. Before approving anNDA or BLA, the FDA often inspects the facility or facilities where the product is manufactured and will not approve an applicationunless it determines that the manufacturing processes and facilities are in compliance with good manufacturing practices. Additionally,the FDA will typically inspect one or more clinical sites to assure compliance with good clinical practices before approving anNDA or BLA. If the FDA determines that an NDA or BLA is not approvable, then the FDA may outline the deficiencies and often willrequest that additional information be provided or additional clinical trials be completed. Notwithstanding the submission ofany requested additional testing or information, the FDA ultimately may decide that the application does not satisfy the regulatorycriteria for approval.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <!-- Field: Page; Sequence: 17; Value: 1 -->      <div style="margin-bottom: 6pt; border-bottom: Black 1.5pt solid">       <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">        <tbody>         <tr style="vertical-align: top; text-align: left">          <td style="text-align: center; width: 100%">           <!-- Field: Sequence; Type: Arabic; Name: PageNo -->           15           <!-- Field: /Sequence -->          </td>         </tr>        </tbody>       </table>      </div>      <div style="page-break-before: always; margin-top: 6pt">       <p style="margin: 0pt">       </p>      </div>      <!-- Field: /Page -->      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Further,even if regulatory approval of a product candidate is obtained, such approval would specify the indicated uses for which the productmay be marketed. Additionally, we would be subject to pervasive and continuing regulation by the FDA with respect to any approvedproduct, including requirements related to, among other things, drug or device listing, record-keeping, periodic reporting, productsampling and distribution, manufacturing practices, labeling, advertising, promotion, and reporting of adverse events associatedwith any approved products. Moreover, we could be required to conduct post-approval studies, such as Phase 4 clinical trials,or surveillance programs to monitor the safety of any approved products. FDA has the authority to stop or limit further marketingof a product or impose more stringent labeling restrictions based on the results of these post-approval programs or in the eventof any unexpected or serious health or safety concern regarding any approved product.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <i>         Non-U.S.Regulation        </i>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Ifwe pursue research and/or commercialization activities for our product candidates outside the United States, we would need toobtain necessary approvals from the regulatory authorities comparable to the FDA in applicable jurisdictions before we could commenceclinical trials or marketing of our product candidates in these jurisdictions. In addition, we would become subject to a varietyof foreign regulations regarding safety and efficacy of our product candidates and governing, among other things, clinical trials,commercial activities, manufacture and distribution of our product candidates. The requirements to obtain product approvals varywidely from country to country, and the FDA’s approval requirements, review procedures and timelines may not be the sameas or even similar to the requirements or a comparable foreign regulator. As a result, even if we obtain regulatory approval fora product candidate in one country, we may be required to undertake additional clinical trials or studies, submit additional information,wait for longer review periods or make other efforts in order to obtain regulatory approvals in other desirable geographic markets.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <b>         <i>          HealthcareLaws and Regulations         </i>        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Thehealthcare industry is heavily regulated, constantly evolving and subject to significant change and fluctuation. The U.S. federaland state healthcare laws and regulations that currently impact our business include, among others:       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">       <tbody>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           ●          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           the    laws and regulations administered and enforced by the FDA, including the FDCA, and other federal statutes and regulations,    discussed above;          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           ●          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           the    federal Patient Protection and Affordable Care Act as amended by the Health Care and Education Reconciliation Act, referred    to collectively as the Affordable Care Act, which, in general and among other things, expands the government’s investigative    and enforcement authority, including requiring pharmaceutical companies to record and disclose to government agencies any    transfers of value to doctors and teaching hospitals, and increases the penalties for fraud and abuse, including amendments    to the federal False Claims Act and the Anti-Kickback Statute to make it easier to bring suits under these statutes;          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           ●          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           the    federal Anti-Kickback Statute, which generally prohibits, among other things, soliciting, receiving or providing remuneration    to induce the referral of an individual for an item or service or the purchasing or ordering of an item or service for which    payment may be made under federal healthcare programs, such as the Medicare and Medicaid programs;          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           ●          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           the    federal false claims laws, which generally prohibit, among other things, knowingly presenting or causing to be presented claims    for payment from Medicare, Medicaid or other third-party payors that are false or fraudulent;          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           ●          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           the    federal Health Insurance Portability and Accountability Act of 1986, or HIPAA, as amended by the federal Health Information    Technology for Economic and Clinical Health Act, or HITECH, which, in general and among other things, establish comprehensive    federal standards with respect to the privacy, security and transmission of individually identifiable health information and    impose requirements for the use of standardized electronic transactions with respect to transmission of such information;    and          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           ●          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           analogous    state and foreign laws and regulations, such as anti-kickback and false claims laws that may apply to items or services reimbursed    by any third-party payor, including commercial insurers, and state laws governing the privacy and security of health information    in certain circumstances, many of which differ from each other in significant ways and may not be preempted by applicable    federal laws, thus complicating compliance efforts.          </font>         </td>        </tr>       </tbody>      </table>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <!-- Field: Page; Sequence: 18; Value: 1 -->      <div style="margin-bottom: 6pt; border-bottom: Black 1.5pt solid">       <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">        <tbody>         <tr style="vertical-align: top; text-align: left">          <td style="text-align: center; width: 100%">           <!-- Field: Sequence; Type: Arabic; Name: PageNo -->           16           <!-- Field: /Sequence -->          </td>         </tr>        </tbody>       </table>      </div>      <div style="page-break-before: always; margin-top: 6pt">       <p style="margin: 0pt">       </p>      </div>      <!-- Field: /Page -->      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Additionally,the healthcare compliance environment is continuously changing, with proposed revisions to or replacement of the Affordable CareAct at the federal level and with some states mandating implementation of compliance programs, compliance with industry ethicscodes, spending limits and reporting to state governments of gifts, compensation and other remuneration to physicians. Further,to the extent we continue to pursue operations in foreign countries, such as our clinical activities in Australia, or in Canada,or if we seek to sell any product that obtains regulatory approval in a foreign country, we would be subject to different reportingand other compliance requirements in multiple jurisdictions, including foreign laws and regulations comparable to the U.S. lawsand regulations described above.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Allof these laws impose penalties for non-compliance, some of which may be severe. If we or our operations are found to be in violationof any of these laws or any other governmental regulations that apply to us, we may be subject to civil or criminal penalties,fines or other monetary damages or orders forcing us to curtail or restructure our operations.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <b>         <i>          OtherRegulatory Requirements and Environmental Matters         </i>        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Weare or may become subject to various laws and regulations regarding laboratory practices and the experimental use of animals,as well as environmental laws and regulations governing, among other things, any use and disposal by us of hazardous or potentiallyhazardous substances in connection with our research. In each of these areas, the FDA and other government agencies have broadregulatory and enforcement powers, including, among other things, the ability to levy fines and civil penalties, suspend or delayissuance of approvals, seize or recall products and withdraw approvals.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Inaddition, to the extent we continue to pursue operations in foreign jurisdictions, we will be subject to anti-bribery laws inthe United States and applicable foreign jurisdictions, including the U.S. Foreign Corrupt Practices Act, or FCPA, and comparableforeign laws. Further, we are subject to a variety of laws and regulations relating to other matters, including workplace healthand safety, labor and employment, public reporting and taxation, among others, and our failure to comply with these laws and regulationsmay result in a variety of administrative, civil and criminal enforcement measures, including monetary penalties or impositionof sanctions or other corrective requirements.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <b>        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <b>         RecentEvents        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <b>        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        OnAugust 16, 2020, we completed a registered direct offering for the issuance and sale of 4,608,589 shares of our common stock,at an offering price of $3.25 per share. Aggregate gross proceeds from the offering were approximately $15 million, and net proceedsreceived after deducting placement agent fees and offering expenses were approximately $13.7 million.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <!-- Field: Page; Sequence: 19; Value: 1 -->      <div style="margin-bottom: 6pt; border-bottom: Black 1.5pt solid">       <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">        <tbody>         <tr style="vertical-align: top; text-align: left">          <td style="text-align: center; width: 100%">           <!-- Field: Sequence; Type: Arabic; Name: PageNo -->           17           <!-- Field: /Sequence -->          </td>         </tr>        </tbody>       </table>      </div>      <div style="page-break-before: always; margin-top: 6pt">       <p style="margin: 0pt">       </p>      </div>      <!-- Field: /Page -->      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <b>        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <b>         OurTeam        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Oursenior management team and board of directors have decades of experience, each demonstrating a strong track record of successin the biotechnology and pharmaceutical industries, including in research and development, commercialization and financing activities.In addition, we have assembled a clinical and regulatory team experienced in developing and advancing novel therapeutic approachesthrough clinical testing and regulatory approvals, including extensive technical, manufacturing, analytical and quality experienceto oversee our clinical, manufacturing and testing activities. Our team consists of a relatively small number of employees, aswell as consultants and advisors regarding research and development, regulatory, compliance, healthcare and investor and publicrelations matters. We also expect to engage experts in healthcare and in general business to advise us in various capacities.For instance, we have in the past consulted with various oncology researchers and clinicians to provide counsel as part of ouradvisory panels for our clinical programs, and we expect to continue to establish consulting and advisory relationships with scientific,clinical and medical experts in academia and industry to assist us with FDA submissions, clinical testing and identification anddevelopment of new product candidates.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Asof July 31, 2020, we had a total of 46 employees, including 42 full-time employees and four part-time employees. None of our employeesare represented by a labor union or covered by a collective bargaining agreement, and we believe that our relations withour employees are good.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <b>        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <b>         CorporateInformation        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Wewere incorporated under the laws of the State of Nevada in February 2008 under the name Netventory Solutions Inc. to pursue thebusiness of inventory management solutions. In March 2011, we completed a merger with our subsidiary to change our name to “OncoSecMedical Incorporated,” and we commenced operations as a biotechnology company upon our acquisition of assets from Inoviorelated to the use of drug-medical device combination products for the treatment of various cancers. Our principal executive officesare located at 24 North Main Street, Pennington, NJ 08534 and 3565 General Atomics Court, Suite 100, San Diego, California 92121.The telephone number for our principal executive offices is (855) 662-6732. Our website address is www.oncosec.com. Informationcontained on our website is not, and should not be considered, part of this report. We will make available free of charge throughour website our annual reports on Form 10-K, quarterly reports on Form 10-Q and current reports on Form 8-K, and any amendmentsto these reports, as soon as reasonably practicable after we electronically file such material with, or furnish such materialto, the Securities and Exchange Commission, or SEC. We are not including the information on our website as a part of, nor incorporatingit by reference into, this report. Additionally, the SEC maintains a website that contains annual, quarterly, and currentreports, proxy statements, and other information that issuers (including us) file electronically with the SEC. The SEC’swebsite address is http://www.sec.gov/.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Inaddition, we intend to use our media and investor relations website, SEC filings press releases, public conference calls and webcastsas wells as social media to communicate with our subscribers and the public about the Company, its services and other issues.It is possible that the information we post on social media could be deemed to be material information. Therefore, in light ofthe SEC’s guidance, we encourage investors, the media and others interested in the Company to review the information wepost on the U.S. social media channels listed on our website.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <!-- Field: Page; Sequence: 20; Value: 1 -->      <div style="margin-bottom: 6pt; border-bottom: Black 1.5pt solid">       <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">        <tbody>         <tr style="vertical-align: top; text-align: left">          <td style="text-align: center; width: 100%">           <!-- Field: Sequence; Type: Arabic; Name: PageNo -->           18           <!-- Field: /Sequence -->          </td>         </tr>        </tbody>       </table>      </div>      <div style="page-break-before: always; margin-top: 6pt">       <p style="margin: 0pt">       </p>      </div>      <!-- Field: /Page -->      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif">        <a name="b_004">        </a>        <font style="font-size: 10pt; text-transform: uppercase">         <b>          ITEM1A. RISK FACTORS         </b>        </font>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <i>         Investingin our securities involves a high degree of risk. You should carefully consider each of the following risks, together with theother information contained in this report and the other documents we file with the SEC before making any investment decisionwith respect to our securities. If any of the risks described below materialize, our business, financial condition, prospectsand/or operating results could be materially and adversely affected. These factors could cause the trading price of our commonstock to decline, and you could lose all or a substantial part of your investment. The risks described below are not the onlyrisks we face. Additional risks and uncertainties not currently known to us may also materially and adversely affect our businessoperations and financial condition or the price of our common stock.        </i>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <b>         RisksRelated to Our Business        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <b>         <i>          Ourmajority stockholder may have significant influence over the outcome of matters submitted to our stockholders for approval, whichmay prevent us from engaging in certain transactions.         </i>        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Asthe date hereof, one shareholder owns approximately 43% of the Company’s common stock. As a result, this stockholder mayexercise significant influence over all matters requiring stockholder approval, including the appointment of our directors andthe approval of significant corporate transactions. This ownership and control may also have the effect of delaying or preventinga future change in control, impeding a merger, consolidation, takeover or other business combination that may be in the best interestof the Company and any other stockholders.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <b>         <i>          Wehave never generated, and may never generate, revenue from our operations.         </i>        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Wehave not generated any revenue from our operations since our inception, and we do not anticipate generating meaningful revenuein the near term. During our fiscal year ended July 31, 2020, we incurred a net loss of approximately $42.3 million, and frominception through July 31, 2020, we have incurred an aggregate net loss of approximately $207 million. We will need significantadditional funding to continue our operations and pursue our strategic plans, including continued development of our ImmunoPulse®IL-12. Although we have been and expect to continue to tightly manage our operating expenses, we expect our operating expenseswill continue to increase as we further our development activities and pursue FDA approval for one or more of our product candidates.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Becauseof the numerous risks and uncertainties associated with our product development and planned commercialization efforts, many ofwhich are discussed in these risk factors, we are unable to predict the extent of our future losses or when or if we will generatemeaningful revenue or become profitable, and it is possible we will never achieve these goals. Our failure to develop our investmentsin our proprietary technologies and product candidates into revenue-generating operations would have a material adverse effecton our business, results of operations, financial condition, and prospects and could result in our inability to continue operations.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <b>         <i>          Wehave limited working capital and a history of losses, which raises substantial doubt as to whether we will be able to continueas a going concern.         </i>        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Ourauditor’s report on our financial statements for the year ended July 31, 2020 includes a going concern paragraph. The Companyhas never generated any cash from its operations and does not expect to generate such cash in the near term. As a result, theCompany has suffered recurring losses and requires significant cash resources to execute its business plans. These losses areexpected to continue for an extended period of time. The aforementioned factors raise substantial doubt about the Company’sability to continue as a going concern within one year from the date of filing. The accompanying financial statements have beenprepared on a going concern basis, which contemplates the realization of assets and the satisfaction of liabilities in the normalcourse of business. The financial statements do not include any adjustments relating to the recoverability and classificationof asset amounts or the classification of liabilities that might be necessary should the Company be unable to continue as a goingconcern within one year after the date the financial statements are issued.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <!-- Field: Page; Sequence: 21; Value: 1 -->      <div style="margin-bottom: 6pt; border-bottom: Black 1.5pt solid">       <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">        <tbody>         <tr style="vertical-align: top; text-align: left">          <td style="text-align: center; width: 100%">           <!-- Field: Sequence; Type: Arabic; Name: PageNo -->           19           <!-- Field: /Sequence -->          </td>         </tr>        </tbody>       </table>      </div>      <div style="page-break-before: always; margin-top: 6pt">       <p style="margin: 0pt">       </p>      </div>      <!-- Field: /Page -->      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Ourability to obtain additional financing will depend on a number of factors, including, among others, our ability to generate positivedata from our clinical and pre-clinical studies, the condition of the capital markets and the other risks described in these riskfactors. If any one of these factors is unfavorable, we may not be able to obtain additional funding, in which case, our businesscould be jeopardized and we may not be able to continue our operations or pursue our strategic plans. If we are forced to scaledown, limit or cease operations, our stockholders could lose all of their investment in our Company.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <b>         <i>          Wewill need to raise additional capital to continue operating our business, and additional funds may not be available when needed,on acceptable terms or at all.         </i>        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Asof July 31, 2020, we had cash and cash equivalents of approximately $20.4 million and, as of that date, we estimated our cashrequirements for the following 12 months to be approximately $28 million. We do not generate any cash from our operations.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Historically,we have raised the majority of the funding for our business through offerings of our common stock and warrants to purchase ourcommon stock. We are exploring other ways of funding our operations that involve less dilution to our existing stockholders, including,among others, technology licensing or other collaboration arrangements, debt financings or grants. We may need to continue toseek funding for our operations through additional dilutive public or private equity financings.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Ifwe issue equity or convertible debt securities to raise additional funds, our existing stockholders would experience further dilution,and the new equity or debt securities may have rights, preferences and privileges senior to those of our existing stockholders.If we incur debt, our fixed payment obligations, liabilities and leverage relative to our equity capitalization would increase,which could increase the cost of future capital. Further, the terms of any debt securities we issue or borrowings we incur, ifavailable, could impose significant restrictions on our operations, such as limitations on our ability to incur additional debtor issue additional equity or other operating restrictions that could adversely affect our ability to conduct our business, andany such debt could be secured by any or all of our assets pledged as collateral. Additionally, we may incur substantial costsin pursuing future capital, including investment banking, legal and accounting fees, printing and distribution expenses and othercosts.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Moreover,equity or debt financings or any other source of capital may not be available to us when needed or at all, or, if available, maynot be available on commercially reasonable terms. Weak economic and capital market conditions generally or uncertain conditionsin our industry could increase the challenges we face in raising capital for our operations. In recent periods, the capital andfinancial markets for early and development-stage biotechnology and life science company stocks have been volatile and uncertain.If we cannot raise the funds that we need, we could be forced to delay or scale down some or all of our development activitiesor cease all operations, and our stockholders could lose all of their investment in our Company.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <b>         <i>         </i>        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <b>         <i>          Weare a clinical-stage company with a limited operating history and no approved products, which makes assessment of our future viabilitydifficult and which may hinder our ability to generate revenue and meet our other objectives.         </i>        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Weare a clinical-stage, pre-commercial company with only a limited operating history upon which to base an evaluation of our currentbusiness and future prospects and how we will respond to competitive, financial or technological challenges. Excluding the SASprogram under the Emerge agreement, none of our product candidates are commercially available. Additionally, although we are investigatinglicensing and partnering opportunities, no such opportunities have been finalized and, even if completed, we do not expect thatthese potential opportunities would generate any significant near-term revenue. Our operations to date have been limited to organizing,staffing and financing, applying for patent rights, undertaking clinical trials of TAVO-EP and engaging in other research anddevelopment activities, including pre-clinical and other clinical studies of our other product candidates. We have not demonstratedan ability to obtain regulatory approval of a product candidate, or conduct the sales and marketing activities necessary for successfulproduct commercialization. Consequently, the revenue-generating potential of our business is unproven and uncertain.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <!-- Field: Page; Sequence: 22; Value: 1 -->      <div style="margin-bottom: 6pt; border-bottom: Black 1.5pt solid">       <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">        <tbody>         <tr style="vertical-align: top; text-align: left">          <td style="text-align: center; width: 100%">           <!-- Field: Sequence; Type: Arabic; Name: PageNo -->           20           <!-- Field: /Sequence -->          </td>         </tr>        </tbody>       </table>      </div>      <div style="page-break-before: always; margin-top: 6pt">       <p style="margin: 0pt">       </p>      </div>      <!-- Field: /Page -->      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Inaddition, we have limited insight into trends that may emerge and affect our business or our industry. We will be subject to therisks, uncertainties and difficulties frequently encountered by clinical-stage companies in evolving markets, and we may not beable to successfully address any or all of these risks and uncertainties. Further, errors may be made in predicting and reactingto relevant business or industry trends. The occurrence of any of these risks could cause our business, results of operations,and financial condition to suffer or fail.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <b>         <i>          Weare significantly dependent on the success of our ImmunoPulse® technology platform and our product candidates basedon this platform, including our lead product candidate TAVO.         </i>        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Wehave invested, and we expect to continue to invest, significant efforts and financial resources in the development of productcandidates based on our electroporation technology, including primarily our lead product candidate TAVO. Our ability to generatemeaningful revenue, which may not occur for the foreseeable future, if ever, will depend heavily on the successful development,regulatory approval and commercialization of one or more of these product candidates, and such regulatory approval and commercializationmay never occur. We are working on the commercial version of the OMS Electroporation Device which is currently being used inthe KEYNOTE-695 trial so that it complies with current regulatory standards as a prerequisite for FDA clearance. We anticipateusing this version of the OMS Electroporation Device in KEYNOTE-695 or in an expansion cohort of approximately 25 patients toenable our plan to file for accelerated approval. We are currently seeking FDA concurrence to use this updated version in theongoing trial. We anticipate that we will also need to have clinical experience with this device before we seek regulatoryapproval for our product candidate. If we experience delays in completion of this work or FDA approval in using the modernizedOMS Electroporation Device in our ongoing clinical trials, it could delay our clinical programs, necessitate enrolling more patientsin our ongoing clinical trials, the commercialization our product candidate and have a material adverse effect on our business,results of operations, financial condition and prospects.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Thesuccess of TAVO our OMS Electroporation Devices or any other product candidates based on our electroporation technology will dependon a number of factors, including, among others:       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">       <tbody>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; width: 48px">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; width: 48px">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           ●          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           our    ability to conduct and complete pre-clinical and clinical studies and trials, including the time, costs and uncertainties    associated with all aspects of these trials;          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           ●          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           the    data we obtain from pre-clinical and clinical testing of the product candidates, including data demonstrating the required    level of safety and efficacy of the product candidates (for example, a key factor in determining whether we are able to successfully    develop and commercialize TAVO in melanoma will be the data we obtain from our  KEYNOTE-695 study, which is our ongoing    study of TAVO in combination with Merck’s approved therapy for melanoma in patients who have shown resistance to or    relapse from certain other cancer therapies);          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           ●          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           the    regulatory approval pathway we choose to pursue for our product candidates in the United States of America or any other jurisdiction;          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           ●          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           our    ability to obtain required regulatory approvals for one or more of our product candidates in the United States and in other    jurisdictions, and the time required to obtain these approvals, if they are ever obtained;          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           ●          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           the    manufacturing arrangements we are able to establish with third-party manufacturers, both for the manufacture of the product    candidates for clinical trial use and for the potential commercial manufacture of products, if and when approved;          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           ●          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           our    ability to build an infrastructure capable of supporting product sales, marketing and distribution of any approved products    in territories where we pursue commercialization directly;          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           ●          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           our    ability to establish commercial distribution agreements with third-party distributors for any approved products in territories    where we do not pursue commercialization directly;          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           ●          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           the    labeling requirements for any product candidates that are approved, including obtaining sufficiently broad labels that would    not unduly restrict our ability to market the product;          </font>         </td>        </tr>       </tbody>      </table>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <!-- Field: Page; Sequence: 23; Value: 1 -->      <div style="margin-bottom: 6pt; border-bottom: Black 1.5pt solid">       <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">        <tbody>         <tr style="vertical-align: top; text-align: left">          <td style="text-align: center; width: 100%">           <!-- Field: Sequence; Type: Arabic; Name: PageNo -->           21           <!-- Field: /Sequence -->          </td>         </tr>        </tbody>       </table>      </div>      <div style="page-break-before: always; margin-top: 6pt">       <p style="margin: 0pt">       </p>      </div>      <!-- Field: /Page -->      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">       <tbody>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; width: 48px">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; width: 48px">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           ●          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           acceptance    of our products, if and when approved, by patients and the medical community;          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           ●          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           the    ability of our products, if and when approved, to effectively compete with other cancer treatments;          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           ●          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           a    continued acceptable safety profile for any product candidates that are approved following such approval;          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           ●          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           our    level of success in obtaining and maintaining patent and trade secret protection and otherwise protecting our rights in our    intellectual property portfolio;          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           ●          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           the    levels of coverage and reimbursement we are able to secure for any product candidates that receive regulatory approval;          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           ●          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           our    ability to establish a commercially viable price for our products, if and when approved; and          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           ●          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           delays    or unanticipated costs, including those related to any of the foregoing.          </font>         </td>        </tr>       </tbody>      </table>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Ifone or more of these factors is unfavorable, we could experience significant delays or we may not be able to successfully commercializeTAVO or any of our other product candidates, which would materially harm our business.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <b>         <i>          Wemay not be successful in our efforts to identify or discover additional product candidates and may fail to capitalize on programsor product candidates that may present a greater commercial opportunity or for which there is a greater likelihood of success.         </i>        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Thesuccess of our business depends upon our ability to identify, develop and commercialize product candidates based on our programs.If we do not successfully develop and eventually commercialize products, we will face difficulty in obtaining product revenuein future periods, or may never obtain such revenue, resulting in significant harm to our financial position and adversely affectingour share price. Research programs to identify new product candidates require substantial technical, financial and human resources.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Additionally,because we have limited resources, we may forego or delay pursuit of opportunities with certain programs or product candidatesor for indications that later prove to have greater commercial potential. Our estimates regarding the potential market for a productcandidate could be inaccurate, and our spending on current and future research and development programs may not yield any commerciallyviable products. If we do not accurately evaluate the commercial potential for a particular product candidate, we may relinquishvaluable rights to that product candidate through strategic collaboration, licensing or other arrangements in cases in which itwould have been more advantageous for us to retain sole development and commercialization rights to such product candidate. Alternatively,we may allocate internal resources to a product candidate in a therapeutic area in which it would have been more advantageousto enter into a partnering arrangement.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Ifany of these events occur, we may be forced to abandon or delay our development efforts with respect to a particular product candidateor fail to develop a potentially successful product candidate, which could have a material adverse effect on our business, financialcondition, results of operations and prospects.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <b>         <i>          Itmay be difficult to identify and enroll patients due to clinical trial inclusion-exclusion criteria or other factors, which hasin the past, and may in the future, lead to delays in enrollment and in generating clinical data for our trials.         </i>        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Ourclinical trials have had, and may have in the future, strict inclusion criteria for patient enrollment. These criteria could presentsignificant obstacles to the timely recruitment and enrollment of a sufficient number of eligible patients into our trials. Wemay experience slower than expected patient enrollment in our existing or future clinical trials. Any inability to successfullyenroll the number of patients meeting the criteria for any of our clinical trials could cause significant delays in the trialand increase the costs associated with the trial, which could materially harm our business and prospects.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <!-- Field: Page; Sequence: 24; Value: 1 -->      <div style="margin-bottom: 6pt; border-bottom: Black 1.5pt solid">       <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">        <tbody>         <tr style="vertical-align: top; text-align: left">          <td style="text-align: center; width: 100%">           <!-- Field: Sequence; Type: Arabic; Name: PageNo -->           22           <!-- Field: /Sequence -->          </td>         </tr>        </tbody>       </table>      </div>      <div style="page-break-before: always; margin-top: 6pt">       <p style="margin: 0pt">       </p>      </div>      <!-- Field: /Page -->      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Patientenrollment in a clinical trial may be affected by many factors, including:       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">       <tbody>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; width: 48px">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; width: 48px">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           ●          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           the    severity of the disease under investigation;          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           ●          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           the    design of the study protocol;          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           ●          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           the    eligibility criteria for the study;          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           ●          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           the    perceived risks, benefits and convenience of administration of the product candidate being studied;          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           ●          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           the    novel 2019 coronavirus (“COVID-19”);          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           ●          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           the    competitive disease space with many trials for patients to select from; and          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           ●          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           the    proximity and availability of clinical trial sites to prospective patients.          </font>         </td>        </tr>       </tbody>      </table>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <b>         <i>         </i>        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <b>         <i>          Businessor economic disruptions or global health concerns could seriously harm our development efforts and increase our costs and expenses.         </i>        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <b>         <i>         </i>        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Broad-basedbusiness or economic disruptions could adversely affect our ongoing or planned research and development or clinical activities.For example, in December 2019 an outbreak of a novel strain of coronavirus originated in Wuhan, China, and has since spread toa number of other countries, including the United States. To date, this outbreak has already resulted in extended shutdowns ofcertain businesses in the Wuhan region and has had ripple effects to businesses around the world. The outbreak may result in additionalor more extensive travel restrictions, closures, disruptions of businesses or facilities in China or other affected regions aroundthe world or lead to social, economic, political or labor instability in the affected areas may impact our suppliers’ orour customers’ operations.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Globalepidemics, such as the coronavirus, could also negatively affect the hospitals and clinical sites in which we conduct any of ourclinical trials, which could have a material adverse effect on our business and our results of operations and financial condition.We cannot presently predict the scope and severity of any potential business shutdowns or disruptions, but if we or any of thethird parties with whom we engage, including the suppliers, clinical trial sites, regulators and other third parties with whomwe conduct business, were to experience shutdowns or other business disruptions, our ability to conduct our business in the mannerand on the timelines presently planned could be materially and negatively impacted.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <b>         <i>          Certaincharacteristics of our ImmunoPulse® platform may negatively impact market acceptance of the platform.         </i>        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Physicians,patients, and third-party payors may be less accepting of product candidates based on our ImmunoPulse® technology platformdue to certain characteristics of this platform. For example, these parties may have concerns about the complexity inherent ina combination therapy approach or the clinical application of electroporation technology, which is less prevalent in the UnitedStates than in certain foreign markets. Moreover, our efforts to educate the medical community and third-party payors about thebenefits of any of our technologies and product candidates may require significant resources and may never be successful. As aresult, even if any of our product candidates achieve regulatory approval, a lack of acceptance by physicians, third-party payorsand patients of the products or underlying technologies could prevent their successful commercialization and could materiallylimit our revenue potential.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt; background-color: white">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <b>         <i>         </i>        </b>       </font>      </p>      <!-- Field: Page; Sequence: 25; Value: 1 -->      <div style="margin-bottom: 6pt; border-bottom: Black 1.5pt solid">       <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">        <tbody>         <tr style="vertical-align: top; text-align: left">          <td style="text-align: center; width: 100%">           <!-- Field: Sequence; Type: Arabic; Name: PageNo -->           23           <!-- Field: /Sequence -->          </td>         </tr>        </tbody>       </table>      </div>      <div style="page-break-before: always; margin-top: 6pt">       <p style="margin: 0pt">       </p>      </div>      <!-- Field: /Page -->      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <b>         <i>         </i>        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt; background-color: white">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <b>         <i>          Ourbusiness and operations could be adversely affected by the effects of health epidemics, including the ongoing COVID-19 pandemic.         </i>        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt; background-color: white">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt; background-color: white">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Ouroperational and financial performance have already been affected by the impact of the COVID-19 pandemic. Our clinical trials haveexperienced delays in patient enrollment, potentially due to prioritization of hospital resources toward the COVID-19 pandemic,or concerns among patients about participating in clinical trials during a public health emergency. The COVID-19 pandemic is alsoaffecting the operations of government entities, such as the FDA, as well as contract research organizations, third-party manufacturers,and other third-parties upon whom we rely. As a result of “shelter-in-place” orders, quarantines or similar ordersor restrictions to control the spread of COVID-19, many companies, including our own, have implemented work-from-home policiesfor their employees. The effects of these stay at home orders and work-from-home policies may be negatively impacting productivity,resulting in delays in our clinical programs and timelines. The extent of the impact on our operations depends in part on thetime these restrictions remain in place, and whether restrictions are reinstated as a result of a rising surge in COVID-19 cases.These and similar disruptions in our operations could negatively impact our business, operating results and financial condition.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt; background-color: white">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt; background-color: white">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Thespread of COVID-19 has also led to disruption and volatility in the global capital markets, which increases the cost of, and adverselyimpacts access to, capital and increases economic uncertainty. To the extent the COVID-19 pandemic adversely affects our business,financial results and value of our common stock, it may also affect our ability to access capital and obtain financing, whichcould in the future negatively affect our liquidity and ability to continue as a going concern.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt; background-color: white">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt; background-color: white">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Theglobal pandemic of COVID-19 continues to evolve rapidly, and the ultimate impact of the COVID-19 pandemic or a similar healthepidemic is highly uncertain and subject to change. We do not yet know the full impact of potential delays or effects on our business,our clinical trials, our ability to access the capital markets, or supply chains or on the global economy as a whole. However,these effects could have a material impact on our operations, and we will continue to monitor the COVID-19 situation closely.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <b>         <i>          Ifthe commencement or completion of clinical testing for our product candidates is delayed or prevented, we could experience significantlyincreased costs and our ability to pursue regulatory approval or generate revenue could be delayed or limited.         </i>        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Clinicaltrials are very expensive, time-consuming, unpredictable and difficult to design and implement. Even if we are able to completeour ongoing and currently proposed clinical trials and assuming the results are favorable, clinical trials for product candidatesbased on our technology are planned to continue for several years and may take significantly longer than expected to complete.Even with the Fast Track designation we received from the FDA for TAVO in metastatic melanoma in February 2017, additional clinicaltrials, which can take years to complete, are still required.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Delaysin the commencement or completion of clinical testing could significantly affect our product development costs and business plan.We do not know and cannot predict whether any of our ongoing or planned trials or studies will be completed on schedule or atall. We also do not know and cannot predict whether any other pre-clinical or clinical trials, including Phase 3 clinical trialsto follow completion of our ongoing or any other Phase 2 clinical trials, will be planned or will begin, and in many cases suchfuture trials would be dependent on obtaining favorable results from preceding studies.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Thecommencement and completion of clinical trials can be delayed or prevented for many reasons, including due to delays or issuesrelated to:       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">       <tbody>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; width: 48px">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; width: 48px">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           ●          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           obtaining    clearance or approval from the FDA or a comparable international regulatory body and other applicable agencies, including    the U.S. National Institutes of Health, to commence a clinical trial;          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           ●          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           reaching    agreement on acceptable terms with prospective clinical research organizations, or CROs, clinical investigators and trial    sites;          </font>         </td>        </tr>       </tbody>      </table>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <!-- Field: Page; Sequence: 26; Value: 1 -->      <div style="margin-bottom: 6pt; border-bottom: Black 1.5pt solid">       <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">        <tbody>         <tr style="vertical-align: top; text-align: left">          <td style="text-align: center; width: 100%">           <!-- Field: Sequence; Type: Arabic; Name: PageNo -->           24           <!-- Field: /Sequence -->          </td>         </tr>        </tbody>       </table>      </div>      <div style="page-break-before: always; margin-top: 6pt">       <p style="margin: 0pt">       </p>      </div>      <!-- Field: /Page -->      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">       <tbody>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; width: 48px">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; width: 48px">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           ●          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           obtaining    institutional review board, or IRB, and institutional biological committee, or IBC, approval to initiate and conduct a clinical    trial at a prospective site;          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           ●          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           identifying,    recruiting and training suitable clinical investigators;          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           ●          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           identifying,    recruiting and enrolling subjects to participate in clinical trials, which can pose challenges for a variety of reasons, including    competition from other clinical trial programs for similar indications, requirements for larger than anticipated patient populations,    slower than expected enrollment, or higher than predicted rates of patient drop-out or withdrawal;          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           ●          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           natural    disaster, epidemics, pandemics, political crisis (such as terrorism, war, political instability or other conflict), or other    events outside of our control;          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           ●          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           retaining    patients who have initiated a clinical trial but who may be prone to withdraw due to side effects from the therapy, lack of    efficacy, personal issues, death or for any other reason, or who are lost to further follow-up; and          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           ●          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           identifying    and maintaining a sufficient supply of necessary products or product candidates, including those produced by third parties,    on commercially reasonable terms.          </font>         </td>        </tr>       </tbody>      </table>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Withrespect to any clinical trial we plan, the FDA could determine it is not satisfied with our plan or the details of our clinicaltrial protocols and designs and could put a clinical hold on the proposed trials, or issue a clinical holder after a trial hascommenced. Any such determination could delay the commencement or completion of the trials and would be a setback for the commercializationstrategy for the product candidate that is the subject of the trial. Additionally, changes in applicable regulatory requirementsand guidance may occur, in which case clinical trial protocols may need to be amended to reflect these changes. Any such amendmentscould require us to resubmit our clinical trial protocols to IRBs or IBCs for reexamination, which could impact the costs, timingand successful completion of a clinical trial. If we experience delays in completion of, or if we terminate, any of our ongoing,planned or future clinical trials, the commercial prospects for our product candidates could be harmed, which could have a materialadverse effect on our business, results of operations, financial condition and prospects.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <b>         <i>          Tothe extent we conduct clinical trials of our product candidates in combination with third parties’ products, we will faceadditional risks relating to these products.         </i>        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Tothe extent our commercialization strategy includes the combination of our product candidates with third parties’ productsor product candidates, we will likely be required to conduct clinical studies to evaluate the combinations. We have several ongoingand planned combination trials, and these combination studies involve additional risks due to their reliance on circumstancesoutside our control, such as those relating to the availability and marketability of the third-party product involved in the study.If the marketability of third-party products such as KEYTRUDA® is impacted, or if we are unable to secure and maintain a sufficientsupply of such third-party products when needed on commercially reasonable terms, our clinical studies could be delayed or wecould be forced to terminate these studies. Such a delay or termination could have a material negative impact on our developmentstrategy, business, results of operations, financial condition, and prospects.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <!-- Field: Page; Sequence: 27; Value: 1 -->      <div style="margin-bottom: 6pt; border-bottom: Black 1.5pt solid">       <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">        <tbody>         <tr style="vertical-align: top; text-align: left">          <td style="text-align: center; width: 100%">           <!-- Field: Sequence; Type: Arabic; Name: PageNo -->           25           <!-- Field: /Sequence -->          </td>         </tr>        </tbody>       </table>      </div>      <div style="page-break-before: always; margin-top: 6pt">       <p style="margin: 0pt">       </p>      </div>      <!-- Field: /Page -->      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <b>         <i>         </i>        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <b>         <i>          Ifserious adverse or unacceptable side effects are identified during the development of one or more of our product candidates orany future product candidate, we may need to address any serious safety concerns as part of ongoing or post-marketing surveillanceefforts; otherwise we may need to modify, limit or discontinue development efforts related to some of our product candidates.         </i>        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Establishingthe safety of a new product is one of the principal objectives of any clinical trial. Adverse events, including serious adverseevents, suspected adverse reactions, and unexpected adverse events, and their proper reporting, form the basis of the criticalrisk-benefit analysis of investigational drug therapies. If adverse events are identified during the development of one or moreof our product candidates or any future product candidates, we may need to address any serious safety concerns as part of ongoingor post market surveillance efforts. Alternatively, we may need to modify, limit or discontinue the development of these productcandidates to more narrow uses or subpopulations in which the adverse events, undesirable side effects or other characteristicsare less prevalent, less severe or more acceptable from a risk-benefit perspective. In the development of new and investigationaldrug therapies in this industry, many compounds that initially showed promise in early stage testing have later been associatedwith adverse events, including serious adverse events that have subsequently prevented further development of the compound. Itis not uncommon for an adverse event to be encountered during a clinical trial. Upon discovery of an adverse event, sponsors aregenerally required to investigate this event in order to determine whether there is enough evidence to suggest that there wasa reasonable possibility that the drug caused the adverse event.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Inthe event that adverse events, including serious adverse events, suspected adverse reactions, and unexpected adverse events areidentified during any of our clinical trials, these trials could be modified, limited, suspended or terminated. Such adverse eventsmay trigger a notification requirement to the FDA or comparable foreign regulatory authorities, who in turn could order us tocease further development or deny approval of one or more of our product candidates or any future product candidates for any orall targeted indications. The FDA could also issue a letter requesting additional data or information prior to making a finaldecision regarding whether or not to approve a product candidate. The number of requests for additional data or information issuedby the FDA in recent years has increased and has resulted in substantial delays in the approval of several new drugs. Adverseevents or undesirable side effects caused by one or more of our product candidates or any future product candidates could alsoresult in the inclusion of unfavorable information in our product labeling, such as a Black Box warning, or denial of regulatoryapproval by the FDA or other regulatory authorities for any or all targeted indications, and in turn prevent us from commercializingand generating market acceptance and revenues from the sale of that product candidate. Adverse events or side effects could affectpatient recruitment or the ability of enrolled patients to complete the trial and could result in potential product liabilityclaims.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Nomatter how extensive clinical trials and premarket studies may be, the safety profile of a new therapeutic product can only befully characterized by continuing safety surveillance through a spontaneous adverse event monitoring system and a post-marketingsurveillance study. FDA may require post-marketing testing, known as Phase 4 testing, risk evaluation and mitigation strategies,and surveillance to monitor the effects of an approved product or place conditions on an approval that could restrict the distributionor use of the product. Regulatory authorities may withdraw product approvals or request product recalls if a company fails tocomply with regulatory standards, if it encounters problems following initial marketing, or if previously unrecognized problemsare subsequently discovered. It well understood in the drug development process that drug safety can never be considered an absolute,since the safety profile of a new therapeutic product will continue to evolve as more and more information is generated, gathered,and assessed.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Additionally,if one or more of our product candidates or any future product candidates receive marketing approval and we or others later identifyundesirable side effects caused by this product, a number of potentially significant negative consequences could result, including:       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">       <tbody>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; width: 72px">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; width: 24px">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           ●          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           regulatory    authorities may require the addition of unfavorable labeling statements, including specific warnings, black box warnings,    adverse reactions, precautions, and/or contraindications;          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           ●          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           regulatory    authorities may suspend or withdraw their approval of the product, and/or require it to be removed from the market;          </font>         </td>        </tr>       </tbody>      </table>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <!-- Field: Page; Sequence: 28; Value: 1 -->      <div style="margin-bottom: 6pt; border-bottom: Black 1.5pt solid">       <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">        <tbody>         <tr style="vertical-align: top; text-align: left">          <td style="text-align: center; width: 100%">           <!-- Field: Sequence; Type: Arabic; Name: PageNo -->           26           <!-- Field: /Sequence -->          </td>         </tr>        </tbody>       </table>      </div>      <div style="page-break-before: always; margin-top: 6pt">       <p style="margin: 0pt">       </p>      </div>      <!-- Field: /Page -->      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">       <tbody>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; width: 72px">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; width: 24px">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           ●          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           we    may be required to change the way the product is administered, conduct additional clinical trials or change the labeling of    the product; or          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           ●          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           our    reputation may suffer.          </font>         </td>        </tr>       </tbody>      </table>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.25in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Anyof these events could prevent us from achieving or maintaining market acceptance of any of our product candidates or any futureproduct candidates, or could substantially increase our commercialization costs and expenses, which in turn could delay or preventus from generating significant revenues, or any revenues, from its sale.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <b>         <i>         </i>        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <b>         <i>          Werely on third parties to conduct our clinical trials and other studies, and if these third parties do not successfully carry outtheir duties or meet expected deadlines, we may not be able to obtain regulatory approval for or commercialize our product candidatesand our business could be substantially harmed.         </i>        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Wehave entered into, and expect to continue to enter into, agreements with third-party CROs to help us manage critical aspects ofthe clinical trials we sponsor. We rely on these third parties for the execution of certain of our clinical and pre-clinical studies,and we only control certain aspects of their activities. We and our CROs are required to comply with the FDA’s regulationsfor conducting clinical trials and good clinical practice, as well as the guidelines of the International Conference on Harmonizationof Technical Requirements for Registration of Pharmaceuticals for Human Use. We are also required to harmonize standard operatingprocedures between companies and conduct periodic internal and vendor audits to ensure compliance. Additionally, the FDA and comparableforeign regulators enforce these good clinical practice regulations through periodic inspections of trial sponsors, principalinvestigators, trial sites, laboratories and other entities involved in the completion of the study protocol and processing ofdata.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Ifwe or our CROs fail to comply with applicable good clinical practice or other regulations, the data generated in our clinicaltrials may be deemed unreliable and/or the FDA or comparable foreign regulators may refuse to accept the data, and these regulatorsmay require us to perform additional or repeat clinical trials, which could significantly increase costs and delay the regulatoryapproval process. Additionally, repeated compliance failures could prompt the FDA or other regulatory authority to suspend orterminate a clinical trial, which could cause significant approval delays and increased costs. Further, if CROs do not otherwisesuccessfully carry out their contractual duties or obligations or meet expected deadlines or if the quality or accuracy of theclinical data they obtain is compromised for any reason, our clinical trials may need to be extended, delayed or terminated orwe may not be able to rely on the data produced by the trials. Moreover, if any of our relationships with third-party CROs terminatebefore completion of a clinical trial, we may not be able to establish arrangements with alternative CROs on commercially reasonableterms, on a timely basis or at all, which could materially delay or jeopardize the trial. Any such occurrence could delay or preventus from obtaining regulatory approval for our product candidates or successfully commercializing our product candidates, whichcould increase our costs, delay or eliminate our prospects for generating revenue, and otherwise materially harm the results ofour operations, financial condition and prospects.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <b>         <i>         </i>        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <b>         <i>          Werely on clinical data and results obtained by third parties that could ultimately prove to be inaccurate or unreliable.         </i>        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Aspart of the strategy implemented to mitigate development risk, we seek to develop product candidates with well-studied mechanismsof action and we utilize biomarkers to assess potential clinical efficacy early in the development process. This strategy necessarilyrelies upon clinical data and other results produced or obtained by third parties, which may ultimately prove to be inaccurateor unreliable. If the third party data and results we rely upon prove to be inaccurate, unreliable or not applicable to our productcandidates, we could make inaccurate assumptions and conclusions about the product candidates, and our research and developmentefforts could be compromised and called into question for any marketing applications we submit.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <!-- Field: Page; Sequence: 29; Value: 1 -->      <div style="margin-bottom: 6pt; border-bottom: Black 1.5pt solid">       <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">        <tbody>         <tr style="vertical-align: top; text-align: left">          <td style="text-align: center; width: 100%">           <!-- Field: Sequence; Type: Arabic; Name: PageNo -->           27           <!-- Field: /Sequence -->          </td>         </tr>        </tbody>       </table>      </div>      <div style="page-break-before: always; margin-top: 6pt">       <p style="margin: 0pt">       </p>      </div>      <!-- Field: /Page -->      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <b>         <i>         </i>        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <b>         <i>          Wemay be subject to claims that our consultants or independent contractors have wrongfully used or disclosed to us alleged tradesecrets of their other clients or former employers.         </i>        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Asis common in the biopharmaceutical industry, we engage the services of consultants to assist in the development of product candidates.Many of these consultants were previously employed at or may have previously been or are currently providing consulting servicesto, other pharmaceutical companies, including our competitors or potential competitors. We may become subject to claims relatedto whether these consultants have inadvertently or otherwise used or disclosed trade secrets or other proprietary informationof their former employers or their former or current customers. Litigation may be necessary to defend against these claims. Evenif we are successful in defending these claims, litigation could result in substantial costs and be a distraction to management.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <b>         <i>         </i>        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <b>         <i>          Wehave participated in, and continue to participate in, clinical trials conducted under an approved investigator-sponsored investigationalnew drug application, and we have little or no control over the conduct or timing of, or FDA communications regarding, these trials.         </i>        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Wehave participated in and continue to participate in clinical trials conducted under an approved investigator-sponsored investigationalnew drug, (IND), application. We also have plans to participate in future investigator-sponsored trials under both INDs and InvestigationalDevice Exemptions (IDEs), since our product candidates are drug-device combination products. In investigator-initiated trials,the investigator typically designs and implements the study and the investigator or its institution acts as the sponsor of thetrial. This trial has control over the design, conduct and timing of the trial, and as a result, we have limited or no controlover the commencement, conduct and completion of these investigator-initiated trials. In addition, regulations and guidelinesimposed by the FDA with respect to INDs and IDEs include a requirement that the sponsor of a clinical trial perform the studyin accordance with an approved investigational plan, and provide ongoing communication with the FDA as it pertains to the safetyof the drug, device, or treatment being tested. It is the responsibility of the investigator, as the sponsor of the trial, tobe the sole point of contact with the FDA for these communications and to exercise all decision-making authority regarding theseor other submissions to the FDA about the trial. Consequently, we may have little or no control over the content or timing ofthese communications, including whether they are timely, accurate or complete. Any failures by the investigator sponsoring thesetrials could result in reviews, audits, delays or clinical holds by the FDA that could negatively affect the timelines for thesetrials or jeopardize their completion. As a result, our lack of control over the conduct and timing of, and communications withthe FDA regarding, these investigator-sponsored trials expose us to additional risks, many of which are outside of our controland the occurrence of which could severely harm our performance and the commercial prospects for our product candidates.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <b>         <i>          Regulatoryauthorities may not approve our product candidates, or any approvals we achieve may be too limited or too late for us to earnmeaningful, or any, revenue.         </i>        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Theresearch, testing, and possible eventual manufacturing, labeling, approval, selling, marketing and distribution of our productcandidates are subject to extensive regulation by the FDA and other regulatory authorities in the United States, as well as comparableregulatory bodies in other countries. These regulatory agencies have the authority to delay approval of or refuse to approve ourproduct candidates for a variety of reasons, including, among others, the occurrence of adverse reactions or a failure to meetsafety and efficacy endpoints in our clinical trials or otherwise to the satisfaction of the regulator, disapproval of our orour partners’ trial design, or disagreement with our interpretation of data from pre-clinical studies or clinical trials.As a result, even if our product candidates achieve their endpoints in clinical trials, they still may not be approved by anyof these regulatory agencies. Moreover, the requirements to obtain product approvals vary widely from country to country, andthe FDA’s approval requirements, review procedures and timelines may not be the same as or even similar to the requirementsof a comparable foreign regulator. As a result, even if we obtain regulatory approval for a product candidate in one country,we may be required to undertake additional clinical trials or studies, submit additional information, wait for longer review periodsor make other efforts in order to obtain regulatory approvals in other desirable geographic markets, or may not be able to achieveapproval in those other desirable geographic markets.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <!-- Field: Page; Sequence: 30; Value: 1 -->      <div style="margin-bottom: 6pt; border-bottom: Black 1.5pt solid">       <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">        <tbody>         <tr style="vertical-align: top; text-align: left">          <td style="text-align: center; width: 100%">           <!-- Field: Sequence; Type: Arabic; Name: PageNo -->           28           <!-- Field: /Sequence -->          </td>         </tr>        </tbody>       </table>      </div>      <div style="page-break-before: always; margin-top: 6pt">       <p style="margin: 0pt">       </p>      </div>      <!-- Field: /Page -->      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Althoughwe have seen no systemic drug-related adverse events in our trials and studies to date, if we cannot adequately demonstrate throughthe clinical trial process that a product candidate we are developing is safe and effective, regulatory approval of that productcandidate may never be achieved, which could impair our reputation, increase our costs and delay or prevent us from generatingrevenue. Importantly, success in pre-clinical testing and early clinical studies does not ensure that later clinical trials willgenerate adequate data to demonstrate the required level of efficacy and safety of an investigational drug. A number of companiesin the pharmaceutical and biotechnology industries, including many with greater resources and experience than we have, have sufferedsignificant setbacks in clinical trials, even after obtaining promising results in Phase 2, and earlier studies. Further, evenif a product candidate is approved, it may be approved for fewer or more limited indications than requested, may include substantialsafety warnings or the approval may be subject to the performance of significant post-marketing studies. In addition, regulatoryagencies may not approve the labeling claims that are necessary or desirable for the successful commercialization of our productcandidates. Any limitation, condition or denial of approval could have an adverse effect on our business, reputation and resultsof operations.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Furthermore,because of the substantial competition we face, even if we are ultimately able to achieve regulatory approval for one or moreof our product candidates, delays in such regulatory approval could delay, limit or prevent our ability to successfully commercializeour product candidates if competing products obtain approvals before ours and gain market traction against which we are not ableto compete. Moreover, we may be forced to reevaluate our development strategies and plans in the face of setbacks or other delaysthat could jeopardize the value of any regulatory approval that is obtained, which could include abandoning planned clinical trialefforts for a product candidate that we no longer believe has promising value as a commercial product. If we are not able to obtainor maintain required regulatory approvals for our product candidates or if we decide or are forced to abandon our efforts to obtainor maintain these approvals, we would have expended significant costs on assets that may never generate any return. Such an outcomewould have a material adverse effect on our business, results of operations and financial condition, as well as on our continuedviability as a company.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <b>         <i>         </i>        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <b>         <i>          Wewill need to obtain FDA approval of any proposed product brand names, and any failure or delay associated with such approval mayadversely impact our business.         </i>        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Apharmaceutical product cannot be marketed in the U.S. or other countries until we have completed a rigorous and extensiveregulatory review process, including approval of a brand name. Any brand names we intend to use for our product candidates inthe U.S. will require approval from the FDA regardless of whether we have secured a formal trademark registration fromthe U.S. Patent and Trademark Office (“PTO”). The FDA typically conducts a review of proposed productbrand names, including an evaluation, for example, of potential for confusion with other product names. The FDA may also objectto a product brand name if it believes the name implies inappropriate promotional claims. If the FDA objects to any of our proposedproduct brand names, we may be required to adopt an alternative brand name for our product candidates. If we adopt an alternativebrand name, we would lose the benefit of our existing trademark applications for such product candidate and may be required toexpend significant additional resources in an effort to identify a suitable product brand name that would qualify under applicabletrademark laws, not infringe the existing rights of third parties and be acceptable to the FDA. We may be unable to build a successfulbrand identity for a new trademark in a timely manner or at all, which would limit our ability to commercialize our product candidates.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <b>         <i>          Ourin-licensed intellectual property may not provide us with sufficient rights and may not prevent competitors from pursuing similartechnology.         </i>        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Inaddition to our owned proprietary rights, we have also exclusively licensed certain patents and patent applications that coverour current and future clinical platforms. These patents will expire between 2024 and 2032. These method patents protect the useof a product for a specified method under certain defined parameters. This type of patent does not prevent a competitor from makingand marketing a product that is identical or similar to the protected product under parameters that are outside the scope of thepatented method claims. Moreover, even if competitors do not actively promote such a product for the indications protected bythe method patent, physicians could prescribe the products for these methods on an off-label basis. Although such off-label prescriptionsmay infringe or contribute to the infringement of method-of-use patents, the practice is common and such infringement is difficultto detect, prevent or prosecute.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <!-- Field: Page; Sequence: 31; Value: 1 -->      <div style="margin-bottom: 6pt; border-bottom: Black 1.5pt solid">       <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">        <tbody>         <tr style="vertical-align: top; text-align: left">          <td style="text-align: center; width: 100%">           <!-- Field: Sequence; Type: Arabic; Name: PageNo -->           29           <!-- Field: /Sequence -->          </td>         </tr>        </tbody>       </table>      </div>      <div style="page-break-before: always; margin-top: 6pt">       <p style="margin: 0pt">       </p>      </div>      <!-- Field: /Page -->      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="margin: 0; font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif">        Weentered into a cross-license agreement with Inovio in 2011 for certain electroporation technology, which includes among otherthings, patents protecting our OMS Electroporation Device. Under the terms of the agreement, Inovio granted us a non-exclusive,worldwide license under certain of its electroporation patents, and in exchange, we granted to Inovio an exclusive license tocertain aspects of our technology in a limited field of use. However, with the expiration of patents in 2020, no patents acquiredby OncoSec under the agreement and licensed to Inovio remain active.  Although we do not currently rely on the technologycovered by the intellectual property licensed from Inovio, our product candidates could in the future utilize this technology. This license is non-exclusive. As such, Inovio could use the technology to compete with us or other competitors could usethe technology that was covered by the intellectual property to compete with us.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Weentered into a license agreement with Gaeta Therapuetics in May 2019. Under the license, we obtained exclusive worldwide rightsto Gaeta Therapeutics’ broad portfolio of patents and applications covering the combination use of IL-12 protein or DNAand various checkpoint inhibitor therapies, including anti-CTLA-4 and anti-PD-1 compounds, in key global markets. Although wedo not currently rely on the intellectual property we have licensed from Gaeta, our product candidates could in the future utilizethis intellectual property. The in-licensing of this portfolio provides patent protection on our current clinical methods in certaincountries until at least 2032 and also gives us the potential to block others utilizing IL-12 in combination with various checkpointinhibitors, which may not be part of our current clinical platform.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Ifwe are not able to maintain our existing in-licenses or if we are not able to establish new in-licenses for any other third-partyrights we need, we could become subject to significant costs or royalty or other fees to establish alternative license arrangements,if such licenses are available when needed, on acceptable terms or at all, or we could be forced to develop modifications to theaffected product candidates or technologies to avoid reliance on the third-party rights, if such modifications are possible. Ifthere is any conflict, dispute, disagreement or issue of non-performance between us and the respective licensing partner regardingthe rights or obligations under the license agreements, including any conflict, dispute or disagreement arising from a failureto satisfy payment obligations under such agreements, the ability to develop and commercialize the affected product candidatemay be adversely affected. Any inability to secure and maintain adequate rights to any third-party technologies necessary forthe development of our product candidates could severely limit our continued research and development activities, our effortsto obtain product approvals and, if such approvals are obtained, our ability to commercialize the approved products, any of whichwould materially adversely impact our business and prospects.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <b>         <i>          Wemay become involved in litigation or other proceedings in our efforts to protect our patent and other intellectual property rights,which could require significant time and costs and would be subject to unpredictable outcomes.         </i>        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Wemay become aware of activities by third parties, including our competitors, that infringe our issued patents or other intellectualproperty rights. If we choose to file a lawsuit against a potentially infringing third party to try to enforce our patents orother intellectual property rights, the third party may seek a ruling that the patents are invalid and/or should not be enforced.Such a ruling could severely limit our ability to protect our rights from use by third parties. Further, patent law is a constantlyevolving body of law, and changes can affect our rights and our ability to execute on our strategy and our financial results.In the past several years, the U.S. Supreme Court has revised certain tests regarding assessing the validity of patents, whichcould result in the invalidation of issued patents and/or their claims based on the application of the current patent validitystandards. As a result, in the event of any patent infringement litigation or other proceedings involving our patents, our patentscould be subject to challenge and subsequent invalidation or significant narrowing of claim scope under the current standards.Moreover, even if the validity of our patents is upheld in a patent infringement lawsuit, a court could refuse to stop a thirdparty’s activities on the grounds that the activities do not infringe the specific claims of our patents. Further, evenif we were successful in stopping the infringing activity, patent infringement lawsuits are expensive and could consume significanttime, management attention, capital and other resources. Any claims we assert against accused infringers could provoke these partiesto assert counterclaims against us alleging that we infringe their patents; or provoke those parties to petition the United StatesPatent and Trademark Office, or USPTO, to institute        <i>         inter partes        </i>        review against the asserted patents, which may lead toa finding that all or some of the claims of the patent are invalid.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <!-- Field: Page; Sequence: 32; Value: 1 -->      <div style="margin-bottom: 6pt; border-bottom: Black 1.5pt solid">       <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">        <tbody>         <tr style="vertical-align: top; text-align: left">          <td style="text-align: center; width: 100%">           <!-- Field: Sequence; Type: Arabic; Name: PageNo -->           30           <!-- Field: /Sequence -->          </td>         </tr>        </tbody>       </table>      </div>      <div style="page-break-before: always; margin-top: 6pt">       <p style="margin: 0pt">       </p>      </div>      <!-- Field: /Page -->      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Theserisks of third parties’ infringement of our intellectual property rights may increase if we engage in discussions, collaborationsor other strategic arrangements with third parties. Also, new challenges could arise if and to the extent we pursue engagementswith third parties located outside the United States. These factors could increase the risks and costs associated with buildingand protecting our intellectual property portfolio and could adversely affect our performance and our business prospects. Despiteefforts to protect our proprietary information during such discussions, third parties may unintentionally or willfully discloseor convert our proprietary information, including our trade secrets, and we may not be able to obtain adequate remedies for suchbreaches.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <b>         <i>         </i>        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <b>         <i>          Thirdparties may claim that we infringe their proprietary rights, which could prevent us from pursuing our clinical and other studiesand other research and development activities.         </i>        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Thevalidity and infringement of patents or proprietary rights of third parties has been the subject of substantial litigation inthe biotechnology industry. In the course of our research and development activities, we could become subject to legal claimsthat we, our activities or our product candidates or technologies infringe the rights of others. This type of patent infringementlitigation is costly and time-consuming and diverts the attention of management and technical personnel. In addition, if we orour product candidates or technologies are found to infringe the rights of others, we could lose our ability to continue our developmentprograms or could be forced to pay monetary damages. Although the parties to patent and intellectual property disputes in thebiotechnology industry have often settled their disputes by establishing licenses or similar arrangements, the costs associatedwith these arrangements may be substantial and could include ongoing royalties. Furthermore, any such licenses may not be availablewhen needed, on commercially reasonable terms or at all. These risks may be amplified due to our small size and limited experienceand resources relative to many of our competitors. As a result, any claims of infringement against us, adverse determination ina judicial or administrative proceeding or failure to obtain necessary licenses could materially delay, hinder or restrict ourdevelopment efforts or prevent us from continuing to pursue our operational and strategic plans, which could have a material adverseeffect on our business, prospects and results of operations.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Publicationsof discoveries in the scientific literature often lag behind the actual discoveries, and patent applications in the U.S. and otherjurisdictions are typically not published until 18 months after a first filing, or in some cases not at all. Therefore, we cannotknow with certainty whether we or our licensors were the first to make the inventions claimed in patents or pending patent applicationsthat we own or licensed, or that we or our licensors were the first to file for patent protection of such inventions. In the eventthat a third party has also filed a U.S. patent application relating to our product candidates or a similar invention, dependingupon the priority dates claimed by the competing parties, we may have to participate in interference proceedings declared by thePTO to determine priority of invention in the U.S. The costs of these proceedings could be substantial, and it is possiblethat our efforts to establish priority of invention would be unsuccessful, resulting in a material adverse effect on our U.S.patent position. As a result, the issuance, scope, validity, enforceability and commercial value of our patent rights are highlyuncertain.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <b>         <i>          Ifwe fail to comply with environmental, health and safety laws and regulations, we could become subject to fines or penalties orincur costs that could harm our business; even if we comply with such laws and regulations, they may result in higher costs forus in the form of higher raw material, energy, freight and compliance costs.         </i>        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Weare subject to numerous environmental, health and safety laws and regulations, including those governing laboratory proceduresand the handling, use, storage, treatment and disposal of hazardous materials and wastes. Our operations involve the use of hazardousand flammable materials, including chemicals and biological materials. Our operations also produce hazardous waste products. Wegenerally contract with third parties for the disposal of these materials and wastes. We cannot eliminate the risk of contaminationor injury from these materials. Although we believe that the safety procedures for handling and disposing of these materials complywith the standards prescribed by these laws and regulations, we cannot eliminate the risk of accidental contamination or injuryfrom these materials. In the event of contamination or injury resulting from our use of hazardous materials, we could be heldliable for any resulting damages, and any liability could exceed our resources. We also could incur significant costs associatedwith civil or criminal fines and penalties for failure to comply with such laws and regulations.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <!-- Field: Page; Sequence: 33; Value: 1 -->      <div style="margin-bottom: 6pt; border-bottom: Black 1.5pt solid">       <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">        <tbody>         <tr style="vertical-align: top; text-align: left">          <td style="text-align: center; width: 100%">           <!-- Field: Sequence; Type: Arabic; Name: PageNo -->           31           <!-- Field: /Sequence -->          </td>         </tr>        </tbody>       </table>      </div>      <div style="page-break-before: always; margin-top: 6pt">       <p style="margin: 0pt">       </p>      </div>      <!-- Field: /Page -->      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Althoughwe maintain workers’ compensation insurance to cover us for costs and expenses we may incur due to injuries to our employeesresulting from the use of hazardous materials, this insurance may not provide adequate coverage against potential liabilities.We do not maintain insurance for environmental liability or toxic tort claims that may be asserted against us in connection withour storage or disposal of biological, hazardous or radioactive materials.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Inaddition, we may incur substantial costs in order to comply with current or future environmental, health and safety laws and regulations.These current or future laws and regulations may impair our research, development or production efforts. Our failure to complywith these laws and regulations also may result in substantial fines, penalties or other sanctions. Increased environmental legislationor regulation could also result in higher costs for us in the form of higher raw materials, as well as energy and freight costs.It is possible that certain materials might cease to be permitted to be used in our processes. We could also incur additionalcompliance costs for monitoring and reporting emissions and for maintaining permits.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <b>         <i>          Thebiotechnology industry is highly competitive, and many of our competitors are significantly larger and more experienced than weare.         </i>        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Thebiotechnology industry is intensely competitive. This competitive environment stimulates an ongoing and extensive search for technologicalinnovation and necessitates effective and targeted marketing strategies to communicate the effectiveness, safety and value ofproducts to healthcare professionals in private practice and group practices and payors in managed care organizations, group purchasingorganizations, and Medicare and Medicaid services.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Weface competition from a number of sources, including large pharmaceutical companies, biotechnology companies, academic institutions,government agencies and private and public research institutions. We compete against all other developers of cancer treatments,including other immunotherapy treatments as well as other types of treatments for the cancer indications on which we are focused.In particular, a number of companies, some of which are large, well-established pharmaceutical companies, have development strategiessimilar to our current focus. These companies could include, among others, Bristol Myers-Squibb, Iovance Therapeutics, Syndax,Dynavax Technologies, Checkmate Pharmaceuticals and Idera Pharmaceuticals. In addition, we also compete with other clinical-stagebiotechnology companies for funding and support from healthcare and other investors and potential collaboration relationshipswith larger pharmaceutical or other companies, as well as for personnel with expertise in our industry. We are smaller, less experiencedand less well-funded than many of our competitors, and we have a shorter and less proven operating history and a less recognizableand established brand name than many of our competitors. In addition, some of our competitors have commercially available products,which provide them with operating revenue and other competitive advantages. Furthermore, recent trends in the biotechnology industryare for large drug companies to acquire smaller outfits and consolidate into a smaller number of very large entities, which furtherconcentrates financial, technical, and market strength and increases competitive pressure in the industry.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Ourcompetitors may obtain regulatory approval of their product candidates more rapidly than we can or may obtain more robust patentprotection or other intellectual property rights to protect their product candidates and technologies, which could limit or preventus from developing or commercializing our product candidates. If we are able to obtain regulatory approval of one or more of ourproduct candidates, we would face competition from approved products or products under development by larger companies that mayaddress our targeted indications. If we directly compete with these very large entities for the same markets and/or customers,their greater resources, brand recognition, sales and marketing experience and financial strength could prevent us from capturinga share of these markets or customers. Our competitors may also develop products that are more effective, more useful, bettertolerated, subject to fewer or less severe side effects, more widely prescribed, less costly or more widely accepted for otherreasons than any of our products that might obtain regulatory approvals, and our competitors may also be more successful thanus in manufacturing, distributing and otherwise marketing their products.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <!-- Field: Page; Sequence: 34; Value: 1 -->      <div style="margin-bottom: 6pt; border-bottom: Black 1.5pt solid">       <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">        <tbody>         <tr style="vertical-align: top; text-align: left">          <td style="text-align: center; width: 100%">           <!-- Field: Sequence; Type: Arabic; Name: PageNo -->           32           <!-- Field: /Sequence -->          </td>         </tr>        </tbody>       </table>      </div>      <div style="page-break-before: always; margin-top: 6pt">       <p style="margin: 0pt">       </p>      </div>      <!-- Field: /Page -->      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Weexpect our product candidates, if approved and commercialized, to compete on the basis of, among other things, product efficacyand safety, time to market, price, coverage and reimbursement by third-party payors, extent of adverse side effects and convenienceof treatment procedures. We may not be able to effectively compete in any of these areas, or we may be prevented from being ableto compete at all in these areas due to the performance of our products during clinical trials and/or the circumstances of anapproval. Presently, we compete with other biotechnology companies for funding and support on the basis of our technology platformsand the potential value of our product candidates based on the factors described above.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Ifwe are unable to compete effectively, our business, results of operations, financial condition, and prospects may be materiallyadversely affected.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <b>         <i>         </i>        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <b>         <i>          Wemay incur liability if our presentations of information regarding our product candidates are determined, or are perceived, tobe inconsistent with regulatory requirements or guidelines.         </i>        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        TheFDA provides guidelines regarding appropriate presentation of product information and continuing medical and health educationactivities. Even though we do not have any FDA approved products, these guidelines apply to our current activities with respectto disclosures, presentations or other communications about our product candidates and technologies at healthcare conferencesor in other forums. Although we endeavor to follow these guidelines, the FDA, the Office of the Inspector General of the U.S.Department of Health and Human Services, or the Department of Justice could disagree, in which case we could be subject to significantliability, including civil and administrative remedies as well as criminal sanctions. In addition, management’s attentioncould be diverted and our reputation could be damaged, any of which could materially harm our business and prospects.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <b>         <i>         </i>        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <b>         <i>          Ifwe and our contract manufacturers fail to produce our systems and product candidates in the volumes and within the timelines werequire, or if they fail to comply with applicable regulations, we could face delays in the development and commercializationof our equipment and product candidates.         </i>        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Currently,we assemble certain components of our EP system, which is our proprietary delivery mechanism for our TAVO product candidate, andwe utilize the services of contract manufacturers to manufacture the remaining components of these systems and for the manufacture,testing and storage of all of our supply of our plasmid product candidate for clinical trials or other studies. Except for thefacility used to assemble certain components of our electroporation system, we do not own and have no plans to build our own clinicalor commercial manufacturing capabilities, and we expect to increase our reliance on third-party manufacturers if and when we commercializeany of our product candidates and systems.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Themanufacture of our systems and product supplies requires significant expertise and capital investment, including the use of advancedmanufacturing techniques and process controls. Manufacturers often encounter difficulties in production, particularly in scalingup for commercial production if regulatory approvals are obtained. These difficulties include, among others: problems with productioncosts and yields; quality control issues, including qualification of the equipment, stability of product candidates and compliancewith testing requirements; shortages of qualified personnel; and compliance with strictly enforced federal, state and foreignregulations. If we or our manufacturers were to encounter any of these difficulties or our manufacturers otherwise fail to complywith their contractual obligations to us, our ability to provide our electroporation equipment to our partners and product candidatesto patients enrolled in our clinical trials, or to commercially launch a product if regulatory approvals are obtained, would bejeopardized. Any delay or interruption in the supply of clinical trial supplies could delay the completion of our clinical trials,increase the costs associated with maintaining our clinical trial programs, and, depending upon the period of delay, require usto commence new trials at significant additional expense or terminate the development program completely.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <!-- Field: Page; Sequence: 35; Value: 1 -->      <div style="margin-bottom: 6pt; border-bottom: Black 1.5pt solid">       <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">        <tbody>         <tr style="vertical-align: top; text-align: left">          <td style="text-align: center; width: 100%">           <!-- Field: Sequence; Type: Arabic; Name: PageNo -->           33           <!-- Field: /Sequence -->          </td>         </tr>        </tbody>       </table>      </div>      <div style="page-break-before: always; margin-top: 6pt">       <p style="margin: 0pt">       </p>      </div>      <!-- Field: /Page -->      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Inaddition, all manufacturers of our products must comply with current good manufacturing practices, which are regulated by theFDA through its facilities inspection programs. These practices include requirements regarding, among other things, quality control,quality assurance and the generation and maintenance of records and documentation. We are required by law to establish adequateoversight and control over raw materials, components and finished products furnished by our third-party manufacturers, but wehave limited direct control over our manufacturers’ compliance with these regulations and standards. Any failure by ourmanufacturers, including our non-U.S. contract manufacturers, to comply with these requirements could potentially result in finesand civil penalties, suspension of production, restrictions on imports and exports, suspension or delay in product approval, productseizure or recall or withdrawal of product approval. Additionally, if the safety of any product candidate or approved productis compromised due to our or our manufacturers’ failure to adhere to applicable regulatory requirements or for other reasons,we may not be able to obtain or maintain regulatory approval for or successfully commercialize our products, and we may be heldliable for any injuries sustained as a result of the failure. Any of these factors could cause delays in clinical trials, regulatorysubmissions or approvals, entail significant costs or hinder our ability to effectively commercialize our product candidates.Furthermore, assuming we are successful in receiving approval for and commercializing one or more of our product candidates, ifour manufacturers fail to deliver the required commercial quantities on a timely basis, pursuant to provided specifications andat commercially reasonable prices, we may be unable to meet demand for our products and we could lose potential revenue.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <b>         <i>          Ourbusiness and operations could suffer in the event of cyber-attacks or system failures.         </i>        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Despitethe implementation of security measures, our internal computer systems and those of our current and any future partners, contractorsand consultants are vulnerable to damage from cyber-attacks, computer viruses, unauthorized access, natural disasters, terrorism,war and telecommunication and electrical failures. System failures, accidents or security breaches could cause material disruptionsto our commercialization activities, clinical and other development programs, financial and disclosure controls and other reportingfunctions and the administrative aspects of our business, in addition to possibly requiring substantial expenditures of capitaland other resources to remedy. Further, any loss of clinical trial data from completed or future clinical trials as a result ofsuch a disruption could result in delays in our regulatory approval efforts and significantly increase our costs to recover orreproduce the lost data. Moreover, to the extent any such disruption results in the loss of or damage to our data or applicationsor inappropriate disclosure of confidential or proprietary information, we could incur significant liabilities. The occurrenceof any of these circumstances could cause our operations and our performance to suffer.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <b>         <i>          Wemay be unable to acquire or develop new product candidates or technologies, or we may never be able to commercialize any productcandidates or technologies we do successfully acquire or develop.         </i>        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Aspart of our business strategy, we plan to expand our clinical pipeline and build our portfolio of product candidates through thedevelopment, acquisition or licensing of assets or businesses, product candidates or approved products. The process of identifying,planning, negotiating, implementing and integrating an acquisition or license of a new business, product candidate or approvedproduct can be lengthy and complex and can involve numerous difficulties, including difficulties related to:       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">       <tbody>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; width: 48px">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; width: 48px">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           ●          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           identifying    new potential product candidates or promising technologies;          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           ●          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           competing    with other companies for the acquisition or license, including many of our competitors with substantially greater financial,    marketing and sales resources;          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           ●          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           negotiating    the terms of the acquisition or license, at which we have relatively little experience;          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           ●          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           accurately    judging the value or worth of a potential acquisition or in-license candidate;          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           ●          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           paying    for an acquisition or license, including the consideration to acquire or license a business, technology or asset (which could    include cash and/or issuance of equity or debt securities);          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           ●          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           acquisition    and integration efforts could disrupt our business and divert the time and attention of management and other internal personnel    from existing operations;          </font>         </td>        </tr>       </tbody>      </table>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <!-- Field: Page; Sequence: 36; Value: 1 -->      <div style="margin-bottom: 6pt; border-bottom: Black 1.5pt solid">       <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">        <tbody>         <tr style="vertical-align: top; text-align: left">          <td style="text-align: center; width: 100%">           <!-- Field: Sequence; Type: Arabic; Name: PageNo -->           34           <!-- Field: /Sequence -->          </td>         </tr>        </tbody>       </table>      </div>      <div style="page-break-before: always; margin-top: 6pt">       <p style="margin: 0pt">       </p>      </div>      <!-- Field: /Page -->      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">       <tbody>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; width: 48px">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; width: 48px">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           ●          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           any    integration failures could result in the loss or impairment of relationships with employees, consultants, suppliers and other    vendors and partners;          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           ●          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           exposure    to unknown or contingent liabilities based on an acquired company’s operations or assets;          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           ●          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           acquisition    and integration efforts and costs could reduce available liquidity and other resources to pursue other acquisitions or strategic    transactions;          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           ●          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           challenges    establishing appropriate controls and procedures for any acquisition by us of a private company;          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           ●          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           failing    to recoup our investment of time, capital and other resources into a proposed acquisition or license, as a result of failing    to complete the transaction or, for transactions that are completed, failing to realize the anticipated benefits of acquired    or licensed business or asset; and          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           ●          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           challenges    developing and commercializing any product candidates or technologies that we are successful in acquiring or licensing, which    is subject to all of the risks described throughout these risk factors regarding the development of our current product candidates.          </font>         </td>        </tr>       </tbody>      </table>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Asa result of these and other difficulties, any efforts to acquire or develop new product candidates, technologies or businessesmay not produce commercially successful products or otherwise result in meaningful revenue or profitability for our business.As a result, the pursuit of these activities could have a material adverse effect on our business, results of operations, financialcondition and prospects.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <b>         <i>          Anycollaboration arrangements we may establish may not be successful, which could adversely affect our ability to develop and commercializeour product candidates.         </i>        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Wemay seek collaboration arrangements for the development or commercialization of our current and any future product candidates.To the extent we pursue collaboration arrangements, we would face significant risks in connection with establishing and maintainingthe arrangements, including, among others:       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">       <tbody>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; width: 48px">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; width: 48px">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           ●          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           we    could be subject to intense competition in seeking appropriate collaborators;          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           ●          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           collaboration    arrangements are complex, costly and time-consuming to negotiate, document and implement, and they could require our payment    to the collaborator of cash or other consideration, including issuances of equity or debt securities, in order to establish    the relationship;          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           ●          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           we    may be unsuccessful in establishing and implementing any collaboration we desire to pursue, or the terms of the arrangement    may not be favorable to us;          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           ●          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           collaborations    often would require that we relinquish some or all of the control over the future success of the product candidate to the    third-party collaborator;          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           ●          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           the    success of any collaboration arrangements we may establish would depend heavily on the efforts and activities of our collaborators,    who would likely have significant discretion in determining the efforts and resources they would apply to these collaborations;          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           ●          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           disagreements    between collaborators regarding clinical development and commercialization matters can be difficult to resolve and can lead    to delays in the development process or commercialization of the applicable product candidate and, in some cases, termination    of the arrangement; and          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           ●          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           any    termination of a collaboration arrangement that we are able to establish could adversely affect our performance, particularly    to the extent we become reliant upon the collaboration for revenue or important commercialization processes or efforts.          </font>         </td>        </tr>       </tbody>      </table>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <!-- Field: Page; Sequence: 37; Value: 1 -->      <div style="margin-bottom: 6pt; border-bottom: Black 1.5pt solid">       <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">        <tbody>         <tr style="vertical-align: top; text-align: left">          <td style="text-align: center; width: 100%">           <!-- Field: Sequence; Type: Arabic; Name: PageNo -->           35           <!-- Field: /Sequence -->          </td>         </tr>        </tbody>       </table>      </div>      <div style="page-break-before: always; margin-top: 6pt">       <p style="margin: 0pt">       </p>      </div>      <!-- Field: /Page -->      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Inaddition, collaboration arrangements may also include our pursuit of combination trials to develop and commercialize our productcandidates as combination products, such as our KEYNOTE-695 and KEYNOTE-890 studies with Merck’s KEYTRUDA®. To the extentwe continue to pursue these or any other similar collaborative arrangement, we will face certain additional risks and uncertaintiesin development, as drug/device combination products are particularly complex, expensive and time-consuming to develop due to thenumber of variables involved in the final product design, including ease of patient and doctor use, establishing clinical efficacy,reliability and cost of manufacturing, regulatory approval requirements and standards and other important factors. Additionally,combination products face continued risk and uncertainty post-development in connection with manufacturing and supply regardingthe establishment of a reliable commercial supply chain.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Theoccurrence of any of these risks with respect to any collaboration arrangements we pursue or establish could materially adverselyaffect our performance, financial condition and reputation.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <b>         <i>         </i>        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <b>         <i>          Ourresults of operations and liquidity needs could be materially negatively affected by market fluctuations and economic downturn.         </i>        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Ourresults of operations could be materially negatively affected by economic conditions generally, both in the U.S. and elsewherearound the world. Continuing concerns over inflation, energy costs, geopolitical issues, the availability and cost of credit,the U.S. mortgage market and residential real estate market in the U.S. have contributed to increased volatility and diminishedexpectations for the economy and the markets going forward. These factors, combined with volatile oil prices, declining businessand consumer confidence and increased unemployment, have precipitated an economic recession and fears of a possible depression.Domestic and international equity markets continue to experience heightened volatility and turmoil. These events and the continuingmarket upheavals may have an adverse effect on us. In the event of a continuing market downturn, our results of operations couldbe adversely affected by those factors in many ways, including making it more difficult for us to raise funds if necessary, andour stock price may further decline.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <b>         <i>          Unfavorableglobal economic conditions could adversely affect our business, financial condition or results of operations.         </i>        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Ourresults of operations could be adversely affected by general conditions in the global economy and in the global financial markets.For example, the global financial crisis caused extreme volatility and disruptions in the capital and credit markets. A severeor prolonged economic downturn, such as the global financial crisis, could result in a variety of risks to our business, including,weakened demand for our drug candidates and our ability to raise additional capital when needed on acceptable terms, if at all.A weak or declining economy could also strain our suppliers, possibly resulting in supply disruption, or cause our customers todelay making payments for our services.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Followingits June 23, 2016 vote to leave the European Union, on March 29, 2017, the United Kingdom invoked Article 50 of the Lisbon Treatyand formally began the process of exiting the European Union. Although Brexit has already and may continue to adversely affectEuropean and/or worldwide economic or market, political or regulatory conditions and may contribute to instability in the globalfinancial markets, political institutions and regulatory agencies, the resulting immediate changes in foreign currency exchangerates have had a limited overall impact due to natural hedging. The long-term impact of Brexit, including on our business andour industry, will depend on the terms that are negotiated in relation to the United Kingdom’s future relationship withthe European Union, and we are closely monitoring the Brexit developments in order to determine, quantify and proactively addresschanges as they become clear. Despite the Brexit developments, we do not expect macroeconomic conditions to have a significantimpact on our liquidity needs, financial condition or results of operations.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <!-- Field: Page; Sequence: 38; Value: 1 -->      <div style="margin-bottom: 6pt; border-bottom: Black 1.5pt solid">       <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">        <tbody>         <tr style="vertical-align: top; text-align: left">          <td style="text-align: center; width: 100%">           <!-- Field: Sequence; Type: Arabic; Name: PageNo -->           36           <!-- Field: /Sequence -->          </td>         </tr>        </tbody>       </table>      </div>      <div style="page-break-before: always; margin-top: 6pt">       <p style="margin: 0pt">       </p>      </div>      <!-- Field: /Page -->      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <b>         <i>         </i>        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <b>         <i>          Wemay not be successful in executing our sales and marketing strategy for the commercialization of any of our product candidates,should they be approved, in which case we may not be able to generate significant, or any, revenue.         </i>        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Ifone or more of our product candidates are approved, our commercialization strategy may include the establishment of our own sales,marketing and distribution capabilities to market products to our target markets. Developing these capabilities would requiresignificant expenditures on personnel and infrastructure. Moreover, we have no experience with these activities. While we currentlyexpect that any approved products would be marketed for a relatively small patient population, we might not be able to createan effective sales force to address even a niche market. In addition, some of our product candidates could require, if approved,a large sales force to call on and educate physicians and patients. We could decide in the future to pursue collaborations withone or more pharmaceutical companies to sell, market and distribute any approved products, but we may not be able to establishany such arrangement when desired, on acceptable terms or at all. Further, any such collaboration we do establish may not be effectivein generating meaningful revenue to us.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Wemay be unsuccessful in implementing the commercialization strategies we have planned. Further, we have not proven our abilityto succeed in the biotechnology industry and are not certain that our commercialization strategies, even if implemented as weenvision, would lead to significant revenue. If we are unable to successfully implement our commercialization plans and driveadoption by patients and physicians of any product candidates that obtain regulatory approval, then we will not generate meaningful,or any, revenue, which would have a material adverse effect on our business, results of operations, financial condition and prospects.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <b>         <i>         </i>        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <b>         <i>          Ifany product candidate that receives regulatory approval does not achieve broad market acceptance, our revenue potential may belimited.         </i>        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Thecommercial success of any product candidate that obtains marketing approval from the FDA or comparable foreign regulatory authoritieswill depend on the acceptance of these products by physicians, patients, third-party payors and the medical community. The degreeof market acceptance of any product candidate that receives regulatory approval will depend on a number of factors, including:       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">       <tbody>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; width: 48px">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; width: 48px">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           ●          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           our    ability to provide acceptable evidence of safety and efficacy;          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           ●          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           acceptance    by physicians and patients of the product as a safe and effective treatment;          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           ●          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           the    prevalence and severity of adverse effects;          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           ●          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           limitations    or warnings contained in a product’s FDA-approved or other regulator-approved labeling;          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           ●          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           the    clinical indications for which the product is approved;          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           ●          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           the    availability and perceived advantages of alternative treatments;          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           ●          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           any    negative publicity related to the product or any competing product;          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           ●          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           the    effectiveness of our or any current or future collaborators’ sales, marketing and distribution strategies;          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           ●          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           pricing    and cost effectiveness;          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           ●          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           our    ability to obtain adequate third-party payor coverage or reimbursement; and          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           ●          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           the    willingness of patients to pay out-of-pocket in the absence of adequate third-party payor coverage and reimbursement.          </font>         </td>        </tr>       </tbody>      </table>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <!-- Field: Page; Sequence: 39; Value: 1 -->      <div style="margin-bottom: 6pt; border-bottom: Black 1.5pt solid">       <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">        <tbody>         <tr style="vertical-align: top; text-align: left">          <td style="text-align: center; width: 100%">           <!-- Field: Sequence; Type: Arabic; Name: PageNo -->           37           <!-- Field: /Sequence -->          </td>         </tr>        </tbody>       </table>      </div>      <div style="page-break-before: always; margin-top: 6pt">       <p style="margin: 0pt">       </p>      </div>      <!-- Field: /Page -->      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif">        Failureswith respect to any one of these factors could severely limit the commercial potential of any product candidate that obtains regulatoryapproval, which could materially adversely affect our performance and prospects.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif">        <b>         <i>         </i>        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif">        <b>         <i>          Wemay not be able to establish adequate coverage and reimbursement by third-party payors for any product candidate that achievesregulatory approvals, which could severely limit our market potential, performance and prospects.         </i>        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif">        Costcontainment has become a significant trend in the U.S. healthcare industry. Third-party payors have attempted to control costsby limiting coverage and the amount of reimbursement for certain products and procedures. Increasingly, third-party payors arerequiring that companies provide them with predetermined discounts from list prices and are challenging the prices charged formedical products and treatments. In addition, recent trends in U.S. politics suggest that the U.S. healthcare insurance frameworkmay experience significant changes in the near term. For all of these and other reasons, coverage and reimbursement at adequateor any levels may not be available for any product candidate that achieves regulatory approval. If coverage and reimbursementis not available or is not available at an adequate level for any approved product, the demand for or price of the product couldbe materially negatively affected, which could severely limit our revenue potential and prospects.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif">        Inaddition, the regulations that govern marketing approvals, pricing, coverage and reimbursement for new therapeutic products varywidely from country to country. Some countries require approval of the sale price of a product before it can be marketed. In manycountries, the pricing review period begins after marketing or product licensing approval is granted. In some foreign markets,prescription pharmaceutical pricing remains subject to continuing government control even after initial approval is granted. Asa result, even if we obtain regulatory approval for a product candidate in a particular country, we could be subject to continuingpricing regulations that could delay our commercial launch of the product or negatively impact the revenue potential for the productin that country.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif">        <b>         <i>         </i>        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif">        <b>         <i>          Futuregrowth, including growth in international operations, could strain our resources, and if we are unable to manage any growth wemay experience, we may not be able to successfully implement our business plans.         </i>        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif">        Inlate 2016, we established a subsidiary corporation in Australia in preparation for planned clinical trials in that country. Inaddition, our business plan includes continued growth of our operations, including, among other things, growth in our workforce,expansion of our clinical trial efforts within and outside of the United States, and expansion of our portfolio of product candidates.This growth could place an additional strain on our management, administrative, operational and financial infrastructure, andwill require that we incur significant additional costs and hire and train additional personnel to support our expanding operations.Further, we must maintain and continue to improve our operational, financial and management controls and reporting systems andprocedures, which can be more challenging during periods of expansion. As a result, our future success will depend in part onthe ability of management to effectively manage any of this growth we may experience. If we fail to successfully manage any growthwe may experience, we may be unable to execute on our business plan.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif">        Inconnection with any geographic expansion we may pursue, international operations would involve substantial additional risks, including,among others:       </font>      </p>      <p style="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif">       </font>      </p>      <table cellpadding="0" cellspacing="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">       <tbody>        <tr style="vertical-align: top">         <td style="width: 0.5in">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="width: 0.5in">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           ●          </font>         </td>         <td style="text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           difficulties complying    with the U.S. Foreign Corrupt Practices Act and other applicable anti-bribery laws, such as the United Kingdom Bribery Act    2010, and similar antibribery and anticorruption laws in other jurisdictions;          </font>         </td>        </tr>        <tr style="vertical-align: top">         <td>          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td>          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="vertical-align: top">         <td>          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td>          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           ●          </font>         </td>         <td style="text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           difficulties complying    with foreign laws, regulations, standards and regulatory guidance governing the collection, use, disclosure, retention, security    and transfer of personal data, including the European Union General Data Privacy Regulation, which introduces strict requirements    for processing personal data of individuals within the European Union;          </font>         </td>        </tr>        <tr style="vertical-align: top">         <td>          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td>          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="vertical-align: top">         <td>          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td>          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           ●          </font>         </td>         <td style="text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           difficulties maintaining    compliance with the varied and potentially conflicting laws and regulations of multiple jurisdictions that may be applicable    to our business, many of which may be unfamiliar to us;          </font>         </td>        </tr>        <tr style="vertical-align: top">         <td>          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td>          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="vertical-align: top">         <td>          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td>          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           ●          </font>         </td>         <td style="text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           difficulties in    managing foreign operations;          </font>         </td>        </tr>       </tbody>      </table>      <p style="font: 12pt Times New Roman, Times, Serif; margin: 0">       <font style="font-family: Times New Roman, Times, Serif">       </font>      </p>      <!-- Field: Page; Sequence: 40; Options: NewSection; Value: 38 -->      <div style="margin-bottom: 6pt; border-bottom: Black 1.5pt solid">       <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">        <tbody>         <tr style="vertical-align: top; text-align: left">          <td style="text-align: center; width: 100%">           <!-- Field: Sequence; Type: Arabic; Name: PageNo -->           38           <!-- Field: /Sequence -->          </td>         </tr>        </tbody>       </table>      </div>      <div style="page-break-before: always; margin-top: 6pt">       <p style="margin: 0pt">       </p>      </div>      <!-- Field: /Page -->      <p style="font: 12pt Times New Roman, Times, Serif; margin: 0">       <font style="font-family: Times New Roman, Times, Serif">       </font>      </p>      <table cellpadding="0" cellspacing="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">       <tbody>        <tr style="vertical-align: top">         <td>          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td>          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           ●          </font>         </td>         <td style="text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           financial risks,    such as longer payment cycles, difficulty in enforcing contracts and collecting accounts receivable, and exposure to foreign    currency exchange rate fluctuations;          </font>         </td>        </tr>        <tr style="vertical-align: top">         <td>          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td>          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td style="text-align: justify">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>        </tr>        <tr style="vertical-align: top">         <td>          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td>          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           ●          </font>         </td>         <td>          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           complexities associated with managing multiple    payor-reimbursement regimes or self-pay systems;          </font>         </td>        </tr>        <tr style="vertical-align: top">         <td>          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td>          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td>          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="vertical-align: top">         <td>          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td>          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           ●          </font>         </td>         <td style="text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           more complexity    in our regulatory and accounting compliance;          </font>         </td>        </tr>        <tr style="vertical-align: top">         <td>          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td>          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="vertical-align: top">         <td>          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td>          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           ●          </font>         </td>         <td style="text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           differing or changing    obligations regarding taxes, duties or other fees;          </font>         </td>        </tr>        <tr style="vertical-align: top">         <td>          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td>          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="vertical-align: top">         <td>          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td>          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           ●          </font>         </td>         <td style="text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           limited intellectual    property protection in some jurisdictions;          </font>         </td>        </tr>        <tr style="vertical-align: top">         <td>          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td>          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="vertical-align: top">         <td>          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td>          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           ●          </font>         </td>         <td style="text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           risks associated    with currency exchange and convertibility, including vulnerability to appreciation and depreciation of foreign currencies    against the U.S. dollar;          </font>         </td>        </tr>        <tr style="vertical-align: top">         <td>          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td>          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td style="text-align: justify">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>        </tr>        <tr style="vertical-align: top">         <td style="width: 0.5in">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="width: 0.5in">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           ●          </font>         </td>         <td style="text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           uncertainty related    to developing legal and regulatory systems and standards for economic and business activities in some jurisdictions;          </font>         </td>        </tr>        <tr style="vertical-align: top">         <td>          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td>          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="vertical-align: top">         <td>          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td>          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           ●          </font>         </td>         <td style="text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           trade restrictions    or barriers, including tariffs or other charges and import-export regulations, which are subject to increased uncertainty    following the results of the 2016 U.S. presidential election and the trade policies of the current administration regarding    existing and proposed trade agreements and the ability to import goods into the United States;          </font>         </td>        </tr>        <tr style="vertical-align: top">         <td>          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td>          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="vertical-align: top">         <td>          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td>          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           ●          </font>         </td>         <td style="text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           changes in applicable    laws or policies;          </font>         </td>        </tr>        <tr style="vertical-align: top">         <td>          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td>          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="vertical-align: top">         <td>          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td>          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           ●          </font>         </td>         <td style="text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           possible failure    by us or our distributors to obtain appropriate licenses or regulatory approvals for the sale or use of our product candidates,    if approved, in various countries; and          </font>         </td>        </tr>        <tr style="vertical-align: top">         <td>          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td>          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="vertical-align: top">         <td>          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td>          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           ●          </font>         </td>         <td style="text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           business interruptions    resulting from geopolitical actions, economic instability, or the impact of and response to natural disasters, including,    but not limited to, wars and terrorism, political unrest, outbreak of disease, earthquakes, boycotts, curtailment of trade,    and other business restrictions.          </font>         </td>        </tr>       </tbody>      </table>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif">        Theoccurrence of any of these risks could limit our ability to pursue international expansion, increase our costs or expose us tofines or other legal sanctions, any of which could negatively impact our business, reputation and financial condition.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif">        <b>         <i>         </i>        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif">        <b>         <i>          Ifwe are unable to successfully recruit and retain qualified personnel, we may not be able to maintain or grow our business.         </i>        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif">        Inorder to successfully implement and manage our business plans, we depend on, among other things, successfully recruiting and retainingqualified executives, managers, scientists and other employees with relevant experience in life sciences and the biotechnologyindustry. Competition for qualified individuals is intense, particularly in our industry, due to the many larger and more establishedlife science and biotechnology companies that compete with us for talent. We also experience competition for the hiring of scientificand clinical personnel from universities and research institutions. In addition, we heavily rely on consultants and advisors,including scientific, clinical and regulatory advisors, to assist us in formulating our research and development and commercializationstrategies. Our consultants and advisors may be employed by others or may have commitments under consulting or advisory contractswith other entities that may limit their availability to support us. If we are not able to retain existing personnel, consultantsand/or advisors, and find, attract and retain new qualified personnel, consultants and/or advisors on acceptable terms and ina timely manner to coincide with our needs, we may not be able to successfully maintain or grow our operations and our businessand prospects could suffer.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif">       </font>      </p>      <!-- Field: Page; Sequence: 41; Value: 38 -->      <div style="margin-bottom: 6pt; border-bottom: Black 1.5pt solid">       <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">        <tbody>         <tr style="vertical-align: top; text-align: left">          <td style="text-align: center; width: 100%">           <!-- Field: Sequence; Type: Arabic; Name: PageNo -->           39           <!-- Field: /Sequence -->          </td>         </tr>        </tbody>       </table>      </div>      <div style="page-break-before: always; margin-top: 6pt">       <p style="margin: 0pt">       </p>      </div>      <!-- Field: /Page -->      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">       <font style="font-family: Times New Roman, Times, Serif">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif">        Additionally,although we have employment agreements with each of our executive officers, these agreements are terminable by them at will. Theloss of the services of any one or more members of our current senior management team could, among other things, disrupt or divertour focus from pursuing our business plans while we seek to recruit other executives, impact the perceptions of our existing andprospective employees, partners and investors regarding our business and prospects, cause us to incur substantial costs in connectionwith managing transitions and recruiting suitable replacements and, if the departing personnel are crucial to any of our clinicalor other development programs, delay or prevent the development and commercialization of the affected product candidates. Theserisks would be amplified if we are not able to recruit suitable replacements for any departing personnel on acceptable terms andin a timely manner. The occurrence of any of these or other potential consequences could cause significant harm to our business.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif">        <b>         <i>          Extensiveindustry regulation has had, and will continue to have, a significant impact on our business, especially our product development,manufacturing and distribution capabilities.         </i>        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif">        Biotechnologycompanies are subject to extensive, complex, costly and evolving government regulation relating to the ability to market and sellany drug or medical device. In the United States, these regulations are principally administered and enforced by the FDA and,to a lesser extent, by the U.S. Drug Enforcement Agency, or DEA, and comparable state government agencies, and outside the UnitedStates, these types of regulations are typically administered by various regulatory agencies comparable to the FDA in foreigncountries where products or product candidates are researched, tested, manufactured and/or marketed.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       The FDCA, the ControlledSubstances Act, and other federal statutes and regulations, as well as similar state and foreign statutes and regulations, governor influence, among other things, the research, development, testing, manufacture, storage, record-keeping, approval, labeling,promotion, marketing, distribution, post-approval monitoring and reporting, sampling, import and export of product candidatessuch as ours. Under these regulations, we and our contract manufacturers may become subject to periodic inspection of our facilities,quality control and other procedures, and operations and/or product candidate testing by the FDA, DEA and other authorities duringand after the approval process for a product candidate, to confirm compliance with all applicable regulations, including currentgood manufacturing practices and other applicable requirements. Further, even if regulatory approval of a product candidate isobtained, such approval would, in the U.S. at least, impose limitations on the indicated uses for which the product may be marketed,and these limitations could materially limit a product’s market and revenue potential. Additionally, we would be subjectto pervasive and continuing regulation by the FDA and/or comparable foreign regulators with respect to any approved product. Moreover,we could be required to conduct potentially costly post-approval studies or surveillance programs to monitor the effect of anyapproved products, and the FDA and comparable foreign regulators have the authority to stop or limit further marketing of a productor impose more stringent labeling restrictions based on the results of these post-approval tests and programs or in the eventof any unexpected or serious health or safety concern regarding any approved product.      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif">        Possiblepenalties or other consequences for failure to comply with these regulatory requirements include, among others, observations,notices, citations and/or warning letters that could force us to modify our clinical programs or other activities; clinical holdson our ongoing clinical programs; adverse publicity from the FDA or others; the FDA’s suspension of its review of pendingapplications; fines; product recalls or seizures; total or partial suspension of production and/or distribution; labeling changes;withdrawal of previously granted product approvals; enforcement actions; restrictions on imports and exports; injunctions andcivil or criminal prosecution. Any such sanctions, if imposed, could have a material adverse effect on our business, operatingresults and financial condition.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif">        Moreover,the regulations, policies and guidance of the FDA or other regulatory agencies could change and new or additional statutes orregulations could be enacted or promulgated. If changes or new laws are more stringent or impose additional or more challengingrequirements, our costs of compliance could increase, regulatory approval of our product candidates could be delayed or jeopardized,or post-approval activities for any product candidates that obtain regulatory approval could be further restricted or regulated.If we are not able to achieve and maintain regulatory compliance, we may not be permitted to market any of our product candidates,which would materially adversely affect our prospects to generate revenue.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif">       </font>      </p>      <!-- Field: Page; Sequence: 42; Value: 38 -->      <div style="margin-bottom: 6pt; border-bottom: Black 1.5pt solid">       <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">        <tbody>         <tr style="vertical-align: top; text-align: left">          <td style="text-align: center; width: 100%">           <!-- Field: Sequence; Type: Arabic; Name: PageNo -->           40           <!-- Field: /Sequence -->          </td>         </tr>        </tbody>       </table>      </div>      <div style="page-break-before: always; margin-top: 6pt">       <p style="margin: 0pt">       </p>      </div>      <!-- Field: /Page -->      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">       <font style="font-family: Times New Roman, Times, Serif">        <b>         <i>         </i>        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif">        <b>         <i>          Ifwe fail to comply with applicable healthcare laws and regulations, we could face substantial penalties and our business, operations,prospects and financial condition could be adversely affected.         </i>        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif">        Thehealthcare industry is heavily regulated, constantly evolving and subject to significant change and fluctuation. The U.S. federaland state healthcare laws and regulations that impact our business include, among others:       </font>      </p>      <p style="font: 12pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify; text-indent: -0.5in">       <font style="font-family: Times New Roman, Times, Serif">       </font>      </p>      <table cellpadding="0" cellspacing="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">       <tbody>        <tr style="vertical-align: top">         <td style="width: 48px">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="width: 48px">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           ●          </font>         </td>         <td style="text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           the laws and regulations    administered and enforced by the FDA, including the FDCA, Controlled Substances Act and other federal statutes and regulations,    discussed above;          </font>         </td>        </tr>        <tr style="vertical-align: top">         <td>          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td>          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="vertical-align: top">         <td>          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td>          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           ●          </font>         </td>         <td style="text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           the federal Anti-Kickback    Statute, which generally prohibits, among other things, soliciting, receiving or providing remuneration to induce the referral    of an individual for an item or service or the purchasing or ordering of an item or service for which payment may be made    under federal healthcare programs, such as the Medicare and Medicaid programs;          </font>         </td>        </tr>        <tr style="vertical-align: top">         <td>          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td>          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="vertical-align: top">         <td>          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td>          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           ●          </font>         </td>         <td style="text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           the federal false    claims laws, which generally prohibit, among other things, knowingly presenting or causing to be presented claims for payment    from Medicare, Medicaid or other third-party payors that are false or fraudulent;          </font>         </td>        </tr>        <tr style="vertical-align: top">         <td>          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td>          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="vertical-align: top">         <td>          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td>          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           ●          </font>         </td>         <td style="text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           the Affordable Care    Act, which, in general and among other things, expands the government’s investigative and enforcement authority, including    requiring pharmaceutical companies to record and disclose to government agencies any transfers of value to doctors and teaching    hospitals, and increases the penalties for fraud and abuse, including amendments to the federal False Claims Act and the Anti-Kickback    Statute to make it easier to file lawsuits under these statutes;          </font>         </td>        </tr>        <tr style="vertical-align: top">         <td>          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td>          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="vertical-align: top">         <td>          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td>          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           ●          </font>         </td>         <td style="text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           HIPAA and HITECH,    which, in general and among other things, establish comprehensive federal standards with respect to the privacy, security    and transmission of individually identifiable health information and impose requirements for the use of standardized electronic    transactions with respect to transmission of such information;          </font>         </td>        </tr>        <tr style="vertical-align: top">         <td>          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td>          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="vertical-align: top">         <td>          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td>          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           ●          </font>         </td>         <td style="text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           the FCPA and other    applicable anti-bribery laws; and          </font>         </td>        </tr>        <tr style="vertical-align: top">         <td>          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td>          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="vertical-align: top">         <td>          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td>          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           ●          </font>         </td>         <td style="text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           state law equivalents    of each of these federal laws, such as anti-kickback and false claims laws that may apply to items or services reimbursed    by any third-party payor, including commercial insurers, and state laws governing the privacy and security of health information    in certain circumstances, many of which differ from each other in significant ways and may not be preempted by applicable    federal laws, thus complicating compliance efforts.          </font>         </td>        </tr>       </tbody>      </table>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif">        Additionally,the healthcare compliance environment is continuously changing, with proposed revisions to or replacement of the Affordable CareAct at the federal level and with some states mandating implementation of compliance programs, compliance with industry ethicscodes, registration requirements for sales personnel, spending limits and reporting to state governments of gifts, compensationand other remuneration to physicians. This shifting regulatory environment, as well as our obligation to comply with differentreporting and other compliance requirements, in multiple jurisdictions, including foreign laws and regulations comparable to theU.S. laws and regulations described above, to the extent we continue to pursue operations in foreign countries, such as our clinicalactivities in Australia, or if we seek to sell any product that obtains regulatory approval in a foreign country, increases thepossibility that we may violate one or more of these laws. In addition, these conditions may also adversely affect our abilityto obtain regulatory approval for any of our product candidates, the availability of capital, our ability to generate meaningfulor any revenue and, if any of our product candidates achieve regulatory approval, our ability to establish a price we believeis fair for the approved product. Further, even though we do not and will not control referrals of healthcare services or billdirectly to third-party payors, certain federal and state healthcare laws and regulations pertaining to fraud and abuse and patients’rights would be applicable to our business, if any of our product candidates obtain regulatory approval and become commerciallyavailable.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif">       </font>      </p>      <!-- Field: Page; Sequence: 43; Value: 38 -->      <div style="margin-bottom: 6pt; border-bottom: Black 1.5pt solid">       <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">        <tbody>         <tr style="vertical-align: top; text-align: left">          <td style="text-align: center; width: 100%">           <!-- Field: Sequence; Type: Arabic; Name: PageNo -->           41           <!-- Field: /Sequence -->          </td>         </tr>        </tbody>       </table>      </div>      <div style="page-break-before: always; margin-top: 6pt">       <p style="margin: 0pt">       </p>      </div>      <!-- Field: /Page -->      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">       <font style="font-family: Times New Roman, Times, Serif">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif">        Allof these laws impose penalties or other consequences for non-compliance, some of which may be severe. If we or our operationsare found to be in violation of any of these laws or any other governmental regulations that apply to us, the consequences couldinclude, but are not limited to, fines or other monetary damages, orders forcing us to curtail or restructure our operations,injunctions and civil or criminal prosecution. Any such penalties could adversely affect our ability to operate our business andpursue our strategic plans. Additionally, any action against us for violation of these laws, even if we successfully defend againstit, could cause us to incur significant legal expenses and divert management’s attention from the operation of our business.Moreover, achieving and sustaining compliance with the various U.S. federal and state and foreign laws and regulations that applyto our business could prove costly. The occurrence of any of these risks could cause our performance and financial condition tomaterially suffer.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif">        <b>         <i>         </i>        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif">        <b>         <i>          Weare subject to new legislation and regulatory proposals that may affect costs for compliance and adversely affect revenue.         </i>        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif">        <b>         <i>         </i>        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif">        The116        <sup>         th        </sup>        Congress has closely monitored health care spending in the United States. Many members of Congress have prioritizedhealth care spending and are committed to lowering spending in federal government programs. Legislative efforts to reduce healthcare spending within federal programs may affect overall health care spending in the United States. The Senate Health, Education,Labor, and Pensions (HELP Committee) advanced legislation in June 2019 intended to improve price transparency for health careservices and products. The provisions would increase public access to pricing information and allow patients to choose lower costcare options. This may drive down health care spending and impact medical device prices. Further, there are efforts by the HouseEnergy and Commerce Committee as well as the House Ways and Means Committee to broadly address spending for prescription drugs.It is possible that the Committees could attempt legislate on medical device costs as well. Lastly, the House and Senate JudiciaryCommittees have also focused heavily on patent and exclusivity reform for prescription drugs. It is also possible that the JudiciaryCommittees could expand into device-related issues. While we cannot predict what proposals may ultimately become law, elementsunder consideration could significantly change health care spending in which the medical device market operates.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif">        PresidentDonald Trump and the Department of Health and Human Services (HHS) are also addressing price transparency in the health care industry.On June 24, 2019, President Trump signed an Executive Order (EO) directing federal agencies to improve price transparency. Sincethen, HHS has proposed regulations to improve price transparency in various health care settings that utilize medical devices(e.g., hospitals). Although these are broad efforts to improve transparency across sectors, it is possible the rulemaking couldimpact health care costs generally.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif">        <b>         <i>         </i>        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif">        <b>         <i>          Anyproduct for which we obtain marketing approval could be subject to restrictions or withdrawal from the market and we may be subjectto penalties if we fail to comply with regulatory requirements or if we experience unanticipated problems with products, whenand if any of them is approved.         </i>        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif">        Anyproduct for which we might obtain marketing approval, along with the manufacturing processes and facilities, post-approval data,labeling, advertising and promotional activities for such product, will be subject to continual requirements of and review bythe FDA and comparable regulatory authorities. These requirements include submissions of safety and other post-marketing informationand reports, registration requirements, industry standards and regulatory requirements (e.g. CGMPs) relating to quality control,quality assurance and corresponding maintenance of records and documents, requirements regarding the distribution of samples tophysicians and recordkeeping, and requirements regarding company presentations and interactions with healthcare professionals.Even if we obtain regulatory approval of a product, the approval may be subject to limitations on the indicated uses for whichthe product may be marketed or to the conditions of approval, or contain requirements for costly post-marketing testing, studies,and surveillance to monitor the safety or efficacy of the product. We also may be subject to state laws and registration requirementscovering the marketing, promotion, and distribution of products. Later discovery of previously unknown problems with products,manufacturers or manufacturing processes, or failure to comply with legal and regulatory requirements, may result in actions suchas:       </font>      </p>      <p style="font: 12pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.25in">       <font style="font-family: Times New Roman, Times, Serif">       </font>      </p>      <table cellpadding="0" cellspacing="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">       <tbody>        <tr style="vertical-align: top">         <td style="width: 0.25in">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="width: 0.25in">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           ●          </font>         </td>         <td style="text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           restrictions on    product manufacturing, distribution or use;          </font>         </td>        </tr>       </tbody>      </table>      <p style="font: 12pt Times New Roman, Times, Serif; margin: 0">       <font style="font-family: Times New Roman, Times, Serif">       </font>      </p>      <table cellpadding="0" cellspacing="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">       <tbody>        <tr style="vertical-align: top">         <td style="width: 24px">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="width: 24px">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           ●          </font>         </td>         <td style="text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           restrictions on    the labeling, marketing, or promotion of a product;          </font>         </td>        </tr>        <tr style="vertical-align: top">         <td>          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td>          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="vertical-align: top">         <td>          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td>          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           ●          </font>         </td>         <td style="text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           requirements to    conduct post-marketing studies or clinical trials;          </font>         </td>        </tr>       </tbody>      </table>      <p style="font: 12pt Times New Roman, Times, Serif; margin: 0">       <font style="font-family: Times New Roman, Times, Serif">       </font>      </p>      <!-- Field: Page; Sequence: 44; Value: 38 -->      <div style="margin-bottom: 6pt; border-bottom: Black 1.5pt solid">       <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">        <tbody>         <tr style="vertical-align: top; text-align: left">          <td style="text-align: center; width: 100%">           <!-- Field: Sequence; Type: Arabic; Name: PageNo -->           42           <!-- Field: /Sequence -->          </td>         </tr>        </tbody>       </table>      </div>      <div style="page-break-before: always; margin-top: 6pt">       <p style="margin: 0pt">       </p>      </div>      <!-- Field: /Page -->      <p style="font: 12pt Times New Roman, Times, Serif; margin: 0">       <font style="font-family: Times New Roman, Times, Serif">       </font>      </p>      <table cellpadding="0" cellspacing="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">       <tbody>        <tr style="vertical-align: top">         <td style="width: 0.25in">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="width: 0.25in">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           ●          </font>         </td>         <td style="text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           Inspectional observations    or warning letters from regulatory authorities;          </font>         </td>        </tr>        <tr style="vertical-align: top">         <td>          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td>          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="vertical-align: top">         <td>          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td>          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           ●          </font>         </td>         <td style="text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           withdrawal of the    products from the market;          </font>         </td>        </tr>        <tr style="vertical-align: top">         <td>          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td>          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="vertical-align: top">         <td>          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td>          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           ●          </font>         </td>         <td style="text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           refusal to approve    pending applications or supplements to approved applications that we submit;          </font>         </td>        </tr>        <tr style="vertical-align: top">         <td>          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td>          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="vertical-align: top">         <td>          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td>          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           ●          </font>         </td>         <td style="text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           voluntary or mandatory    recall;          </font>         </td>        </tr>        <tr style="vertical-align: top">         <td>          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td>          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="vertical-align: top">         <td>          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td>          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           ●          </font>         </td>         <td style="text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           fines;          </font>         </td>        </tr>        <tr style="vertical-align: top">         <td>          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td>          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="vertical-align: top">         <td>          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td>          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           ●          </font>         </td>         <td style="text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           suspension or withdrawal    of marketing or regulatory approvals;          </font>         </td>        </tr>        <tr style="vertical-align: top">         <td>          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td>          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="vertical-align: top">         <td>          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td>          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           ●          </font>         </td>         <td style="text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           refusal to permit    the import or export of products;          </font>         </td>        </tr>        <tr style="vertical-align: top">         <td>          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td>          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="vertical-align: top">         <td>          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td>          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           ●          </font>         </td>         <td style="text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           product seizure    or detentions;          </font>         </td>        </tr>        <tr style="vertical-align: top">         <td>          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td>          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="vertical-align: top">         <td>          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td>          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           ●          </font>         </td>         <td style="text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           injunctions or the    imposition of civil or criminal penalties; and          </font>         </td>        </tr>        <tr style="vertical-align: top">         <td>          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td>          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="vertical-align: top">         <td>          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td>          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           ●          </font>         </td>         <td style="text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           adverse publicity.          </font>         </td>        </tr>       </tbody>      </table>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif">        Ifwe or our respective suppliers, third-party contractors, clinical investigators or collaborators are slow to adapt, or are unableto adapt, to changes in existing regulatory requirements or adoption of new regulatory requirements or policies, we or our respectivecollaborators may experience one or more of the actions above, resulting in decreased revenue from milestones, product sales orroyalties.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif">        <b>         <i>         </i>        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif">        <b>         <i>          Weare heavily dependent on the success of our clinical product candidates and we cannot provide any assurance that any of our productcandidates will be approved, commercialized or successfully marketed in the future.         </i>        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif">        <b>         <i>         </i>        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif">        Weplan to seek regulatory approval to commercialize our product candidates in the United States, and potentially in the EuropeanUnion and additional foreign countries. While the scope of regulatory review and approval can be similar in other countries, toobtain separate regulatory review and approval in many other countries, we must comply with the numerous and varying regulatoryrequirements of such countries, including those regarding safety and efficacy, clinical trials, manufacturing, post-marketingcommitments, and commercial sales, pricing and distribution of our product candidates, and we cannot predict success in thosejurisdictions.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif">        Inaddition, the clinical trial requirements of the FDA, the European Commission, the European Medicines Agency, or the EMA, thecompetent authorities of the European Union, or EU, Member States and other regulatory authorities and the criteria these regulatorsuse to determine the safety and efficacy of a product candidate vary substantially according to the type, complexity, noveltyand intended use and market of such product candidates. The regulatory approval process for novel product candidates such as ourscan be more expensive and take longer than for other, better known or more extensively studied product candidates. Even if weare successful in developing additional product candidates, it is difficult to determine how long it will take or how much itwill cost to obtain regulatory approvals for these product candidates in either the United States or the EU, or how long it willtake to commercialize any other products for which we receive marketing approval. In addition, any future marketing authorizationgranted by the European Commission may not be indicative of what FDA may require for approval and vice versa.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif">        Further,in the U.S., the European Union member states, and elsewhere, there have been, and we expect there will continue to be, effortsto control and reduce healthcare costs. In the U.S. for example, the price of drugs has come under intense scrutiny by the U.S.Congress. Third party payers decide which drugs they will pay for and establish reimbursement and co-payment levels. Governmentand other third-party payers are increasingly challenging the prices charged for healthcare products, examining the cost effectivenessof drugs in addition to their safety and efficacy, and limiting or attempting to limit both coverage and the level of reimbursementfor prescription drugs.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif">       </font>      </p>      <!-- Field: Page; Sequence: 45; Value: 38 -->      <div style="margin-bottom: 6pt; border-bottom: Black 1.5pt solid">       <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">        <tbody>         <tr style="vertical-align: top; text-align: left">          <td style="text-align: center; width: 100%">           <!-- Field: Sequence; Type: Arabic; Name: PageNo -->           43           <!-- Field: /Sequence -->          </td>         </tr>        </tbody>       </table>      </div>      <div style="page-break-before: always; margin-top: 6pt">       <p style="margin: 0pt">       </p>      </div>      <!-- Field: /Page -->      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">       <font style="font-family: Times New Roman, Times, Serif">        <b>         <i>         </i>        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif">        <b>         <i>          Europehas enacted a new data privacy regulation, the General Data Protection Regulation, a violation of which could subject us to significantfines.         </i>        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif">        InMay 2018, a new privacy regime, the General Data Protection Regulation, or GDPR, took effect across all member states of the EuropeanEconomic Area. The new regime increases our obligations with respect to clinical trials conducted in the member states by expandingthe definition of personal data to include coded data, and requiring changes to informed consent practices and more detailed noticesfor clinical trial subjects and investigators. In addition, it increases the scrutiny that clinical trial sites located in themember states should apply to transfers of personal data from such sites to countries that are considered to lack an adequatelevel of data protection, such as the United States. The regime imposes substantial fines for breaches of data protection requirements,which can be up to four percent of global revenues or 20 million Euros, whichever is greater, and it also confers a private rightof action on data subjects for breaches of data protection requirements. Compliance with these directives is a rigorous and time-intensiveprocess that may increase our cost of doing business, and the failure to comply with these laws could subject us to significantfines.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif">        <b>         <i>         </i>        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif">        <b>         <i>          Ouremployees, consultants, or third-party partners may engage in misconduct or other improper activities, including but not necessarilylimited to noncompliance with regulatory standards and requirements or internal procedures, policies or agreements to which suchemployees, consultants and partners are subject, any of which could have a material adverse effect on our business.         </i>        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif">        Weare exposed to the risk of employee fraud or other misconduct. Misconduct by employees, consultants, or third party partners couldinclude intentional failures to comply with FDA regulations, to provide accurate information to the FDA, to comply with manufacturingstandards, including those we have established, to comply with federal and state healthcare fraud and abuse laws and regulations,to report financial information or data accurately, to comply with internal procedures, policies or agreements to which such employees,consultants or partners are subject, or to disclose unauthorized activities to us. In particular, sales, marketing and businessarrangements in the healthcare industry are subject to extensive laws and regulations intended to prevent fraud, kickbacks, self-dealingand other abusive practices. These laws and regulations may restrict or prohibit a wide range of pricing, discounting, marketing,promotion, sales commission, customer incentive programs and other business arrangements. Employee, consultant, or third-partymisconduct could also involve the improper use of information obtained in the course of clinical trials, which could result inregulatory sanctions and serious harm to our reputation. The precautions we take to detect and prevent this activity may not beeffective in controlling unknown or unmanaged risks or losses or in protecting us from governmental investigations or other actionsor lawsuits stemming from a failure to be in compliance with such laws or regulations. If any such actions are instituted againstus, and we are not successful in defending ourselves or asserting our rights, those actions could have a significant impact onour business and results of operations, including the imposition of significant fines or other sanctions.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif">        Wereceive a large amount of proprietary information from potential or existing licensors of intellectual property and potentialacquisition target companies, all pursuant to confidentiality agreements. The confidentiality and proprietary invention assignmentagreements that we have in place with each of our employees and consultants prohibit the unauthorized disclosure of such information,but such employees or consultants may nonetheless disclose such information through negligence or willful misconduct. Any suchunauthorized disclosures could subject us to monetary damages and/or injunctive or equitable relief. The notes, analyses and memorandathat we have generated based off such information are also valuable to our businesses, and the unauthorized disclosure or misappropriationof such materials by our employees and consultants could significantly harm our strategic initiatives, especially if such disclosuresare made to our competitor companies.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif">       </font>      </p>      <!-- Field: Page; Sequence: 46; Value: 38 -->      <div style="margin-bottom: 6pt; border-bottom: Black 1.5pt solid">       <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">        <tbody>         <tr style="vertical-align: top; text-align: left">          <td style="text-align: center; width: 100%">           <!-- Field: Sequence; Type: Arabic; Name: PageNo -->           44           <!-- Field: /Sequence -->          </td>         </tr>        </tbody>       </table>      </div>      <div style="page-break-before: always; margin-top: 6pt">       <p style="margin: 0pt">       </p>      </div>      <!-- Field: /Page -->      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">       <font style="font-family: Times New Roman, Times, Serif">        <b>         <i>         </i>        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif">        <b>         <i>          Wemay use biological materials and hazardous materials, and any claims relating to improper handling, storage or disposal of thesematerials could be time consuming and costly.         </i>        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif">        Wemay use hazardous materials, including chemicals and biological agents and compounds that could be dangerous to human health andsafety or the environment. Our operations may also produce hazardous waste products. Federal, state and local laws and regulationsgovern the use, generation, manufacture, storage, handling and disposal of these materials and wastes. Compliance with applicableenvironmental laws and regulations may be expensive, and current or future environmental laws and regulations may impair our productdevelopment efforts. In addition, we cannot entirely eliminate the risk of accidental injury or contamination from these materialsor wastes. We do not carry specific biological or hazardous waste insurance coverage, and our property and casualty and generalliability insurance policies specifically exclude coverage for damages and fines arising from biological or hazardous waste exposureor contamination. Accordingly, in the event of contamination or injury, we could be held liable for damages or penalized withfines in an amount exceeding our respective resources, and clinical trials or regulatory approvals could be suspended.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif">        Althoughwe maintain workers’ compensation insurance to cover costs and expenses incurred due to injuries to our employees resultingfrom the use of hazardous materials, this insurance may not provide adequate coverage against potential liabilities. We do nothave insurance for environmental liability or toxic tort claims that may be asserted in connection with the storage or disposalof biological or hazardous materials.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif">        Inaddition, we may incur substantial costs in order to comply with current or future environmental, health and safety laws and regulations.These current or future laws and regulations may impair our research, development or production efforts. Failure to comply withthese laws and regulations also may result in substantial fines, penalties or other sanctions.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif">        <b>         <i>         </i>        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif">        <b>         <i>          Weface potential product liability exposure, and if successful claims are brought against us, we could incur substantial liability.         </i>        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif">        Theclinical use of our product candidates and, if any of our product candidates achieves regulatory approval, any future commercialuse of the approved products, exposes us to the risk of product liability claims. Any side effects, manufacturing defects, misuse,or abuse associated with our product candidates or any approved products could result in injury to a patient or even death. Inaddition, a liability claim could be brought against us even if our product candidates or any approved products merely appearto have caused an injury. These product liability claims could be brought against us by consumers, healthcare providers, pharmaceuticalcompanies or others that come into contact with our product candidates or any approved products.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif">        Regardlessof merit or potential outcome, product liability claims against us could result in, among other effects, the inability to continueclinical testing of our product candidates or, for any approved products, commercialization of the products, impairment of ourbusiness reputation, withdrawal of clinical trial participants and distraction of management’s attention from our primarybusiness activities. In addition, if we cannot successfully defend against product liability claims, we could incur substantialliabilities, including liabilities that may be beyond the scope or limits of any applicable insurance policies we may have inplace. Any of these outcomes could severely harm our business, financial condition and prospects.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif">        <b>         <i>         </i>        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif">        <b>         <i>          Ourbusiness depends in large part on our ability to protect our proprietary rights and technologies, and we may be unsuccessful inthese efforts.         </i>        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif">        Webelieve our success and ability to compete depends in large part on obtaining and maintaining patent, trademark and trade secretprotection of our product candidates and their respective components and underlying technologies, including devices, formulations,manufacturing methods and methods of treatment, as well as successfully defending our intellectual property rights against third-partychallenges. Our ability to stop third parties from making, using or selling products that infringe on our intellectual propertyrights depends on the extent to which we have secured and properly safeguarded these rights under valid and enforceable patentsor trade secrets.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif">       </font>      </p>      <!-- Field: Page; Sequence: 47; Value: 38 -->      <div style="margin-bottom: 6pt; border-bottom: Black 1.5pt solid">       <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">        <tbody>         <tr style="vertical-align: top; text-align: left">          <td style="text-align: center; width: 100%">           <!-- Field: Sequence; Type: Arabic; Name: PageNo -->           45           <!-- Field: /Sequence -->          </td>         </tr>        </tbody>       </table>      </div>      <div style="page-break-before: always; margin-top: 6pt">       <p style="margin: 0pt">       </p>      </div>      <!-- Field: /Page -->      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">       <font style="font-family: Times New Roman, Times, Serif">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif">        Althoughwe previously owned patents protecting our OMS EP Devices, our primary U.S. and foreign patents providing such protection expiredin 2017 and 2018, and the final foreign patents expired in late 2019. As a result, we may have limited ability to enforce theserights against third parties to prevent them from making or selling competing products that rely upon the protected technology,which could harm our competitive position and prospects. In addition to these proprietary rights that expired between 2017 and2019, we also own or have exclusively licensed certain patents and applications that cover our current clinical methods. Thesepatents will expire between 2024 and 2037. These method patents protect the use of a product for a specified method under certaindefined parameters. These types of method patents do not prevent a competitor from making and marketing a product that is identicalor similar to the protected product under parameters that are outside the scope of the patented method claims. Moreover, evenif competitors do not actively promote such a product for the indications protected by the method patent, physicians could prescribethe products for these methods on an off-label basis. Although such off-label prescriptions may infringe or contribute to theinfringement of method-of-use patents, the practice is common and such infringement is difficult to detect, prevent or prosecute.Furthermore, our licensed patents expiring between 2024 and 2032 may not have as broad a scope as our patents that expired between2017 and 2019, which in turn may limit our remedies against competitors making and marketing a product that is identical or similarto ours.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif">        Tothe extent our existing patents or pending or planned patent applications expire before we are able to commercialize product dependingon the technology or do not otherwise provide sufficient protection, we could be subject to substantially increased competitionand our business and ability to commercialize or license our technology or product candidates could be materially adversely affected.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif">        Evenif we secure patents that cover our proprietary technology, our efforts to protect our intellectual property rights with patentsmay prove inadequate. For instance, the breadth of claims in a patent application is often restricted during patent prosecution,resulting in granted claims with a more limited scope than the claims in the original application. Additionally, pending or futurepatent applications may not result in issued patents. Laws and regulations for the prosecution of patents are continuously evolving,and the U.S. Supreme Court has, in the past several years, revised certain tests regarding both the grant and review of patentsthat could make it more difficult to obtain issued patents. Also, any patents that are granted could be subject to post-grantproceedings that could limit their scope or enforceability, and claims that are amended during post-grant proceedings may notbe broad enough to provide meaningful protection. Moreover, any patents that are issued to us or any future collaborators maybe circumvented or invalidated by third-party efforts, may expire before or shortly after obtaining necessary regulatory approvals,or may not provide sufficient proprietary protection or competitive advantage for other reasons. Such challenges could includethird-party pre-issuance submissions of prior art to the PTO, or opposition, derivation, reexamination, inter parties review,or post-grant review or interference proceedings challenging our patent rights or the patent rights of others. The cost of theseproceedings could be substantial, and it is possible that our efforts to establish priority or validity of the inventionwould be unsuccessful, resulting in a material adverse effect on our U.S. patent position. An adverse determination in any suchsubmission, patent office trial, proceeding or litigation could reduce the scope of, render unenforceable, or invalidate, ourpatent rights, allow third parties to commercialize our technology or products and compete directly with us, without payment tous, or result in our inability to manufacture or commercialize products without infringing third-party patent rights. In addition,if the breadth or strength of protection provided by our patents and patent applications is threatened, it could dissuade companiesfrom collaborating with us to license, develop or commercialize current or future product candidates. Further, obtaining and maintainingpatent protection depends on compliance with various procedural, document submission, fee payment, and other requirements imposedby government patent agencies, and our patent protection could be reduced or eliminated for non-compliance with these requirements.These risks may be amplified in some foreign jurisdictions, where patent protection may not be as strong or as effective as itis in the United States.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif">       </font>      </p>      <!-- Field: Page; Sequence: 48; Value: 38 -->      <div style="margin-bottom: 6pt; border-bottom: Black 1.5pt solid">       <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">        <tbody>         <tr style="vertical-align: top; text-align: left">          <td style="text-align: center; width: 100%">           <!-- Field: Sequence; Type: Arabic; Name: PageNo -->           46           <!-- Field: /Sequence -->          </td>         </tr>        </tbody>       </table>      </div>      <div style="page-break-before: always; margin-top: 6pt">       <p style="margin: 0pt">       </p>      </div>      <!-- Field: /Page -->      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">       <font style="font-family: Times New Roman, Times, Serif">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif">        Ourreliance on unpatented proprietary rights, including trade secrets and know-how, may also pose significant risks. For instance,it can be difficult to protect these rights and they may lose their value if they are independently developed by a third partyor if their secrecy is lost. Although we have taken measures to protect these rights, including establishing confidentiality agreementswith employees, consultants and other third parties, these measures may not sufficiently safeguard our unpatented proprietaryrights and may not provide adequate remedies in the event of unauthorized use or disclosure of the confidential information. Despitethese efforts, any of these parties may breach the agreements and may unintentionally or willfully disclose our proprietary information,including our trade secrets, and we may not be able to obtain adequate remedies for such breaches. Enforcing a claim that a partyillegally disclosed or misappropriated a trade secret is difficult, expensive and time-consuming, and the outcome is unpredictable.In addition, some courts inside and outside the U.S. are less willing or unwilling to protect trade secrets. Moreover, if anyof our trade secrets were to be lawfully obtained or independently developed by a competitor, we would have no right to preventthem, or those to whom they communicate it, from using that technology or information to compete with us. If any of our tradesecrets were to be disclosed to or independently developed by a competitor, our competitive position would be harmed.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif">        Ifwe are unable to secure patent protection for our patentable technologies, if any of our issued patents are limited or found tobe invalid or unenforceable, or if we are otherwise unable to adequately protect our patented or unpatented proprietary rights,our business and prospects could be materially negatively affected.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif">        <b>         <i>         </i>        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif">        <b>         <i>          Ifwe fail to maintain an effective system of internal controls, we may not be able to accurately report our financial results andstockholders and the investment community could lose confidence in our financial reporting, which could harm our business.         </i>        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif">        Ourmanagement is responsible for establishing and maintaining adequate internal control over financial reporting. Although managementhas determined that our internal control over financial reporting was effective as of July 31, 2020, our controls over financialprocesses and reporting may not continue to be effective, or we may identify significant deficiencies or material weaknesses inour internal controls in the future. Any failure to maintain effective internal control over financial reporting, including failuresto implement new or improved controls as needed in a timely and effective manner or remediate any significant deficiency or materialweakness that is identified in the future, could cause noncompliance with our public reporting obligations, an inability to producereliable financial reports or material misstatements in our financial statements or other public disclosures. If any of thesecircumstances were to occur, investors could lose confidence in our financial and other reported information, our reputation couldotherwise be harmed, the investment of our stockholders in our company could be negatively affected and the costs to us of raisingadditional capital could materially increase, any of which could harm our business and prospects.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif">        <b>         <i>         </i>        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif">        <b>         <i>          Maintainingcompliance with our reporting and other obligations as a public company could strain our resources and distract management.         </i>        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif">        Asa public company, we experience significant demands that are not applicable to private companies. For example, the Sarbanes-OxleyAct of 2002 and related and other rules implemented by the SEC and the Nasdaq Capital Market, which maintains the securities exchangeon which our common stock is listed for trading, impose a number of requirements on public companies, including with respect tocorporate governance practices, periodic reporting and other disclosure requirements and financial and disclosure controls andprocedures. Further, the SEC and other regulators have continued to adopt new rules and make changes to existing regulations thatrequire our compliance, such as the Dodd-Frank Wall Street Reform and Consumer Protection Act of 2010 and the corporate governanceand executive compensation-related disclosure requirements of this legislation.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif">        Maintainingcompliance with the rules and regulations applicable to public companies involves significant legal, accounting and financialcosts. Additionally, if we grow as anticipated, we may need to hire additional personnel and implement new and more sophisticatedfinancial and accounting systems and procedures to continue to meet our public company obligations. Our management and other personneldevote substantial attention to maintaining our compliance with these obligations, which diverts attention from other aspectsof our business. Any failure to comply with these public company requirements could have a material adverse effect on our businessand prospects and could materially harm our stockholders’ investment in our Company.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif">        <b>         <i>         </i>        </b>       </font>      </p>      <!-- Field: Page; Sequence: 49; Value: 38 -->      <div style="margin-bottom: 6pt; border-bottom: Black 1.5pt solid">       <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">        <tbody>         <tr style="vertical-align: top; text-align: left">          <td style="text-align: center; width: 100%">           <!-- Field: Sequence; Type: Arabic; Name: PageNo -->           47           <!-- Field: /Sequence -->          </td>         </tr>        </tbody>       </table>      </div>      <div style="page-break-before: always; margin-top: 6pt">       <p style="margin: 0pt">       </p>      </div>      <!-- Field: /Page -->      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">       <font style="font-family: Times New Roman, Times, Serif">        <b>         <i>         </i>        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif">        <b>         <i>          Wemay not be able to realize value from, or otherwise preserve and utilize, our net operating loss carryforwards and certain othertax attributes.         </i>        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif">        Ifa corporation undergoes an “ownership change” within the meaning of Section 382 of the Internal Revenue Code of 1986,as amended, the corporation’s net operating loss carryforwards and certain other tax attributes arising prior to the ownershipchange are subject to limitations on use after the ownership change. In general, an ownership change occurs if there is a cumulativechange in the corporation’s equity ownership by certain stockholders that exceeds 50% over a rolling three-year period.Similar rules may apply under state tax laws. If we experience such an ownership change, our net operating loss carryforwardsgenerated prior to the ownership change would be subject to annual limitations that could reduce, eliminate or defer the utilizationof these losses.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif">        Moreover,the recognition and measurement of net operating loss carryforwards may include estimates and judgments by management, and theInternal Revenue Service could, upon audit or other investigation, disagree with the amount of net operating loss carryforwardsor the determination of whether an ownership change has occurred. Additionally, legislative or regulatory changes or judicialdecisions could further negatively impact the ability to use any tax benefits associated with net operating loss carryforwards.Any inability to use net operating loss carryforwards to reduce our U.S. federal or state income tax liability could materiallyharm our financial condition and results of operations.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif">        <b>         <i>         </i>        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif">        <b>         <i>          Ourtax position could be affected by recent changes in United States federal income tax laws.         </i>        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif">        OnDecember 22, 2017, legislation commonly referred to as the “Tax Cuts and Jobs Act” was signed into law and is generallyeffective after December 31, 2017. The Tax Cuts and Jobs Act made significant changes to the United States federal income taxrules for taxation of individuals and business entities. Most of the changes applicable to individuals are temporary and applyonly to taxable years beginning after December 31, 2017 and before January 1, 2026. For corporations, the Tax Cuts and Jobs Actreduced the top corporate income tax rate to 21% and repealed the corporate alternative minimum tax, limits the deduction fornet interest expense, limits the deduction for net operating losses and eliminates net operating loss carrybacks, modifies orrepeals many business deductions and credits, shifts the United States toward a more territorial tax system, and imposes new taxesto combat erosion of the United States federal income tax base. The Company accounted for the identified changes and adjustedthe carrying amounts of gross deferred tax assets and corresponding valuation allowance in the year ended July 31, 2018. Therewas no net impact to the Company’s financial statements as a result. affect us. However, the effect of the Tax Cuts andJobs Act on us and our affiliates, whether adverse or favorable, is uncertain, and may not become evident for some period of time.This document does not discuss such legislation or the manner in which it might affect us or purchasers of our common stock. Prospectiveinvestors are urged to consult with their legal and tax advisors with respect to the Tax Cuts and Jobs Act and any other regulatoryor administrative developments and proposals, and their potential effects on them based on their unique circumstances.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif">        <b>         RisksRelated to our Growth Strategy        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif">        <b>         <i>         </i>        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif">        <b>         <i>          Ifwe acquire, enter into joint ventures with or obtain a controlling interest in companies in the future, it could adversely affectour operating results and the value of our Common Stock thereby diluting stockholder value and disrupting our business.         </i>        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif">        Aspart of our growth strategy, we might acquire, enter into joint ventures with, or obtain a significant ownership stake in othercompanies. Acquisitions of, joint ventures with and investments in other companies involve numerous risks, including, but notnecessarily limited to:       </font>      </p>      <p style="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif">       </font>      </p>      <table cellpadding="0" cellspacing="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">       <tbody>        <tr style="vertical-align: top">         <td style="width: 0.5in">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           ●          </font>         </td>         <td style="text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           risk of entering    new markets in which we have little to no experience;          </font>         </td>        </tr>        <tr style="vertical-align: top">         <td>          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="vertical-align: top">         <td>          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           ●          </font>         </td>         <td style="text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           diversion of financial    and managerial resources from existing operations;          </font>         </td>        </tr>        <tr style="vertical-align: top">         <td>          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="vertical-align: top">         <td>          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           ●          </font>         </td>         <td style="text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           successfully negotiating    a proposed acquisition or investment timely and at a price or on terms and conditions favorable to us;          </font>         </td>        </tr>        <tr style="vertical-align: top">         <td>          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="vertical-align: top">         <td>          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           ●          </font>         </td>         <td style="text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           the impact of regulatory    reviews on a proposed acquisition or investment;          </font>         </td>        </tr>       </tbody>      </table>      <p style="font: 12pt Times New Roman, Times, Serif; margin: 0">       <font style="font-family: Times New Roman, Times, Serif">       </font>      </p>      <!-- Field: Page; Sequence: 50; Value: 38 -->      <div style="margin-bottom: 6pt; border-bottom: Black 1.5pt solid">       <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">        <tbody>         <tr style="vertical-align: top; text-align: left">          <td style="text-align: center; width: 100%">           <!-- Field: Sequence; Type: Arabic; Name: PageNo -->           48           <!-- Field: /Sequence -->          </td>         </tr>        </tbody>       </table>      </div>      <div style="page-break-before: always; margin-top: 6pt">       <p style="margin: 0pt">       </p>      </div>      <!-- Field: /Page -->      <p style="font: 12pt Times New Roman, Times, Serif; margin: 0">       <font style="font-family: Times New Roman, Times, Serif">       </font>      </p>      <table cellpadding="0" cellspacing="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">       <tbody>        <tr style="vertical-align: top">         <td style="width: 0.5in">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           ●          </font>         </td>         <td style="text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           the outcome of any    legal proceedings that may be instituted with respect to the proposed acquisitions or investment;          </font>         </td>        </tr>        <tr style="vertical-align: top">         <td>          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="vertical-align: top">         <td>          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           ●          </font>         </td>         <td style="text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           with respect to    an acquisition, difficulties in integrating operations, technologies, services and personnel; and          </font>         </td>        </tr>        <tr style="vertical-align: top">         <td>          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="vertical-align: top">         <td>          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           ●          </font>         </td>         <td style="text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           potential inability    to maintain relationships with customers of the companies we may acquire or invest in.          </font>         </td>        </tr>       </tbody>      </table>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif">        Ifwe fail to properly evaluate potential acquisitions, joint ventures or investments, we might not achieve the anticipated benefitsof any such transaction, we might incur costs in excess of what we anticipate, and management resources and attention might bediverted from other necessary or valuable activities.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif">        <b>         <i>          Ifwe cannot continue to fund our research and development programs, we may be required to reduce product development, which willadversely impact our growth strategy.         </i>        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif">        Ourresearch and development (“R&amp;D”) programs will require substantial additional capital to conduct research, preclinicaltesting and human studies, establish pilot scale and commercial scale manufacturing processes and facilities, and establish anddevelop quality control, regulatory, marketing, sales and administrative capabilities to support these programs. We expect tofund our R&amp;D activities from a combination of cash generated from royalties and milestones from our partners in various past,ongoing and future collaborations and additional equity or debt financings from third parties. These financings could depressour stock price. If additional funds are required to support our operations and such funds cannot be obtained on favorable terms,we may not be able to develop products, which will adversely impact our growth strategy.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif">        <b>         RisksRelated to Our Common Stock        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif">        <b>         <i>         </i>        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif">        <b>         <i>          Theprice and trading volume of our common stock may be subject to extreme volatility, and stockholders could lose all or part oftheir investment in our company.         </i>        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif">        Thetrading volume and market price of our common stock has experienced, and is likely to continue to experience, significant volatility.This volatility could negatively impact our ability to raise additional capital or utilize equity as consideration in any acquisitiontransactions we may seek to pursue, and could make it more difficult for existing stockholders to sell their shares of our commonstock at a price they consider acceptable or at all. This volatility is caused by a variety of factors, including, among the otherrisks described in these risk factors:       </font>      </p>      <p style="font: 12pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify; text-indent: -0.5in">       <font style="font-family: Times New Roman, Times, Serif">       </font>      </p>      <table cellpadding="0" cellspacing="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">       <tbody>        <tr style="vertical-align: top">         <td style="width: 0.5in">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="width: 0.5in">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           ●          </font>         </td>         <td style="text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           adverse research    and development or clinical trial results;          </font>         </td>        </tr>        <tr style="vertical-align: top">         <td>          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td>          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="vertical-align: top">         <td>          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td>          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           ●          </font>         </td>         <td style="text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           our liquidity and    ability to obtain additional capital, including the market’s reaction to any capital-raising transaction we may pursue;          </font>         </td>        </tr>        <tr style="vertical-align: top">         <td>          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td>          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="vertical-align: top">         <td>          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td>          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           ●          </font>         </td>         <td style="text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           declining working    capital to fund operations, or other signs of financial uncertainty;          </font>         </td>        </tr>        <tr style="vertical-align: top">         <td>          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td>          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="vertical-align: top">         <td>          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td>          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           ●          </font>         </td>         <td style="text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           any negative announcement    by the FDA or comparable regulatory bodies outside the United States, including that it has denied any request to approve    any of our product candidates for commercialization;          </font>         </td>        </tr>        <tr style="vertical-align: top">         <td>          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td>          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="vertical-align: top">         <td>          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td>          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           ●          </font>         </td>         <td style="text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           conducting open-ended    clinical trials, which could lead to results (either positive or negative) being available to the public prior to a formal    announcement;          </font>         </td>        </tr>       </tbody>      </table>      <p style="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif">       </font>      </p>      <table cellpadding="0" cellspacing="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">       <tbody>        <tr style="vertical-align: top">         <td style="width: 0.5in">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="width: 0.5in">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           ●          </font>         </td>         <td style="text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           market assessments    of any strategic transaction or collaboration arrangement we may pursue;          </font>         </td>        </tr>        <tr style="vertical-align: top">         <td>          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td>          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="vertical-align: top">         <td>          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td>          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           ●          </font>         </td>         <td style="text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           potential negative    market reaction to the terms or volume of any issuance of shares of our common stock or other securities to new investors    pursuant to strategic or capital-raising transactions or to employees, directors or other service providers;          </font>         </td>        </tr>       </tbody>      </table>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">       <font style="font-family: Times New Roman, Times, Serif">       </font>      </p>      <!-- Field: Page; Sequence: 51; Value: 38 -->      <div style="margin-bottom: 6pt; border-bottom: Black 1.5pt solid">       <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">        <tbody>         <tr style="vertical-align: top; text-align: left">          <td style="text-align: center; width: 100%">           <!-- Field: Sequence; Type: Arabic; Name: PageNo -->           49           <!-- Field: /Sequence -->          </td>         </tr>        </tbody>       </table>      </div>      <div style="page-break-before: always; margin-top: 6pt">       <p style="margin: 0pt">       </p>      </div>      <!-- Field: /Page -->      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">       <font style="font-family: Times New Roman, Times, Serif">       </font>      </p>      <table cellpadding="0" cellspacing="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">       <tbody>        <tr style="vertical-align: top">         <td style="width: 48px">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="width: 48px">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           ●          </font>         </td>         <td style="text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           sales of substantial    amounts of our common stock, or the perception that substantial amounts of our common stock may be sold, by stockholders in    the public market;          </font>         </td>        </tr>        <tr style="vertical-align: top">         <td>          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td>          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="vertical-align: top">         <td>          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td>          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           ●          </font>         </td>         <td style="text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           issuance of new    or updated research or reports by securities analysts or changed recommendations for our common stock;          </font>         </td>        </tr>        <tr style="vertical-align: top">         <td>          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td>          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="vertical-align: top">         <td>          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td>          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           ●          </font>         </td>         <td style="text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           significant advances    made by competitors that adversely affect our competitive position;          </font>         </td>        </tr>        <tr style="vertical-align: top">         <td>          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td>          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="vertical-align: top">         <td>          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td>          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           ●          </font>         </td>         <td style="text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           the loss of key    personnel and the inability to attract and retain additional highly-skilled personnel; and          </font>         </td>        </tr>        <tr style="vertical-align: top">         <td>          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td>          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="vertical-align: top">         <td>          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td>          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           ●          </font>         </td>         <td style="text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           general market and    economic conditions, including factors not directly related to our operating performance or the operating performance of our    competitors, such as increased uncertainty in the U.S. healthcare regulatory environment following the results of the 2020    U.S. presidential election.          </font>         </td>        </tr>       </tbody>      </table>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif">        Inaddition, the stock market in general, and the market for stock of companies in the life sciences and biotechnology industriesin particular, has experienced extreme price and volume fluctuations that have often been unrelated or disproportionate to theoperating performance of specific companies. In addition, in the past, following periods of volatility in the overall market andthe market price of a particular company’s securities, securities class action litigation has often been instituted againsta company. This type of litigation, if instituted against us, could result in substantial costs and a diversion of our management’sattention and resources.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif">        <b>         <i>          Thepossibility of the economy’s return to recessionary conditions and the possibility of further turmoil or volatility in thefinancial markets would likely have an adverse effect on our business, financial position, and results of operations.         </i>        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif">        Theeconomy in the United States and globally has experienced volatility in recent years and may continue to experience such volatilityfor the foreseeable future. There can be no assurance that economic conditions will not worsen. Unfavorable or uncertain economicconditions can be caused by declines in economic growth, business activity, or investor or business confidence, limitations onthe availability or increases in the cost of credit and capital, the timing and impact of changing governmental policies, naturaldisasters, epidemics / pandemics, such as COVID-19, terrorist attacks, acts of war, or a combination of these or other factors.A worsening of business and economic conditions could have adverse effects on our business, including substantial fluctuationsin the market price of our common stock, which could decline below current levels.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif">        <b>         <i>          Ifwe issue additional equity securities in the future, our existing stockholders would be diluted.         </i>        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif">        Ourarticles of incorporation authorize the issuance of up to 100,000,000 shares of our common stock. In addition to capital-raisingactivities, on which we have historically relied for cash to fund our operations, other possible business and financial uses forour authorized common stock include, among others, stock splits, acquiring other businesses or assets in exchange for shares ofour common stock, issuing shares of our common stock to collaborators in connection with strategic alliances, issuing common stockto vendors for services performed, attracting and retaining employees with equity compensation or other transactions and corporatepurposes that our Board of Directors deems to be in the best interest of our Company. Additionally, issuances of common stockcould be used for anti-takeover purposes or to delay or prevent changes in control or management of our Company. Any future issuancesof our common stock may be consummated on terms that are not favorable, may not enhance stockholder value and may adversely affectthe trading price of our common stock. Further, any such issuance will reduce the book value per share of our common stock andreduce the proportionate ownership and voting power of our existing stockholders.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif">       </font>      </p>      <!-- Field: Page; Sequence: 52; Value: 38 -->      <div style="margin-bottom: 6pt; border-bottom: Black 1.5pt solid">       <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">        <tbody>         <tr style="vertical-align: top; text-align: left">          <td style="text-align: center; width: 100%">           <!-- Field: Sequence; Type: Arabic; Name: PageNo -->           50           <!-- Field: /Sequence -->          </td>         </tr>        </tbody>       </table>      </div>      <div style="page-break-before: always; margin-top: 6pt">       <p style="margin: 0pt">       </p>      </div>      <!-- Field: /Page -->      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">       <font style="font-family: Times New Roman, Times, Serif">        <b>         <i>         </i>        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif">        <b>         <i>          Wehave not paid dividends in the past and do not expect to pay dividends in the future, and any return on investment may be limitedto the value of your stock.         </i>        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif">        Wehave never paid dividends on our common stock and do not anticipate paying any dividends for the foreseeable future. You shouldnot rely on an investment in our stock if you require dividend income. Further, you will only realize income on an investmentin our stock in the event you sell or otherwise dispose of your shares at a price higher than the price you paid for your shares.Such a gain would result only from an increase in the market price of our common stock, which is uncertain and unpredictable.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif">        <b>         <i>         </i>        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif">        <b>         <i>          Ifoutstanding options or warrants to purchase shares of our common stock are exercised or outstanding restricted stock units vestand settle, our existing stockholders would be diluted.         </i>        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif">        Asof July 31, 2020, we had outstanding (i) options to purchase 1.4 million shares of our common stock, (ii) warrants to purchase3.1 million shares of our common stock, and (iii) 0.1 million restricted stock units. In addition, as of July 31, 2020, therewere approximately 1.6 million shares reserved for future issuance under our stock incentive and stock purchase plans. The exerciseof options and warrants, the vesting and settlement of restricted stock units or the issuance of additional equity awards underour stock incentive and stock purchase plans could have an adverse effect on the market for our common stock, including the pricethat any stockholder could obtain for its shares. Further, our existing stockholders could experience significant dilution inthe net tangible book value of their investment upon the issuance of additional shares of our common stock through the exerciseof derivative securities that are currently outstanding or that we may issue in the future.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif">        <b>         <i>         </i>        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif">        <b>         <i>          Salesof common stock by our stockholders, or the perception that such sales may occur, could depress the market price of our commonstock.         </i>        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif">        Themarket price of our common stock could decline as a result of sales by, or the perceived possibility of sales by, our existingstockholders. Since March 2011, we have completed a number of offerings of our common stock and warrants. Future sales of commonstock by significant stockholders, including by those who acquired their shares in our prior equity offerings, or the perceptionthat such sales may occur, could depress the price of our common stock.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; text-transform: uppercase">        <b>         <a name="cj_001">         </a>         ITEM1B. UNRESOLVED STAFF COMMENTS        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif">        None.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; text-transform: uppercase">        <b>         <a name="cj_002">         </a>         ITEM2. PROPERTIES        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif">        Ourcorporate and executive office is located in Pennington, New Jersey, where we lease space at 24 N. Main Street, Pennington, NewJersey, pursuant to a lease agreement which expires in 2021. Our Company also has an office located in San Diego, California,where we lease space at 3565 General Atomics Court, Suite 100, San Diego, CA, 92121, pursuant to lease which expires in 2023.Additionally, we entered into a lease assignment agreement for space located at 5820 Nancy Ridge Drive, San Diego, California,92121 which expires in 2025. We have also entered into lease arrangements for lab space in San Diego, California to support ourresearch and development department.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif">        Webelieve our current facilities are adequate to meet our current operating needs and will remain adequate for the foreseeable future.Should we need additional space, we currently do not foresee significant difficulties in obtaining additional facilities.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; text-transform: uppercase">        <b>        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; text-transform: uppercase">        <b>         <a name="cj_003">         </a>         ITEM3. LEGAL PROCEEDINGS        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif">        Inthe ordinary course of business, we may become a party to lawsuits involving various matters. The impact and outcome of litigation,if any, is subject to inherent uncertainties, and an adverse result in these or other matters may arise from time to time thatmay harm our business. We are not currently a party, and our properties are not currently subject, to any legal proceedings that,in the opinion of management, are expected to have a material adverse effect on our business, financial condition or results ofoperations.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif">       </font>      </p>      <!-- Field: Page; Sequence: 53; Value: 38 -->      <div style="margin-bottom: 6pt; border-bottom: Black 1.5pt solid">       <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">        <tbody>         <tr style="vertical-align: top; text-align: left">          <td style="text-align: center; width: 100%">           <!-- Field: Sequence; Type: Arabic; Name: PageNo -->           51           <!-- Field: /Sequence -->          </td>         </tr>        </tbody>       </table>      </div>      <div style="page-break-before: always; margin-top: 6pt">       <p style="margin: 0pt">       </p>      </div>      <!-- Field: /Page -->      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">       <font style="font-family: Times New Roman, Times, Serif; text-transform: uppercase">        <b>        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; text-transform: uppercase">        <b>         <a name="cj_004">         </a>         ITEM4. MINE SAFETY DISCLOSURES        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif">        Notapplicable.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">       <font style="font-family: Times New Roman, Times, Serif; text-transform: uppercase">        <a name="cj_005">        </a>        <b>         PARTII        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">       <font style="font-family: Times New Roman, Times, Serif; text-transform: uppercase">        <b>        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; text-transform: uppercase">        <b>         <a name="cj_006">         </a>         ITEM5. MARKET FOR REGISTRANT’S COMMON EQUITY, RELATED STOCKHOLDER MATTERS AND ISSUER PURCHASES OF EQUITY SECURITIES        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif">        <b>        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif">        <b>         TradingInformation        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif">        Ourcommon stock began trading on the NASDAQ Capital Market tier under the symbol “ONCS” since May 29, 2015.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif">        Thefollowing table sets forth the range of reported high and low sales prices for our common stock for the fiscal quarters indicated,as reported on the NASDAQ:       </font>      </p>      <p style="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif">       </font>      </p>      <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">       <tbody>        <tr style="vertical-align: bottom">         <td style="text-align: center">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td style="font-weight: bold; padding-bottom: 1.5pt">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">          <font style="font-family: Times New Roman, Times, Serif">           High          </font>         </td>         <td style="padding-bottom: 1.5pt; font-weight: bold">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td style="font-weight: bold; padding-bottom: 1.5pt">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">          <font style="font-family: Times New Roman, Times, Serif">           Low          </font>         </td>         <td style="padding-bottom: 1.5pt; font-weight: bold">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>        </tr>        <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">         <td style="font-weight: bold">          <font style="font-family: Times New Roman, Times, Serif">           Fiscal Year Ended July 31, 2020 *          </font>         </td>         <td>          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td style="text-align: left">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td style="text-align: right">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td style="text-align: left">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td>          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td style="text-align: left">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td style="text-align: right">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td style="text-align: left">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>        </tr>        <tr style="vertical-align: bottom; background-color: White">         <td style="width: 60%">          <font style="font-family: Times New Roman, Times, Serif">           First Quarter ended October 31, 2019          </font>         </td>         <td style="width: 2%">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td style="width: 1%; text-align: left">          <font style="font-family: Times New Roman, Times, Serif">           $          </font>         </td>         <td style="width: 16%; text-align: right">          <font style="font-family: Times New Roman, Times, Serif">           2.65          </font>         </td>         <td style="width: 1%; text-align: left">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td style="width: 2%">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td style="width: 1%; text-align: left">          <font style="font-family: Times New Roman, Times, Serif">           $          </font>         </td>         <td style="width: 16%; text-align: right">          <font style="font-family: Times New Roman, Times, Serif">           1.60          </font>         </td>         <td style="width: 1%; text-align: left">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>        </tr>        <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">         <td>          <font style="font-family: Times New Roman, Times, Serif">           Second Quarter ended January 31, 2020          </font>         </td>         <td>          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td style="text-align: left">          <font style="font-family: Times New Roman, Times, Serif">           $          </font>         </td>         <td style="text-align: right">          <font style="font-family: Times New Roman, Times, Serif">           2.50          </font>         </td>         <td style="text-align: left">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td>          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td style="text-align: left">          <font style="font-family: Times New Roman, Times, Serif">           $          </font>         </td>         <td style="text-align: right">          <font style="font-family: Times New Roman, Times, Serif">           1.70          </font>         </td>         <td style="text-align: left">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>        </tr>        <tr style="vertical-align: bottom; background-color: White">         <td>          <font style="font-family: Times New Roman, Times, Serif">           Third Quarter ended April 30, 2020          </font>         </td>         <td>          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td style="text-align: left">          <font style="font-family: Times New Roman, Times, Serif">           $          </font>         </td>         <td style="text-align: right">          <font style="font-family: Times New Roman, Times, Serif">           2.54          </font>         </td>         <td style="text-align: left">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td>          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td style="text-align: left">          <font style="font-family: Times New Roman, Times, Serif">           $          </font>         </td>         <td style="text-align: right">          <font style="font-family: Times New Roman, Times, Serif">           1.04          </font>         </td>         <td style="text-align: left">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>        </tr>        <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">         <td>          <font style="font-family: Times New Roman, Times, Serif">           Fourth Quarter ended July 31, 2020          </font>         </td>         <td>          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td style="text-align: left">          <font style="font-family: Times New Roman, Times, Serif">           $          </font>         </td>         <td style="text-align: right">          <font style="font-family: Times New Roman, Times, Serif">           4.89          </font>         </td>         <td style="text-align: left">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td>          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td style="text-align: left">          <font style="font-family: Times New Roman, Times, Serif">           $          </font>         </td>         <td style="text-align: right">          <font style="font-family: Times New Roman, Times, Serif">           1.51          </font>         </td>         <td style="text-align: left">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>        </tr>        <tr style="vertical-align: bottom; background-color: White">         <td>          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td>          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td style="text-align: left">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td style="text-align: right">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td style="text-align: left">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td>          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td style="text-align: left">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td style="text-align: right">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td style="text-align: left">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>        </tr>        <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">         <td style="font-weight: bold">          <font style="font-family: Times New Roman, Times, Serif">           Fiscal Year Ended July 31, 2019 *          </font>         </td>         <td>          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td style="text-align: left">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td style="text-align: right">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td style="text-align: left">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td>          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td style="text-align: left">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td style="text-align: right">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td style="text-align: left">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>        </tr>        <tr style="vertical-align: bottom; background-color: White">         <td>          <font style="font-family: Times New Roman, Times, Serif">           First Quarter ended October 31, 2018          </font>         </td>         <td>          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td style="text-align: left">          <font style="font-family: Times New Roman, Times, Serif">           $          </font>         </td>         <td style="text-align: right">          <font style="font-family: Times New Roman, Times, Serif">           18.60          </font>         </td>         <td style="text-align: left">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td>          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td style="text-align: left">          <font style="font-family: Times New Roman, Times, Serif">           $          </font>         </td>         <td style="text-align: right">          <font style="font-family: Times New Roman, Times, Serif">           11.70          </font>         </td>         <td style="text-align: left">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>        </tr>        <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">         <td>          <font style="font-family: Times New Roman, Times, Serif">           Second Quarter ended January 31, 2019          </font>         </td>         <td>          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td style="text-align: left">          <font style="font-family: Times New Roman, Times, Serif">           $          </font>         </td>         <td style="text-align: right">          <font style="font-family: Times New Roman, Times, Serif">           19.60          </font>         </td>         <td style="text-align: left">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td>          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td style="text-align: left">          <font style="font-family: Times New Roman, Times, Serif">           $          </font>         </td>         <td style="text-align: right">          <font style="font-family: Times New Roman, Times, Serif">           5.40          </font>         </td>         <td style="text-align: left">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>        </tr>        <tr style="vertical-align: bottom; background-color: White">         <td>          <font style="font-family: Times New Roman, Times, Serif">           Third Quarter ended April 30, 2019          </font>         </td>         <td>          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td style="text-align: left">          <font style="font-family: Times New Roman, Times, Serif">           $          </font>         </td>         <td style="text-align: right">          <font style="font-family: Times New Roman, Times, Serif">           8.10          </font>         </td>         <td style="text-align: left">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td>          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td style="text-align: left">          <font style="font-family: Times New Roman, Times, Serif">           $          </font>         </td>         <td style="text-align: right">          <font style="font-family: Times New Roman, Times, Serif">           4.20          </font>         </td>         <td style="text-align: left">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>        </tr>        <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">         <td>          <font style="font-family: Times New Roman, Times, Serif">           Fourth Quarter ended July 31, 2019          </font>         </td>         <td>          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td style="text-align: left">          <font style="font-family: Times New Roman, Times, Serif">           $          </font>         </td>         <td style="text-align: right">          <font style="font-family: Times New Roman, Times, Serif">           5.90          </font>         </td>         <td style="text-align: left">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td>          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td style="text-align: left">          <font style="font-family: Times New Roman, Times, Serif">           $          </font>         </td>         <td style="text-align: right">          <font style="font-family: Times New Roman, Times, Serif">           2.02          </font>         </td>         <td style="text-align: left">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>        </tr>       </tbody>      </table>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif">        *prices reflect 1:10 reverse stock split effectuated by the Company on May 20, 2019       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif">        <b>         Holders        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif">        Asof October 28, 2020, there were 45 holders of record of our common stock, plus an indeterminate number of additionalstockholders whose shares of our common stock are held on their behalf by brokerage firms or other agents.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif">        <b>        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif">        <b>         Dividends        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif">        Wehave never declared or paid any cash dividends or distributions on our capital stock. We currently intend to retain future earnings,if any, to support operations and to finance expansion and therefore we do not anticipate paying any cash dividends on our commonstock in the foreseeable future.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif">        <b>        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif">        <b>         SecuritiesAuthorized for Issuance under Equity Compensation Plans        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif">        Theinformation included under Item 12 of Part III of this report, “Security Ownership of Certain Beneficial Owners and Managementand Related Stockholder Matters,” is hereby incorporated by reference into this Item 5 of Part II of this report.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; text-transform: uppercase">        <b>        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; text-transform: uppercase">        <b>         <a name="cj_007">         </a>         ITEM6. SELECTED FINANCIAL DATA        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif">        Notapplicable.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif">       </font>      </p>      <!-- Field: Page; Sequence: 54; Value: 38 -->      <div style="margin-bottom: 6pt; border-bottom: Black 1.5pt solid">       <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">        <tbody>         <tr style="vertical-align: top; text-align: left">          <td style="text-align: center; width: 100%">           <!-- Field: Sequence; Type: Arabic; Name: PageNo -->           52           <!-- Field: /Sequence -->          </td>         </tr>        </tbody>       </table>      </div>      <div style="page-break-before: always; margin-top: 6pt">       <p style="margin: 0pt">       </p>      </div>      <!-- Field: /Page -->      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">       <font style="font-family: Times New Roman, Times, Serif; text-transform: uppercase">        <b>        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; text-transform: uppercase">        <b>         <a name="cj_008">         </a>         ITEM7. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif">        <i>        </i>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif">        <i>         ThisManagement’s Discussion and Analysis of Financial Conditions and Results of Operations and other portions of this reportcontain forward-looking information that involves risks and uncertainties. Our actual results could differ materially from thoseanticipated by the forward-looking information. Factors that may cause such differences include, but are not limited to, availabilityand cost of financial resources, product demand, market acceptance and other factors discussed in this report under the heading“Risk Factors”. This Management’s Discussion and Analysis of Financial Condition and Results of Operations shouldbe read in conjunction with our financial statements and the related notes included elsewhere in this report.        </i>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif">        <b>        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif">        <b>         Overview        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif">        Weare a late-stage biotechnology company focused on designing, developing and commercializing innovative therapies and proprietarymedical approaches to stimulate and to guide an anti-tumor immune response for the treatment of cancer. Our core technology platform,ImmunoPulse®is a drug-device therapeutic modality platform comprised of proprietary intratumoral electroporation (“EP”)delivery, devices (the “OncoSec Medical System (OMS) Electroporation Device” or “OMS EP device”.The OMS EP device is designed to deliver plasmid DNA-encoded drugs directly into a solid tumor and promote an immunological responseagainst cancer. The OMS EP device can be adapted to treat different tumor types, and consists of an electrical pulse generator,a reusable handle and disposable applicators. Our lead product candidate is a DNA-encoded interleukin-12 (“IL-12”)called tavokinogene telseplasmid (“TAVO”). The OMS EP device is used to deliver TAVO intratumorally, with the aimof reversing the immunosuppressive microenvironment in the treated tumor. The activation of the appropriate inflammatory responsecan drive a systemic anti-tumor response against untreated tumors in other parts of the body. In 2017, we received Fast Trackdesignation and Orphan Drug Designation from the U.S. Food and Drug Administration (“FDA”) for TAVO in metastaticmelanoma, which could qualify TAVO for expedited FDA review, a rolling Biologics License Application review and certain otherbenefits.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif">        Wehave completed monotherapy and combination programs and our current focus is to pursue clinical development programs with TAVO,in combination with anti-PD-1 checkpoint inhibitors, in metastatic melanoma, triple negative breast cancer (“TNBC”)and squamous cell carcinoma head and neck (“SCCHN”). The Company intends to continue to pursue other ongoing or potentialnew trials and studies related to TAVO, in various tumor types. In addition to TAVO, we have identified and are developing newDNA-encoded therapeutic candidates and tumor indications for use with our new Visceral Lesion Applicator (“VLA”),to target deep visceral lesions, such as liver, lung, bladder, pancreatic and other difficult to treat visceral lesions.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif">        <b>         <i>          PerformanceOutlook         </i>        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif">        Weexpect to use our available working capital in the near term primarily for the advancement of our existing and planned clinicalprograms, including performance of the KEYNOTE-695 and KEYNOTE-890 studies and, to a lesser extent, the continuation of our otherclinical trials and studies. We anticipate our spending on clinical programs and the development of our next-generation OMS EPdevice will continue throughout our current fiscal year, primarily in support of the KEYNOTE-695 and KEYNOTE-890 studies, whileour spending on research and development programs will be prioritized, based on our focus on the KEYNOTE-695 and KEYNOTE-890 studies.We expect our cash-based general and administrative expenses to remain relatively flat in the near term, as we seek to continueto leverage internal resources and automate processes to decrease our outside services expenses. See “Results of Operations”below for more information.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif">       </font>      </p>      <!-- Field: Page; Sequence: 55; Value: 38 -->      <div style="margin-bottom: 6pt; border-bottom: Black 1.5pt solid">       <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">        <tbody>         <tr style="vertical-align: top; text-align: left">          <td style="text-align: center; width: 100%">           <!-- Field: Sequence; Type: Arabic; Name: PageNo -->           53           <!-- Field: /Sequence -->          </td>         </tr>        </tbody>       </table>      </div>      <div style="page-break-before: always; margin-top: 6pt">       <p style="margin: 0pt">       </p>      </div>      <!-- Field: /Page -->      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">       <font style="font-family: Times New Roman, Times, Serif">        <b>        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif">        <b>         Resultsof Operations for the Year Ended July 31, 2020 Compared to the Year Ended July 31, 2019        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif">        Thefinancial data for the years ended July 31, 2020 and July 31, 2019 is presented in the following table and the results of thesetwo periods are included in the discussion thereafter.       </font>      </p>      <p style="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif">       </font>      </p>      <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">       <tbody>        <tr style="vertical-align: bottom">         <td style="text-align: right">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td style="font-weight: bold; padding-bottom: 1.5pt">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">          <font style="font-family: Times New Roman, Times, Serif">           July    31, 2020          </font>         </td>         <td style="padding-bottom: 1.5pt; font-weight: bold">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td style="font-weight: bold; padding-bottom: 1.5pt">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">          <font style="font-family: Times New Roman, Times, Serif">           July    31, 2019          </font>         </td>         <td style="padding-bottom: 1.5pt; font-weight: bold">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td style="font-weight: bold; padding-bottom: 1.5pt">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">          <font style="font-family: Times New Roman, Times, Serif">           $    Change          </font>         </td>         <td style="padding-bottom: 1.5pt; font-weight: bold">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td style="font-weight: bold; padding-bottom: 1.5pt">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">          <font style="font-family: Times New Roman, Times, Serif">           %    Change          </font>         </td>         <td style="padding-bottom: 1.5pt; font-weight: bold">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>        </tr>        <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">         <td style="font-weight: bold; padding-bottom: 1.5pt">          <font style="font-family: Times New Roman, Times, Serif">           Revenue          </font>         </td>         <td style="padding-bottom: 1.5pt">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td style="border-bottom: Black 1.5pt solid; text-align: left">          <font style="font-family: Times New Roman, Times, Serif">           $          </font>         </td>         <td style="border-bottom: Black 1.5pt solid; text-align: right">          <font style="font-family: Times New Roman, Times, Serif">           -          </font>         </td>         <td style="padding-bottom: 1.5pt; text-align: left">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td style="padding-bottom: 1.5pt">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td style="border-bottom: Black 1.5pt solid; text-align: left">          <font style="font-family: Times New Roman, Times, Serif">           $          </font>         </td>         <td style="border-bottom: Black 1.5pt solid; text-align: right">          <font style="font-family: Times New Roman, Times, Serif">           -          </font>         </td>         <td style="padding-bottom: 1.5pt; text-align: left">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td style="padding-bottom: 1.5pt">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td style="border-bottom: Black 1.5pt solid; text-align: left">          <font style="font-family: Times New Roman, Times, Serif">           $          </font>         </td>         <td style="border-bottom: Black 1.5pt solid; text-align: right">          <font style="font-family: Times New Roman, Times, Serif">           -          </font>         </td>         <td style="padding-bottom: 1.5pt; text-align: left">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td style="padding-bottom: 1.5pt">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td style="border-bottom: Black 1.5pt solid; text-align: left">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td style="border-bottom: Black 1.5pt solid; text-align: right">          <font style="font-family: Times New Roman, Times, Serif">           -          </font>         </td>         <td style="padding-bottom: 1.5pt; text-align: left">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>        </tr>        <tr style="vertical-align: bottom; background-color: White">         <td style="font-weight: bold">          <font style="font-family: Times New Roman, Times, Serif">           Expenses          </font>         </td>         <td>          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td style="text-align: left">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td style="text-align: right">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td style="text-align: left">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td>          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td style="text-align: left">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td style="text-align: right">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td style="text-align: left">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td>          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td style="text-align: left">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td style="text-align: right">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td style="text-align: left">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td>          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td style="text-align: left">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td style="text-align: right">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td style="text-align: left">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>        </tr>        <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">         <td style="padding-left: 10pt; width: 36%; text-align: left">          <font style="font-family: Times New Roman, Times, Serif">           Research    and development          </font>         </td>         <td style="width: 2%">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td style="width: 1%; text-align: left">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td style="width: 12%; text-align: right">          <font style="font-family: Times New Roman, Times, Serif">           25,096,817          </font>         </td>         <td style="width: 1%; text-align: left">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td style="width: 2%">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td style="width: 1%; text-align: left">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td style="width: 12%; text-align: right">          <font style="font-family: Times New Roman, Times, Serif">           18,445,199          </font>         </td>         <td style="width: 1%; text-align: left">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td style="width: 2%">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td style="width: 1%; text-align: left">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td style="width: 12%; text-align: right">          <font style="font-family: Times New Roman, Times, Serif">           6,651,618          </font>         </td>         <td style="width: 1%; text-align: left">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td style="width: 2%">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td style="width: 1%; text-align: left">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td style="width: 12%; text-align: right">          <font style="font-family: Times New Roman, Times, Serif">           36          </font>         </td>         <td style="width: 1%; text-align: left">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>        </tr>        <tr style="vertical-align: bottom; background-color: White">         <td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">          <font style="font-family: Times New Roman, Times, Serif">           General    and administrative          </font>         </td>         <td style="padding-bottom: 1.5pt">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td style="border-bottom: Black 1.5pt solid; text-align: left">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td style="border-bottom: Black 1.5pt solid; text-align: right">          <font style="font-family: Times New Roman, Times, Serif">           18,312,268          </font>         </td>         <td style="padding-bottom: 1.5pt; text-align: left">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td style="padding-bottom: 1.5pt">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td style="border-bottom: Black 1.5pt solid; text-align: left">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td style="border-bottom: Black 1.5pt solid; text-align: right">          <font style="font-family: Times New Roman, Times, Serif">           11,971,479          </font>         </td>         <td style="padding-bottom: 1.5pt; text-align: left">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td style="padding-bottom: 1.5pt">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td style="border-bottom: Black 1.5pt solid; text-align: left">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td style="border-bottom: Black 1.5pt solid; text-align: right">          <font style="font-family: Times New Roman, Times, Serif">           6,340,789          </font>         </td>         <td style="padding-bottom: 1.5pt; text-align: left">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td style="padding-bottom: 1.5pt">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td style="border-bottom: Black 1.5pt solid; text-align: left">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td style="border-bottom: Black 1.5pt solid; text-align: right">          <font style="font-family: Times New Roman, Times, Serif">           53          </font>         </td>         <td style="padding-bottom: 1.5pt; text-align: left">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>        </tr>        <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">         <td style="font-weight: bold; text-align: left">          <font style="font-family: Times New Roman, Times, Serif">           Loss from operations          </font>         </td>         <td>          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td style="text-align: left">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td style="text-align: right">          <font style="font-family: Times New Roman, Times, Serif">           (43,409,085          </font>         </td>         <td style="text-align: left">          <font style="font-family: Times New Roman, Times, Serif">           )          </font>         </td>         <td>          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td style="text-align: left">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td style="text-align: right">          <font style="font-family: Times New Roman, Times, Serif">           (30,416,678          </font>         </td>         <td style="text-align: left">          <font style="font-family: Times New Roman, Times, Serif">           )          </font>         </td>         <td>          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td style="text-align: left">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td style="text-align: right">          <font style="font-family: Times New Roman, Times, Serif">           12,992,407          </font>         </td>         <td style="text-align: left">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td>          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td style="text-align: left">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td style="text-align: right">          <font style="font-family: Times New Roman, Times, Serif">           43          </font>         </td>         <td style="text-align: left">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>        </tr>        <tr style="vertical-align: bottom; background-color: White">         <td style="padding-left: 10pt; text-align: left">          <font style="font-family: Times New Roman, Times, Serif">           Other income, net          </font>         </td>         <td>          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td style="text-align: left">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td style="text-align: right">          <font style="font-family: Times New Roman, Times, Serif">           185,052          </font>         </td>         <td style="text-align: left">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td>          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td style="text-align: left">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td style="text-align: right">          <font style="font-family: Times New Roman, Times, Serif">           440,037          </font>         </td>         <td style="text-align: left">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td>          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td style="text-align: left">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td style="text-align: right">          <font style="font-family: Times New Roman, Times, Serif">           (254,985          </font>         </td>         <td style="text-align: left">          <font style="font-family: Times New Roman, Times, Serif">           )          </font>         </td>         <td>          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td style="text-align: left">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td style="text-align: right">          <font style="font-family: Times New Roman, Times, Serif">           (58          </font>         </td>         <td style="text-align: left">          <font style="font-family: Times New Roman, Times, Serif">           )          </font>         </td>        </tr>        <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">         <td style="padding-left: 10pt; text-align: left">          <font style="font-family: Times New Roman, Times, Serif">           Interest expense          </font>         </td>         <td>          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td style="text-align: left">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td style="text-align: right">          <font style="font-family: Times New Roman, Times, Serif">           (5,114          </font>         </td>         <td style="text-align: left">          <font style="font-family: Times New Roman, Times, Serif">           )          </font>         </td>         <td>          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td style="text-align: left">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td style="text-align: right">          <font style="font-family: Times New Roman, Times, Serif">           (3,805          </font>         </td>         <td style="text-align: left">          <font style="font-family: Times New Roman, Times, Serif">           )          </font>         </td>         <td>          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td style="text-align: left">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td style="text-align: right">          <font style="font-family: Times New Roman, Times, Serif">           1,309          </font>         </td>         <td style="text-align: left">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td>          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td style="text-align: left">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td style="text-align: right">          <font style="font-family: Times New Roman, Times, Serif">           34          </font>         </td>         <td style="text-align: left">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>        </tr>        <tr style="vertical-align: bottom; background-color: White">         <td style="padding-left: 10pt; text-align: left">          <font style="font-family: Times New Roman, Times, Serif">           Loss on disposal    of property and equipment          </font>         </td>         <td>          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td style="text-align: left">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td style="text-align: right">          <font style="font-family: Times New Roman, Times, Serif">           -          </font>         </td>         <td style="text-align: left">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td>          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td style="text-align: left">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td style="text-align: right">          <font style="font-family: Times New Roman, Times, Serif">           (703          </font>         </td>         <td style="text-align: left">          <font style="font-family: Times New Roman, Times, Serif">           )          </font>         </td>         <td>          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td style="text-align: left">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td style="text-align: right">          <font style="font-family: Times New Roman, Times, Serif">           (703          </font>         </td>         <td style="text-align: left">          <font style="font-family: Times New Roman, Times, Serif">           )          </font>         </td>         <td>          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td style="text-align: left">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td style="text-align: right">          <font style="font-family: Times New Roman, Times, Serif">           (100          </font>         </td>         <td style="text-align: left">          <font style="font-family: Times New Roman, Times, Serif">           )          </font>         </td>        </tr>        <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">         <td style="padding-left: 10pt; text-align: left">          <font style="font-family: Times New Roman, Times, Serif">           Foreign currency    exchange gain/(loss), net          </font>         </td>         <td>          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td style="text-align: left">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td style="text-align: right">          <font style="font-family: Times New Roman, Times, Serif">           103,136          </font>         </td>         <td style="text-align: left">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td>          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td style="text-align: left">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td style="text-align: right">          <font style="font-family: Times New Roman, Times, Serif">           (281,473          </font>         </td>         <td style="text-align: left">          <font style="font-family: Times New Roman, Times, Serif">           )          </font>         </td>         <td>          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td style="text-align: left">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td style="text-align: right">          <font style="font-family: Times New Roman, Times, Serif">           (384,609          </font>         </td>         <td style="text-align: left">          <font style="font-family: Times New Roman, Times, Serif">           )          </font>         </td>         <td>          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td style="text-align: left">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td style="text-align: right">          <font style="font-family: Times New Roman, Times, Serif">           (137          </font>         </td>         <td style="text-align: left">          <font style="font-family: Times New Roman, Times, Serif">           )          </font>         </td>        </tr>        <tr style="vertical-align: bottom; background-color: White">         <td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">          <font style="font-family: Times New Roman, Times, Serif">           Realized    loss on sale of securities, net          </font>         </td>         <td style="padding-bottom: 1.5pt">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td style="border-bottom: Black 1.5pt solid; text-align: left">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td style="border-bottom: Black 1.5pt solid; text-align: right">          <font style="font-family: Times New Roman, Times, Serif">           -          </font>         </td>         <td style="padding-bottom: 1.5pt; text-align: left">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td style="padding-bottom: 1.5pt">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td style="border-bottom: Black 1.5pt solid; text-align: left">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td style="border-bottom: Black 1.5pt solid; text-align: right">          <font style="font-family: Times New Roman, Times, Serif">           (12,134          </font>         </td>         <td style="padding-bottom: 1.5pt; text-align: left">          <font style="font-family: Times New Roman, Times, Serif">           )          </font>         </td>         <td style="padding-bottom: 1.5pt">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td style="border-bottom: Black 1.5pt solid; text-align: left">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td style="border-bottom: Black 1.5pt solid; text-align: right">          <font style="font-family: Times New Roman, Times, Serif">           (12,134          </font>         </td>         <td style="padding-bottom: 1.5pt; text-align: left">          <font style="font-family: Times New Roman, Times, Serif">           )          </font>         </td>         <td style="padding-bottom: 1.5pt">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td style="border-bottom: Black 1.5pt solid; text-align: left">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td style="border-bottom: Black 1.5pt solid; text-align: right">          <font style="font-family: Times New Roman, Times, Serif">           (100          </font>         </td>         <td style="padding-bottom: 1.5pt; text-align: left">          <font style="font-family: Times New Roman, Times, Serif">           )          </font>         </td>        </tr>        <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">         <td style="font-weight: bold; text-align: left">          <font style="font-family: Times New Roman, Times, Serif">           Loss before income    taxes          </font>         </td>         <td>          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td style="text-align: left">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td style="text-align: right">          <font style="font-family: Times New Roman, Times, Serif">           (43,126,011          </font>         </td>         <td style="text-align: left">          <font style="font-family: Times New Roman, Times, Serif">           )          </font>         </td>         <td>          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td style="text-align: left">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td style="text-align: right">          <font style="font-family: Times New Roman, Times, Serif">           (30,274,756          </font>         </td>         <td style="text-align: left">          <font style="font-family: Times New Roman, Times, Serif">           )          </font>         </td>         <td>          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td style="text-align: left">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td style="text-align: right">          <font style="font-family: Times New Roman, Times, Serif">           12,851,255          </font>         </td>         <td style="text-align: left">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td>          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td style="text-align: left">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td style="text-align: right">          <font style="font-family: Times New Roman, Times, Serif">           42          </font>         </td>         <td style="text-align: left">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>        </tr>        <tr style="vertical-align: bottom; background-color: White">         <td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">          <font style="font-family: Times New Roman, Times, Serif">           Income    tax expense (benefit)          </font>         </td>         <td style="padding-bottom: 1.5pt">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td style="border-bottom: Black 1.5pt solid; text-align: left">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td style="border-bottom: Black 1.5pt solid; text-align: right">          <font style="font-family: Times New Roman, Times, Serif">           (872,585          </font>         </td>         <td style="padding-bottom: 1.5pt; text-align: left">          <font style="font-family: Times New Roman, Times, Serif">           )          </font>         </td>         <td style="padding-bottom: 1.5pt">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td style="border-bottom: Black 1.5pt solid; text-align: left">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td style="border-bottom: Black 1.5pt solid; text-align: right">          <font style="font-family: Times New Roman, Times, Serif">           1,297          </font>         </td>         <td style="padding-bottom: 1.5pt; text-align: left">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td style="padding-bottom: 1.5pt">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td style="border-bottom: Black 1.5pt solid; text-align: left">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td style="border-bottom: Black 1.5pt solid; text-align: right">          <font style="font-family: Times New Roman, Times, Serif">           (873,882          </font>         </td>         <td style="padding-bottom: 1.5pt; text-align: left">          <font style="font-family: Times New Roman, Times, Serif">           )          </font>         </td>         <td style="padding-bottom: 1.5pt">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td style="border-bottom: Black 1.5pt solid; text-align: left">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td style="border-bottom: Black 1.5pt solid; text-align: right">          <font style="font-family: Times New Roman, Times, Serif">           (67,377          </font>         </td>         <td style="padding-bottom: 1.5pt; text-align: left">          <font style="font-family: Times New Roman, Times, Serif">           )          </font>         </td>        </tr>        <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">         <td style="font-weight: bold; text-align: left; padding-bottom: 2.5pt">          <font style="font-family: Times New Roman, Times, Serif">           Net    loss          </font>         </td>         <td style="padding-bottom: 2.5pt">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td style="border-bottom: Black 2.5pt double; text-align: left">          <font style="font-family: Times New Roman, Times, Serif">           $          </font>         </td>         <td style="border-bottom: Black 2.5pt double; text-align: right">          <font style="font-family: Times New Roman, Times, Serif">           (42,253,426          </font>         </td>         <td style="padding-bottom: 2.5pt; text-align: left">          <font style="font-family: Times New Roman, Times, Serif">           )          </font>         </td>         <td style="padding-bottom: 2.5pt">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td style="border-bottom: Black 2.5pt double; text-align: left">          <font style="font-family: Times New Roman, Times, Serif">           $          </font>         </td>         <td style="border-bottom: Black 2.5pt double; text-align: right">          <font style="font-family: Times New Roman, Times, Serif">           (30,276,053          </font>         </td>         <td style="padding-bottom: 2.5pt; text-align: left">          <font style="font-family: Times New Roman, Times, Serif">           )          </font>         </td>         <td style="padding-bottom: 2.5pt">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td style="border-bottom: Black 2.5pt double; text-align: left">          <font style="font-family: Times New Roman, Times, Serif">           $          </font>         </td>         <td style="border-bottom: Black 2.5pt double; text-align: right">          <font style="font-family: Times New Roman, Times, Serif">           11,977,373          </font>         </td>         <td style="padding-bottom: 2.5pt; text-align: left">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td style="padding-bottom: 2.5pt">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td style="border-bottom: Black 2.5pt double; text-align: left">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td style="border-bottom: Black 2.5pt double; text-align: right">          <font style="font-family: Times New Roman, Times, Serif">           40          </font>         </td>         <td style="padding-bottom: 2.5pt; text-align: left">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>        </tr>       </tbody>      </table>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif">        <b>         <i>          Revenue         </i>        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif">        Wehave not generated any revenue since our inception, and we do not anticipate generating meaningful revenue in the near term.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif">        <b>         <i>          Researchand Development Expenses         </i>        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif">        Ourresearch and development expenses increased by approximately $6.7 million, from $18.4 million during the year ended July 31, 2019to $25.1 million during the year ended July 31, 2020. This increase was primarily due to the following approximate increases:(i) $5.7 million in clinical trial-related costs to support our various clinical studies and costs for discovery research andproduct development (ii) $0.5 million in higher rent expense as a result of the adoption of ASC 842 for our operating leases onAugust 1, 2019 and (iii) $0.6 million increase in payroll and related benefits expenses, primarily due to additional headcountand merit increases. These increases were partially offset by a $0.1 million reduction in stock-based compensation expense foremployees and consultants.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif">        <b>         <i>         </i>        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif">        <b>         <i>          Generaland Administrative         </i>        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif">        Ourgeneral and administrative expenses increased by approximately $6.3 million, from $12.0 million during the year ended July 31,2019, to $18.3 million during the year ended July 31, 2020. This increase was largely due to the following approximate increases:(i) $4.8 million in legal costs primarily related to the Alpha Holdings litigation and the contested proxy; (ii) $0.9 millionin consulting costs, primarily due to business development and public relations (iii) $0.8 million in proxy costs primarily relatedto the Company’s special meeting held in February 2020 and (iv) $0.5 million increase in payroll and related benefits expensesprimarily due to additional headcount and merit increases. These increases were partially offset by a $0.5 million reduction instock-based compensation expense for employees and consultants, and $0.2 million in travel and travel related expenses due toCOVID-19 restrictions. The Company believes a significant portion of its legal costs related to the Alpha Holdings litigationare recoverable and are likely to be recovered. At this point, no amount for insurance recoveries has been recorded.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif">        <b>         <i>          OtherIncome, Net         </i>        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif">        Otherincome, net, decreased by approximately $0.2 million from $0.4 million for the year ended July 31, 2019 to $0.2 million for theyear ended July 31, 2020. This decrease was primarily due to reduced interest income as a result of lower cash balances as wellas a lower return on our investments for these respective periods.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif">       </font>      </p>      <!-- Field: Page; Sequence: 56; Value: 38 -->      <div style="margin-bottom: 6pt; border-bottom: Black 1.5pt solid">       <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">        <tbody>         <tr style="vertical-align: top; text-align: left">          <td style="text-align: center; width: 100%">           <!-- Field: Sequence; Type: Arabic; Name: PageNo -->           54           <!-- Field: /Sequence -->          </td>         </tr>        </tbody>       </table>      </div>      <div style="page-break-before: always; margin-top: 6pt">       <p style="margin: 0pt">       </p>      </div>      <!-- Field: /Page -->      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">       <font style="font-family: Times New Roman, Times, Serif">        <b>         <i>         </i>        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif">        <b>         <i>          ForeignCurrency Exchange Gain/(Loss), Net         </i>        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif">        Foreigncurrency exchange gain/(loss), net, increased by approximately $0.4 million from a loss of $(0.3) million for the year ended July31, 2019 to a gain of $0.1 million for the year ended July 31, 2020. The increase was primarily due to unrealized foreign currencytransaction gains and losses recognized in connection with the Australian subsidiary’s intercompany loan.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif">        <b>         <i>          IncomeTax expense (benefit)         </i>        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif">        InMay 2020, the Company received $0.9 million in net proceeds from the sale of its New Jersey Net Operating Losses under the Stateof New Jersey NOL Transfer Program. The Company incurred minimum tax expense during the period ended July 31, 2019.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif">        <b>        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif">        <b>         Liquidityand Capital Resources        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif">        <b>         <i>          WorkingCapital         </i>        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif">        Thefollowing table and subsequent discussion summarize our working capital as of each of the periods presented:       </font>      </p>      <p style="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif">       </font>      </p>      <table align="CENTER" cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 75%; font: 10pt Times New Roman, Times, Serif">       <tbody>        <tr style="vertical-align: bottom">         <td style="text-align: center">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td style="padding-bottom: 1.5pt">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">          <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">           <font style="font-family: Times New Roman, Times, Serif">            <b>             At            </b>           </font>          </p>          <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">           <font style="font-family: Times New Roman, Times, Serif">            <b>             July                                         31, 2020            </b>           </font>          </p>         </td>         <td style="padding-bottom: 1.5pt">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td style="padding-bottom: 1.5pt">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">          <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">           <font style="font-family: Times New Roman, Times, Serif">            <b>             At            </b>           </font>          </p>          <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">           <font style="font-family: Times New Roman, Times, Serif">            <b>             July                                         31, 2019            </b>           </font>          </p>         </td>         <td style="padding-bottom: 1.5pt">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>        </tr>        <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">         <td style="width: 60%; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif">           Current assets          </font>         </td>         <td style="width: 2%">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td style="width: 1%; text-align: left">          <font style="font-family: Times New Roman, Times, Serif">           $          </font>         </td>         <td style="width: 16%; text-align: right">          <font style="font-family: Times New Roman, Times, Serif">           22,821,685          </font>         </td>         <td style="width: 1%; text-align: left">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td style="width: 2%">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td style="width: 1%; text-align: left">          <font style="font-family: Times New Roman, Times, Serif">           $          </font>         </td>         <td style="width: 16%; text-align: right">          <font style="font-family: Times New Roman, Times, Serif">           28,507,336          </font>         </td>         <td style="width: 1%; text-align: left">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>        </tr>        <tr style="vertical-align: bottom; background-color: White">         <td style="text-align: justify; padding-bottom: 1.5pt">          <font style="font-family: Times New Roman, Times, Serif">           Current liabilities          </font>         </td>         <td style="padding-bottom: 1.5pt">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td style="border-bottom: Black 1.5pt solid; text-align: left">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td style="border-bottom: Black 1.5pt solid; text-align: right">          <font style="font-family: Times New Roman, Times, Serif">           9,678,030          </font>         </td>         <td style="padding-bottom: 1.5pt; text-align: left">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td style="padding-bottom: 1.5pt">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td style="border-bottom: Black 1.5pt solid; text-align: left">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td style="border-bottom: Black 1.5pt solid; text-align: right">          <font style="font-family: Times New Roman, Times, Serif">           4,977,000          </font>         </td>         <td style="padding-bottom: 1.5pt; text-align: left">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>        </tr>        <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">         <td style="text-align: justify; padding-bottom: 2.5pt">          <font style="font-family: Times New Roman, Times, Serif">           Working capital          </font>         </td>         <td style="padding-bottom: 2.5pt">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td style="border-bottom: Black 2.5pt double; text-align: left">          <font style="font-family: Times New Roman, Times, Serif">           $          </font>         </td>         <td style="border-bottom: Black 2.5pt double; text-align: right">          <font style="font-family: Times New Roman, Times, Serif">           13,143,655          </font>         </td>         <td style="padding-bottom: 2.5pt; text-align: left">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td style="padding-bottom: 2.5pt">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td style="border-bottom: Black 2.5pt double; text-align: left">          <font style="font-family: Times New Roman, Times, Serif">           $          </font>         </td>         <td style="border-bottom: Black 2.5pt double; text-align: right">          <font style="font-family: Times New Roman, Times, Serif">           23,530,336          </font>         </td>         <td style="padding-bottom: 2.5pt; text-align: left">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>        </tr>       </tbody>      </table>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif">        <i>         CurrentAssets        </i>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif">        Currentassets as of July 31, 2020 decreased by $5.7 million to $22.8 million, from $28.5 million as of July 31, 2019. In February 2020,the Company received $28.0 million net proceeds from the China Grand Pharmaceutical and Healthcare Holdings Limited (“CGP”),and Sirtex Medical US Holdings, Inc. (“Sirtex”) financing transaction. The proceeds from CGP and Sirtex financingwere offset by cash used to support our operations during the year ended July 31, 2020.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif">        <i>         CurrentLiabilities        </i>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif">        Currentliabilities as of July 31, 2020 increased by $4.7 million to $9.7 million, from $5.0 million as of July 31, 2019. This increasewas primarily due to an increase in accounts payable related to the Alpha Holdings litigation and contested proxy as well as theaddition of operating lease liabilities to the balance sheet as a result of the adoption of ASC 842.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif">        <b>         <i>          CashFlow         </i>        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif">        <i>         CashUsed in Operating Activities        </i>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif">        Netcash used in operating activities for the year ended July 31, 2020 was $33.1 million, as compared to $29.0 million for the yearended July 31, 2019. The $4.1 million increase in cash used in operating activities was primarily attributable to an increasein cash used to support our operating activities, including but not limited to, our clinical trials, an increase in R&amp;D activities,amounts for the Alpha litigation and contested proxy and general working capital requirements.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif">       </font>      </p>      <!-- Field: Page; Sequence: 57; Value: 38 -->      <div style="margin-bottom: 6pt; border-bottom: Black 1.5pt solid">       <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">        <tbody>         <tr style="vertical-align: top; text-align: left">          <td style="text-align: center; width: 100%">           <!-- Field: Sequence; Type: Arabic; Name: PageNo -->           55           <!-- Field: /Sequence -->          </td>         </tr>        </tbody>       </table>      </div>      <div style="page-break-before: always; margin-top: 6pt">       <p style="margin: 0pt">       </p>      </div>      <!-- Field: /Page -->      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">       <font style="font-family: Times New Roman, Times, Serif">        <i>        </i>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif">        <i>         CashProvided by Investing Activities        </i>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif">        Netcash provided by investing activities for year ended July 31, 2020 was $0, as compared to $23.2 million provided by investingactivities for the year ended July 31, 2019. Net cash provided by investing activities for the year ended July 31, 2019 was relatedto maturities and sales of certain investment securities. We have an investment policy which is administered by management andreviewed by the Board of Directors. We believe our investment policy is conservative and maximizes returns, while minimizes risk,since we rely on the cash to fund operations.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif">        <i>         CashProvided by Financing Activities        </i>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif">        Netcash provided by financing activities was $28.4 million for the year ended July 31, 2020, as compared to $27.2 million providedby financing activities for the year ended July 31, 2019. Net proceeds during the year ended July 31, 2020 was primarily attributableto the $28.0 million received from the CGP and Sirtex offering (see “Sources of Capital” below). Net proceeds duringthe year ended July 31, 2019 was primarily attributable to the net proceeds received from the May 2019 Offering and the AlphaHoldings offering (see “Sources of Capital” below).       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif">        <b>         <i>         </i>        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif">        <b>         <i>          Usesof Cash and Cash Requirements         </i>        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif">        Ourprimary uses of cash have been to finance clinical and research and development activities focused on the identification and discoveryof new potential product candidates, the development of innovative and proprietary medical approaches for the treatment of cancer,and the design and advancement of pre-clinical and clinical trials and studies related to our pipeline of product candidates.We have also used our capital resources on general and administrative activities, including legal fees associated with the AlphaHoldings litigation and building and strengthening our corporate infrastructure, programs and procedures to enable compliancewith applicable federal, state and local laws and regulations.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif">        Ourprimary objectives for the next 12 months are to continue the advancement of our KEYNOTE-695 and KEYNOTE-890 studies and, to alesser extent, our other ongoing clinical trials and studies, and to continue our research and development activities for ournext-generation EP device and drug discovery efforts. In addition, we expect to pursue capital-raising transactions, which couldinclude equity or debt financings, in the near term to fund our existing and planned operations and acquire and develop additionalassets and technology consistent with our business objectives as opportunities arise.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif">        <b>         <i>          GoingConcern and Managements Plans         </i>        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif">        TheCompany has sustained losses in all reporting periods since inception, with an inception-to date-loss of $207 million as of July31, 2020. These losses are expected to continue for an extended period of time. Further, the Company has never generated any cashfrom its operations and does not expect to generate such cash in the near term. The aforementioned factors raise substantial doubtabout the Company’s ability to continue as a going concern within one year from the issuance date of the consolidated financialstatements elsewhere in this Form 10-K. The accompanying consolidated financial statements have been prepared on a going concernbasis, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. Theconsolidated financial statements do not include any adjustments relating to the recoverability and classification of asset amountsor the classification of liabilities that might be necessary should the Company be unable to continue as a going concern withinone year after the date the consolidated financial statements are issued.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       As of October 13,2020, the Company had cash and cash equivalents of $25.2 million. Since inception, cash flows from financing activitieshas been the primary source of the Company’s liquidity. The Company currently estimates its monthly working capital requirementsto be approximately $2.3 million, although the Company may modify or deviate from this estimate and it is likely that the Company’sactual operating expenses and working capital requirements will vary from its estimate. Based on these expectations regardingfuture expenses, rate of consumption, as well as its current cash levels, the Company believes its cash resources are insufficientto meet the Company’s anticipated needs for the 12 months following the date the consolidated financial statements are issued.      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif">       </font>      </p>      <!-- Field: Page; Sequence: 58; Value: 38 -->      <div style="margin-bottom: 6pt; border-bottom: Black 1.5pt solid">       <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">        <tbody>         <tr style="vertical-align: top; text-align: left">          <td style="text-align: center; width: 100%">           <!-- Field: Sequence; Type: Arabic; Name: PageNo -->           56           <!-- Field: /Sequence -->          </td>         </tr>        </tbody>       </table>      </div>      <div style="page-break-before: always; margin-top: 6pt">       <p style="margin: 0pt">       </p>      </div>      <!-- Field: /Page -->      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">       <font style="font-family: Times New Roman, Times, Serif">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif">        TheCompany recognizes it will need to raise additional capital to continue operating its business and fund its planned operations,including research and development, clinical trials and, if regulatory approval is obtained, commercialization of its productcandidates. In addition, the Company will require additional financing if it desires to in-license or acquire new assets, researchand develop new compounds or new technologies and pursue related patent protection, or obtain any other intellectual propertyrights or other assets. There is no assurance that additional financing will be available when needed or that management willbe able to obtain financing on terms acceptable to the Company or whether the Company will become profitable and generate positiveoperating cash flow. If the Company is unable to raise sufficient additional funds when needed, on favorable terms or at all,the Company will not be able to continue development of its product candidates as currently planned or at all, will need to reevaluateits planned operations and may need to delay, scale back or eliminate some or all of its development programs, reduce expensesor cease operations, any of which would have a significant negative impact on its prospects and financial condition.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif">        <b>         <i>          Sourcesof Capital         </i>        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif">        Wehave not generated any revenue since our inception, and we do not anticipate generating meaningful revenue in the near term. Historically,we have raised the majority of the funding for our business through offerings of our common stock and warrants to purchase ourcommon stock. If we issue equity or convertible debt securities to raise additional funds, our existing stockholders would experiencefurther dilution, and the new equity or debt securities may have rights, preferences and privileges senior to those of our existingstockholders. If we incur debt, our fixed payment obligations, liabilities and leverage relative to our equity capitalizationwould increase, which could increase the cost of future capital. Further, the terms of any debt securities we issue or borrowingswe incur, if available, could impose significant restrictions on our operations, such as limitations on our ability to incur additionaldebt or issue additional equity or other operating restrictions that could adversely affect our ability to conduct our business,and any such debt could be secured by any or all of our assets pledged as collateral. Additionally, we may incur substantial costsin pursuing future capital, including investment banking, legal and accounting fees, printing and distribution expenses and othercosts.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif">        <i>         RegisteredDirect Offering        </i>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif">        OnAugust 19, 2020, the Company completed the offer and sale of an aggregate of 4,608,589 shares of its common stock at a purchaseprice of $3.25 per share in a registered direct offering. The gross proceeds of the offering were approximately $15.0 million,and the net proceeds, after deducting the placement agent’s fee and other offering fees and expenses paid by the Company,were approximately $13.7 million. In connection with the offering, the Company paid the placement agent and other financial advisorsan aggregate cash fee equal to 8.0% of the gross proceeds of the offering, as well as legal and other expenses equal to $75,000.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif">        <i>        </i>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif">        <i>         Saleof New Jersey Net Operating Losses (NOLs)        </i>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif">        InMay 2020, the Company received $0.9 million in net proceeds from the sale of its New Jersey Net Operating Losses under the Stateof New Jersey NOL Transfer Program for the period ended July 31, 2019.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif">        <i>         SmallBusiness Administration Loan        </i>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif">        OnApril 27, 2020, the Company was granted a loan (the “Loan”) from the Banc of California in the aggregate amount of$952,744, pursuant to the Paycheck Protection Program (the “PPP”) under the Coronavirus Aid, Relief, and EconomicSecurity Act (“CARES Act”), which was enacted March 27, 2020. The term of the loan is two years, with monthly paymentsdue the first day of each month, beginning seven months from the date of initial disbursement, or December 1, 2020. Interest accruesat 1% per year, effective on the date of initial disbursement.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif">       </font>      </p>      <!-- Field: Page; Sequence: 59; Value: 38 -->      <div style="margin-bottom: 6pt; border-bottom: Black 1.5pt solid">       <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">        <tbody>         <tr style="vertical-align: top; text-align: left">          <td style="text-align: center; width: 100%">           <!-- Field: Sequence; Type: Arabic; Name: PageNo -->           57           <!-- Field: /Sequence -->          </td>         </tr>        </tbody>       </table>      </div>      <div style="page-break-before: always; margin-top: 6pt">       <p style="margin: 0pt">       </p>      </div>      <!-- Field: /Page -->      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">       <font style="font-family: Times New Roman, Times, Serif">        <i>        </i>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif">        <i>         CGPand Sirtex        </i>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif">        OnFebruary 7, 2020, the Company closed (the “Closing”) a strategic transaction (the “Transaction”) withCGP and its affiliate, Sirtex. On October 10, 2019, the Company and the Buyers entered into Stock Purchase Agreements (as amended,the “Purchase Agreements”) pursuant to which the Company agreed to sell and issue to CGP and Sirtex 10,000,000 sharesand 2,000,000 shares, respectively, of the Company’s common stock for an aggregate purchase price of $30 million. The netproceeds, after deducting offering fees and expenses paid by us, were approximately $28.0 million.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif">        <i>        </i>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif">        <i>         May2019 Offering        </i>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif">        OnMay 24, 2019, we completed our offer and sale of an aggregate of 3,492,063 shares of our common stock, together with 3,492,063accompanying warrants to purchase an aggregate of 2,619,047 shares of our common stock, at a combined purchase price of $3.15per share of common stock and warrant. The warrants have an exercise price of $3.45 per full share, became exercisable on May24, 2019 and expire on May 24, 2024. The gross proceeds of the offering were approximately $11.0 million, and the net proceeds,after deducting the placement agent’s fee and other offering fees and expenses paid by us, were approximately $10.0 million.In connection with the offering, we paid the placement agent a cash fee equal to 6.5% of the gross proceeds of the offering, aswell as legal and other expenses equal to $90,000. In addition, pursuant to the underwriting agreement, the Company granted theunderwriters an option, exercisable for 45 days, to purchase up to an additional 523,809 shares of our common stock (the “OptionShares”) and/or warrants to purchase up to 392,857 shares of common stock (the “Option Warrants”). On May 24,2019, the underwriters partially exercised their option and purchased 238,095 Option Warrants to purchase an aggregate of 178,571shares of our common stock, at a purchase price of $0.01 per warrant before underwriting discounts, or $2,381. The Option Warrantshave an exercise price of $3.45 per full share, became exercisable on May 24, 2019 and expire on May 24, 2024.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif">        <i>         AspireCapital        </i>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif">        OnMarch 29, 2019, the Company entered into a common stock purchase agreement (the “Purchase Agreement”) with AspireCapital Fund, LLC, (“Aspire Capital”) pursuant to which the Company agreed to issue and sell to Aspire Capital sharesof its common stock equal to an aggregate amount of up to $20.0 million at the Company’s request from time to time duringa 30-month period. The Company filed with the Securities and Exchange Commission a prospectus supplement to the Company’seffective shelf registration statement on Form S-3 registering all the shares of common stock that have been offered to AspireCapital from time to time. In consideration for entering into the Purchase Agreement, the Company issued to Aspire Capital 120,201shares of the Company’s common stock which represented 3% of the aggregate commitment.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif">        Underthe Purchase Agreement, on any trading day selected by the Company, the Company had the right, in its sole discretion, to presentAspire Capital with a purchase notice, directing Aspire Capital to purchase up to 30,000 shares of the Company’s commonstock per business day, up to $20.0 million of the Company’s common stock in the aggregate at a per share price equal tothe lesser of:       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif">       </font>      </p>      <table cellpadding="0" cellspacing="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">       <tbody>        <tr style="vertical-align: top">         <td style="width: 0.25in; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="width: 0.25in; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           ●          </font>         </td>         <td style="text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           the lowest sale    price of the Company’s common stock on the purchase date; or          </font>         </td>        </tr>        <tr style="vertical-align: top">         <td style="text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="vertical-align: top">         <td style="text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           <b>           </b>          </font>         </td>         <td style="text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           ●          </font>         </td>         <td style="text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           the arithmetic average    of the three (3) lowest closing sale prices for the Company’s common stock during the ten (10) consecutive trading days    ending on the trading day immediately preceding the purchase date.          </font>         </td>        </tr>       </tbody>      </table>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif">        Uponexecution of the Purchase Agreement, the Company agreed to sell to Aspire Capital 400,674 shares of common stock for total proceeds,before expenses, of $2,000,000. Additionally, in April 2019, the Company sold a total of 90,000 shares of its common stock toAspire Capital resulting in the Company receiving total proceeds, before expenses, of approximately $520,000 in cash. There wereno underwriting or placement agent fees associated with the offering.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif">        OnMay 27, 2019, the Company terminated the Purchase Agreement.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif">       </font>      </p>      <!-- Field: Page; Sequence: 60; Value: 38 -->      <div style="margin-bottom: 6pt; border-bottom: Black 1.5pt solid">       <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">        <tbody>         <tr style="vertical-align: top; text-align: left">          <td style="text-align: center; width: 100%">           <!-- Field: Sequence; Type: Arabic; Name: PageNo -->           58           <!-- Field: /Sequence -->          </td>         </tr>        </tbody>       </table>      </div>      <div style="page-break-before: always; margin-top: 6pt">       <p style="margin: 0pt">       </p>      </div>      <!-- Field: /Page -->      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">       <font style="font-family: Times New Roman, Times, Serif">        <i>        </i>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif">        <i>         AlphaHoldings        </i>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif">        OnAugust 31, 2018, the Company entered into a stock purchase agreement with Alpha Holdings, Inc. (“Alpha Holdings”),pursuant to which the Company agreed to issue and sell to Alpha Holdings shares of its common stock equal to an aggregate amountof up to $15.0 million at a market purchase price of $15.00 per share, which was the closing price of the Company’s commonstock the day immediately before the agreement was executed by the parties.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif">        OnOctober 9, 2018, the Company received total proceeds, before expenses, of $8.0 million in cash from the offering and issued AlphaHoldings 533,333 shares of common stock. There were no underwriting or placement agent fees associated with the offering.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif">        OnDecember 6, 2018, the Company received total proceeds, before expenses, of $7.0 million in cash from the offering and issued AlphaHoldings 466,667 shares of common stock. There were no underwriting or placement agent fees associated with the offering.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif">        <b>         CriticalAccounting Policies        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif">        <i>         Accountingfor Long-Lived Assets        </i>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif">        Weassess the impairment of long-lived assets, consisting of property and equipment, periodically and whenever events or circumstancesindicate that the carrying value may not be recoverable. Examples of such circumstances may include: (1) the asset’s abilityto continue to generate income from operations and positive cash flow in future periods; (2) loss of legal ownership or titleto an asset; (3) significant changes in our strategic business objectives and utilization of the assets; and (4) the impact ofsignificant negative industry or economic trends. If a change were to occur in any of these or similar factors, the likelihoodof a material change in our net loss would increase.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif">        Recoverabilityof assets to be held and used in operations is measured by a comparison of the carrying amount of an asset to the future net cashflows expected to be generated by the assets. Although we believe the factors used by management to evaluate future net cash flowsare reasonable, this evaluation requires a high degree of judgment, and results could vary if the actual amounts are materiallydifferent than management’s estimates. In addition, we base estimates of useful lives and related amortization or depreciationexpense on our subjective estimate of the period the assets will generate revenue or otherwise be used by us. If long-lived assetsare considered impaired, the impairment to be recognized is measured by the amount by which the carrying amount of the assetsexceeds the fair value of the assets. Assets to be disposed of are reported at the lower of the carrying amount or fair value,less selling costs.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif">        <i>         Equity-BasedAwards        </i>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif">        TheCompany grants equity-based awards (typically stock options or restricted stock units) under our stock-based compensation planand outside of our stock-based compensation plan, with terms generally similar to the terms under our stock-based compensationplan. The Company estimates the fair value of stock option awards using the Black-Scholes option valuation model. For employees,directors and consultants, the fair value of the award is measured on the grant date. The fair value amount is then recognizedover the period during which services are required to be provided in exchange for the award, usually the vesting period. The Black-Scholesoption valuation model requires the input of subjective assumptions, including price volatility of the underlying stock, risk-freeinterest rate, dividend yield, and expected life of the option. The Company estimates the fair value of restricted stock unitawards based on the closing price of the Company’s common stock on the date of issuance.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif">       </font>      </p>      <!-- Field: Page; Sequence: 61; Value: 38 -->      <div style="margin-bottom: 6pt; border-bottom: Black 1.5pt solid">       <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">        <tbody>         <tr style="vertical-align: top; text-align: left">          <td style="text-align: center; width: 100%">           <!-- Field: Sequence; Type: Arabic; Name: PageNo -->           59           <!-- Field: /Sequence -->          </td>         </tr>        </tbody>       </table>      </div>      <div style="page-break-before: always; margin-top: 6pt">       <p style="margin: 0pt">       </p>      </div>      <!-- Field: /Page -->      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">       <font style="font-family: Times New Roman, Times, Serif">        <i>        </i>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif">        <i>         EmployeeStock Purchase Plan        </i>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif">        Employeesmay elect to participate in our stockholder approved employee stock purchase plan. The stock purchase plan allows for the purchaseof our common stock at not less than 85% of the lesser of (i) the fair market value of a share of stock on the beginning dateof the offering period or (ii) the fair market value of a share of stock on the purchase date of the offering period, subjectto a share and dollar limit as defined in the plan and subject to the applicable legal requirements. There are two 6-month offeringperiods during each fiscal year, ending on January 31 and July 31. In accordance with applicable accounting guidance, the fairvalue of awards under the stock purchase plan is calculated at the beginning of each offering period. We estimate the fair valueof the awards using the Black-Scholes option valuation model. The Black-Scholes option valuation model requires the input of subjectiveassumptions, including price volatility of the underlying stock, risk-free interest rate, dividend yield, and the offering period.This fair value is then amortized at the beginning of the offering period. Stock-based compensation expense is based on awardsexpected to be purchased at the beginning of the offering period, and therefore is reduced when participants withdraw during theoffering period.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif">        <i>         AustraliaResearch and Development Tax Credit        </i>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif">        OurAustralian, wholly-owned, subsidiary incurs research and development expenses, primarily in the course of conducting clinicaltrials. The Australian research and development activities qualify for the Australian government’s tax credit program, whichprovides a 41% credit for qualifying research and development expenses. The tax credit does not depend on our generation of futuretaxable income or ongoing tax status or position. Accordingly, the credit is not considered an element of income tax accountingunder ASC 740 and is recorded against qualifying research and development expenses in the Company’s consolidated statementsof operations.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif">        <i>         Leases        </i>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif">        TheCompany determines if an arrangement is a lease at inception. Operating lease right-of-use (“ROU”) assets representthe Company’s right to use an underlying asset during the lease term, and operating lease liabilities represent the Company’sobligation to make lease payments arising from the lease. Operating leases are included in ROU assets, current operating leaseliabilities, and long-term operating lease liabilities on the Company’s consolidated balance sheets.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif">        LeaseROU assets and lease liabilities are initially recognized based on the present value of the future minimum lease payments overthe lease term at commencement date calculated using our incremental borrowing rate applicable to the lease asset, unless theimplicit rate is readily determinable. ROU assets also include any lease payments made at or before lease commencement and excludeany lease incentives received. The Company’s lease terms may include options to extend or terminate the lease when it isreasonably certain that the Company will exercise that option. Leases with a term of 12 months or less are not recognized on theconsolidated balance sheet. The Company’s leases do not contain any residual value guarantees. Lease expense for minimumlease payments is recognized on a straight-line basis over the lease term. The Company accounts for lease and non-lease componentsas a single lease component for all its leases.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif">        <b>         <i>          RecentAccounting Pronouncements         </i>        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif">        Informationregarding recent accounting pronouncements is contained in Note 2 to our consolidated financial statements included in this report.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif">        <b>         Off-BalanceSheet Arrangements        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif">        Wedo not have any off-balance sheet arrangements that have or are reasonably likely to have a current or future effect on our financialcondition, changes in financial condition, revenues or expenses, results of operations, liquidity, capital expenditure or capitalresources that is material to investors.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; text-transform: uppercase">        <b>        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; text-transform: uppercase">        <b>         <a name="cj_009">         </a>         ITEM7A. QUANTITATIVE AND QUALITATIVE DISCLOSURE ABOUT MARKET RISK        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif">        Notapplicable.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; text-transform: uppercase">        <b>        </b>       </font>      </p>      <!-- Field: Page; Sequence: 62; Value: 38 -->      <div style="margin-bottom: 6pt; border-bottom: Black 1.5pt solid">       <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">        <tbody>         <tr style="vertical-align: top; text-align: left">          <td style="text-align: center; width: 100%">           <!-- Field: Sequence; Type: Arabic; Name: PageNo -->           60           <!-- Field: /Sequence -->          </td>         </tr>        </tbody>       </table>      </div>      <div style="page-break-before: always; margin-top: 6pt">       <p style="margin: 0pt">       </p>      </div>      <!-- Field: /Page -->      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">       <font style="font-family: Times New Roman, Times, Serif; text-transform: uppercase">        <b>        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; text-transform: uppercase">        <b>         <a name="cj_010">         </a>         ITEM8. FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif">        Theinformation required by this Item 8 is incorporated by reference to our consolidated financial statements and the related notesand the report of our independent registered public accounting firm beginning at page F-1 of this report.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; text-transform: uppercase">        <b>        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; text-transform: uppercase">        <b>         <a name="cj_011">         </a>         ITEM9. CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL DISCLOSURE        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif">        None.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; text-transform: uppercase">        <b>        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; text-transform: uppercase">        <b>         <a name="cj_012">         </a>         ITEM9A. CONTROLS AND PROCEDURES        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif">        <b>        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif">        <b>         Evaluationof Disclosure Controls and Procedures        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif">        Wemaintain disclosure controls and procedures that are designed to ensure that information required to be disclosed in our ExchangeAct reports is recorded, processed, summarized, and reported within the time periods specified in the SEC’s rules and forms,and that such information is accumulated and communicated to our management, including our Chief Executive Officer and Chief FinancialOfficer, as appropriate, to allow timely decisions regarding required disclosure. In designing and evaluating the disclosure controlsand procedures, management recognizes that any controls and procedures, no matter how well designed and operated, can provideonly reasonable assurance of achieving the desired control objectives. In addition, the design of disclosure controls and proceduresreflects the fact that there are resource constraints and that management is required to apply its judgment in evaluating thebenefits of possible controls and procedures relative to their costs.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif">        Asrequired by Rule 13a-15(b) under the Exchange Act, our management, under the supervision and with the participation of our Presidentand Chief Executive Officer and Principal Accounting Officer, conducted an evaluation of the effectiveness of our disclosure controlsand procedures as of July 31, 2020. Based on such evaluation, our President and Chief Executive Officer and Principal AccountingOfficer concluded that, as of July 31, 2020, our disclosure controls and procedures were effective.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif">        <b>        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif">        <b>         Management’sAnnual Report on Internal Control over Financial Reporting        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif">        Ourmanagement is responsible for establishing and maintaining adequate internal control over financial reporting, as defined in Rule13a-15(f) under the Exchange Act. With the participation of our President and Chief Executive Officer and Principal AccountingOfficer, our management conducted an evaluation of the effectiveness of our internal control over financial reporting as of July31, 2020. In conducting such evaluation, management used the criteria set forth in the report entitled “        <i>         Internal Control— Integrated Framework        </i>        ” published by the Committee of Sponsoring Organizations of the Treadway Commission (2013framework) to evaluate the effectiveness of our internal control over financial reporting. Based on this evaluation, managementhas concluded that our internal control over financial reporting was effective as of July 31, 2020, based on those criteria.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif">        Thisreport does not include an attestation report of our independent registered public accounting firm regarding our internal controlover financial reporting, in accordance with applicable SEC rules that permit us to provide only management’s report inthis report.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif">        <b>        </b>       </font>      </p>      <!-- Field: Page; Sequence: 63; Value: 38 -->      <div style="margin-bottom: 6pt; border-bottom: Black 1.5pt solid">       <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">        <tbody>         <tr style="vertical-align: top; text-align: left">          <td style="text-align: center; width: 100%">           <!-- Field: Sequence; Type: Arabic; Name: PageNo -->           61           <!-- Field: /Sequence -->          </td>         </tr>        </tbody>       </table>      </div>      <div style="page-break-before: always; margin-top: 6pt">       <p style="margin: 0pt">       </p>      </div>      <!-- Field: /Page -->      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">       <font style="font-family: Times New Roman, Times, Serif">        <b>        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif">        <b>         Changesin Internal Control Over Financial Reporting        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif">        Therewas no change in our internal control over financial reporting during the year ended July 31, 2020, that has materially affected,or is reasonably likely to materially affect, our internal control over financial reporting.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif">        Internalcontrol over financial reporting is designed to provide reasonable assurance regarding the reliability of financial reportingand the preparation of financial statements prepared for external purposes in accordance with generally accepted accounting principles.Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also,projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate becauseof changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; text-transform: uppercase">        <b>        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; text-transform: uppercase">        <b>         <a name="cj_013">         </a>         ITEM9B. OTHER INFORMATION        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif">        None       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">       <font style="font-family: Times New Roman, Times, Serif; text-transform: uppercase">        <b>         <a name="cj_014">         </a>         PARTIII        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; text-transform: uppercase">        <b>        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; text-transform: uppercase">        <b>         <a name="cj_015">         </a>         ITEM10. DIRECTORS, EXECUTIVE OFFICERS AND CORPORATE GOVERNANCE        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif">        Theinformation required by this Item 10 is incorporated herein by reference from our Proxy Statement for our 2020 Annual Meetingof Stockholders.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; text-transform: uppercase">        <b>        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; text-transform: uppercase">        <b>         <a name="cj_016">         </a>         ITEM11. EXECUTIVE COMPENSATION        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif">        Theinformation required by this Item 11 is incorporated herein by reference from our Proxy Statement for our 2020 Annual Meetingof Stockholders.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; text-transform: uppercase">        <b>        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; text-transform: uppercase">        <b>         <a name="cj_017">         </a>         ITEM12. SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif">        Theinformation required by this Item 12 is incorporated herein by reference from our Proxy Statement for our 2020 Annual Meetingof Stockholders.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; text-transform: uppercase">        <b>         <a name="cj_018">         </a>         ITEM13. CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS, AND DIRECTOR INDEPENDENCE        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif">        Directorindependence and other information required by this Item 13 is incorporated herein by reference from our Proxy Statement for our2020 Annual Meeting of Stockholders.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; text-transform: uppercase">        <b>        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; text-transform: uppercase">        <b>         <a name="cj_019">         </a>         ITEM14. PRINCIPAL ACCOUNTING FEES AND SERVICES        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif">        Theinformation required by this Item 14 is incorporated herein by reference from our Proxy Statement for our 2020 Annual Meetingof Stockholders.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif">       </font>      </p>      <!-- Field: Page; Sequence: 64; Value: 38 -->      <div style="margin-bottom: 6pt; border-bottom: Black 1.5pt solid">       <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">        <tbody>         <tr style="vertical-align: top; text-align: left">          <td style="text-align: center; width: 100%">           <!-- Field: Sequence; Type: Arabic; Name: PageNo -->           62           <!-- Field: /Sequence -->          </td>         </tr>        </tbody>       </table>      </div>      <div style="page-break-before: always; margin-top: 6pt">       <p style="margin: 0pt">       </p>      </div>      <!-- Field: /Page -->      <p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0">       <font style="font-family: Times New Roman, Times, Serif">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">       <font style="font-family: Times New Roman, Times, Serif; text-transform: uppercase">        <a name="cj_020">        </a>        <b>         PARTIV        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; text-transform: uppercase">        <b>        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; text-transform: uppercase">        <b>         <a name="cj_021">         </a>         ITEM15. EXHIBITS, FINANCIAL STATEMENT SCHEDULES        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif">        (a)(1)The following financial statements of OncoSec Medical Incorporated are filed as part of this report under Item 8 — FinancialStatements and Supplementary Data:       </font>      </p>      <p style="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif">       </font>      </p>      <table cellpadding="0" cellspacing="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">       <tbody>        <tr style="vertical-align: top; background-color: #CCEEFF">         <td style="text-align: justify">          <font style="font-family: Times New Roman, Times, Serif">           <a href="#cj_028">            <font style="font-size: 10pt">             Report    of Independent Registered Public Accounting Firm            </font>           </a>          </font>         </td>         <td style="width: 0.5in; text-align: center">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           F-1          </font>         </td>        </tr>        <tr style="vertical-align: top; background-color: white">         <td style="text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="text-align: center">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="vertical-align: top; background-color: #CCEEFF">         <td style="text-align: justify">          <font style="font-family: Times New Roman, Times, Serif">           <a href="#cj_022">            <font style="font-size: 10pt">             Consolidated    Balance Sheets at July 31, 2020 and 2019            </font>           </a>          </font>         </td>         <td style="text-align: center">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           F-2          </font>         </td>        </tr>        <tr style="vertical-align: top; background-color: white">         <td style="text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="text-align: center">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="vertical-align: top; background-color: #CCEEFF">         <td style="text-align: justify">          <font style="font-family: Times New Roman, Times, Serif">           <a href="#cj_023">            <font style="font-size: 10pt">             Consolidated    Statements of Operations for the Years Ended July 31, 2020 and 2019            </font>           </a>          </font>         </td>         <td style="text-align: center">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           F-3          </font>         </td>        </tr>        <tr style="vertical-align: top; background-color: white">         <td style="text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="text-align: center">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="vertical-align: top; background-color: #CCEEFF">         <td style="text-align: justify">          <font style="font-family: Times New Roman, Times, Serif">           <a href="#cj_024">            <font style="font-size: 10pt">             Consolidated    Statements of Comprehensive Loss for the Years Ended July 31, 2020 and 2019            </font>           </a>          </font>         </td>         <td style="text-align: center">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           F-4          </font>         </td>        </tr>        <tr style="vertical-align: top; background-color: white">         <td style="text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="text-align: center">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="vertical-align: top; background-color: #CCEEFF">         <td style="text-align: justify">          <font style="font-family: Times New Roman, Times, Serif">           <a href="#cj_025">            <font style="font-size: 10pt">             Consolidated    Statements of Stockholders’ Equity for the Years Ended July 31, 2020 and 2019            </font>           </a>          </font>         </td>         <td style="text-align: center">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           F-5          </font>         </td>        </tr>        <tr style="vertical-align: top; background-color: white">         <td style="text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="text-align: center">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="vertical-align: top; background-color: #CCEEFF">         <td style="text-align: justify">          <font style="font-family: Times New Roman, Times, Serif">           <a href="#cj_026">            <font style="font-size: 10pt">             Consolidated    Statements of Cash Flows for the Years Ended July 31, 2020 and 2019            </font>           </a>          </font>         </td>         <td style="text-align: center">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           F-6          </font>         </td>        </tr>        <tr style="vertical-align: top; background-color: white">         <td style="text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="text-align: center">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="vertical-align: top; background-color: #CCEEFF">         <td style="text-align: justify">          <font style="font-family: Times New Roman, Times, Serif">           <a href="#cj_027">            <font style="font-size: 10pt">             Notes    to Consolidated Financial Statements            </font>           </a>          </font>         </td>         <td style="text-align: center">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           F-7          </font>         </td>        </tr>       </tbody>      </table>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif">        (a)(2)All financial statement schedules are omitted because they are not required, or are not applicable, or the required informationis shown in the consolidated financial statements or notes thereto included in this report.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif">        (a)(3)The exhibits listed in the Exhibit Index, which appears immediately following the last page of this report and is incorporatedherein by reference, are filed or incorporated by reference as part of this report.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif">       </font>      </p>      <!-- Field: Page; Sequence: 65; Options: NewSection; Value: 63 -->      <div style="margin-bottom: 6pt; border-bottom: Black 1.5pt solid">       <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">        <tbody>         <tr style="vertical-align: top; text-align: left">          <td style="width: 33%">          </td>          <td style="text-align: center; width: 34%">           <!-- Field: Sequence; Type: Arabic; Name: PageNo -->           63           <!-- Field: /Sequence -->          </td>          <td style="width: 33%">          </td>         </tr>        </tbody>       </table>      </div>      <div style="page-break-before: always; margin-top: 6pt">       <p style="margin: 0pt">       </p>      </div>      <!-- Field: /Page -->      <p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <b>         <a name="cj_028">         </a>         REPORTOF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Tothe Board of Directors and       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Stockholdersof        <b>         OncoSec Medical Incorporated        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <b>         Opinionon the Consolidated Financial Statements        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <b>        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Wehave audited the accompanying consolidated balance sheets of        <b>         OncoSec Medical Incorporated        </b>        (the “Company”) asof July 31, 2020 and 2019, and the related consolidated statements of operations, comprehensive loss, stockholders’ equity,and cash flows for each of the years in the two-year period ended July 31, 2020, and the related notes (collectively referredto as the “financial statements”). In our opinion, the financial statements present fairly, in all material respects,the financial position of the Company as of July 31, 2020 and 2019, and the results of its operations and its cash flows for eachof the years in the two-year period ended July 31, 2020, in conformity with accounting principles generally accepted in the UnitedStates of America.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <b>         GoingConcern Uncertainty        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Theaccompanying financial statements have been prepared assuming the Company will continue as a going concern. As discussed in Note3 to the financial statements, the Company has incurred recurring losses from operations, and is dependent on additional financingto fund operations. These conditions raise substantial doubt about the Company’s ability to continue as a going concern.Management’s plans in regard to these matters are described in Note 3 to the financial statements. The financial statementsdo not include any adjustments to reflect the possible future effects on the recoverability and classification of assets or theamounts and classification of liabilities that may result from the outcome of this uncertainty.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <b>         Adoptionof New Accounting Standard        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Asdiscussed in Note 2 to the financial statements, the Company changed its method of accounting for leases as a result of the adoptionof Accounting Standards Codification Topic 842, Leases. Our opinion is not modified with respect to this matter.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <b>         Basisfor Opinion        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <b>        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Thesefinancial statements are the responsibility of the Company’s management. Our responsibility is to express an opinion onthe Company’s financial statements based on our audits. We are a public accounting firm registered with the Public CompanyAccounting Oversight Board (United States) (PCAOB) and are required to be independent with respect to the Company in accordancewith the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and thePCAOB.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Weconducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the auditto obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to erroror fraud. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financialreporting. As part of our audits, we are required to obtain an understanding of internal control over financial reporting, butnot for the purpose of expressing an opinion on the effectiveness of the Company’s internal control over financial reporting.Accordingly, we express no such opinion.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Ouraudits included performing procedures to assess the risks of material misstatement of the financial statements, whether due toerror or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidenceregarding the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principlesused and significant estimates made by management, as well as evaluating the overall presentation of the financial statements.We believe that our audits provide a reasonable basis for our opinion.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">      </p>      <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; margin-bottom: 0.35pt; font: 10pt Times New Roman, Times, Serif">       <tbody>        <tr style="vertical-align: top">         <td style="border-bottom: Black 1.5pt solid; text-align: justify; width: 50%">          <font style="font-family: Times New Roman, Times, Serif">           /           <font style="font-size: 10pt">            <i>             s/    Mayer Hoffman McCann P.C.            </i>           </font>          </font>         </td>         <td style="text-align: justify; width: 50%">         </td>        </tr>       </tbody>      </table>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Wehave served as the Company’s auditor since 2011.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        SanDiego, California       </font>       <font style="font: 10pt Times New Roman, Times, Serif">       </font>      </p>      <p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        October28, 2020       </font>       <font style="font: 10pt Times New Roman, Times, Serif">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <!-- Field: Page; Sequence: 66; Options: NewSection; Value: 1 -->      <div style="margin-bottom: 6pt; border-bottom: Black 1.5pt solid">       <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">        <tbody>         <tr style="vertical-align: top; text-align: left">          <td style="width: 33%">          </td>          <td style="text-align: center; width: 34%">           F-           <!-- Field: Sequence; Type: Arabic; Name: PageNo -->           1           <!-- Field: /Sequence -->          </td>          <td style="width: 33%">          </td>         </tr>        </tbody>       </table>      </div>      <div style="page-break-before: always; margin-top: 6pt">       <p style="margin: 0pt">       </p>      </div>      <!-- Field: /Page -->      <p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">       <font style="font-family: Times New Roman, Times, Serif">        <b>        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">       <font style="font-family: Times New Roman, Times, Serif">        <b>         <a name="cj_022">         </a>         OncoSecMedical Incorporated        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">       <font style="font-family: Times New Roman, Times, Serif">        <b>         ConsolidatedBalance Sheets        </b>       </font>      </p>      <p style="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: center">       <font style="font-family: Times New Roman, Times, Serif">       </font>      </p>      <p style="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: center">       <font style="font-family: Times New Roman, Times, Serif">       </font>      </p>      <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">       <tbody>        <tr style="vertical-align: bottom">         <td style="text-align: left">         </td>         <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1.5pt">         </td>         <td colspan="2" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">          July 31, 2020         </td>         <td style="padding-bottom: 1.5pt; font-size: 10pt; font-weight: bold">         </td>         <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1.5pt">         </td>         <td colspan="2" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">          July 31, 2019         </td>         <td style="padding-bottom: 1.5pt; font-size: 10pt; font-weight: bold">         </td>        </tr>        <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">         <td style="text-align: left; font-size: 10pt; font-weight: bold">          Assets         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">         </td>         <td style="text-align: left">         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">         </td>         <td style="text-align: left">         </td>        </tr>        <tr style="vertical-align: bottom; background-color: White">         <td style="font-size: 10pt; text-align: left">          Current assets         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">         </td>         <td style="text-align: left">         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">         </td>         <td style="text-align: left">         </td>        </tr>        <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">         <td style="width: 60%; font-size: 10pt; text-align: left">          Cash and cash equivalents         </td>         <td style="width: 2%; font-size: 10pt">         </td>         <td style="width: 1%; font-size: 10pt; text-align: left">          $         </td>         <td style="width: 16%; font-size: 10pt; text-align: right">          20,354,462         </td>         <td style="width: 1%; font-size: 10pt; text-align: left">         </td>         <td style="width: 2%; font-size: 10pt">         </td>         <td style="width: 1%; font-size: 10pt; text-align: left">          $         </td>         <td style="width: 16%; font-size: 10pt; text-align: right">          25,147,780         </td>         <td style="width: 1%; font-size: 10pt; text-align: left">         </td>        </tr>        <tr style="vertical-align: bottom; background-color: White">         <td style="font-size: 10pt; text-align: left; padding-bottom: 1.5pt">          Prepaid expenses and other current assets         </td>         <td style="font-size: 10pt; padding-bottom: 1.5pt">         </td>         <td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: left">         </td>         <td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: right">          2,467,223         </td>         <td style="padding-bottom: 1.5pt; font-size: 10pt; text-align: left">         </td>         <td style="font-size: 10pt; padding-bottom: 1.5pt">         </td>         <td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: left">         </td>         <td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: right">          3,359,556         </td>         <td style="padding-bottom: 1.5pt; font-size: 10pt; text-align: left">         </td>        </tr>        <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">         <td style="font-size: 10pt; text-align: left">          Total Current Assets         </td>         <td style="font-size: 10pt">         </td>         <td style="font-size: 10pt; text-align: left">         </td>         <td style="font-size: 10pt; text-align: right">          22,821,685         </td>         <td style="font-size: 10pt; text-align: left">         </td>         <td style="font-size: 10pt">         </td>         <td style="font-size: 10pt; text-align: left">         </td>         <td style="font-size: 10pt; text-align: right">          28,507,336         </td>         <td style="font-size: 10pt; text-align: left">         </td>        </tr>        <tr style="vertical-align: bottom; background-color: White">         <td style="font-size: 10pt; text-align: left">          Property and equipment, net         </td>         <td style="font-size: 10pt">         </td>         <td style="font-size: 10pt; text-align: left">         </td>         <td style="font-size: 10pt; text-align: right">          814,494         </td>         <td style="font-size: 10pt; text-align: left">         </td>         <td style="font-size: 10pt">         </td>         <td style="font-size: 10pt; text-align: left">         </td>         <td style="font-size: 10pt; text-align: right">          1,031,129         </td>         <td style="font-size: 10pt; text-align: left">         </td>        </tr>        <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">         <td style="font-size: 10pt; text-align: left">          Operating right-of-use assets         </td>         <td style="font-size: 10pt">         </td>         <td style="font-size: 10pt; text-align: left">         </td>         <td style="font-size: 10pt; text-align: right">          5,948,224         </td>         <td style="font-size: 10pt; text-align: left">         </td>         <td style="font-size: 10pt">         </td>         <td style="font-size: 10pt; text-align: left">         </td>         <td style="font-size: 10pt; text-align: right">          -         </td>         <td style="font-size: 10pt; text-align: left">         </td>        </tr>        <tr style="vertical-align: bottom; background-color: White">         <td style="font-size: 10pt; text-align: left; padding-bottom: 1.5pt">          Other long-term assets         </td>         <td style="font-size: 10pt; padding-bottom: 1.5pt">         </td>         <td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: left">         </td>         <td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: right">          319,058         </td>         <td style="padding-bottom: 1.5pt; font-size: 10pt; text-align: left">         </td>         <td style="font-size: 10pt; padding-bottom: 1.5pt">         </td>         <td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: left">         </td>         <td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: right">          353,547         </td>         <td style="padding-bottom: 1.5pt; font-size: 10pt; text-align: left">         </td>        </tr>        <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">         <td style="font-size: 10pt; text-align: left; padding-bottom: 2.5pt">          Total Assets         </td>         <td style="font-size: 10pt; padding-bottom: 2.5pt">         </td>         <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">          $         </td>         <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">          29,903,461         </td>         <td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">         </td>         <td style="font-size: 10pt; padding-bottom: 2.5pt">         </td>         <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">          $         </td>         <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">          29,892,012         </td>         <td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">         </td>        </tr>        <tr style="vertical-align: bottom; background-color: White">         <td style="text-align: left">         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">         </td>         <td style="text-align: left">         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">         </td>         <td style="text-align: left">         </td>        </tr>        <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">         <td style="font-size: 10pt; font-weight: bold; text-align: left">          Liabilities and Stockholders’ Equity         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">         </td>         <td style="text-align: left">         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">         </td>         <td style="text-align: left">         </td>        </tr>        <tr style="vertical-align: bottom; background-color: White">         <td style="text-align: left">         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">         </td>         <td style="text-align: left">         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">         </td>         <td style="text-align: left">         </td>        </tr>        <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">         <td style="text-align: left; font-size: 10pt; font-weight: bold">          Liabilities         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">         </td>         <td style="text-align: left">         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">         </td>         <td style="text-align: left">         </td>        </tr>        <tr style="vertical-align: bottom; background-color: White">         <td style="font-size: 10pt; text-align: left">          Current liabilities         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">         </td>         <td style="text-align: left">         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">         </td>         <td style="text-align: left">         </td>        </tr>        <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">         <td style="font-size: 10pt; text-align: left">          Accounts payable and accrued liabilities         </td>         <td style="font-size: 10pt">         </td>         <td style="font-size: 10pt; text-align: left">          $         </td>         <td style="font-size: 10pt; text-align: right">          7,923,036         </td>         <td style="font-size: 10pt; text-align: left">         </td>         <td style="font-size: 10pt">         </td>         <td style="font-size: 10pt; text-align: left">          $         </td>         <td style="font-size: 10pt; text-align: right">          4,217,017         </td>         <td style="font-size: 10pt; text-align: left">         </td>        </tr>        <tr style="vertical-align: bottom; background-color: White">         <td style="font-size: 10pt; text-align: left">          Accrued compensation related         </td>         <td style="font-size: 10pt">         </td>         <td style="font-size: 10pt; text-align: left">         </td>         <td style="font-size: 10pt; text-align: right">          285,127         </td>         <td style="font-size: 10pt; text-align: left">         </td>         <td style="font-size: 10pt">         </td>         <td style="font-size: 10pt; text-align: left">         </td>         <td style="font-size: 10pt; text-align: right">          676,223         </td>         <td style="font-size: 10pt; text-align: left">         </td>        </tr>        <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">         <td style="font-size: 10pt; text-align: left">          Operating lease liabilities         </td>         <td style="font-size: 10pt">         </td>         <td style="font-size: 10pt; text-align: left">         </td>         <td style="font-size: 10pt; text-align: right">          500,357         </td>         <td style="font-size: 10pt; text-align: left">         </td>         <td style="font-size: 10pt">         </td>         <td style="font-size: 10pt; text-align: left">         </td>         <td style="font-size: 10pt; text-align: right">          -         </td>         <td style="font-size: 10pt; text-align: left">         </td>        </tr>        <tr style="vertical-align: bottom; background-color: White">         <td style="font-size: 10pt; text-align: left; padding-bottom: 1.5pt">          Notes payable         </td>         <td style="font-size: 10pt; padding-bottom: 1.5pt">         </td>         <td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: left">         </td>         <td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: right">          969,509         </td>         <td style="padding-bottom: 1.5pt; font-size: 10pt; text-align: left">         </td>         <td style="font-size: 10pt; padding-bottom: 1.5pt">         </td>         <td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: left">         </td>         <td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: right">          83,760         </td>         <td style="padding-bottom: 1.5pt; font-size: 10pt; text-align: left">         </td>        </tr>        <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">         <td style="font-size: 10pt; text-align: left">          Total Current Liabilities         </td>         <td style="font-size: 10pt">         </td>         <td style="font-size: 10pt; text-align: left">         </td>         <td style="font-size: 10pt; text-align: right">          9,678,029         </td>         <td style="font-size: 10pt; text-align: left">         </td>         <td style="font-size: 10pt">         </td>         <td style="font-size: 10pt; text-align: left">         </td>         <td style="font-size: 10pt; text-align: right">          4,977,000         </td>         <td style="font-size: 10pt; text-align: left">         </td>        </tr>        <tr style="vertical-align: bottom; background-color: White">         <td style="font-size: 10pt; text-align: left">          Operating lease liabilities, net of current portion         </td>         <td style="font-size: 10pt">         </td>         <td style="font-size: 10pt; text-align: left">         </td>         <td style="font-size: 10pt; text-align: right">          5,874,442         </td>         <td style="font-size: 10pt; text-align: left">         </td>         <td style="font-size: 10pt">         </td>         <td style="font-size: 10pt; text-align: left">         </td>         <td style="font-size: 10pt; text-align: right">          -         </td>         <td style="font-size: 10pt; text-align: left">         </td>        </tr>        <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">         <td style="font-size: 10pt; text-align: left">          Notes payable, net of current portion         </td>         <td style="font-size: 10pt">         </td>         <td style="font-size: 10pt; text-align: left">         </td>         <td style="font-size: 10pt; text-align: right">          480,554         </td>         <td style="font-size: 10pt; text-align: left">         </td>         <td style="font-size: 10pt">         </td>         <td style="font-size: 10pt; text-align: left">         </td>         <td style="font-size: 10pt; text-align: right">          -         </td>         <td style="font-size: 10pt; text-align: left">         </td>        </tr>        <tr style="vertical-align: bottom; background-color: White">         <td style="font-size: 10pt; text-align: left; padding-bottom: 1.5pt">          Other long-term liabilities         </td>         <td style="font-size: 10pt; padding-bottom: 1.5pt">         </td>         <td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: left">         </td>         <td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: right">          -         </td>         <td style="padding-bottom: 1.5pt; font-size: 10pt; text-align: left">         </td>         <td style="font-size: 10pt; padding-bottom: 1.5pt">         </td>         <td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: left">         </td>         <td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: right">          635,913         </td>         <td style="padding-bottom: 1.5pt; font-size: 10pt; text-align: left">         </td>        </tr>        <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">         <td style="font-size: 10pt; text-align: left; padding-bottom: 1.5pt">          Total Liabilities         </td>         <td style="font-size: 10pt; padding-bottom: 1.5pt">         </td>         <td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: left">         </td>         <td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: right">          16,033,025         </td>         <td style="padding-bottom: 1.5pt; font-size: 10pt; text-align: left">         </td>         <td style="font-size: 10pt; padding-bottom: 1.5pt">         </td>         <td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: left">         </td>         <td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: right">          5,612,913         </td>         <td style="padding-bottom: 1.5pt; font-size: 10pt; text-align: left">         </td>        </tr>        <tr style="vertical-align: bottom; background-color: White">         <td style="text-align: left">         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">         </td>         <td style="text-align: left">         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">         </td>         <td style="text-align: left">         </td>        </tr>        <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">         <td style="font-size: 10pt; font-weight: bold; text-align: left">          Commitments and Contingencies (Note 10)         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">         </td>         <td style="text-align: left">         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">         </td>         <td style="text-align: left">         </td>        </tr>        <tr style="vertical-align: bottom; background-color: White">         <td style="text-align: left">         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">         </td>         <td style="text-align: left">         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">         </td>         <td style="text-align: left">         </td>        </tr>        <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">         <td style="font-size: 10pt; font-weight: bold; text-align: left">          Stockholders’ Equity         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">         </td>         <td style="text-align: left">         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">         </td>         <td style="text-align: left">         </td>        </tr>        <tr style="vertical-align: bottom; background-color: White">         <td style="font-size: 10pt; text-align: left">          Common stock authorized - 100,000,000 and 16,000,000 common shares with a par value of $0.0001 as of July 31, 2020 and July 31, 2019, respectively, common stock issued and outstanding — 23,054,474 and 10,633,043 common shares as of July 31, 2020 and July 31, 2019, respectively         </td>         <td style="font-size: 10pt">         </td>         <td style="font-size: 10pt; text-align: left">         </td>         <td style="font-size: 10pt; text-align: right">          2,305         </td>         <td style="font-size: 10pt; text-align: left">         </td>         <td style="font-size: 10pt">         </td>         <td style="font-size: 10pt; text-align: left">         </td>         <td style="font-size: 10pt; text-align: right">          1,063         </td>         <td style="font-size: 10pt; text-align: left">         </td>        </tr>        <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">         <td style="font-size: 10pt; text-align: left">          Additional paid-in capital         </td>         <td style="font-size: 10pt">         </td>         <td style="font-size: 10pt; text-align: left">         </td>         <td style="font-size: 10pt; text-align: right">          214,789,808         </td>         <td style="font-size: 10pt; text-align: left">         </td>         <td style="font-size: 10pt">         </td>         <td style="font-size: 10pt; text-align: left">         </td>         <td style="font-size: 10pt; text-align: right">          177,656,149         </td>         <td style="font-size: 10pt; text-align: left">         </td>        </tr>        <tr style="vertical-align: bottom; background-color: White">         <td style="font-size: 10pt; text-align: left">          Warrants issued and outstanding – 3,114,288 and 3,631,953 warrants as of July 31, 2020 and July 31, 2019, respectively         </td>         <td style="font-size: 10pt">         </td>         <td style="font-size: 10pt; text-align: left">         </td>         <td style="font-size: 10pt; text-align: right">          5,708,127         </td>         <td style="font-size: 10pt; text-align: left">         </td>         <td style="font-size: 10pt">         </td>         <td style="font-size: 10pt; text-align: left">         </td>         <td style="font-size: 10pt; text-align: right">          10,809,724         </td>         <td style="font-size: 10pt; text-align: left">         </td>        </tr>        <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">         <td style="font-size: 10pt; text-align: left">          Accumulated other comprehensive income (loss)         </td>         <td style="font-size: 10pt">         </td>         <td style="font-size: 10pt; text-align: left">         </td>         <td style="font-size: 10pt; text-align: right">          (19,504         </td>         <td style="font-size: 10pt; text-align: left">          )         </td>         <td style="font-size: 10pt">         </td>         <td style="font-size: 10pt; text-align: left">         </td>         <td style="font-size: 10pt; text-align: right">          169,037         </td>         <td style="font-size: 10pt; text-align: left">         </td>        </tr>        <tr style="vertical-align: bottom; background-color: White">         <td style="font-size: 10pt; text-align: left; padding-bottom: 1.5pt">          Accumulated deficit         </td>         <td style="font-size: 10pt; padding-bottom: 1.5pt">         </td>         <td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: left">         </td>         <td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: right">          (206,610,300         </td>         <td style="padding-bottom: 1.5pt; font-size: 10pt; text-align: left">          )         </td>         <td style="font-size: 10pt; padding-bottom: 1.5pt">         </td>         <td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: left">         </td>         <td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: right">          (164,356,874         </td>         <td style="padding-bottom: 1.5pt; font-size: 10pt; text-align: left">          )         </td>        </tr>        <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">         <td style="font-size: 10pt; text-align: left; padding-bottom: 1.5pt">          Total Stockholders’ Equity         </td>         <td style="font-size: 10pt; padding-bottom: 1.5pt">         </td>         <td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: left">         </td>         <td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: right">          13,870,436         </td>         <td style="padding-bottom: 1.5pt; font-size: 10pt; text-align: left">         </td>         <td style="font-size: 10pt; padding-bottom: 1.5pt">         </td>         <td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: left">         </td>         <td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: right">          24,279,099         </td>         <td style="padding-bottom: 1.5pt; font-size: 10pt; text-align: left">         </td>        </tr>        <tr style="vertical-align: bottom; background-color: White">         <td style="font-size: 10pt; text-align: left; padding-bottom: 2.5pt">          Total Liabilities and Stockholders’ Equity         </td>         <td style="font-size: 10pt; padding-bottom: 2.5pt">         </td>         <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">          $         </td>         <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">          29,903,461         </td>         <td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">         </td>         <td style="font-size: 10pt; padding-bottom: 2.5pt">         </td>         <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">          $         </td>         <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">          29,892,012         </td>         <td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">         </td>        </tr>       </tbody>      </table>      <p style="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: center">       <font style="font-family: Times New Roman, Times, Serif">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">       <font style="font-family: Times New Roman, Times, Serif">        Theaccompanying notes are an integral part of these consolidated financial statements.       </font>      </p>      <p style="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif">       </font>      </p>      <!-- Field: Page; Sequence: 67; Value: 1 -->      <div style="margin-bottom: 6pt; border-bottom: Black 1.5pt solid">       <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">        <tbody>         <tr style="vertical-align: top; text-align: left">          <td style="width: 33%">          </td>          <td style="text-align: center; width: 34%">           F-           <!-- Field: Sequence; Type: Arabic; Name: PageNo -->           2           <!-- Field: /Sequence -->          </td>          <td style="width: 33%">          </td>         </tr>        </tbody>       </table>      </div>      <div style="page-break-before: always; margin-top: 6pt">       <p style="margin: 0pt">       </p>      </div>      <!-- Field: /Page -->      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">       <font style="font-family: Times New Roman, Times, Serif">        <b>        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">       <font style="font-family: Times New Roman, Times, Serif">        <a name="cj_023">        </a>        <b>         OncoSecMedical Incorporated        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">       <font style="font-family: Times New Roman, Times, Serif">        <b>         ConsolidatedStatements of Operations        </b>       </font>      </p>      <p style="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif">       </font>      </p>      <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">       <tbody>        <tr style="vertical-align: bottom">         <td>          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td style="font-weight: bold">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td colspan="2" style="font-weight: bold; text-align: center">          <font style="font-family: Times New Roman, Times, Serif">           Year    Ended          </font>         </td>         <td style="font-weight: bold">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td style="font-weight: bold">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td colspan="2" style="font-weight: bold; text-align: center">          <font style="font-family: Times New Roman, Times, Serif">           Year    Ended          </font>         </td>         <td style="font-weight: bold">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>        </tr>        <tr style="vertical-align: bottom">         <td>          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td style="font-weight: bold; padding-bottom: 1.5pt">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">          <font style="font-family: Times New Roman, Times, Serif">           July    31, 2020          </font>         </td>         <td style="padding-bottom: 1.5pt; font-weight: bold">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td style="font-weight: bold; padding-bottom: 1.5pt">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">          <font style="font-family: Times New Roman, Times, Serif">           July    31, 2019          </font>         </td>         <td style="padding-bottom: 1.5pt; font-weight: bold">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>        </tr>        <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">         <td style="padding-bottom: 1.5pt">          <font style="font-family: Times New Roman, Times, Serif">           Revenue          </font>         </td>         <td style="padding-bottom: 1.5pt">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td style="border-bottom: Black 1.5pt solid; text-align: left">          <font style="font-family: Times New Roman, Times, Serif">           $          </font>         </td>         <td style="border-bottom: Black 1.5pt solid; text-align: right">          <font style="font-family: Times New Roman, Times, Serif">           -          </font>         </td>         <td style="padding-bottom: 1.5pt; text-align: left">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td style="padding-bottom: 1.5pt">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td style="border-bottom: Black 1.5pt solid; text-align: left">          <font style="font-family: Times New Roman, Times, Serif">           $          </font>         </td>         <td style="border-bottom: Black 1.5pt solid; text-align: right">          <font style="font-family: Times New Roman, Times, Serif">           -          </font>         </td>         <td style="padding-bottom: 1.5pt; text-align: left">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>        </tr>        <tr style="vertical-align: bottom; background-color: White">         <td>          <font style="font-family: Times New Roman, Times, Serif">           Expenses:          </font>         </td>         <td>          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td style="text-align: left">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td style="text-align: right">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td style="text-align: left">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td>          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td style="text-align: left">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td style="text-align: right">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td style="text-align: left">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>        </tr>        <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">         <td style="padding-left: 10pt; width: 60%; text-align: left">          <font style="font-family: Times New Roman, Times, Serif">           Research    and development          </font>         </td>         <td style="width: 2%">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td style="width: 1%; text-align: left">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td style="width: 16%; text-align: right">          <font style="font-family: Times New Roman, Times, Serif">           25,096,817          </font>         </td>         <td style="width: 1%; text-align: left">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td style="width: 2%">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td style="width: 1%; text-align: left">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td style="width: 16%; text-align: right">          <font style="font-family: Times New Roman, Times, Serif">           18,445,199          </font>         </td>         <td style="width: 1%; text-align: left">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>        </tr>        <tr style="vertical-align: bottom; background-color: White">         <td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">          <font style="font-family: Times New Roman, Times, Serif">           General    and administrative          </font>         </td>         <td style="padding-bottom: 1.5pt">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td style="border-bottom: Black 1.5pt solid; text-align: left">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td style="border-bottom: Black 1.5pt solid; text-align: right">          <font style="font-family: Times New Roman, Times, Serif">           18,312,268          </font>         </td>         <td style="padding-bottom: 1.5pt; text-align: left">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td style="padding-bottom: 1.5pt">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td style="border-bottom: Black 1.5pt solid; text-align: left">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td style="border-bottom: Black 1.5pt solid; text-align: right">          <font style="font-family: Times New Roman, Times, Serif">           11,971,479          </font>         </td>         <td style="padding-bottom: 1.5pt; text-align: left">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>        </tr>        <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">         <td style="text-align: left">          <font style="font-family: Times New Roman, Times, Serif">           Loss from operations          </font>         </td>         <td>          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td style="text-align: left">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td style="text-align: right">          <font style="font-family: Times New Roman, Times, Serif">           (43,409,085          </font>         </td>         <td style="text-align: left">          <font style="font-family: Times New Roman, Times, Serif">           )          </font>         </td>         <td>          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td style="text-align: left">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td style="text-align: right">          <font style="font-family: Times New Roman, Times, Serif">           (30,416,678          </font>         </td>         <td style="text-align: left">          <font style="font-family: Times New Roman, Times, Serif">           )          </font>         </td>        </tr>        <tr style="vertical-align: bottom; background-color: White">         <td style="padding-left: 10pt; text-align: left">          <font style="font-family: Times New Roman, Times, Serif">           Other income, net          </font>         </td>         <td>          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td style="text-align: left">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td style="text-align: right">          <font style="font-family: Times New Roman, Times, Serif">           185,052          </font>         </td>         <td style="text-align: left">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td>          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td style="text-align: left">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td style="text-align: right">          <font style="font-family: Times New Roman, Times, Serif">           440,037          </font>         </td>         <td style="text-align: left">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>        </tr>        <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">         <td style="padding-left: 10pt; text-align: left">          <font style="font-family: Times New Roman, Times, Serif">           Interest expense          </font>         </td>         <td>          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td style="text-align: left">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td style="text-align: right">          <font style="font-family: Times New Roman, Times, Serif">           (5,114          </font>         </td>         <td style="text-align: left">          <font style="font-family: Times New Roman, Times, Serif">           )          </font>         </td>         <td>          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td style="text-align: left">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td style="text-align: right">          <font style="font-family: Times New Roman, Times, Serif">           (3,805          </font>         </td>         <td style="text-align: left">          <font style="font-family: Times New Roman, Times, Serif">           )          </font>         </td>        </tr>        <tr style="vertical-align: bottom; background-color: White">         <td style="padding-left: 10pt; text-align: left">          <font style="font-family: Times New Roman, Times, Serif">           Loss on disposal    of property and equipment          </font>         </td>         <td>          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td style="text-align: left">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td style="text-align: right">          <font style="font-family: Times New Roman, Times, Serif">           -          </font>         </td>         <td style="text-align: left">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td>          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td style="text-align: left">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td style="text-align: right">          <font style="font-family: Times New Roman, Times, Serif">           (703          </font>         </td>         <td style="text-align: left">          <font style="font-family: Times New Roman, Times, Serif">           )          </font>         </td>        </tr>        <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">         <td style="padding-left: 10pt; text-align: left">          <font style="font-family: Times New Roman, Times, Serif">           Foreign currency    exchange gain (loss), net          </font>         </td>         <td>          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td style="text-align: left">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td style="text-align: right">          <font style="font-family: Times New Roman, Times, Serif">           103,136          </font>         </td>         <td style="text-align: left">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td>          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td style="text-align: left">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td style="text-align: right">          <font style="font-family: Times New Roman, Times, Serif">           (281,473          </font>         </td>         <td style="text-align: left">          <font style="font-family: Times New Roman, Times, Serif">           )          </font>         </td>        </tr>        <tr style="vertical-align: bottom; background-color: White">         <td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">          <font style="font-family: Times New Roman, Times, Serif">           Realized    loss on sale of securities, net          </font>         </td>         <td style="padding-bottom: 1.5pt">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td style="border-bottom: Black 1.5pt solid; text-align: left">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td style="border-bottom: Black 1.5pt solid; text-align: right">          <font style="font-family: Times New Roman, Times, Serif">           -          </font>         </td>         <td style="padding-bottom: 1.5pt; text-align: left">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td style="padding-bottom: 1.5pt">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td style="border-bottom: Black 1.5pt solid; text-align: left">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td style="border-bottom: Black 1.5pt solid; text-align: right">          <font style="font-family: Times New Roman, Times, Serif">           (12,134          </font>         </td>         <td style="padding-bottom: 1.5pt; text-align: left">          <font style="font-family: Times New Roman, Times, Serif">           )          </font>         </td>        </tr>        <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">         <td style="text-align: left">          <font style="font-family: Times New Roman, Times, Serif">           Loss before income taxes          </font>         </td>         <td>          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td style="text-align: left">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td style="text-align: right">          <font style="font-family: Times New Roman, Times, Serif">           (43,126,011          </font>         </td>         <td style="text-align: left">          <font style="font-family: Times New Roman, Times, Serif">           )          </font>         </td>         <td>          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td style="text-align: left">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td style="text-align: right">          <font style="font-family: Times New Roman, Times, Serif">           (30,274,756          </font>         </td>         <td style="text-align: left">          <font style="font-family: Times New Roman, Times, Serif">           )          </font>         </td>        </tr>        <tr style="vertical-align: bottom; background-color: White">         <td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">          <font style="font-family: Times New Roman, Times, Serif">           Income    tax expense (benefit)          </font>         </td>         <td style="padding-bottom: 1.5pt">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td style="border-bottom: Black 1.5pt solid; text-align: left">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td style="border-bottom: Black 1.5pt solid; text-align: right">          <font style="font-family: Times New Roman, Times, Serif">           (872,585          </font>         </td>         <td style="padding-bottom: 1.5pt; text-align: left">          <font style="font-family: Times New Roman, Times, Serif">           )          </font>         </td>         <td style="padding-bottom: 1.5pt">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td style="border-bottom: Black 1.5pt solid; text-align: left">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td style="border-bottom: Black 1.5pt solid; text-align: right">          <font style="font-family: Times New Roman, Times, Serif">           1,297          </font>         </td>         <td style="padding-bottom: 1.5pt; text-align: left">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>        </tr>        <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">         <td style="text-align: left; padding-bottom: 2.5pt">          <font style="font-family: Times New Roman, Times, Serif">           Net loss          </font>         </td>         <td style="padding-bottom: 2.5pt">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td style="border-bottom: Black 2.5pt double; text-align: left">          <font style="font-family: Times New Roman, Times, Serif">           $          </font>         </td>         <td style="border-bottom: Black 2.5pt double; text-align: right">          <font style="font-family: Times New Roman, Times, Serif">           (42,253,426          </font>         </td>         <td style="padding-bottom: 2.5pt; text-align: left">          <font style="font-family: Times New Roman, Times, Serif">           )          </font>         </td>         <td style="padding-bottom: 2.5pt">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td style="border-bottom: Black 2.5pt double; text-align: left">          <font style="font-family: Times New Roman, Times, Serif">           $          </font>         </td>         <td style="border-bottom: Black 2.5pt double; text-align: right">          <font style="font-family: Times New Roman, Times, Serif">           (30,276,053          </font>         </td>         <td style="padding-bottom: 2.5pt; text-align: left">          <font style="font-family: Times New Roman, Times, Serif">           )          </font>         </td>        </tr>        <tr style="vertical-align: bottom; background-color: White">         <td style="text-align: left; padding-bottom: 2.5pt">          <font style="font-family: Times New Roman, Times, Serif">           Basic and diluted    net loss per common share          </font>         </td>         <td style="padding-bottom: 2.5pt">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td style="border-bottom: Black 2.5pt double; text-align: left">          <font style="font-family: Times New Roman, Times, Serif">           $          </font>         </td>         <td style="border-bottom: Black 2.5pt double; text-align: right">          <font style="font-family: Times New Roman, Times, Serif">           (2.56          </font>         </td>         <td style="padding-bottom: 2.5pt; text-align: left">          <font style="font-family: Times New Roman, Times, Serif">           )          </font>         </td>         <td style="padding-bottom: 2.5pt">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td style="border-bottom: Black 2.5pt double; text-align: left">          <font style="font-family: Times New Roman, Times, Serif">           $          </font>         </td>         <td style="border-bottom: Black 2.5pt double; text-align: right">          <font style="font-family: Times New Roman, Times, Serif">           (4.29          </font>         </td>         <td style="padding-bottom: 2.5pt; text-align: left">          <font style="font-family: Times New Roman, Times, Serif">           )          </font>         </td>        </tr>        <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">         <td style="text-align: left; padding-bottom: 2.5pt">          <font style="font-family: Times New Roman, Times, Serif">           Weighted average    shares used in computing basic and diluted net loss per common share          </font>         </td>         <td style="padding-bottom: 2.5pt">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td style="border-bottom: Black 2.5pt double; text-align: left">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td style="border-bottom: Black 2.5pt double; text-align: right">          <font style="font-family: Times New Roman, Times, Serif">           16,534,551          </font>         </td>         <td style="padding-bottom: 2.5pt; text-align: left">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td style="padding-bottom: 2.5pt">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td style="border-bottom: Black 2.5pt double; text-align: left">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td style="border-bottom: Black 2.5pt double; text-align: right">          <font style="font-family: Times New Roman, Times, Serif">           7,053,279          </font>         </td>         <td style="padding-bottom: 2.5pt; text-align: left">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>        </tr>       </tbody>      </table>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">       <font style="font-family: Times New Roman, Times, Serif">        Theaccompanying notes are an integral part of these consolidated financial statements.       </font>      </p>      <p style="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif">       </font>      </p>      <!-- Field: Page; Sequence: 68; Value: 1 -->      <div style="margin-bottom: 6pt; border-bottom: Black 1.5pt solid">       <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">        <tbody>         <tr style="vertical-align: top; text-align: left">          <td style="width: 33%">          </td>          <td style="text-align: center; width: 34%">           F-           <!-- Field: Sequence; Type: Arabic; Name: PageNo -->           3           <!-- Field: /Sequence -->          </td>          <td style="width: 33%">          </td>         </tr>        </tbody>       </table>      </div>      <div style="page-break-before: always; margin-top: 6pt">       <p style="margin: 0pt">       </p>      </div>      <!-- Field: /Page -->      <p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">       <font style="font-family: Times New Roman, Times, Serif">        <b>        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">       <font style="font-family: Times New Roman, Times, Serif">        <a name="cj_024">        </a>        <b>         OncoSecMedical Incorporated        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">       <font style="font-family: Times New Roman, Times, Serif">        <b>         ConsolidatedStatements of Comprehensive Loss        </b>       </font>      </p>      <p style="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif">       </font>      </p>      <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">       <tbody>        <tr style="vertical-align: bottom">         <td style="text-align: center">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td style="font-weight: bold">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td colspan="2" style="font-weight: bold; text-align: center">          <font style="font-family: Times New Roman, Times, Serif">           Year    Ended          </font>         </td>         <td style="font-weight: bold">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td style="font-weight: bold">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td colspan="2" style="font-weight: bold; text-align: center">          <font style="font-family: Times New Roman, Times, Serif">           Year    Ended          </font>         </td>         <td style="font-weight: bold">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>        </tr>        <tr style="vertical-align: bottom">         <td style="text-align: center">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td style="font-weight: bold; padding-bottom: 1.5pt">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">          <font style="font-family: Times New Roman, Times, Serif">           July    31, 2020          </font>         </td>         <td style="padding-bottom: 1.5pt; font-weight: bold">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td style="font-weight: bold; padding-bottom: 1.5pt">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">          <font style="font-family: Times New Roman, Times, Serif">           July    31, 2019          </font>         </td>         <td style="padding-bottom: 1.5pt; font-weight: bold">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>        </tr>        <tr style="vertical-align: bottom">         <td style="text-align: right">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td>          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td colspan="2" style="text-align: right">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td>          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td>          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td colspan="2" style="text-align: right">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td>          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>        </tr>        <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">         <td style="width: 60%; text-align: left">          <font style="font-family: Times New Roman, Times, Serif">           Net Loss          </font>         </td>         <td style="width: 2%">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td style="width: 1%; text-align: left">          <font style="font-family: Times New Roman, Times, Serif">           $          </font>         </td>         <td style="width: 16%; text-align: right">          <font style="font-family: Times New Roman, Times, Serif">           (42,253,426          </font>         </td>         <td style="width: 1%; text-align: left">          <font style="font-family: Times New Roman, Times, Serif">           )          </font>         </td>         <td style="width: 2%">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td style="width: 1%; text-align: left">          <font style="font-family: Times New Roman, Times, Serif">           $          </font>         </td>         <td style="width: 16%; text-align: right">          <font style="font-family: Times New Roman, Times, Serif">           (30,276,053          </font>         </td>         <td style="width: 1%; text-align: left">          <font style="font-family: Times New Roman, Times, Serif">           )          </font>         </td>        </tr>        <tr style="vertical-align: bottom; background-color: White">         <td style="text-align: left; padding-bottom: 1.5pt">          <font style="font-family: Times New Roman, Times, Serif">           Foreign currency    translation adjustments          </font>         </td>         <td style="padding-bottom: 1.5pt">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td style="border-bottom: Black 1.5pt solid; text-align: left">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td style="border-bottom: Black 1.5pt solid; text-align: right">          <font style="font-family: Times New Roman, Times, Serif">           (188,541          </font>         </td>         <td style="padding-bottom: 1.5pt; text-align: left">          <font style="font-family: Times New Roman, Times, Serif">           )          </font>         </td>         <td style="padding-bottom: 1.5pt">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td style="border-bottom: Black 1.5pt solid; text-align: left">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td style="border-bottom: Black 1.5pt solid; text-align: right">          <font style="font-family: Times New Roman, Times, Serif">           185,061          </font>         </td>         <td style="padding-bottom: 1.5pt; text-align: left">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>        </tr>        <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">         <td style="text-align: left; padding-bottom: 2.5pt">          <font style="font-family: Times New Roman, Times, Serif">           Comprehensive    Loss          </font>         </td>         <td style="padding-bottom: 2.5pt">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td style="border-bottom: Black 2.5pt double; text-align: left">          <font style="font-family: Times New Roman, Times, Serif">           $          </font>         </td>         <td style="border-bottom: Black 2.5pt double; text-align: right">          <font style="font-family: Times New Roman, Times, Serif">           (42,441,967          </font>         </td>         <td style="padding-bottom: 2.5pt; text-align: left">          <font style="font-family: Times New Roman, Times, Serif">           )          </font>         </td>         <td style="padding-bottom: 2.5pt">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td style="border-bottom: Black 2.5pt double; text-align: left">          <font style="font-family: Times New Roman, Times, Serif">           $          </font>         </td>         <td style="border-bottom: Black 2.5pt double; text-align: right">          <font style="font-family: Times New Roman, Times, Serif">           (30,090,992          </font>         </td>         <td style="padding-bottom: 2.5pt; text-align: left">          <font style="font-family: Times New Roman, Times, Serif">           )          </font>         </td>        </tr>       </tbody>      </table>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">       <font style="font-family: Times New Roman, Times, Serif">        Theaccompanying notes are an integral part of these consolidated financial statements.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">       <font style="font-family: Times New Roman, Times, Serif">        <b>        </b>       </font>      </p>      <!-- Field: Page; Sequence: 69; Value: 1 -->      <div style="margin-bottom: 6pt; border-bottom: Black 1.5pt solid">       <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">        <tbody>         <tr style="vertical-align: top; text-align: left">          <td style="width: 33%">          </td>          <td style="text-align: center; width: 34%">           F-           <!-- Field: Sequence; Type: Arabic; Name: PageNo -->           4           <!-- Field: /Sequence -->          </td>          <td style="width: 33%">          </td>         </tr>        </tbody>       </table>      </div>      <div style="page-break-before: always; margin-top: 6pt">       <p style="margin: 0pt">       </p>      </div>      <!-- Field: /Page -->      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">       <font style="font-family: Times New Roman, Times, Serif">        <b>        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">       <font style="font-family: Times New Roman, Times, Serif">        <b>         <a name="cj_025">         </a>         OncoSecMedical Incorporated        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">       <font style="font-family: Times New Roman, Times, Serif">        <b>         ConsolidatedStatements of Stockholders’ Equity        </b>       </font>      </p>      <p style="font: 12pt Times New Roman, Times, Serif; margin: 0">       <font style="font-family: Times New Roman, Times, Serif">       </font>      </p>      <table cellpadding="0" cellspacing="0" style="font: 8pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">       <tbody>        <tr style="font: 8pt Times New Roman, Times, Serif; vertical-align: bottom">         <td style="font: 8pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">          </font>         </td>         <td style="font: bold 8pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">          </font>         </td>         <td colspan="6" style="border-bottom: Black 1.5pt solid; font: bold 8pt Times New Roman, Times, Serif; text-align: center">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">           Common    Stock          </font>         </td>         <td style="font: bold 8pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">          </font>         </td>         <td colspan="2" style="font: 8pt Times New Roman, Times, Serif; text-align: center">          <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">            <b>             Additional            </b>           </font>          </p>          <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">            <b>             Paid-In            </b>           </font>          </p>         </td>         <td style="font: 8pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">          </font>         </td>         <td style="font: bold 8pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">          </font>         </td>         <td colspan="6" style="border-bottom: Black 1.5pt solid; font: bold 8pt Times New Roman, Times, Serif; text-align: center">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">           Warrants          </font>         </td>         <td style="font: bold 8pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">          </font>         </td>         <td style="font: bold 8pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">          </font>         </td>         <td colspan="2" style="font: bold 8pt Times New Roman, Times, Serif; text-align: center">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">           Accumulated    Other Comprehensive          </font>         </td>         <td style="font: bold 8pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">          </font>         </td>         <td style="font: bold 8pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">          </font>         </td>         <td colspan="2" style="font: bold 8pt Times New Roman, Times, Serif; text-align: center">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">           Accumulated          </font>         </td>         <td style="font: bold 8pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">          </font>         </td>         <td style="font: bold 8pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">          </font>         </td>         <td colspan="2" style="font: bold 8pt Times New Roman, Times, Serif; text-align: center">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">           Total    Stockholders’          </font>         </td>         <td style="font: bold 8pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">          </font>         </td>        </tr>        <tr style="font: 8pt Times New Roman, Times, Serif; vertical-align: bottom">         <td style="font: 8pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">          </font>         </td>         <td style="font: bold 8pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">          </font>         </td>         <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 8pt Times New Roman, Times, Serif; text-align: center">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">           Shares          </font>         </td>         <td style="font: bold 8pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">          </font>         </td>         <td style="font: bold 8pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">          </font>         </td>         <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 8pt Times New Roman, Times, Serif; text-align: center">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">           Amount          </font>         </td>         <td style="font: bold 8pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">          </font>         </td>         <td style="font: bold 8pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">          </font>         </td>         <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 8pt Times New Roman, Times, Serif; text-align: center">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">           Capital          </font>         </td>         <td style="font: bold 8pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">          </font>         </td>         <td style="font: bold 8pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">          </font>         </td>         <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 8pt Times New Roman, Times, Serif; text-align: center">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">           Shares          </font>         </td>         <td style="font: bold 8pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">          </font>         </td>         <td style="font: bold 8pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">          </font>         </td>         <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 8pt Times New Roman, Times, Serif; text-align: center">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">           Amount          </font>         </td>         <td style="font: bold 8pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">          </font>         </td>         <td style="font: bold 8pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">          </font>         </td>         <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 8pt Times New Roman, Times, Serif; text-align: center">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">           Income    (Loss)          </font>         </td>         <td style="font: bold 8pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">          </font>         </td>         <td style="font: bold 8pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">          </font>         </td>         <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 8pt Times New Roman, Times, Serif; text-align: center">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">           Deficit          </font>         </td>         <td style="font: bold 8pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">          </font>         </td>         <td style="font: bold 8pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">          </font>         </td>         <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 8pt Times New Roman, Times, Serif; text-align: center">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">           Equity          </font>         </td>         <td style="font: bold 8pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">          </font>         </td>        </tr>        <tr style="font: 8pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">         <td style="font: 8pt Times New Roman, Times, Serif; width: 28%">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">           Balance,    July 31, 2018          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif; width: 2%">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif; width: 1%; text-align: left">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif; width: 5%; text-align: right">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">           5,351,290          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif; width: 1%; text-align: left">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif; width: 2%">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif; width: 1%; text-align: left">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">           $          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif; width: 5%; text-align: right">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">           535          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif; width: 1%; text-align: left">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif; width: 2%">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif; width: 1%; text-align: left">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">           $          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif; width: 5%; text-align: right">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">           145,749,189          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif; width: 1%; text-align: left">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif; width: 2%">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif; width: 1%; text-align: left">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif; width: 5%; text-align: right">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">           895,805          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif; width: 1%; text-align: left">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif; width: 2%">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif; width: 1%; text-align: left">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">           $          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif; width: 5%; text-align: right">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">           11,271,327          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif; width: 1%; text-align: left">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif; width: 2%">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif; width: 1%; text-align: left">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">           $          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif; width: 5%; text-align: right">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">           (16,024          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif; width: 1%; text-align: left">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">           )          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif; width: 2%">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif; width: 1%; text-align: left">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">           $          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif; width: 5%; text-align: right">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">           (134,080,821          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif; width: 1%; text-align: left">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">           )          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif; width: 2%">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif; width: 1%; text-align: left">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">           $          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif; width: 5%; text-align: right">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">           22,924,206          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif; width: 1%; text-align: left">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">          </font>         </td>        </tr>        <tr style="font: 8pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">         <td style="font: 8pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">           Repurchase    of fractional shares          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif; text-align: left">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif; text-align: right">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">           (1,456          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif; text-align: left">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">           )          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif; text-align: left">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif; text-align: right">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">           —          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif; text-align: left">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif; text-align: left">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif; text-align: right">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">           (567          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif; text-align: left">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">           )          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif; text-align: left">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif; text-align: right">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">           —          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif; text-align: left">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif; text-align: left">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif; text-align: right">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">           —          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif; text-align: left">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif; text-align: left">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif; text-align: right">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">           —          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif; text-align: left">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif; text-align: left">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif; text-align: right">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">           —          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif; text-align: left">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif; text-align: left">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif; text-align: right">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">           (567          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif; text-align: left">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">           )          </font>         </td>        </tr>        <tr style="font: 8pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">         <td style="font: 8pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">           Exercise    of common stock options          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif; text-align: left">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif; text-align: right">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">           43,029          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif; text-align: left">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif; text-align: left">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif; text-align: right">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">           4          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif; text-align: left">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif; text-align: left">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif; text-align: right">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">           566,131          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif; text-align: left">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif; text-align: left">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif; text-align: right">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">           —          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif; text-align: left">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif; text-align: left">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif; text-align: right">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">           —          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif; text-align: left">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif; text-align: left">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif; text-align: right">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">           —          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif; text-align: left">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif; text-align: left">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif; text-align: right">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">           —          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif; text-align: left">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif; text-align: left">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif; text-align: right">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">           566,135          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif; text-align: left">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">          </font>         </td>        </tr>        <tr style="font: 8pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">         <td style="font: 8pt Times New Roman, Times, Serif; text-align: left">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">           Common    stock issued for employee stock purchase plan          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif; text-align: left">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif; text-align: right">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">           4,688          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif; text-align: left">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif; text-align: left">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif; text-align: right">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">           1          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif; text-align: left">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif; text-align: left">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif; text-align: right">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">           27,290          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif; text-align: left">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif; text-align: left">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif; text-align: right">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">           —          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif; text-align: left">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif; text-align: left">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif; text-align: right">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">           —          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif; text-align: left">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif; text-align: left">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif; text-align: right">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">           —          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif; text-align: left">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif; text-align: left">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif; text-align: right">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">           —          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif; text-align: left">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif; text-align: left">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif; text-align: right">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">           27,291          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif; text-align: left">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">          </font>         </td>        </tr>        <tr style="font: 8pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">         <td style="font: 8pt Times New Roman, Times, Serif; text-align: left">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">           Stock-based    compensation expense          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif; text-align: left">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif; text-align: right">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">           54,755          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif; text-align: left">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif; text-align: left">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif; text-align: right">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">           5          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif; text-align: left">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif; text-align: left">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif; text-align: right">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">           3,364,366          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif; text-align: left">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif; text-align: left">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif; text-align: right">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">           —          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif; text-align: left">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif; text-align: left">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif; text-align: right">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">           —          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif; text-align: left">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif; text-align: left">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif; text-align: right">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">           —          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif; text-align: left">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif; text-align: left">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif; text-align: right">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">           —          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif; text-align: left">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif; text-align: left">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif; text-align: right">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">           3,364,371          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif; text-align: left">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">          </font>         </td>        </tr>        <tr style="font: 8pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">         <td style="font: 8pt Times New Roman, Times, Serif; text-align: left">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">           Tax    withholdings paid on equity awards          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif; text-align: left">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif; text-align: right">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">           —          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif; text-align: left">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif; text-align: left">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif; text-align: right">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">           —          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif; text-align: left">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif; text-align: left">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif; text-align: right">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">           (101,480          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif; text-align: left">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">           )          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif; text-align: left">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif; text-align: right">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">           —          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif; text-align: left">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif; text-align: left">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif; text-align: right">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">           —          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif; text-align: left">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif; text-align: left">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif; text-align: right">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">           —          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif; text-align: left">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif; text-align: left">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif; text-align: right">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">           —          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif; text-align: left">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif; text-align: left">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif; text-align: right">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">           (101,480          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif; text-align: left">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">           )          </font>         </td>        </tr>        <tr style="font: 8pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">         <td style="font: 8pt Times New Roman, Times, Serif; text-align: left">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">           Tax    shares sold to pay for tax withholdings on equity awards          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif; text-align: left">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif; text-align: right">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">           —          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif; text-align: left">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif; text-align: left">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif; text-align: right">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">           —          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif; text-align: left">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif; text-align: left">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif; text-align: right">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">           83,246          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif; text-align: left">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif; text-align: left">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif; text-align: right">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">           —          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif; text-align: left">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif; text-align: left">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif; text-align: right">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">           —          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif; text-align: left">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif; text-align: left">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif; text-align: right">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">           —          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif; text-align: left">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif; text-align: left">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif; text-align: right">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">           —          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif; text-align: left">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif; text-align: left">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif; text-align: right">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">           83,246          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif; text-align: left">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">          </font>         </td>        </tr>        <tr style="font: 8pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">         <td style="font: 8pt Times New Roman, Times, Serif; text-align: left">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">           Tax    withholdings paid related to net share settlement of equity awards          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif; text-align: left">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif; text-align: right">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">           —          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif; text-align: left">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif; text-align: left">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif; text-align: right">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">           —          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif; text-align: left">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif; text-align: left">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif; text-align: right">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">           (32,505          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif; text-align: left">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">           )          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif; text-align: left">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif; text-align: right">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">           —          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif; text-align: left">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif; text-align: left">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif; text-align: right">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">           —          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif; text-align: left">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif; text-align: left">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif; text-align: right">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">           —          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif; text-align: left">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif; text-align: left">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif; text-align: right">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">           —          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif; text-align: left">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif; text-align: left">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif; text-align: right">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">           (32,505          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif; text-align: left">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">           )          </font>         </td>        </tr>        <tr style="font: 8pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">         <td style="font: 8pt Times New Roman, Times, Serif; text-align: left">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">           Private    placement on October 8, 2018, net of issuance costs of $573,189          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif; text-align: left">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif; text-align: right">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">           533,333          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif; text-align: left">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif; text-align: left">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif; text-align: right">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">           53          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif; text-align: left">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif; text-align: left">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif; text-align: right">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">           7,446,758          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif; text-align: left">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif; text-align: left">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif; text-align: right">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">           —          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif; text-align: left">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif; text-align: left">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif; text-align: right">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">           —          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif; text-align: left">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif; text-align: left">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif; text-align: right">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">           —          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif; text-align: left">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif; text-align: left">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif; text-align: right">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">           —          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif; text-align: left">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif; text-align: left">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif; text-align: right">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">           7,446,811          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif; text-align: left">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">          </font>         </td>        </tr>        <tr style="font: 8pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">         <td style="font: 8pt Times New Roman, Times, Serif; text-align: left">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">           Private    placement on December 6, 2018, net of issuance costs of $304,916          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif; text-align: left">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif; text-align: right">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">           466,666          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif; text-align: left">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif; text-align: left">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif; text-align: right">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">           47          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif; text-align: left">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif; text-align: left">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif; text-align: right">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">           6,695,038          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif; text-align: left">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif; text-align: left">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif; text-align: right">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">           —          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif; text-align: left">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif; text-align: left">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif; text-align: right">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">           —          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif; text-align: left">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif; text-align: left">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif; text-align: right">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">           —          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif; text-align: left">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif; text-align: left">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif; text-align: right">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">           —          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif; text-align: left">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif; text-align: left">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif; text-align: right">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">           6,695,085          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif; text-align: left">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">          </font>         </td>        </tr>        <tr style="font: 8pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">         <td style="font: 8pt Times New Roman, Times, Serif; text-align: left">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">           Private    placement on May 24, 2019, net of issuance costs of $1,025,655          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif; text-align: left">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif; text-align: right">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">           3,492,063          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif; text-align: left">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif; text-align: left">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif; text-align: right">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">           349          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif; text-align: left">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif; text-align: left">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif; text-align: right">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">           6,377,220          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif; text-align: left">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif; text-align: left">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif; text-align: right">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">           2,797,618          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif; text-align: left">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif; text-align: left">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif; text-align: right">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">           3,599,156          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif; text-align: left">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif; text-align: left">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif; text-align: right">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">           —          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif; text-align: left">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif; text-align: left">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif; text-align: right">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">           —          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif; text-align: left">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif; text-align: left">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif; text-align: right">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">           9,976,725          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif; text-align: left">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">          </font>         </td>        </tr>        <tr style="font: 8pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">         <td style="font: 8pt Times New Roman, Times, Serif; text-align: left">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">           Private    placement, net of issuance costs of $80,575          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif; text-align: left">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif; text-align: right">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">           610,875          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif; text-align: left">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif; text-align: left">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif; text-align: right">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">           61          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif; text-align: left">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif; text-align: left">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif; text-align: right">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">           2,439,293          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif; text-align: left">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif; text-align: left">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif; text-align: right">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">           —          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif; text-align: left">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif; text-align: left">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif; text-align: right">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">           —          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif; text-align: left">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif; text-align: left">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif; text-align: right">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">           —          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif; text-align: left">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif; text-align: left">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif; text-align: right">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">           —          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif; text-align: left">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif; text-align: left">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif; text-align: right">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">           2,439,354          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif; text-align: left">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">          </font>         </td>        </tr>        <tr style="font: 8pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">         <td style="font: 8pt Times New Roman, Times, Serif; text-align: left">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">           Cancellation    of expired warrants          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif; text-align: left">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif; text-align: right">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">           —          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif; text-align: left">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif; text-align: left">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif; text-align: right">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">           —          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif; text-align: left">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif; text-align: left">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif; text-align: right">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">           4,060,759          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif; text-align: left">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif; text-align: left">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif; text-align: right">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">           (61,470          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif; text-align: left">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">           )          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif; text-align: left">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif; text-align: right">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">           (4,060,759          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif; text-align: left">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">           )          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif; text-align: left">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif; text-align: right">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">           —          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif; text-align: left">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif; text-align: left">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif; text-align: right">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">           —          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif; text-align: left">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif; text-align: left">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif; text-align: right">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">           —          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif; text-align: left">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">          </font>         </td>        </tr>        <tr style="font: 8pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">         <td style="font: 8pt Times New Roman, Times, Serif; text-align: left">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">           Common    stock issued for services          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif; text-align: left">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif; text-align: right">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">           60,300          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif; text-align: left">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif; text-align: left">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif; text-align: right">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">           6          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif; text-align: left">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif; text-align: left">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif; text-align: right">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">           845,988          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif; text-align: left">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif; text-align: left">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif; text-align: right">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">           —          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif; text-align: left">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif; text-align: left">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif; text-align: right">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">           —          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif; text-align: left">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif; text-align: left">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif; text-align: right">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">           —          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif; text-align: left">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif; text-align: left">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif; text-align: right">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">           —          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif; text-align: left">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif; text-align: left">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif; text-align: right">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">           845,994          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif; text-align: left">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">          </font>         </td>        </tr>        <tr style="font: 8pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">         <td style="font: 8pt Times New Roman, Times, Serif; text-align: left">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">           Modification    of equity award          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif; text-align: left">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif; text-align: right">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">           17,500          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif; text-align: left">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif; text-align: left">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif; text-align: right">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">           2          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif; text-align: left">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif; text-align: left">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif; text-align: right">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">           135,423          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif; text-align: left">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif; text-align: left">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif; text-align: right">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">           —          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif; text-align: left">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif; text-align: left">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif; text-align: right">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">           —          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif; text-align: left">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif; text-align: left">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif; text-align: right">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">           —          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif; text-align: left">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif; text-align: left">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif; text-align: right">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">           —          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif; text-align: left">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif; text-align: left">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif; text-align: right">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">           135,425          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif; text-align: left">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">          </font>         </td>        </tr>        <tr style="font: 8pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">         <td style="font: 8pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">           Net    loss and comprehensive loss          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">          </font>         </td>         <td style="border-bottom: Black 1.5pt solid; font: 8pt Times New Roman, Times, Serif; text-align: left">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">          </font>         </td>         <td style="border-bottom: Black 1.5pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">           —          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">          </font>         </td>         <td style="border-bottom: Black 1.5pt solid; font: 8pt Times New Roman, Times, Serif; text-align: left">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">          </font>         </td>         <td style="border-bottom: Black 1.5pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">           —          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">          </font>         </td>         <td style="border-bottom: Black 1.5pt solid; font: 8pt Times New Roman, Times, Serif; text-align: left">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">          </font>         </td>         <td style="border-bottom: Black 1.5pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">           —          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">          </font>         </td>         <td style="border-bottom: Black 1.5pt solid; font: 8pt Times New Roman, Times, Serif; text-align: left">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">          </font>         </td>         <td style="border-bottom: Black 1.5pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">           —          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">          </font>         </td>         <td style="border-bottom: Black 1.5pt solid; font: 8pt Times New Roman, Times, Serif; text-align: left">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">          </font>         </td>         <td style="border-bottom: Black 1.5pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">           —          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">          </font>         </td>         <td style="border-bottom: Black 1.5pt solid; font: 8pt Times New Roman, Times, Serif; text-align: left">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">          </font>         </td>         <td style="border-bottom: Black 1.5pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">           185,061          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">          </font>         </td>         <td style="border-bottom: Black 1.5pt solid; font: 8pt Times New Roman, Times, Serif; text-align: left">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">          </font>         </td>         <td style="border-bottom: Black 1.5pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">           (30,276,053          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">           )          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">          </font>         </td>         <td style="border-bottom: Black 1.5pt solid; font: 8pt Times New Roman, Times, Serif; text-align: left">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">          </font>         </td>         <td style="border-bottom: Black 1.5pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">           (30,090,992          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">           )          </font>         </td>        </tr>        <tr style="font: 8pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">         <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">           Balance,    July 31, 2019          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">          </font>         </td>         <td style="border-bottom: Black 1.5pt solid; font: 8pt Times New Roman, Times, Serif; text-align: left">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">          </font>         </td>         <td style="border-bottom: Black 1.5pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">           10,633,043          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">          </font>         </td>         <td style="border-bottom: Black 1.5pt solid; font: 8pt Times New Roman, Times, Serif; text-align: left">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">          </font>         </td>         <td style="border-bottom: Black 1.5pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">           1,063          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">          </font>         </td>         <td style="border-bottom: Black 1.5pt solid; font: 8pt Times New Roman, Times, Serif; text-align: left">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">          </font>         </td>         <td style="border-bottom: Black 1.5pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">           177,656,149          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">          </font>         </td>         <td style="border-bottom: Black 1.5pt solid; font: 8pt Times New Roman, Times, Serif; text-align: left">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">          </font>         </td>         <td style="border-bottom: Black 1.5pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">           3,631,953          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">          </font>         </td>         <td style="border-bottom: Black 1.5pt solid; font: 8pt Times New Roman, Times, Serif; text-align: left">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">          </font>         </td>         <td style="border-bottom: Black 1.5pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">           10,809,724          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">          </font>         </td>         <td style="border-bottom: Black 1.5pt solid; font: 8pt Times New Roman, Times, Serif; text-align: left">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">          </font>         </td>         <td style="border-bottom: Black 1.5pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">           169,037          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">          </font>         </td>         <td style="border-bottom: Black 1.5pt solid; font: 8pt Times New Roman, Times, Serif; text-align: left">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">          </font>         </td>         <td style="border-bottom: Black 1.5pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">           (164,356,874          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">           )          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">          </font>         </td>         <td style="border-bottom: Black 1.5pt solid; font: 8pt Times New Roman, Times, Serif; text-align: left">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">          </font>         </td>         <td style="border-bottom: Black 1.5pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">           24,279,099          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">          </font>         </td>        </tr>        <tr style="font: 8pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">         <td style="font: 8pt Times New Roman, Times, Serif; text-align: left">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">           Common    stock issued for employee stock purchase plan          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif; text-align: left">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif; text-align: right">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">           4,199          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif; text-align: left">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif; text-align: left">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif; text-align: right">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">           —          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif; text-align: left">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif; text-align: left">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif; text-align: right">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">           7,012          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif; text-align: left">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif; text-align: left">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif; text-align: right">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">           —          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif; text-align: left">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif; text-align: left">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif; text-align: right">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">           —          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif; text-align: left">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif; text-align: left">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif; text-align: right">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">           —          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif; text-align: left">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif; text-align: left">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif; text-align: right">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">           —          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif; text-align: left">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif; text-align: left">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif; text-align: right">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">           7,012          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif; text-align: left">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">          </font>         </td>        </tr>        <tr style="font: 8pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">         <td style="font: 8pt Times New Roman, Times, Serif; text-align: left">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">           Stock-based    compensation expense          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif; text-align: left">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif; text-align: right">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">           220,233          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif; text-align: left">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif; text-align: left">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif; text-align: right">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">           22          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif; text-align: left">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif; text-align: left">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif; text-align: right">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">           3,517,106          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif; text-align: left">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif; text-align: left">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif; text-align: right">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">           —          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif; text-align: left">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif; text-align: left">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif; text-align: right">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">           —          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif; text-align: left">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif; text-align: left">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif; text-align: right">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">           —          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif; text-align: left">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif; text-align: left">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif; text-align: right">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">           —          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif; text-align: left">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif; text-align: left">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif; text-align: right">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">           3,517,128          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif; text-align: left">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">          </font>         </td>        </tr>        <tr style="font: 8pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">         <td style="font: 8pt Times New Roman, Times, Serif; text-align: left">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">           Cash    paid for stock options cancellation          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif; text-align: left">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif; text-align: right">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">           —          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif; text-align: left">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif; text-align: left">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif; text-align: right">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">           —          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif; text-align: left">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif; text-align: left">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif; text-align: right">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">           (25,819          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif; text-align: left">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">           )          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif; text-align: left">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif; text-align: right">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">           —          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif; text-align: left">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif; text-align: left">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif; text-align: right">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">           —          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif; text-align: left">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif; text-align: left">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif; text-align: right">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">           —          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif; text-align: left">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif; text-align: left">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif; text-align: right">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">           —          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif; text-align: left">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif; text-align: left">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif; text-align: right">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">           (25,819          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif; text-align: left">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">           )          </font>         </td>        </tr>        <tr style="font: 8pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">         <td style="font: 8pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">           Repurchase    of warrants          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif; text-align: left">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif; text-align: right">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">           —          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif; text-align: left">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif; text-align: left">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif; text-align: right">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">           —          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif; text-align: left">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif; text-align: left">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif; text-align: right">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">           2,457,976          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif; text-align: left">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif; text-align: left">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif; text-align: right">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">           (266,098          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif; text-align: left">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">           )          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif; text-align: left">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif; text-align: right">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">           (2,636,201          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif; text-align: left">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">           )          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif; text-align: left">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif; text-align: right">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">           —          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif; text-align: left">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif; text-align: left">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif; text-align: right">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">           —          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif; text-align: left">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif; text-align: left">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif; text-align: right">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">           (178,225          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif; text-align: left">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">           )          </font>         </td>        </tr>        <tr style="font: 8pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">         <td style="font: 8pt Times New Roman, Times, Serif; text-align: left">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">           Tax    withholdings paid on equity awards          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif; text-align: left">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif; text-align: right">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">           —          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif; text-align: left">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif; text-align: left">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif; text-align: right">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">           —          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif; text-align: left">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif; text-align: left">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif; text-align: right">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">           (26,859          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif; text-align: left">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">           )          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif; text-align: left">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif; text-align: right">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">           —          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif; text-align: left">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif; text-align: left">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif; text-align: right">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">           —          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif; text-align: left">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif; text-align: left">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif; text-align: right">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">           —          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif; text-align: left">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif; text-align: left">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif; text-align: right">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">           —          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif; text-align: left">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif; text-align: left">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif; text-align: right">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">           (26,859          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif; text-align: left">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">           )          </font>         </td>        </tr>        <tr style="font: 8pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">         <td style="font: 8pt Times New Roman, Times, Serif; text-align: left">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">           Tax    shares sold to pay for tax withholdings on equity awards          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif; text-align: left">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif; text-align: right">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">           —          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif; text-align: left">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif; text-align: left">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif; text-align: right">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">           —          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif; text-align: left">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif; text-align: left">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif; text-align: right">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">           26,495          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif; text-align: left">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif; text-align: left">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif; text-align: right">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">           —          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif; text-align: left">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif; text-align: left">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif; text-align: right">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">           —          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif; text-align: left">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif; text-align: left">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif; text-align: right">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">           —          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif; text-align: left">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif; text-align: left">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif; text-align: right">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">           —          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif; text-align: left">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif; text-align: left">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif; text-align: right">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">           26,495          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif; text-align: left">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">          </font>         </td>        </tr>        <tr style="font: 8pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">         <td style="font: 8pt Times New Roman, Times, Serif; text-align: left">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">           Tax    withholdings paid related to net share settlement of equity awards          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif; text-align: left">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif; text-align: right">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">           —          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif; text-align: left">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif; text-align: left">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif; text-align: right">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">           —          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif; text-align: left">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif; text-align: left">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif; text-align: right">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">           (263,100          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif; text-align: left">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">           )          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif; text-align: left">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif; text-align: right">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">           —          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif; text-align: left">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif; text-align: left">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif; text-align: right">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">           —          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif; text-align: left">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif; text-align: left">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif; text-align: right">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">           —          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif; text-align: left">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif; text-align: left">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif; text-align: right">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">           —          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif; text-align: left">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif; text-align: left">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif; text-align: right">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">           (263,100          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif; text-align: left">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">           )          </font>         </td>        </tr>        <tr style="font: 8pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">         <td style="font: 8pt Times New Roman, Times, Serif; text-align: left">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">           Cancellation    of expired warrants          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif; text-align: left">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif; text-align: right">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">           —          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif; text-align: left">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif; text-align: left">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif; text-align: right">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">           —          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif; text-align: left">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif; text-align: left">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif; text-align: right">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">           2,465,396          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif; text-align: left">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif; text-align: left">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif; text-align: right">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">           (251,567          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif; text-align: left">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">           )          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif; text-align: left">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif; text-align: right">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">           (2,465,396          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif; text-align: left">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">           )          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif; text-align: left">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif; text-align: right">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">           —          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif; text-align: left">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif; text-align: left">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif; text-align: right">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">           —          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif; text-align: left">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif; text-align: left">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif; text-align: right">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">           —          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif; text-align: left">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">          </font>         </td>        </tr>        <tr style="font: 8pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">         <td style="font: 8pt Times New Roman, Times, Serif; text-align: left">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">           February    2020 Financing, net of issuance costs of$1,954,678          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif; text-align: left">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif; text-align: right">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">           12,000,000          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif; text-align: left">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif; text-align: left">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif; text-align: right">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">           1,200          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif; text-align: left">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif; text-align: left">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif; text-align: right">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">           28,044,122          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif; text-align: left">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif; text-align: left">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif; text-align: right">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">           —          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif; text-align: left">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif; text-align: left">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif; text-align: right">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">           —          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif; text-align: left">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif; text-align: left">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif; text-align: right">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">           —          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif; text-align: left">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif; text-align: left">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif; text-align: right">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">           —          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif; text-align: left">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif; text-align: left">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif; text-align: right">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">           28,045,322          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif; text-align: left">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">          </font>         </td>        </tr>        <tr style="font: 8pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">         <td style="font: 8pt Times New Roman, Times, Serif; text-align: left">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">           Common    stock issued for services          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif; text-align: left">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif; text-align: right">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">           196,999          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif; text-align: left">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif; text-align: left">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif; text-align: right">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">           20          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif; text-align: left">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif; text-align: left">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif; text-align: right">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">           931,330          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif; text-align: left">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif; text-align: left">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif; text-align: right">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">           —          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif; text-align: left">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif; text-align: left">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif; text-align: right">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">           —          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif; text-align: left">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif; text-align: left">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif; text-align: right">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">           —          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif; text-align: left">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif; text-align: left">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif; text-align: right">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">           —          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif; text-align: left">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif; text-align: left">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif; text-align: right">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">           931,350          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif; text-align: left">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">          </font>         </td>        </tr>        <tr style="font: 8pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">         <td style="font: 8pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">           Net    loss and comprehensive loss          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">          </font>         </td>         <td style="border-bottom: Black 1.5pt solid; font: 8pt Times New Roman, Times, Serif; text-align: left">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">          </font>         </td>         <td style="border-bottom: Black 1.5pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">           —          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">          </font>         </td>         <td style="border-bottom: Black 1.5pt solid; font: 8pt Times New Roman, Times, Serif; text-align: left">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">          </font>         </td>         <td style="border-bottom: Black 1.5pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">           —          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">          </font>         </td>         <td style="border-bottom: Black 1.5pt solid; font: 8pt Times New Roman, Times, Serif; text-align: left">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">          </font>         </td>         <td style="border-bottom: Black 1.5pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">           —          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">          </font>         </td>         <td style="border-bottom: Black 1.5pt solid; font: 8pt Times New Roman, Times, Serif; text-align: left">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">          </font>         </td>         <td style="border-bottom: Black 1.5pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">           —          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">          </font>         </td>         <td style="border-bottom: Black 1.5pt solid; font: 8pt Times New Roman, Times, Serif; text-align: left">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">          </font>         </td>         <td style="border-bottom: Black 1.5pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">           —          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">          </font>         </td>         <td style="border-bottom: Black 1.5pt solid; font: 8pt Times New Roman, Times, Serif; text-align: left">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">          </font>         </td>         <td style="border-bottom: Black 1.5pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">           (188,541          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">           )          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">          </font>         </td>         <td style="border-bottom: Black 1.5pt solid; font: 8pt Times New Roman, Times, Serif; text-align: left">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">          </font>         </td>         <td style="border-bottom: Black 1.5pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">           (42,253,426          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">           )          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">          </font>         </td>         <td style="border-bottom: Black 1.5pt solid; font: 8pt Times New Roman, Times, Serif; text-align: left">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">          </font>         </td>         <td style="border-bottom: Black 1.5pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">           (42,441,967          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">           )          </font>         </td>        </tr>        <tr style="font: 8pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">         <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">           Balance,    July 31, 2020          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">          </font>         </td>         <td style="border-bottom: Black 2.5pt double; font: 8pt Times New Roman, Times, Serif; text-align: left">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">          </font>         </td>         <td style="border-bottom: Black 2.5pt double; font: 8pt Times New Roman, Times, Serif; text-align: right">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">           23,054,474          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">          </font>         </td>         <td style="border-bottom: Black 2.5pt double; font: 8pt Times New Roman, Times, Serif; text-align: left">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">           $          </font>         </td>         <td style="border-bottom: Black 2.5pt double; font: 8pt Times New Roman, Times, Serif; text-align: right">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">           2,305          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">          </font>         </td>         <td style="border-bottom: Black 2.5pt double; font: 8pt Times New Roman, Times, Serif; text-align: left">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">           $          </font>         </td>         <td style="border-bottom: Black 2.5pt double; font: 8pt Times New Roman, Times, Serif; text-align: right">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">           214,789,808          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">          </font>         </td>         <td style="border-bottom: Black 2.5pt double; font: 8pt Times New Roman, Times, Serif; text-align: left">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">          </font>         </td>         <td style="border-bottom: Black 2.5pt double; font: 8pt Times New Roman, Times, Serif; text-align: right">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">           3,114,288          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">          </font>         </td>         <td style="border-bottom: Black 2.5pt double; font: 8pt Times New Roman, Times, Serif; text-align: left">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">           $          </font>         </td>         <td style="border-bottom: Black 2.5pt double; font: 8pt Times New Roman, Times, Serif; text-align: right">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">           5,708,127          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">          </font>         </td>         <td style="border-bottom: Black 2.5pt double; font: 8pt Times New Roman, Times, Serif; text-align: left">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">           $          </font>         </td>         <td style="border-bottom: Black 2.5pt double; font: 8pt Times New Roman, Times, Serif; text-align: right">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">           (19,504          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">           )          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">          </font>         </td>         <td style="border-bottom: Black 2.5pt double; font: 8pt Times New Roman, Times, Serif; text-align: left">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">           $          </font>         </td>         <td style="border-bottom: Black 2.5pt double; font: 8pt Times New Roman, Times, Serif; text-align: right">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">           (206,610,300          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">           )          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">          </font>         </td>         <td style="border-bottom: Black 2.5pt double; font: 8pt Times New Roman, Times, Serif; text-align: left">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">           $          </font>         </td>         <td style="border-bottom: Black 2.5pt double; font: 8pt Times New Roman, Times, Serif; text-align: right">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">           13,870,436          </font>         </td>         <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">          <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">          </font>         </td>        </tr>       </tbody>      </table>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">       <font style="font-family: Times New Roman, Times, Serif">        Theaccompanying notes are an integral part of these consolidated financial statements.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif">       </font>      </p>      <!-- Field: Page; Sequence: 70; Value: 1 -->      <div style="margin-bottom: 6pt; border-bottom: Black 1.5pt solid">       <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">        <tbody>         <tr style="vertical-align: top; text-align: left">          <td style="width: 33%">          </td>          <td style="text-align: center; width: 34%">           F-           <!-- Field: Sequence; Type: Arabic; Name: PageNo -->           5           <!-- Field: /Sequence -->          </td>          <td style="width: 33%">          </td>         </tr>        </tbody>       </table>      </div>      <div style="page-break-before: always; margin-top: 6pt">       <p style="margin: 0pt">       </p>      </div>      <!-- Field: /Page -->      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">       <font style="font-family: Times New Roman, Times, Serif">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">       <font style="font-family: Times New Roman, Times, Serif">        <a name="cj_026">        </a>        <b>         OncoSecMedical Incorporated        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">       <font style="font-family: Times New Roman, Times, Serif">        <b>         ConsolidatedStatements of Cash Flows        </b>       </font>      </p>      <p style="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif">       </font>      </p>      <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">       <tbody>        <tr style="vertical-align: bottom">         <td>          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td style="font-weight: bold">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td colspan="2" style="font-weight: bold; text-align: center">          <font style="font-family: Times New Roman, Times, Serif">           Year    Ended          </font>         </td>         <td style="font-weight: bold">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td style="font-weight: bold">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td colspan="2" style="font-weight: bold; text-align: center">          <font style="font-family: Times New Roman, Times, Serif">           Year    Ended          </font>         </td>         <td style="font-weight: bold">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>        </tr>        <tr style="vertical-align: bottom">         <td>          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td style="font-weight: bold; padding-bottom: 1.5pt">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">          <font style="font-family: Times New Roman, Times, Serif">           July    31, 2020          </font>         </td>         <td style="padding-bottom: 1.5pt; font-weight: bold">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td style="font-weight: bold; padding-bottom: 1.5pt">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">          <font style="font-family: Times New Roman, Times, Serif">           July    31, 2019          </font>         </td>         <td style="padding-bottom: 1.5pt; font-weight: bold">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>        </tr>        <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">         <td style="font-style: italic; text-align: left">          <font style="font-family: Times New Roman, Times, Serif">           Operating activities          </font>         </td>         <td>          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td style="text-align: left">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td style="text-align: right">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td style="text-align: left">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td>          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td style="text-align: left">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td style="text-align: right">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td style="text-align: left">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>        </tr>        <tr style="vertical-align: bottom; background-color: White">         <td style="width: 60%; text-align: left">          <font style="font-family: Times New Roman, Times, Serif">           Net loss          </font>         </td>         <td style="width: 2%">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td style="width: 1%; text-align: left">          <font style="font-family: Times New Roman, Times, Serif">           $          </font>         </td>         <td style="width: 16%; text-align: right">          <font style="font-family: Times New Roman, Times, Serif">           (42,253,426          </font>         </td>         <td style="width: 1%; text-align: left">          <font style="font-family: Times New Roman, Times, Serif">           )          </font>         </td>         <td style="width: 2%">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td style="width: 1%; text-align: left">          <font style="font-family: Times New Roman, Times, Serif">           $          </font>         </td>         <td style="width: 16%; text-align: right">          <font style="font-family: Times New Roman, Times, Serif">           (30,276,053          </font>         </td>         <td style="width: 1%; text-align: left">          <font style="font-family: Times New Roman, Times, Serif">           )          </font>         </td>        </tr>        <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">         <td style="text-align: left">          <font style="font-family: Times New Roman, Times, Serif">           Adjustments to reconcile net loss to    net cash used in operating activities:          </font>         </td>         <td>          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td style="text-align: left">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td style="text-align: right">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td style="text-align: left">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td>          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td style="text-align: left">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td style="text-align: right">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td style="text-align: left">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>        </tr>        <tr style="vertical-align: bottom; background-color: White">         <td style="padding-left: 10pt; text-align: left">          <font style="font-family: Times New Roman, Times, Serif">           Depreciation and    amortization          </font>         </td>         <td>          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td style="text-align: left">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td style="text-align: right">          <font style="font-family: Times New Roman, Times, Serif">           216,635          </font>         </td>         <td style="text-align: left">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td>          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td style="text-align: left">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td style="text-align: right">          <font style="font-family: Times New Roman, Times, Serif">           243,712          </font>         </td>         <td style="text-align: left">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>        </tr>        <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">         <td style="padding-left: 10pt; text-align: left">          <font style="font-family: Times New Roman, Times, Serif">           Amortization of    right-of-use assets          </font>         </td>         <td>          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td style="text-align: left">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td style="text-align: right">          <font style="font-family: Times New Roman, Times, Serif">           773,653          </font>         </td>         <td style="text-align: left">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td>          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td style="text-align: left">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td style="text-align: right">          <font style="font-family: Times New Roman, Times, Serif">           -          </font>         </td>         <td style="text-align: left">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>        </tr>        <tr style="vertical-align: bottom; background-color: White">         <td style="padding-left: 10pt; text-align: left">          <font style="font-family: Times New Roman, Times, Serif">           Loss on disposal    of property and equipment          </font>         </td>         <td>          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td style="text-align: left">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td style="text-align: right">          <font style="font-family: Times New Roman, Times, Serif">           -          </font>         </td>         <td style="text-align: left">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td>          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td style="text-align: left">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td style="text-align: right">          <font style="font-family: Times New Roman, Times, Serif">           703          </font>         </td>         <td style="text-align: left">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>        </tr>        <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">         <td style="padding-left: 10pt; text-align: left">          <font style="font-family: Times New Roman, Times, Serif">           Amortization of    discount on investments          </font>         </td>         <td>          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td style="text-align: left">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td style="text-align: right">          <font style="font-family: Times New Roman, Times, Serif">           -          </font>         </td>         <td style="text-align: left">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td>          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td style="text-align: left">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td style="text-align: right">          <font style="font-family: Times New Roman, Times, Serif">           (51,481          </font>         </td>         <td style="text-align: left">          <font style="font-family: Times New Roman, Times, Serif">           )          </font>         </td>        </tr>        <tr style="vertical-align: bottom; background-color: White">         <td style="padding-left: 10pt; text-align: left">          <font style="font-family: Times New Roman, Times, Serif">           Stock-based compensation          </font>         </td>         <td>          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td style="text-align: left">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td style="text-align: right">          <font style="font-family: Times New Roman, Times, Serif">           3,517,128          </font>         </td>         <td style="text-align: left">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td>          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td style="text-align: left">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td style="text-align: right">          <font style="font-family: Times New Roman, Times, Serif">           3,364,371          </font>         </td>         <td style="text-align: left">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>        </tr>        <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">         <td style="padding-left: 10pt; text-align: left">          <font style="font-family: Times New Roman, Times, Serif">           Common stock issued    for services          </font>         </td>         <td>          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td style="text-align: left">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td style="text-align: right">          <font style="font-family: Times New Roman, Times, Serif">           931,350          </font>         </td>         <td style="text-align: left">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td>          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td style="text-align: left">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td style="text-align: right">          <font style="font-family: Times New Roman, Times, Serif">           845,994          </font>         </td>         <td style="text-align: left">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>        </tr>        <tr style="vertical-align: bottom; background-color: White">         <td style="padding-left: 10pt; text-align: left">          <font style="font-family: Times New Roman, Times, Serif">           Modification of    equity award          </font>         </td>         <td>          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td style="text-align: left">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td style="text-align: right">          <font style="font-family: Times New Roman, Times, Serif">           -          </font>         </td>         <td style="text-align: left">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td>          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td style="text-align: left">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td style="text-align: right">          <font style="font-family: Times New Roman, Times, Serif">           135,425          </font>         </td>         <td style="text-align: left">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>        </tr>        <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">         <td style="padding-left: 10pt; text-align: left">          <font style="font-family: Times New Roman, Times, Serif">           Foreign currency    exchange loss, net          </font>         </td>         <td>          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td style="text-align: left">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td style="text-align: right">          <font style="font-family: Times New Roman, Times, Serif">           (103,136          </font>         </td>         <td style="text-align: left">          <font style="font-family: Times New Roman, Times, Serif">           )          </font>         </td>         <td>          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td style="text-align: left">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td style="text-align: right">          <font style="font-family: Times New Roman, Times, Serif">           281,473          </font>         </td>         <td style="text-align: left">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>        </tr>        <tr style="vertical-align: bottom; background-color: White">         <td style="text-align: left">          <font style="font-family: Times New Roman, Times, Serif">           Changes in operating assets and liabilities:          </font>         </td>         <td>          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td style="text-align: left">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td style="text-align: right">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td style="text-align: left">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td>          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td style="text-align: left">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td style="text-align: right">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td style="text-align: left">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>        </tr>        <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">         <td style="padding-left: 10pt; text-align: left">          <font style="font-family: Times New Roman, Times, Serif">           Prepaid expenses    and other current assets          </font>         </td>         <td>          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td style="text-align: left">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td style="text-align: right">          <font style="font-family: Times New Roman, Times, Serif">           1,470,982          </font>         </td>         <td style="text-align: left">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td>          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td style="text-align: left">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td style="text-align: right">          <font style="font-family: Times New Roman, Times, Serif">           (1,566,415          </font>         </td>         <td style="text-align: left">          <font style="font-family: Times New Roman, Times, Serif">           )          </font>         </td>        </tr>        <tr style="vertical-align: bottom; background-color: White">         <td style="padding-left: 10pt; text-align: left">          <font style="font-family: Times New Roman, Times, Serif">           Other long-term    assets          </font>         </td>         <td>          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td style="text-align: left">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td style="text-align: right">          <font style="font-family: Times New Roman, Times, Serif">           42,431          </font>         </td>         <td style="text-align: left">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td>          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td style="text-align: left">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td style="text-align: right">          <font style="font-family: Times New Roman, Times, Serif">           (9,035          </font>         </td>         <td style="text-align: left">          <font style="font-family: Times New Roman, Times, Serif">           )          </font>         </td>        </tr>        <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">         <td style="padding-left: 10pt; text-align: left">          <font style="font-family: Times New Roman, Times, Serif">           Accounts payable    and accrued liabilities          </font>         </td>         <td>          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td style="text-align: left">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td style="text-align: right">          <font style="font-family: Times New Roman, Times, Serif">           3,617,923          </font>         </td>         <td style="text-align: left">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td>          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td style="text-align: left">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td style="text-align: right">          <font style="font-family: Times New Roman, Times, Serif">           (741,444          </font>         </td>         <td style="text-align: left">          <font style="font-family: Times New Roman, Times, Serif">           )          </font>         </td>        </tr>        <tr style="vertical-align: bottom; background-color: White">         <td style="padding-left: 10pt; text-align: left">          <font style="font-family: Times New Roman, Times, Serif">           Accrued compensation    related          </font>         </td>         <td>          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td style="text-align: left">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td style="text-align: right">          <font style="font-family: Times New Roman, Times, Serif">           (391,096          </font>         </td>         <td style="text-align: left">          <font style="font-family: Times New Roman, Times, Serif">           )          </font>         </td>         <td>          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td style="text-align: left">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td style="text-align: right">          <font style="font-family: Times New Roman, Times, Serif">           (394,521          </font>         </td>         <td style="text-align: left">          <font style="font-family: Times New Roman, Times, Serif">           )          </font>         </td>        </tr>        <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">         <td style="padding-left: 10pt; text-align: left">          <font style="font-family: Times New Roman, Times, Serif">           Operating lease    liabilities          </font>         </td>         <td>          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td style="text-align: left">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td style="text-align: right">          <font style="font-family: Times New Roman, Times, Serif">           (967,808          </font>         </td>         <td style="text-align: left">          <font style="font-family: Times New Roman, Times, Serif">           )          </font>         </td>         <td>          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td style="text-align: left">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td style="text-align: right">          <font style="font-family: Times New Roman, Times, Serif">           -          </font>         </td>         <td style="text-align: left">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>        </tr>        <tr style="vertical-align: bottom; background-color: White">         <td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">          <font style="font-family: Times New Roman, Times, Serif">           Other    long-term liabilities          </font>         </td>         <td style="padding-bottom: 1.5pt">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td style="border-bottom: Black 1.5pt solid; text-align: left">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td style="border-bottom: Black 1.5pt solid; text-align: right">          <font style="font-family: Times New Roman, Times, Serif">           -          </font>         </td>         <td style="padding-bottom: 1.5pt; text-align: left">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td style="padding-bottom: 1.5pt">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td style="border-bottom: Black 1.5pt solid; text-align: left">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td style="border-bottom: Black 1.5pt solid; text-align: right">          <font style="font-family: Times New Roman, Times, Serif">           (836,714          </font>         </td>         <td style="padding-bottom: 1.5pt; text-align: left">          <font style="font-family: Times New Roman, Times, Serif">           )          </font>         </td>        </tr>        <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">         <td style="text-align: left; padding-bottom: 1.5pt">          <font style="font-family: Times New Roman, Times, Serif">           Net cash used    in operating activities          </font>         </td>         <td style="padding-bottom: 1.5pt">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td style="border-bottom: Black 1.5pt solid; text-align: left">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td style="border-bottom: Black 1.5pt solid; text-align: right">          <font style="font-family: Times New Roman, Times, Serif">           (33,145,364          </font>         </td>         <td style="padding-bottom: 1.5pt; text-align: left">          <font style="font-family: Times New Roman, Times, Serif">           )          </font>         </td>         <td style="padding-bottom: 1.5pt">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td style="border-bottom: Black 1.5pt solid; text-align: left">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td style="border-bottom: Black 1.5pt solid; text-align: right">          <font style="font-family: Times New Roman, Times, Serif">           (29,003,985          </font>         </td>         <td style="padding-bottom: 1.5pt; text-align: left">          <font style="font-family: Times New Roman, Times, Serif">           )          </font>         </td>        </tr>        <tr style="vertical-align: bottom; background-color: White">         <td style="font-style: italic; text-align: left">          <font style="font-family: Times New Roman, Times, Serif">           Investing activities          </font>         </td>         <td>          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td style="text-align: left">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td style="text-align: right">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td style="text-align: left">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td>          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td style="text-align: left">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td style="text-align: right">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td style="text-align: left">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>        </tr>        <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">         <td style="padding-left: 10pt; text-align: left">          <font style="font-family: Times New Roman, Times, Serif">           Purchases of property    and equipment          </font>         </td>         <td>          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td style="text-align: left">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td style="text-align: right">          <font style="font-family: Times New Roman, Times, Serif">           -          </font>         </td>         <td style="text-align: left">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td>          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td style="text-align: left">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td style="text-align: right">          <font style="font-family: Times New Roman, Times, Serif">           (9,882          </font>         </td>         <td style="text-align: left">          <font style="font-family: Times New Roman, Times, Serif">           )          </font>         </td>        </tr>        <tr style="vertical-align: bottom; background-color: White">         <td style="padding-left: 10pt; text-align: left">          <font style="font-family: Times New Roman, Times, Serif">           Maturity of investment    securities          </font>         </td>         <td>          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td style="text-align: left">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td style="text-align: right">          <font style="font-family: Times New Roman, Times, Serif">           -          </font>         </td>         <td style="text-align: left">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td>          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td style="text-align: left">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td style="text-align: right">          <font style="font-family: Times New Roman, Times, Serif">           17,236,000          </font>         </td>         <td style="text-align: left">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>        </tr>        <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">         <td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">          <font style="font-family: Times New Roman, Times, Serif">           Sale    of investment securities          </font>         </td>         <td style="padding-bottom: 1.5pt">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td style="border-bottom: Black 1.5pt solid; text-align: left">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td style="border-bottom: Black 1.5pt solid; text-align: right">          <font style="font-family: Times New Roman, Times, Serif">           -          </font>         </td>         <td style="padding-bottom: 1.5pt; text-align: left">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td style="padding-bottom: 1.5pt">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td style="border-bottom: Black 1.5pt solid; text-align: left">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td style="border-bottom: Black 1.5pt solid; text-align: right">          <font style="font-family: Times New Roman, Times, Serif">           5,977,794          </font>         </td>         <td style="padding-bottom: 1.5pt; text-align: left">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>        </tr>        <tr style="vertical-align: bottom; background-color: White">         <td style="text-align: left; padding-bottom: 1.5pt">          <font style="font-family: Times New Roman, Times, Serif">           Net cash provided    by investing activities          </font>         </td>         <td style="padding-bottom: 1.5pt">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td style="border-bottom: Black 1.5pt solid; text-align: left">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td style="border-bottom: Black 1.5pt solid; text-align: right">          <font style="font-family: Times New Roman, Times, Serif">           -          </font>         </td>         <td style="padding-bottom: 1.5pt; text-align: left">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td style="padding-bottom: 1.5pt">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td style="border-bottom: Black 1.5pt solid; text-align: left">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td style="border-bottom: Black 1.5pt solid; text-align: right">          <font style="font-family: Times New Roman, Times, Serif">           23,203,912          </font>         </td>         <td style="padding-bottom: 1.5pt; text-align: left">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>        </tr>        <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">         <td style="font-style: italic; text-align: left">          <font style="font-family: Times New Roman, Times, Serif">           Financing activities          </font>         </td>         <td>          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td style="text-align: left">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td style="text-align: right">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td style="text-align: left">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td>          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td style="text-align: left">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td style="text-align: right">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td style="text-align: left">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>        </tr>        <tr style="vertical-align: bottom; background-color: White">         <td style="padding-left: 10pt; text-align: left">          <font style="font-family: Times New Roman, Times, Serif">           Proceeds from issuance    of common stock through ESPP          </font>         </td>         <td>          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td style="text-align: left">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td style="text-align: right">          <font style="font-family: Times New Roman, Times, Serif">           7,012          </font>         </td>         <td style="text-align: left">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td>          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td style="text-align: left">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td style="text-align: right">          <font style="font-family: Times New Roman, Times, Serif">           27,291          </font>         </td>         <td style="text-align: left">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>        </tr>        <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">         <td style="padding-left: 10pt; text-align: left">          <font style="font-family: Times New Roman, Times, Serif">           Proceeds from issuance    of common stock and/or warrants          </font>         </td>         <td>          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td style="text-align: left">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td style="text-align: right">          <font style="font-family: Times New Roman, Times, Serif">           30,000,000          </font>         </td>         <td style="text-align: left">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td>          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td style="text-align: left">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td style="text-align: right">          <font style="font-family: Times New Roman, Times, Serif">           27,897,155          </font>         </td>         <td style="text-align: left">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>        </tr>        <tr style="vertical-align: bottom; background-color: White">         <td style="padding-left: 10pt; text-align: left">          <font style="font-family: Times New Roman, Times, Serif">           Payment of financing    and offering costs          </font>         </td>         <td>          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td style="text-align: left">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td style="text-align: right">          <font style="font-family: Times New Roman, Times, Serif">           (1,954,678          </font>         </td>         <td style="text-align: left">          <font style="font-family: Times New Roman, Times, Serif">           )          </font>         </td>         <td>          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td style="text-align: left">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td style="text-align: right">          <font style="font-family: Times New Roman, Times, Serif">           (1,159,180          </font>         </td>         <td style="text-align: left">          <font style="font-family: Times New Roman, Times, Serif">           )          </font>         </td>        </tr>        <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">         <td style="padding-left: 10pt; text-align: left">          <font style="font-family: Times New Roman, Times, Serif">           Cash paid for stock    options cancellation          </font>         </td>         <td>          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td style="text-align: left">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td style="text-align: right">          <font style="font-family: Times New Roman, Times, Serif">           (25,819          </font>         </td>         <td style="text-align: left">          <font style="font-family: Times New Roman, Times, Serif">           )          </font>         </td>         <td>          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td style="text-align: left">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td style="text-align: right">          <font style="font-family: Times New Roman, Times, Serif">           -          </font>         </td>         <td style="text-align: left">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>        </tr>        <tr style="vertical-align: bottom; background-color: White">         <td style="padding-left: 10pt; text-align: left">          <font style="font-family: Times New Roman, Times, Serif">           Cash paid for repurchase    of warrants          </font>         </td>         <td>          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td style="text-align: left">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td style="text-align: right">          <font style="font-family: Times New Roman, Times, Serif">           (178,225          </font>         </td>         <td style="text-align: left">          <font style="font-family: Times New Roman, Times, Serif">           )          </font>         </td>         <td>          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td style="text-align: left">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td style="text-align: right">          <font style="font-family: Times New Roman, Times, Serif">           -          </font>         </td>         <td style="text-align: left">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>        </tr>        <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">         <td style="padding-left: 10pt">          <font style="font-family: Times New Roman, Times, Serif">           Proceeds from exercise of options          </font>         </td>         <td>          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td style="text-align: left">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td style="text-align: right">          <font style="font-family: Times New Roman, Times, Serif">           -          </font>         </td>         <td style="text-align: left">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td>          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td style="text-align: left">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td style="text-align: right">          <font style="font-family: Times New Roman, Times, Serif">           566,135          </font>         </td>         <td style="text-align: left">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>        </tr>        <tr style="vertical-align: bottom; background-color: White">         <td style="padding-left: 10pt; text-align: left">          <font style="font-family: Times New Roman, Times, Serif">           Proceeds from note    payable          </font>         </td>         <td>          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td style="text-align: left">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td style="text-align: right">          <font style="font-family: Times New Roman, Times, Serif">           952,744          </font>         </td>         <td style="text-align: left">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td>          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td style="text-align: left">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td style="text-align: right">          <font style="font-family: Times New Roman, Times, Serif">           -          </font>         </td>         <td style="text-align: left">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>        </tr>        <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">         <td style="padding-left: 10pt; text-align: left">          <font style="font-family: Times New Roman, Times, Serif">           Principal payments    on note payable          </font>         </td>         <td>          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td style="text-align: left">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td style="text-align: right">          <font style="font-family: Times New Roman, Times, Serif">           (138,244          </font>         </td>         <td style="text-align: left">          <font style="font-family: Times New Roman, Times, Serif">           )          </font>         </td>         <td>          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td style="text-align: left">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td style="text-align: right">          <font style="font-family: Times New Roman, Times, Serif">           (81,577          </font>         </td>         <td style="text-align: left">          <font style="font-family: Times New Roman, Times, Serif">           )          </font>         </td>        </tr>        <tr style="vertical-align: bottom; background-color: White">         <td style="padding-left: 10pt; text-align: left">          <font style="font-family: Times New Roman, Times, Serif">           Tax withholdings    paid on equity awards          </font>         </td>         <td>          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td style="text-align: left">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td style="text-align: right">          <font style="font-family: Times New Roman, Times, Serif">           (26,859          </font>         </td>         <td style="text-align: left">          <font style="font-family: Times New Roman, Times, Serif">           )          </font>         </td>         <td>          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td style="text-align: left">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td style="text-align: right">          <font style="font-family: Times New Roman, Times, Serif">           (101,480          </font>         </td>         <td style="text-align: left">          <font style="font-family: Times New Roman, Times, Serif">           )          </font>         </td>        </tr>        <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">         <td style="padding-left: 10pt; text-align: left">          <font style="font-family: Times New Roman, Times, Serif">           Tax withholdings    paid related to net share settlement of equity awards          </font>         </td>         <td>          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td style="text-align: left">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td style="text-align: right">          <font style="font-family: Times New Roman, Times, Serif">           (263,100          </font>         </td>         <td style="text-align: left">          <font style="font-family: Times New Roman, Times, Serif">           )          </font>         </td>         <td>          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td style="text-align: left">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td style="text-align: right">          <font style="font-family: Times New Roman, Times, Serif">           (32,505          </font>         </td>         <td style="text-align: left">          <font style="font-family: Times New Roman, Times, Serif">           )          </font>         </td>        </tr>        <tr style="vertical-align: bottom; background-color: White">         <td style="padding-left: 10pt; text-align: left">          <font style="font-family: Times New Roman, Times, Serif">           Tax shares sold    to pay for tax withholdings on equity awards          </font>         </td>         <td>          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td style="text-align: left">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td style="text-align: right">          <font style="font-family: Times New Roman, Times, Serif">           26,495          </font>         </td>         <td style="text-align: left">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td>          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td style="text-align: left">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td style="text-align: right">          <font style="font-family: Times New Roman, Times, Serif">           83,246          </font>         </td>         <td style="text-align: left">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>        </tr>        <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">         <td style="padding-left: 10pt; padding-bottom: 1.5pt">          <font style="font-family: Times New Roman, Times, Serif">           Repurchase    of fractional shares          </font>         </td>         <td style="padding-bottom: 1.5pt">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td style="border-bottom: Black 1.5pt solid; text-align: left">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td style="border-bottom: Black 1.5pt solid; text-align: right">          <font style="font-family: Times New Roman, Times, Serif">           -          </font>         </td>         <td style="padding-bottom: 1.5pt; text-align: left">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td style="padding-bottom: 1.5pt">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td style="border-bottom: Black 1.5pt solid; text-align: left">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td style="border-bottom: Black 1.5pt solid; text-align: right">          <font style="font-family: Times New Roman, Times, Serif">           (567          </font>         </td>         <td style="padding-bottom: 1.5pt; text-align: left">          <font style="font-family: Times New Roman, Times, Serif">           )          </font>         </td>        </tr>        <tr style="vertical-align: bottom; background-color: White">         <td style="text-align: left">          <font style="font-family: Times New Roman, Times, Serif">           Net cash provided by financing activities          </font>         </td>         <td>          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td style="text-align: left">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td style="text-align: right">          <font style="font-family: Times New Roman, Times, Serif">           28,399,326          </font>         </td>         <td style="text-align: left">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td>          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td style="text-align: left">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td style="text-align: right">          <font style="font-family: Times New Roman, Times, Serif">           27,198,518          </font>         </td>         <td style="text-align: left">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>        </tr>        <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">         <td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">          <font style="font-family: Times New Roman, Times, Serif">           Effect    of exchange rate changes on cash          </font>         </td>         <td style="padding-bottom: 1.5pt">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td style="border-bottom: Black 1.5pt solid; text-align: left">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td style="border-bottom: Black 1.5pt solid; text-align: right">          <font style="font-family: Times New Roman, Times, Serif">           (47,280          </font>         </td>         <td style="padding-bottom: 1.5pt; text-align: left">          <font style="font-family: Times New Roman, Times, Serif">           )          </font>         </td>         <td style="padding-bottom: 1.5pt">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td style="border-bottom: Black 1.5pt solid; text-align: left">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td style="border-bottom: Black 1.5pt solid; text-align: right">          <font style="font-family: Times New Roman, Times, Serif">           (54,292          </font>         </td>         <td style="padding-bottom: 1.5pt; text-align: left">          <font style="font-family: Times New Roman, Times, Serif">           )          </font>         </td>        </tr>        <tr style="vertical-align: bottom; background-color: White">         <td style="text-align: left">          <font style="font-family: Times New Roman, Times, Serif">           Net increase (decrease) in cash and    cash equivalents          </font>         </td>         <td>          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td style="text-align: left">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td style="text-align: right">          <font style="font-family: Times New Roman, Times, Serif">           (4,793,318          </font>         </td>         <td style="text-align: left">          <font style="font-family: Times New Roman, Times, Serif">           )          </font>         </td>         <td>          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td style="text-align: left">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td style="text-align: right">          <font style="font-family: Times New Roman, Times, Serif">           21,344,153          </font>         </td>         <td style="text-align: left">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>        </tr>        <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">         <td style="text-align: left; padding-bottom: 1.5pt">          <font style="font-family: Times New Roman, Times, Serif">           Cash and cash    equivalents, at beginning of year          </font>         </td>         <td style="padding-bottom: 1.5pt">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td style="border-bottom: Black 1.5pt solid; text-align: left">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td style="border-bottom: Black 1.5pt solid; text-align: right">          <font style="font-family: Times New Roman, Times, Serif">           25,147,780          </font>         </td>         <td style="padding-bottom: 1.5pt; text-align: left">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td style="padding-bottom: 1.5pt">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td style="border-bottom: Black 1.5pt solid; text-align: left">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td style="border-bottom: Black 1.5pt solid; text-align: right">          <font style="font-family: Times New Roman, Times, Serif">           3,803,627          </font>         </td>         <td style="padding-bottom: 1.5pt; text-align: left">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>        </tr>        <tr style="vertical-align: bottom; background-color: White">         <td style="text-align: left; padding-bottom: 2.5pt">          <font style="font-family: Times New Roman, Times, Serif">           Cash and cash    equivalents, at end of year          </font>         </td>         <td style="padding-bottom: 2.5pt">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td style="border-bottom: Black 2.5pt double; text-align: left">          <font style="font-family: Times New Roman, Times, Serif">           $          </font>         </td>         <td style="border-bottom: Black 2.5pt double; text-align: right">          <font style="font-family: Times New Roman, Times, Serif">           20,354,462          </font>         </td>         <td style="padding-bottom: 2.5pt; text-align: left">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td style="padding-bottom: 2.5pt">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td style="border-bottom: Black 2.5pt double; text-align: left">          <font style="font-family: Times New Roman, Times, Serif">           $          </font>         </td>         <td style="border-bottom: Black 2.5pt double; text-align: right">          <font style="font-family: Times New Roman, Times, Serif">           25,147,780          </font>         </td>         <td style="padding-bottom: 2.5pt; text-align: left">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>        </tr>        <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">         <td>          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td>          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td style="text-align: left">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td style="text-align: right">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td style="text-align: left">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td>          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td style="text-align: left">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td style="text-align: right">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td style="text-align: left">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>        </tr>        <tr style="vertical-align: bottom; background-color: White">         <td style="text-align: left">          <font style="font-family: Times New Roman, Times, Serif">           Supplemental disclosure for cash flow    information:          </font>         </td>         <td>          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td style="text-align: left">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td style="text-align: right">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td style="text-align: left">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td>          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td style="text-align: left">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td style="text-align: right">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td style="text-align: left">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>        </tr>        <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">         <td style="padding-left: 10pt; text-align: left">          <font style="font-family: Times New Roman, Times, Serif">           Cash paid during    the period for:          </font>         </td>         <td>          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td style="text-align: left">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td style="text-align: right">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td style="text-align: left">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td>          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td style="text-align: left">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td style="text-align: right">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td style="text-align: left">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>        </tr>        <tr style="vertical-align: bottom; background-color: White">         <td>          <font style="font-family: Times New Roman, Times, Serif">           Interest          </font>         </td>         <td>          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td style="text-align: left">          <font style="font-family: Times New Roman, Times, Serif">           $          </font>         </td>         <td style="text-align: right">          <font style="font-family: Times New Roman, Times, Serif">           3,179          </font>         </td>         <td style="text-align: left">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td>          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td style="text-align: left">          <font style="font-family: Times New Roman, Times, Serif">           $          </font>         </td>         <td style="text-align: right">          <font style="font-family: Times New Roman, Times, Serif">           3,253          </font>         </td>         <td style="text-align: left">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>        </tr>        <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">         <td style="text-align: left">          <font style="font-family: Times New Roman, Times, Serif">           Income taxes          </font>         </td>         <td>          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td style="text-align: left">          <font style="font-family: Times New Roman, Times, Serif">           $          </font>         </td>         <td style="text-align: right">          <font style="font-family: Times New Roman, Times, Serif">           2,450          </font>         </td>         <td style="text-align: left">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td>          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td style="text-align: left">          <font style="font-family: Times New Roman, Times, Serif">           $          </font>         </td>         <td style="text-align: right">          <font style="font-family: Times New Roman, Times, Serif">           1,700          </font>         </td>         <td style="text-align: left">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>        </tr>        <tr style="vertical-align: bottom; background-color: White">         <td style="text-align: left">          <font style="font-family: Times New Roman, Times, Serif">           Noncash investing and financing transactions:          </font>         </td>         <td>          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td style="text-align: left">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td style="text-align: right">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td style="text-align: left">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td>          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td style="text-align: left">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td style="text-align: right">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td style="text-align: left">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>        </tr>        <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">         <td>          <font style="font-family: Times New Roman, Times, Serif">           Expiration of warrants          </font>         </td>         <td>          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td style="text-align: left">          <font style="font-family: Times New Roman, Times, Serif">           $          </font>         </td>         <td style="text-align: right">          <font style="font-family: Times New Roman, Times, Serif">           2,465,396          </font>         </td>         <td style="text-align: left">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td>          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td style="text-align: left">          <font style="font-family: Times New Roman, Times, Serif">           $          </font>         </td>         <td style="text-align: right">          <font style="font-family: Times New Roman, Times, Serif">           4,060,759          </font>         </td>         <td style="text-align: left">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>        </tr>        <tr style="vertical-align: bottom; background-color: White">         <td style="text-align: left">          <font style="font-family: Times New Roman, Times, Serif">           Increase in right-of-use assets and    operating lease liabilities resulting from contract modification          </font>         </td>         <td>          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td style="text-align: left">          <font style="font-family: Times New Roman, Times, Serif">           $          </font>         </td>         <td style="text-align: right">          <font style="font-family: Times New Roman, Times, Serif">           5,288,981          </font>         </td>         <td style="text-align: left">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td>          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td style="text-align: left">          <font style="font-family: Times New Roman, Times, Serif">           $          </font>         </td>         <td style="text-align: right">          <font style="font-family: Times New Roman, Times, Serif">           -          </font>         </td>         <td style="text-align: left">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>        </tr>        <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">         <td style="text-align: left">          <font style="font-family: Times New Roman, Times, Serif">           Amounts accrued for offering costs          </font>         </td>         <td>          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td style="text-align: left">          <font style="font-family: Times New Roman, Times, Serif">           $          </font>         </td>         <td style="text-align: right">          <font style="font-family: Times New Roman, Times, Serif">           -          </font>         </td>         <td style="text-align: left">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td>          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td style="text-align: left">          <font style="font-family: Times New Roman, Times, Serif">           $          </font>         </td>         <td style="text-align: right">          <font style="font-family: Times New Roman, Times, Serif">           200,000          </font>         </td>         <td style="text-align: left">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>        </tr>        <tr style="vertical-align: bottom; background-color: White">         <td style="text-align: left">          <font style="font-family: Times New Roman, Times, Serif">           Note issued for insurance premium          </font>         </td>         <td>          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td style="text-align: left">          <font style="font-family: Times New Roman, Times, Serif">           $          </font>         </td>         <td style="text-align: right">          <font style="font-family: Times New Roman, Times, Serif">           551,803          </font>         </td>         <td style="text-align: left">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td>          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td style="text-align: left">          <font style="font-family: Times New Roman, Times, Serif">           $          </font>         </td>         <td style="text-align: right">          <font style="font-family: Times New Roman, Times, Serif">           185,990          </font>         </td>         <td style="text-align: left">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>        </tr>       </tbody>      </table>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">       <font style="font-family: Times New Roman, Times, Serif">        Theaccompanying notes are an integral part of these consolidated financial statements.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">       <font style="font-family: Times New Roman, Times, Serif">        <b>        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">      </p>      <!-- Field: Page; Sequence: 71; Value: 1 -->      <div style="margin-bottom: 6pt; border-bottom: Black 1.5pt solid">       <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">        <tbody>         <tr style="vertical-align: top; text-align: left">          <td style="width: 33%">          </td>          <td style="text-align: center; width: 34%">           F-           <!-- Field: Sequence; Type: Arabic; Name: PageNo -->           6           <!-- Field: /Sequence -->          </td>          <td style="width: 33%">          </td>         </tr>        </tbody>       </table>      </div>      <div style="page-break-before: always; margin-top: 6pt">       <p style="margin: 0pt">       </p>      </div>      <!-- Field: /Page -->      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">       <font style="font-family: Times New Roman, Times, Serif">        <b>        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">       <font style="font-family: Times New Roman, Times, Serif">        <b>         <a name="cj_027">         </a>         OncoSecMedical Incorporated        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">       <font style="font-family: Times New Roman, Times, Serif">        <b>         Notesto Consolidated Financial Statements        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">       <font style="font-family: Times New Roman, Times, Serif">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif">        <b>         Note1—Nature of Operations and Basis of Presentation        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif">        OncoSecMedical Incorporated (together with its subsidiary, unless the context indicates otherwise, being collectively referred to asthe “Company”) began its operations as a biotechnology company in March 2011. The Company has not produced any revenuessince its inception. The Company was incorporated in the State of Nevada on February 8, 2008 under the name of Netventory Solutions,Inc. and changed its name in March 2011 when it began operating as a biotechnology company.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif">        TheCompany is a late-stage biotechnology company focused on designing, developing and commercializing innovative therapies and proprietarymedical approaches to stimulate and to guide an anti-tumor immune response for the treatment of cancer. Its core technology platform,ImmunoPulse®, is a drug-device therapeutic modality comprised of proprietary intratumoral electroporation (“EP”)delivery devices (the “OncoSec Medical System (OMS) Electroporation device” or “OMS EP device”. The OMSEP device is designed to deliver plasmid DNA-encoded drugs directly into a solid tumor and promote an immunological response againstcancer. The OMS EP device can be adapted to treat different tumor types, and consists of an electrical pulse generator, a reusablehandle and disposable applicators. The Company’s lead product candidate is a DNA-encoded interleukin-12 (“IL-12”)called tavokinogene telseplasmid (“TAVO”). The OMS EP device is used to deliver TAVO intratumorally, with the aimof reversing the immunosuppressive microenvironment in the treated tumor. The activation of the appropriate inflammatory responsecan drive a systemic anti-tumor response against untreated tumors in other parts of the body. In 2017, the Company received FastTrack designation and Orphan Drug Designation from the U.S. Food and Drug Administration (“FDA”) for TAVO in metastaticmelanoma, which could qualify TAVO for expedited FDA review, a rolling Biologics License Application review and certain otherbenefits.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif">        TheCompany’s current focus is to pursue our study of TAVO in combination with KEYTRUDA® (pembrolizumab) in melanoma, triplenegative breast cancer (“TNBC”).       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif">        KEYNOTE-695targets melanoma patients who are definitive anti-PD-1 non-responders. In May 2017, we entered into a clinical trial collaborationand supply agreement with a subsidiary of Merck &amp; Co., Inc. (“Merck”) in connection with KEYNOTE-695 study. Pursuantto the terms of the agreement, both companies will bear their own costs related to manufacturing and supply of their product,as well as be responsible for their own internal costs. The Company is the study sponsor and is responsible for external costs.The KEYNOTE-695 study is currently enrolling and treating patients and we plan to complete enrollment or near complete enrollmentin this study in the second half 2020. This study is a registration-directed, Phase 2b open-label, single-arm, multicenter studyin the United States, Canada, Australia and Europe.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif">        InMay 2018, the Company entered into a second clinical trial collaboration and supply agreement with Merck with respect to a Phase2 study of TAVO in combination with KEYTRUDA® to evaluate the safety and efficacy of the combination in patients with inoperablelocally advanced or metastatic TNBC, who have previously failed at least one systemic chemotherapy or immunotherapy. This studyis referred to as KEYNOTE-890, Cohort 1. Pursuant to the terms of the agreement, both companies will bear their own costs relatedto manufacturing and supply of their product, as well as be responsible for their own internal costs. The Company is the studysponsor and is responsible for external costs. The KEYNOTE-890 study, Cohort 1 is currently treating patients. The Company completedenrollment in fourth quarter 2019 and provided interim preliminary data from this study at the San Antonio Breast Cancer Symposium(“SABCS”) in December 2019. The study is a Phase 2 open-label, single-arm, multicenter study in the United Statesand Australia.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">       <font style="font-family: Times New Roman, Times, Serif">       </font>      </p>      <!-- Field: Page; Sequence: 72; Value: 1 -->      <div style="margin-bottom: 6pt; border-bottom: Black 1.5pt solid">       <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">        <tbody>         <tr style="vertical-align: top; text-align: left">          <td style="width: 33%">          </td>          <td style="text-align: center; width: 34%">           F-           <!-- Field: Sequence; Type: Arabic; Name: PageNo -->           7           <!-- Field: /Sequence -->          </td>          <td style="width: 33%">          </td>         </tr>        </tbody>       </table>      </div>      <div style="page-break-before: always; margin-top: 6pt">       <p style="margin: 0pt">       </p>      </div>      <!-- Field: /Page -->      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">       <font style="font-family: Times New Roman, Times, Serif">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       In June 2020, the Companyamended its second clinical trial collaboration and supply agreement with Merck to include another Phase 2 study of TAVOin combination with KEYTRUDA® plus chemotherapy to evaluate the safety and efficacy of the combination in patients with inoperablelocally advanced or metastatic triple negative breast cancer (mTNBC). This study is referred to as KEYNOTE-890, Cohort 2. Pursuantto the terms of the amended agreement, both companies will bear their own costs related to manufacturing and supply of their product,as well as be responsible for their own internal costs. The Company is the study sponsor and are responsible for externalcosts. The KEYNOTE-890, Cohort 2 study is currently expected to begin enrolling patients in Q4 2020/Q1 2021. The Companyexpects to complete enrollment in within fifteen months and provided interim preliminary data from this study at a futuremedical conference. The study is a Phase 2 open-label, single-arm, multicenter study in the United States and Australia.      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif">        InAugust 2020, the Company commenced an investigator-initiated Phase 2 study conducted by the H. Lee Moffitt Cancer Center and ResearchInstitute and the University of South Florida Morsani College of Medicine to evaluate TAVO™ as neoadjuvant treatment (administeredbefore surgery) in combination with intravenous OPDIVO®(nivolumab) in up to 33 patients with operable locally/regionally advancedmelanoma. This investigator-initiated Phase 2 study has been designed to evaluate whether the addition of TAVO can increase thepublished anti-tumor response observed with monotherapy OPDIVO®, an anti-PD-1 checkpoint inhibitor, in patients with locally/regionallyadvanced melanoma prior to surgical resection of tumors. This study is currently enrolling and expected to complete enrollmentwithin eighteen months.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif">        InApril 2020, the Company announced that Providence Cancer Institute, a part of Providence St. Joseph Health (“Providence”),is pursuing a first-in-human Phase 1 clinical trial of OncoSec’s novel DNA-encodable, investigational vaccine, CORVax12,which is designed to act as a prophylactic vaccine to prevent COVID-19. CORVax12 consists of the Company’s existingproduct candidate, TAVO™ (interleukin-12 or “IL-12” plasmid), in combination with an immunogenic component ofthe SARS-CoV-2 virus recently developed by researchers at NIH’s National Institute of Allergy and Infectious Diseases (“NIAID”)and licensed to the Company on a non-exclusive basis.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif">        Providenceinvestigators have filed an Investigator-Initiated Investigational New Drug (IND) Application with the United States Food andDrug Administration (FDA) and have designed a clinical trial protocol that will evaluate the vaccination of healthy adult volunteersutilizing CORVax12 and an investigational low voltage generator technology if FDA clears the IND. The trial will also includeextensive immune monitoring.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       The Company willsupply TAVO and the low voltage electroporation device to Providence as part of this effort and does not anticipate any additionalcapital commitment at this time. Additionally, the Company will contribute manufacturing, preclinical, and prior clinicalinformation and data for TAVO, along with manufacturing data with respect to the generator, to support FDA’s allowance ofthe Providence IND. Providence will hold the IND, if cleared by FDA, and perform the preclinical and clinical development work.The anticipated work and clinical trials outlined above are subject to FDA allowance of the Investigator-Initiated IND filed byProvidence.      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif">        InMay 2019, the Company commenced an investigator-initiated Phase 1 clinical trial conducted by the University of California SanFrancisco Helen Diller Family Comprehensive Cancer Center (OMS-131). This study targets patients with SQUAMOUS CELL CARCINOMAHEAD &amp; NECK CANCER (SCCHN) and is a single-arm open-label clinical trial in which 35 evaluable patients will receive TAVO,KEYTRUDA® and epacadostat. OMS-131 is currently enrolling and treating patients and is expected to complete enrollment withineighteen months.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif">        TheCompany intends to continue to pursue other ongoing or potential new trials and studies related to TAVO, in various tumor types.In addition, the Company is also developing our next-generation EP device and applicator, including advancements toward prototypes,pursuing discovery research to identify other product candidates that, in addition to IL-12, can be encoded into propriety plasmid-DNAand delivered intratumorally using EP. Specifically, we are developing a new, propriety technology to potentially treat liver,lung, bladder, pancreatic and other difficult to treat visceral lesions through the direct delivery of plasmid-based IL-12 witha new Visceral Lesions Applicator (“VLA”).       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif">       </font>      </p>      <!-- Field: Page; Sequence: 73; Value: 1 -->      <div style="margin-bottom: 6pt; border-bottom: Black 1.5pt solid">       <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">        <tbody>         <tr style="vertical-align: top; text-align: left">          <td style="width: 33%">          </td>          <td style="text-align: center; width: 34%">           F-           <!-- Field: Sequence; Type: Arabic; Name: PageNo -->           8           <!-- Field: /Sequence -->          </td>          <td style="width: 33%">          </td>         </tr>        </tbody>       </table>      </div>      <div style="page-break-before: always; margin-top: 6pt">       <p style="margin: 0pt">       </p>      </div>      <!-- Field: /Page -->      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">       <font style="font-family: Times New Roman, Times, Serif">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif">        TheVLA has been designed to work with low voltage EP generators, including but not limited to the Company’s proprietaryAPOLLO        <sup>         TM        </sup>        EP generator to leverage plasmid-optimized EP and enhance the depth of transfection of immunologically relevantgenes into cells located in visceral organs. In early 2020, the Company had two poster presentations, one at the Society for InterventionalOncology (“SIO”) and one at the Society for Interventional Radiology (“SIR”), where it presented preclinicaldata on both the VLA and APOLLO generator. The poster at SIO was awarded “Best Technology Scientific Abstract”. Additionally,the Company has successfully completed several large animal studies and aim to bring the VLA into the clinic in 2021. Byusing the Company’s next-generation technology with the VLA (and in cutaneous/subcutaneous settings as well), theCompany’s goal is to reverse the immunosuppressive mechanisms of a tumor, as well as to expand the Company’spipeline. The Company believes that the flexibility of the Company’s propriety plasmid-DNA technologyallows the Company to deliver other immunologically relevant molecules into the tumor microenvironment in addition to thedelivery of plasmid-DNA encoding for IL-12. In June 2020, the Company had two poster presentations at the 2020 AmericaAssociation for Cancer Research (“AACR”) where the Company presented pre-clinical data regarding its new anti-tumorproduct candidate, which will amplify the power of intratumoral IL-12 through the addition of both CXCL9, a critical T cell chemokine,and anti-CD3, a membrane bound pan T cell stimulator. These other immunologically relevant molecules may complement IL-12’sactivity by limiting or enhancing key pathways associated with tumor immune subversion.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif">        TheCompany has established a collaboration with Emerge Health Pty (“Emerge”), the leading Australian company providingfull registration, reimbursement, sales, marketing and distribution services of therapeutic products in Australia and New Zealand,to commercialize TAVO and made it available under Australia’s Special Access Scheme (“SAS”) in early 2020. Asa specialized Australian pharmaceutical company focused on the marketing and sales of high-quality medicines to the hospital sector,Emerge has previously made numerous other products successfully available under Australia’s SAS.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif">        <i>         ReverseStock Split        </i>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif">        OnMay 20, 2019, the Company effected a one-for-ten reverse stock split of its authorized and outstanding common stock. All shareand per share information has been retroactively adjusted to reflect the reverse stock split. The par value was not adjusted asa result of the reverse stock split.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif">        <i>         Reclassifications        </i>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif">        Certainamounts in the accompanying consolidated statements of cash flows for the year ended July 31, 2019 have been reclassified to conformto the year ended July 31, 2020 presentation, but there was no effect on net loss or total assets for the year ended July 31,2019.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif">        <b>         Note2—Significant Accounting Policies        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif">        <b>        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif">        <i>         Principlesof Consolidation        </i>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif">        Theaccompanying consolidated financial statements include the accounts of the Company and its wholly-owned subsidiary, OncoSec MedicalAustralia PTY LTD. All significant intercompany accounts and transactions have been eliminated in consolidation.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif">       </font>      </p>      <!-- Field: Page; Sequence: 74; Value: 1 -->      <div style="margin-bottom: 6pt; border-bottom: Black 1.5pt solid">       <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">        <tbody>         <tr style="vertical-align: top; text-align: left">          <td style="width: 33%">          </td>          <td style="text-align: center; width: 34%">           F-           <!-- Field: Sequence; Type: Arabic; Name: PageNo -->           9           <!-- Field: /Sequence -->          </td>          <td style="width: 33%">          </td>         </tr>        </tbody>       </table>      </div>      <div style="page-break-before: always; margin-top: 6pt">       <p style="margin: 0pt">       </p>      </div>      <!-- Field: /Page -->      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif">        <i>        </i>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif">        <i>         Useof Estimates        </i>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif">        Theaccompanying consolidated financial statements have been prepared in conformity with U.S. GAAP, which requires management to makeestimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent liabilitiesat the date of the financial statements and the reported amounts of expenses during the reporting period. Such estimates includestock-based compensation, accounting for long-lived assets, determining the Incremental Borrowing Rate (“IBR”) forcalculating Right-Of-Use (“ROU”) assets and lease liabilities and accounting for income taxes, including the relatedvaluation allowance on the deferred tax asset and uncertain tax positions. The Company bases its estimates on historical experienceand on various other assumptions that it believes are reasonable under the circumstances, the results of which form the basisfor making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Onan ongoing basis, the Company reviews its estimates to ensure that they appropriately reflect changes in the business or as newinformation becomes available. Actual results may differ from these estimates.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif">        <i>         SegmentReporting        </i>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif">        TheCompany operates in a single industry segment—the discovery and development of novel immunotherapeutic product candidatesto improve treatment options for patients and physicians, intended to treat a wide range of oncology indications.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif">        <i>         Cashand Cash Equivalents        </i>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif">        TheCompany considers all highly liquid investments that are readily convertible into cash and have an original maturity of threemonths or less at the time of purchase to be cash equivalents.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif">        <i>        </i>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif">        <i>         Concentrationsand Credit Risk        </i>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif">        TheCompany maintains cash balances at a small number of financial institutions and such balances commonly exceed the $250,000 amountinsured by the Federal Deposit Insurance Corporation. The Company has not experienced any losses in such accounts and managementbelieves that the Company does not have significant credit risk with respect to such cash and cash equivalents.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif">        <i>         Propertyand Equipment        </i>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif">        TheCompany’s capitalization threshold is $5,000 for property and equipment. The cost of property and equipment is depreciatedon a straight-line basis over the estimated useful lives of the related assets. The useful lives of property and equipment forthe purpose of computing depreciation are as follows:       </font>      </p>      <p style="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif">       </font>      </p>      <table cellpadding="0" cellspacing="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">       <tbody>        <tr style="vertical-align: top">         <td style="width: 35%">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           Computers and equipment:          </font>         </td>         <td style="width: 10%">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="width: 55%">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           3 to 10 years          </font>         </td>        </tr>        <tr style="vertical-align: top">         <td>          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           Computer software:          </font>         </td>         <td>          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td>          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           1 to 3 years          </font>         </td>        </tr>        <tr style="vertical-align: top">         <td>          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           Leasehold improvements:          </font>         </td>         <td>          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td>          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           Shorter of lease period or useful life          </font>         </td>        </tr>       </tbody>      </table>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif">        <i>        </i>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif">        <i>         Impairmentof Long-Lived Assets        </i>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif">        TheCompany periodically assesses the carrying value of intangible and other long-lived assets, and whenever events or changes incircumstances indicate that the carrying amount of an asset might not be recoverable. The assets are considered to be impairedif the Company determines that the carrying value may not be recoverable based upon its assessment, which includes considerationof the following events or changes in circumstances:       </font>      </p>      <p style="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif">       </font>      </p>      <table cellpadding="0" cellspacing="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">       <tbody>        <tr style="vertical-align: top">         <td style="width: 0.5in">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="width: 0.25in">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           ●          </font>         </td>         <td style="text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           the asset’s    ability to continue to generate income from operations and positive cash flow in future periods;          </font>         </td>        </tr>        <tr style="vertical-align: top">         <td>          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td>          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="vertical-align: top">         <td>          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td>          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           ●          </font>         </td>         <td style="text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           loss of legal ownership    or title to the asset(s);          </font>         </td>        </tr>        <tr style="vertical-align: top">         <td>          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td>          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="vertical-align: top">         <td>          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td>          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           ●          </font>         </td>         <td style="text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           significant changes    in the Company’s strategic business objectives and utilization of the asset(s); and          </font>         </td>        </tr>        <tr style="vertical-align: top">         <td>          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td>          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="vertical-align: top">         <td>          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td>          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           ●          </font>         </td>         <td style="text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           the impact of significant    negative industry or economic trends.          </font>         </td>        </tr>       </tbody>      </table>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif">       </font>      </p>      <!-- Field: Page; Sequence: 75; Value: 1 -->      <div style="margin-bottom: 6pt; border-bottom: Black 1.5pt solid">       <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">        <tbody>         <tr style="vertical-align: top; text-align: left">          <td style="width: 33%">          </td>          <td style="text-align: center; width: 34%">           F-           <!-- Field: Sequence; Type: Arabic; Name: PageNo -->           10           <!-- Field: /Sequence -->          </td>          <td style="width: 33%">          </td>         </tr>        </tbody>       </table>      </div>      <div style="page-break-before: always; margin-top: 6pt">       <p style="margin: 0pt">       </p>      </div>      <!-- Field: /Page -->      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">       <font style="font-family: Times New Roman, Times, Serif">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif">        Ifthe assets are considered to be impaired, the impairment recognized is the amount by which the carrying value of the assets exceedsthe fair value of the assets. Fair value is determined by the application of discounted cash flow models to project cash flowsfrom the assets. In addition, the Company bases estimates of the useful lives and related amortization or depreciation expenseon its subjective estimate of the period the assets will generate revenue or otherwise be used by it. Assets to be disposed ofare reported at the lower of the carrying amount or fair value, less selling costs. The Company also periodically reviews thelives assigned to long-lived assets to ensure that the initial estimates do not exceed any revised estimated periods from whichthe Company expects to realize cash flows from its assets.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif">        <i>        </i>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif">        <i>         FairValue of Financial Instruments        </i>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif">        Thecarrying amounts for cash and cash equivalents, prepaid expenses, accounts payable and accrued expenses and notes payable approximatefair value due to the short-term nature of these instruments. It is management’s opinion that the Company is not exposedto significant interest, currency, or credit risks arising from its other financial instruments and that their fair values approximatetheir carrying values except where expressly disclosed.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif">        Theaccounting standard for fair value measurements provides a framework for measuring fair value and requires disclosures regardingfair value measurements. Fair value is defined as the price that would be received to sell an asset or paid to transfer a liabilityin an orderly transaction between market participants at the measurement date, based on the Company’s principal or, in theabsence of a principal, most advantageous market for the specific asset or liability.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif">        TheCompany uses a three-tier fair value hierarchy to classify and disclose all assets and liabilities measured at fair value on arecurring basis, as well as assets and liabilities measured at fair value on a non-recurring basis, in periods subsequent to theirinitial measurement. The hierarchy requires the Company to use observable inputs when available, and to minimize the use of unobservableinputs, when determining fair value.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif">        Thethree tiers are defined as follows:       </font>      </p>      <p style="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif">       </font>      </p>      <table cellpadding="0" cellspacing="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">       <tbody>        <tr style="vertical-align: top">         <td style="width: 48px; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="width: 24px; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           ●          </font>         </td>         <td style="text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           Level 1—Observable    inputs that reflect quoted market prices (unadjusted) for identical assets or liabilities in active markets at the measurement    date. Since valuations are based on quoted prices that are readily and regularly available in an active market, valuation    of these products does not entail a significant degree of judgment.          </font>         </td>        </tr>        <tr style="vertical-align: top">         <td style="text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="vertical-align: top">         <td style="text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           ●          </font>         </td>         <td style="text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           Level 2—Observable    inputs other than quoted prices in active markets that are observable either directly or indirectly in the marketplace for    identical or similar assets and liabilities.          </font>         </td>        </tr>        <tr style="vertical-align: top">         <td style="text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="vertical-align: top">         <td style="text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           ●          </font>         </td>         <td style="text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           Level 3— Valuations    based on inputs that are unobservable and significant to the overall fair value measurement.          </font>         </td>        </tr>       </tbody>      </table>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif">        Thedevelopment and determination of the unobservable inputs for Level 3 fair value measurements and fair value calculations are theresponsibility of the Company’s Principal Accounting Officer.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif">        Changesin fair value measurements categorized within Level 3 of the fair value hierarchy are analyzed each period based on changes inestimates or assumptions and recorded as appropriate.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif">        TheCompany had no assets or liabilities that required remeasurement on a recurring basis as of July 31, 2020 and 2019.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif">       </font>      </p>      <!-- Field: Page; Sequence: 76; Value: 1 -->      <div style="margin-bottom: 6pt; border-bottom: Black 1.5pt solid">       <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">        <tbody>         <tr style="vertical-align: top; text-align: left">          <td style="width: 33%">          </td>          <td style="text-align: center; width: 34%">           F-           <!-- Field: Sequence; Type: Arabic; Name: PageNo -->           11           <!-- Field: /Sequence -->          </td>          <td style="width: 33%">          </td>         </tr>        </tbody>       </table>      </div>      <div style="page-break-before: always; margin-top: 6pt">       <p style="margin: 0pt">       </p>      </div>      <!-- Field: /Page -->      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">       <font style="font-family: Times New Roman, Times, Serif">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif">        <i>         Warrants        </i>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif">        TheCompany assesses its warrants as either equity or a liability based upon the characteristics and provisions of each instrument.Warrants classified as equity are recorded at fair value as of the date of issuance on the Company’s balance sheet and nofurther adjustments to their valuation are made. Warrants classified as derivative liabilities and other derivative financialinstruments that require separate accounting as liabilities are recorded on the Company’s balance sheet at their fair valueon the date of issuance and are re-measured on each subsequent balance sheet date until such instruments are exercised or expire,with any changes in the fair value between reporting periods recorded as other income or expense. Management estimates the fairvalue of these liabilities using option pricing models and assumptions that are based on the individual characteristics of thewarrants or other instruments on the valuation date, as well as assumptions for future financings, expected volatility, expectedlife, yield and risk-free interest rate. As of July 31, 2020, and 2019, all outstanding warrants issued by the Company were classifiedas equity.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif">        <i>         NetLoss Per Share        </i>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif">        TheCompany computes basic net loss per common share by dividing the applicable net loss by the weighted-average number of commonshares outstanding during the period. Diluted earnings per share is computed by dividing the applicable net loss by the weighted-averagenumber of common shares outstanding during the period plus additional shares to account for the dilutive effect of potential futureissuances of common stock relating to stock options and other potentially dilutive securities using the treasury stock method.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif">        TheCompany did not include shares underlying stock options, restricted stock units and warrants issued and outstanding during anyof the periods presented in the computation of net loss per share, as the effect would have been anti-dilutive. The followingpotentially dilutive outstanding securities were excluded from diluted net loss per share because of their anti-dilutive effect:       </font>      </p>      <p style="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif">       </font>      </p>      <table align="CENTER" cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 85%; font: 10pt Times New Roman, Times, Serif">       <tbody>        <tr style="vertical-align: bottom">         <td style="text-align: justify">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td style="font-weight: bold; padding-bottom: 1.5pt">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">          <font style="font-family: Times New Roman, Times, Serif">           July    31, 2020          </font>         </td>         <td style="padding-bottom: 1.5pt; font-weight: bold">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td style="font-weight: bold; padding-bottom: 1.5pt">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">          <font style="font-family: Times New Roman, Times, Serif">           July    31, 2019          </font>         </td>         <td style="padding-bottom: 1.5pt; font-weight: bold">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>        </tr>        <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">         <td style="width: 60%; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif">           Stock options          </font>         </td>         <td style="width: 2%">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td style="width: 1%; text-align: left">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td style="width: 16%; text-align: right">          <font style="font-family: Times New Roman, Times, Serif">           1,442,856          </font>         </td>         <td style="width: 1%; text-align: left">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td style="width: 2%">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td style="width: 1%; text-align: left">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td style="width: 16%; text-align: right">          <font style="font-family: Times New Roman, Times, Serif">           921,572          </font>         </td>         <td style="width: 1%; text-align: left">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>        </tr>        <tr style="vertical-align: bottom; background-color: White">         <td style="text-align: justify">          <font style="font-family: Times New Roman, Times, Serif">           Restricted stock units          </font>         </td>         <td>          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td style="text-align: left">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td style="text-align: right">          <font style="font-family: Times New Roman, Times, Serif">           34,914          </font>         </td>         <td style="text-align: left">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td>          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td style="text-align: left">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td style="text-align: right">          <font style="font-family: Times New Roman, Times, Serif">           77,956          </font>         </td>         <td style="text-align: left">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>        </tr>        <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">         <td style="text-align: justify; padding-bottom: 1.5pt">          <font style="font-family: Times New Roman, Times, Serif">           Warrants          </font>         </td>         <td style="padding-bottom: 1.5pt">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td style="border-bottom: Black 1.5pt solid; text-align: left">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td style="border-bottom: Black 1.5pt solid; text-align: right">          <font style="font-family: Times New Roman, Times, Serif">           3,114,288          </font>         </td>         <td style="padding-bottom: 1.5pt; text-align: left">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td style="padding-bottom: 1.5pt">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td style="border-bottom: Black 1.5pt solid; text-align: left">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td style="border-bottom: Black 1.5pt solid; text-align: right">          <font style="font-family: Times New Roman, Times, Serif">           3,631,953          </font>         </td>         <td style="padding-bottom: 1.5pt; text-align: left">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>        </tr>        <tr style="vertical-align: bottom; background-color: White">         <td style="text-align: justify; padding-bottom: 2.5pt">          <font style="font-family: Times New Roman, Times, Serif">           Total          </font>         </td>         <td style="padding-bottom: 2.5pt">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td style="border-bottom: Black 2.5pt double; text-align: left">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td style="border-bottom: Black 2.5pt double; text-align: right">          <font style="font-family: Times New Roman, Times, Serif">           4,592,058          </font>         </td>         <td style="padding-bottom: 2.5pt; text-align: left">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td style="padding-bottom: 2.5pt">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td style="border-bottom: Black 2.5pt double; text-align: left">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td style="border-bottom: Black 2.5pt double; text-align: right">          <font style="font-family: Times New Roman, Times, Serif">           4,631,481          </font>         </td>         <td style="padding-bottom: 2.5pt; text-align: left">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>        </tr>       </tbody>      </table>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif">        Subsequentto July 31, 2020, the Company issued shares of common stock that will impact earnings per share in the future. (See Note 13)       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif">        <i>        </i>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif">        <i>         Stock-BasedCompensation        </i>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif">        TheCompany grants equity-based awards (typically stock options or restricted stock units) under its stock-based compensation planand outside of its stock-based compensation plan, with terms generally similar to the terms under the Company’s stock-basedcompensation plan. The Company estimates the fair value of stock option awards using the Black-Scholes option valuation model.For employees, directors and consultants, the fair value of the award is measured on the grant date. The fair value amount isthen recognized over the period during which services are required to be provided in exchange for the award, usually the vestingperiod. The Black-Scholes option valuation model requires the input of subjective assumptions, including price volatility of theunderlying stock, risk-free interest rate, dividend yield, and expected life of the option. The Company estimates the fair valueof restricted stock unit awards based on the closing price of the Company’s common stock on the date of issuance.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">      </p>      <!-- Field: Page; Sequence: 77; Value: 1 -->      <div style="margin-bottom: 6pt; border-bottom: Black 1.5pt solid">       <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">        <tbody>         <tr style="vertical-align: top; text-align: left">          <td style="width: 33%">          </td>          <td style="text-align: center; width: 34%">           F-           <!-- Field: Sequence; Type: Arabic; Name: PageNo -->           12           <!-- Field: /Sequence -->          </td>          <td style="width: 33%">          </td>         </tr>        </tbody>       </table>      </div>      <div style="page-break-before: always; margin-top: 6pt">       <p style="margin: 0pt">       </p>      </div>      <!-- Field: /Page -->      <p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; text-align: left; margin-top: 0; margin-bottom: 0">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <i>        </i>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <i>         EmployeeStock Purchase Plan        </i>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Employeesmay elect to participate in the Company’s stockholder-approved employee stock purchase plan. The stock purchase plan allowsfor the purchase of the Company’s common stock at not less than 85% of the lesser of (i) the fair market value of a shareof common stock on the beginning date of the offering period or (ii) the fair market value of a share of common stock on the purchasedate of the offering period, subject to a share and dollar limit as defined in the plan and subject to the applicable legal requirements.There are two six-month offering periods during each fiscal year, ending on January 31 and July 31.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Inaccordance with applicable accounting guidance, the fair value of awards under the stock purchase plan is calculated at the beginningof each offering period. The Company estimates the fair value of the awards using the Black-Scholes option valuation model. TheBlack-Scholes option valuation model requires the input of subjective assumptions, including price volatility of the underlyingstock, risk-free interest rate, dividend yield, and the offering period. This fair value is then amortized at the beginning ofthe offering period. Stock-based compensation expense is based on awards expected to be purchased at the beginning of the offeringperiod, and therefore is reduced when participants withdraw during the offering period.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <i>         Leases        </i>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        TheCompany determines if an arrangement is a lease at inception. Operating lease right-of-use (“ROU”) assets representthe Company’s right to use an underlying asset during the lease term, and operating lease liabilities represent the Company’sobligation to make lease payments arising from the lease. Operating leases are included in ROU assets, current operating leaseliabilities, and long-term operating lease liabilities on the Company’s consolidated balance sheets.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        LeaseROU assets and lease liabilities are initially recognized based on the present value of the future minimum lease payments overthe lease term at commencement date calculated using the Company’s incremental borrowing rate applicable to the lease asset,unless the implicit rate is readily determinable. ROU assets also include any lease payments made at or before lease commencementand exclude any lease incentives received. The Company’s lease terms may include options to extend or terminate the leasewhen it is reasonably certain that the Company will exercise that option. Leases with a term of 12 months or less are not recognizedon the consolidated balance sheets. The Company’s leases do not contain any residual value guarantees. Lease expense forminimum lease payments is recognized on a straight-line basis over the lease term. The Company accounts for lease and non-leasecomponents as a single lease component for all its leases.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <i>        </i>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <i>         ForeignCurrency Translation        </i>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        TheCompany uses the U.S. Dollar as the reporting currency for its financial statements. Functional currency is the currency of theprimary economic environment in which an entity operates. The functional currency of the Company’s wholly owned subsidiaryis the Australian dollar.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Assetsand liabilities of the Company’s subsidiary are translated into U.S. Dollars at period-end foreign exchange rates, and revenuesand expenses are translated at average rates prevailing throughout the period. Translation adjustments are included in “Accumulatedother comprehensive income” a separate component of stockholders’ equity, and in the “Effect of exchange ratechanges on cash and cash equivalents,” on the Company’s condensed consolidated statements of cash flows. Transactiongains and losses including intercompany transactions denominated in a currency other than the functional currency of the entityinvolved are included in “Foreign currency exchange gain (loss), net” on the Company’s consolidated statementsof operations.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <i>         AccumulatedOther Comprehensive Income (Loss)        </i>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Accumulatedother comprehensive income (loss) includes foreign currency translation adjustments related to the Company’s subsidiaryin Australia and is excluded from the accompanying consolidated statements of operations.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <!-- Field: Page; Sequence: 78; Options: NewSection; Value: 13 -->      <div style="margin-bottom: 6pt; border-bottom: Black 1.5pt solid">       <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">        <tbody>         <tr style="vertical-align: top; text-align: left">          <td style="width: 33%">          </td>          <td style="text-align: center; width: 34%">           F-           <!-- Field: Sequence; Type: Arabic; Name: PageNo -->           13           <!-- Field: /Sequence -->          </td>          <td style="width: 33%">          </td>         </tr>        </tbody>       </table>      </div>      <div style="page-break-before: always; margin-top: 6pt">       <p style="margin: 0pt">       </p>      </div>      <!-- Field: /Page -->      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <i>        </i>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <i>         AustraliaResearch and Development Tax Credit        </i>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        TheCompany’s wholly-owned Australian subsidiary incurs research and development expenses, primarily in the course of conductingclinical trials. The Company’s Australian research and development activities qualify for the Australian government’stax credit program, which provides a 41% credit for qualifying research and development expenses. The tax credit does not dependon the Company’s generation of future taxable income or ongoing tax status or position. Accordingly, the credit is not consideredan element of income tax accounting under ASC 740        <i>         “Income Taxes”        </i>        and is recorded against qualifying researchand development expenses.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <i>        </i>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <i>         TaxReform        </i>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        TheTax Cuts and Jobs Act (the “Act”) was enacted in December 2017. Among other things, the Act reduced the U.S. federalcorporate tax rate from 34 percent to 21 percent as of January 1, 2018 and eliminated the alternative minimum tax (“AMT”)for corporations. Since the deferred tax assets are expected to reverse in a future year, it has been tax effected using the 21%federal corporate tax rate. The effects of the 2017 Tax Act did not have a significant impact on the Company’s consolidatedfinancial statements during the years ended July 31, 2020 and 2019.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        OnMarch 27, 2020, the president signed into law the Coronavirus Aid, Relief and Economic Security Act (“CARES Act”)providing nearly $2 trillion in economic relief to eligible businesses impacted by the coronavirus outbreak. The CARES Act, amongother things, includes provisions relating to refundable payroll tax credits, deferment of employer social security payments,net operating loss (“NOL”) utilization and carryback periods, modifications to the net interest deduction limitationsand technical corrections to tax depreciation methods for qualified improvement property. In addition to the Small Business Administration(“SBA”) loan received in April 2020 (See Note 5), the Company continues to review, and intends to seek, any otheravailable potential benefits under the CARES Act as well as any future legislation signed into law during 2020. Other than theproceeds from the SBA loan, the effects of the CARES Act did not have a significant impact on the Company’s consolidatedfinancial statements during the year ended July 31, 2020.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <i>         RecentAccounting Pronouncements        </i>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        InFebruary 2016, the Financial Accounting Standards Board (“the FASB”) issued Accounting Standards Update No. 2016-02,Leases (“ASU 2016-02”), which supersedes previous lease accounting guidance (Topic 840) and establishes a right-of-usemodel that requires a lessee to record an asset and liability on the balance sheet for all leases with terms longer than 12 months.ASU 2016-02 is effective for fiscal years and interim periods beginning after December 15, 2018. A modified retrospective transitionapproach is required for lessees for capital and operating leases existing at, or entered into after, the beginning of the earliestcomparative period presented in the financial statements. In July 2018, the FASB issued ASU No. 2018-11,        <i>         Leases (Topic 842):Targeted Improvements        </i>        . In issuing ASU No. 2018-11, the FASB decided to provide another transition method in addition to theexisting transition method by allowing entities to initially apply the new leases standard at the adoption date and recognizea cumulative-effect adjustment to the opening balance of retained earnings in the period of adoption. ASU 2016-02 also requiresexpanded financial statement disclosures on leasing activities.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        TheCompany adopted the standard effective August 1, 2019 using the modified retrospective approach with the effective date as thedate of initial application. Consequently, prior period balances and disclosures have not been restated.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        ASC842 provides a number of optional practical expedients in transition. For leases that commenced prior to August 1, 2019, the Companyelected: (1) the “package of practical expedients”, which permits it not to reassess under the new standard its priorconclusions about lease identification, lease classification, and initial direct costs, and (2) the use-of-hindsight in determiningthe lease term and in assessing impairment of ROU assets. In addition, ASC 842 provides practical expedients for an entity’songoing accounting that the Company has elected, comprised of the following: (1) the election for classes of underlying assetto not separate non-lease components from lease components, and (2) the election for short-term lease recognition exemption forall leases that qualify.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        SeeNote 11 for the Company’s additional required disclosures under Topic 842.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <!-- Field: Page; Sequence: 79; Value: 13 -->      <div style="margin-bottom: 6pt; border-bottom: Black 1.5pt solid">       <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">        <tbody>         <tr style="vertical-align: top; text-align: left">          <td style="width: 33%">          </td>          <td style="text-align: center; width: 34%">           F-           <!-- Field: Sequence; Type: Arabic; Name: PageNo -->           14           <!-- Field: /Sequence -->          </td>          <td style="width: 33%">          </td>         </tr>        </tbody>       </table>      </div>      <div style="page-break-before: always; margin-top: 6pt">       <p style="margin: 0pt">       </p>      </div>      <!-- Field: /Page -->      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        InAugust 2020, the FASB issued ASU 2020-06, Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging-Contractsin Entity’s Own Equity (Subtopic 815-40)-Accounting For Convertible Instruments and Contracts in an Entity’s Own Equity.The ASU simplifies accounting for convertible instruments by removing major separation models required under current GAAP. Consequently,more convertible debt instruments will be reported as a single liability instrument with no separate accounting for embedded conversionfeatures. The ASU removes certain settlement conditions that are required for equity contracts to qualify for the derivative scopeexception, which will permit more equity contracts to qualify for it. The ASU also simplifies the diluted net income per sharecalculation in certain areas. The new guidance is effective for annual and interim periods beginning after December 15, 2021,and early adoption is permitted for fiscal years beginning after December 15, 2020, and interim periods within those fiscal years.The Company is currently evaluating the impact that this new guidance will have on its consolidated financial statements.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <b>         Note3—Going Concern and Managements Plans        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        TheCompany has sustained losses in all reporting periods since inception, with an inception-to date-loss of $207 million as of July31, 2020. These losses are expected to continue for an extended period of time. Further, the Company has never generated any cashfrom its operations and does not expect to generate such cash in the near term. The aforementioned factors raise substantial doubtabout the Company’s ability to continue as a going concern within one year from the issuance date of the consolidated financialstatements. The accompanying consolidated financial statements have been prepared on a going concern basis, which contemplatesthe realization of assets and the satisfaction of liabilities in the normal course of business. The consolidated financial statementsdo not include any adjustments relating to the recoverability and classification of asset amounts or the classification of liabilitiesthat might be necessary should the Company be unable to continue as a going concern within one year after the date the consolidatedfinancial statements are issued.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       As of October 13,2020, the Company had cash and cash equivalents of $25.3 million. Since inception, cash flows from financing activitieshas been the primary source of the Company’s liquidity. The Company currently estimates its monthly working capital requirementsto be approximately $2.3 million, although the Company may modify or deviate from this estimate and it is likely that the Company’sactual operating expenses and working capital requirements will vary from its estimate. Based on these expectations regardingfuture expenses, rate of consumption, as well as its current cash levels, the Company believes its cash resources are insufficientto meet the Company’s anticipated needs for the 12 months following the date the consolidated financial statements are issued.      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        TheCompany recognizes it will need to raise additional capital to continue operating its business and fund its planned operations,including research and development, clinical trials and, if regulatory approval is obtained, commercialization of its productcandidates. In addition, the Company will require additional financing if it desires to in-license or acquire new assets, researchand develop new compounds or new technologies and pursue related patent protection, or obtain any other intellectual propertyrights or other assets. There is no assurance that additional financing will be available when needed or that management willbe able to obtain financing on terms acceptable to the Company or whether the Company will become profitable and generate positiveoperating cash flow.       </font>       If the Company is unable to raise sufficient additional funds when needed, on favorable terms orat all, the Company will not be able to continue development of its product candidates as currently planned or at all, will needto reevaluate its planned operations and may need to delay, scale back or eliminate some or all of its development programs, reduceexpenses or cease operations, any of which would have a significant negative impact on its prospects and financial condition.      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font: 10pt Times New Roman, Times, Serif">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <!-- Field: Page; Sequence: 80; Value: 13 -->      <div style="margin-bottom: 6pt; border-bottom: Black 1.5pt solid">       <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">        <tbody>         <tr style="vertical-align: top; text-align: left">          <td style="width: 33%">          </td>          <td style="text-align: center; width: 34%">           F-           <!-- Field: Sequence; Type: Arabic; Name: PageNo -->           15           <!-- Field: /Sequence -->          </td>          <td style="width: 33%">          </td>         </tr>        </tbody>       </table>      </div>      <div style="page-break-before: always; margin-top: 6pt">       <p style="margin: 0pt">       </p>      </div>      <!-- Field: /Page -->      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <b>        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <b>         Note4—Investment Securities        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        TheCompany did not have any investment securities on its consolidated balance sheets as of July 31, 2020 and 2019.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Duringthe year ended July 31, 2019, the Company sold investments, categorized as held to maturity, with a net carrying amount of $5,989,928for gross proceeds of $5,977,794 and realized a loss of $12,134. The sale of the securities was suggested by the Company’sinvestment advisors and the event is isolated. The Company did not sell any investments during the year ended July 31, 2020.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <b>        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <b>         Note5 – Balance Sheet Details        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <i>         Propertyand Equipment        </i>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Propertyand equipment, net, is comprised of the following:       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 93%; margin-left: 0.5in">       <tbody>        <tr style="vertical-align: bottom">         <td style="font-weight: bold">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td style="font-weight: bold; padding-bottom: 1.5pt">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">          <font style="font-family: Times New Roman, Times, Serif">           July    31, 2020          </font>         </td>         <td style="padding-bottom: 1.5pt; font-weight: bold">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td style="font-weight: bold; padding-bottom: 1.5pt">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">          <font style="font-family: Times New Roman, Times, Serif">           July    31, 2019          </font>         </td>         <td style="padding-bottom: 1.5pt; font-weight: bold">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>        </tr>        <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">         <td style="width: 60%; text-align: left">          <font style="font-family: Times New Roman, Times, Serif">           Equipment and furniture          </font>         </td>         <td style="width: 2%">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td style="width: 1%; text-align: left">          <font style="font-family: Times New Roman, Times, Serif">           $          </font>         </td>         <td style="width: 16%; text-align: right">          <font style="font-family: Times New Roman, Times, Serif">           1,859,824          </font>         </td>         <td style="width: 1%; text-align: left">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td style="width: 2%">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td style="width: 1%; text-align: left">          <font style="font-family: Times New Roman, Times, Serif">           $          </font>         </td>         <td style="width: 16%; text-align: right">          <font style="font-family: Times New Roman, Times, Serif">           1,859,824          </font>         </td>         <td style="width: 1%; text-align: left">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>        </tr>        <tr style="vertical-align: bottom; background-color: White">         <td style="text-align: left">          <font style="font-family: Times New Roman, Times, Serif">           Computer software          </font>         </td>         <td>          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td style="text-align: left">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td style="text-align: right">          <font style="font-family: Times New Roman, Times, Serif">           109,242          </font>         </td>         <td style="text-align: left">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td>          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td style="text-align: left">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td style="text-align: right">          <font style="font-family: Times New Roman, Times, Serif">           109,242          </font>         </td>         <td style="text-align: left">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>        </tr>        <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">         <td style="text-align: left; padding-bottom: 1.5pt">          <font style="font-family: Times New Roman, Times, Serif">           Leasehold improvements          </font>         </td>         <td style="padding-bottom: 1.5pt">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td style="border-bottom: Black 1.5pt solid; text-align: left">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td style="border-bottom: Black 1.5pt solid; text-align: right">          <font style="font-family: Times New Roman, Times, Serif">           21,934          </font>         </td>         <td style="padding-bottom: 1.5pt; text-align: left">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td style="padding-bottom: 1.5pt">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td style="border-bottom: Black 1.5pt solid; text-align: left">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td style="border-bottom: Black 1.5pt solid; text-align: right">          <font style="font-family: Times New Roman, Times, Serif">           21,934          </font>         </td>         <td style="padding-bottom: 1.5pt; text-align: left">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>        </tr>        <tr style="vertical-align: bottom; background-color: White">         <td style="text-align: left">          <font style="font-family: Times New Roman, Times, Serif">           Property and equipment, gross          </font>         </td>         <td>          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td style="text-align: left">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td style="text-align: right">          <font style="font-family: Times New Roman, Times, Serif">           1,991,000          </font>         </td>         <td style="text-align: left">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td>          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td style="text-align: left">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td style="text-align: right">          <font style="font-family: Times New Roman, Times, Serif">           1,991,000          </font>         </td>         <td style="text-align: left">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>        </tr>        <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">         <td style="text-align: left; padding-bottom: 1.5pt">          <font style="font-family: Times New Roman, Times, Serif">           Accumulated depreciation    and amortization          </font>         </td>         <td style="padding-bottom: 1.5pt">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td style="border-bottom: Black 1.5pt solid; text-align: left">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td style="border-bottom: Black 1.5pt solid; text-align: right">          <font style="font-family: Times New Roman, Times, Serif">           (1,176,506          </font>         </td>         <td style="padding-bottom: 1.5pt; text-align: left">          <font style="font-family: Times New Roman, Times, Serif">           )          </font>         </td>         <td style="padding-bottom: 1.5pt">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td style="border-bottom: Black 1.5pt solid; text-align: left">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td style="border-bottom: Black 1.5pt solid; text-align: right">          <font style="font-family: Times New Roman, Times, Serif">           (959,871          </font>         </td>         <td style="padding-bottom: 1.5pt; text-align: left">          <font style="font-family: Times New Roman, Times, Serif">           )          </font>         </td>        </tr>        <tr style="vertical-align: bottom; background-color: White">         <td style="padding-bottom: 2.5pt">          <font style="font-family: Times New Roman, Times, Serif">           Total          </font>         </td>         <td style="padding-bottom: 2.5pt">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td style="border-bottom: Black 2.5pt double; text-align: left">          <font style="font-family: Times New Roman, Times, Serif">           $          </font>         </td>         <td style="border-bottom: Black 2.5pt double; text-align: right">          <font style="font-family: Times New Roman, Times, Serif">           814,494          </font>         </td>         <td style="padding-bottom: 2.5pt; text-align: left">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td style="padding-bottom: 2.5pt">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td style="border-bottom: Black 2.5pt double; text-align: left">          <font style="font-family: Times New Roman, Times, Serif">           $          </font>         </td>         <td style="border-bottom: Black 2.5pt double; text-align: right">          <font style="font-family: Times New Roman, Times, Serif">           1,031,129          </font>         </td>         <td style="padding-bottom: 2.5pt; text-align: left">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>        </tr>       </tbody>      </table>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Depreciationand amortization expense recorded for the years ended July 31, 2020 and 2019 was approximately $0.2 million and $0.2 million,respectively.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <i>         AccountsPayable and Accrued Liabilities        </i>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Accountspayable and accrued liabilities are comprised of the following:       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 93%; margin-left: 0.5in">       <tbody>        <tr style="vertical-align: bottom">         <td style="font-weight: bold">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td style="font-weight: bold; padding-bottom: 1.5pt">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">          <font style="font-family: Times New Roman, Times, Serif">           July    31, 2020          </font>         </td>         <td style="padding-bottom: 1.5pt; font-weight: bold">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td style="font-weight: bold; padding-bottom: 1.5pt">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">          <font style="font-family: Times New Roman, Times, Serif">           July    31, 2019          </font>         </td>         <td style="padding-bottom: 1.5pt; font-weight: bold">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>        </tr>        <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">         <td style="width: 60%; text-align: left">          <font style="font-family: Times New Roman, Times, Serif">           Research and development    costs          </font>         </td>         <td style="width: 2%">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td style="width: 1%; text-align: left">          <font style="font-family: Times New Roman, Times, Serif">           $          </font>         </td>         <td style="width: 16%; text-align: right">          <font style="font-family: Times New Roman, Times, Serif">           4,730,347          </font>         </td>         <td style="width: 1%; text-align: left">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td style="width: 2%">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td style="width: 1%; text-align: left">          <font style="font-family: Times New Roman, Times, Serif">           $          </font>         </td>         <td style="width: 16%; text-align: right">          <font style="font-family: Times New Roman, Times, Serif">           2,380,215          </font>         </td>         <td style="width: 1%; text-align: left">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>        </tr>        <tr style="vertical-align: bottom; background-color: White">         <td style="text-align: left">          <font style="font-family: Times New Roman, Times, Serif">           Professional services fees          </font>         </td>         <td>          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td style="text-align: left">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td style="text-align: right">          <font style="font-family: Times New Roman, Times, Serif">           3,097,881          </font>         </td>         <td style="text-align: left">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td>          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td style="text-align: left">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td style="text-align: right">          <font style="font-family: Times New Roman, Times, Serif">           1,702,886          </font>         </td>         <td style="text-align: left">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>        </tr>        <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">         <td style="padding-bottom: 1.5pt">          <font style="font-family: Times New Roman, Times, Serif">           Other          </font>         </td>         <td style="padding-bottom: 1.5pt">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td style="border-bottom: Black 1.5pt solid; text-align: left">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td style="border-bottom: Black 1.5pt solid; text-align: right">          <font style="font-family: Times New Roman, Times, Serif">           94,808          </font>         </td>         <td style="padding-bottom: 1.5pt; text-align: left">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td style="padding-bottom: 1.5pt">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td style="border-bottom: Black 1.5pt solid; text-align: left">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td style="border-bottom: Black 1.5pt solid; text-align: right">          <font style="font-family: Times New Roman, Times, Serif">           133,916          </font>         </td>         <td style="padding-bottom: 1.5pt; text-align: left">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>        </tr>        <tr style="vertical-align: bottom; background-color: White">         <td style="padding-bottom: 2.5pt">          <font style="font-family: Times New Roman, Times, Serif">           Total          </font>         </td>         <td style="padding-bottom: 2.5pt">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td style="border-bottom: Black 2.5pt double; text-align: left">          <font style="font-family: Times New Roman, Times, Serif">           $          </font>         </td>         <td style="border-bottom: Black 2.5pt double; text-align: right">          <font style="font-family: Times New Roman, Times, Serif">           7,923,036          </font>         </td>         <td style="padding-bottom: 2.5pt; text-align: left">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td style="padding-bottom: 2.5pt">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td style="border-bottom: Black 2.5pt double; text-align: left">          <font style="font-family: Times New Roman, Times, Serif">           $          </font>         </td>         <td style="border-bottom: Black 2.5pt double; text-align: right">          <font style="font-family: Times New Roman, Times, Serif">           4,217,017          </font>         </td>         <td style="padding-bottom: 2.5pt; text-align: left">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>        </tr>       </tbody>      </table>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <i>         AccruedCompensation        </i>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Accruedcompensation is comprised of the following:       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 93%; margin-left: 0.5in">       <tbody>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           <b>           </b>          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           <b>           </b>          </font>         </td>         <td colspan="2" style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           <b>            July    31, 2020           </b>          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           <b>           </b>          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           <b>           </b>          </font>         </td>         <td colspan="2" style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           <b>            July    31, 2019           </b>          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           <b>           </b>          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF">         <td style="font: 10pt Times New Roman, Times, Serif; width: 60%">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           Separation    costs          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; width: 2%">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; width: 1%">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           $          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           -          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; width: 1%">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; width: 2%">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; width: 1%">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           $          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           495,004          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; width: 1%">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white">         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           Accrued    payroll          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           279,473          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           181,219          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF">         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           401K    payable          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           5,654          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           -          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white">         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           Total          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           $          </font>         </td>         <td style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           285,127          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           $          </font>         </td>         <td style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           676,223          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>       </tbody>      </table>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <i>         OtherLong-Term Liabilities        </i>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Otherlong-term liabilities are comprised of the following:       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 93%; margin-left: 0.5in">       <tbody>        <tr style="vertical-align: bottom">         <td>          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td style="font-weight: bold; padding-bottom: 1.5pt">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">          <font style="font-family: Times New Roman, Times, Serif">           July    31, 2020          </font>         </td>         <td style="padding-bottom: 1.5pt; font-weight: bold">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td style="font-weight: bold; padding-bottom: 1.5pt">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">          <font style="font-family: Times New Roman, Times, Serif">           July    31, 2019          </font>         </td>         <td style="padding-bottom: 1.5pt; font-weight: bold">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>        </tr>        <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">         <td style="width: 60%; text-align: left; padding-bottom: 1.5pt">          <font style="font-family: Times New Roman, Times, Serif">           Deferred    rent          </font>         </td>         <td style="width: 2%; padding-bottom: 1.5pt">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left">          <font style="font-family: Times New Roman, Times, Serif">           $          </font>         </td>         <td style="width: 16%; border-bottom: Black 1.5pt solid; text-align: right">          <font style="font-family: Times New Roman, Times, Serif">           -          </font>         </td>         <td style="width: 1%; padding-bottom: 1.5pt; text-align: left">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td style="width: 2%; padding-bottom: 1.5pt">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left">          <font style="font-family: Times New Roman, Times, Serif">           $          </font>         </td>         <td style="width: 16%; border-bottom: Black 1.5pt solid; text-align: right">          <font style="font-family: Times New Roman, Times, Serif">           635,913          </font>         </td>         <td style="width: 1%; padding-bottom: 1.5pt; text-align: left">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>        </tr>        <tr style="vertical-align: bottom; background-color: White">         <td style="padding-bottom: 2.5pt">          <font style="font-family: Times New Roman, Times, Serif">           Total          </font>         </td>         <td style="padding-bottom: 2.5pt">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td style="border-bottom: Black 2.5pt double; text-align: left">          <font style="font-family: Times New Roman, Times, Serif">           $          </font>         </td>         <td style="border-bottom: Black 2.5pt double; text-align: right">          <font style="font-family: Times New Roman, Times, Serif">           -          </font>         </td>         <td style="padding-bottom: 2.5pt; text-align: left">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td style="padding-bottom: 2.5pt">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td style="border-bottom: Black 2.5pt double; text-align: left">          <font style="font-family: Times New Roman, Times, Serif">           $          </font>         </td>         <td style="border-bottom: Black 2.5pt double; text-align: right">          <font style="font-family: Times New Roman, Times, Serif">           635,913          </font>         </td>         <td style="padding-bottom: 2.5pt; text-align: left">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>        </tr>       </tbody>      </table>      <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <b>        </b>       </font>      </p>      <!-- Field: Page; Sequence: 81; Value: 13 -->      <div style="margin-bottom: 6pt; border-bottom: Black 1.5pt solid">       <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">        <tbody>         <tr style="vertical-align: top; text-align: left">          <td style="width: 33%">          </td>          <td style="text-align: center; width: 34%">           F-           <!-- Field: Sequence; Type: Arabic; Name: PageNo -->           16           <!-- Field: /Sequence -->          </td>          <td style="width: 33%">          </td>         </tr>        </tbody>       </table>      </div>      <div style="page-break-before: always; margin-top: 6pt">       <p style="margin: 0pt">       </p>      </div>      <!-- Field: /Page -->      <p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <b>        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <b>         Note6 – Notes Payable        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <b>        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        OnMarch 22, 2019, the Company entered into a finance agreement with First Insurance Funding (“FIF”). Pursuant to theterms of the agreement, FIF loaned the Company the principal amount of $185,990, which would accrue interest at 6.25% per annum,to partially fund the payment of the premium of the Company’s Director &amp; Officer insurance. The agreement requires theCompany to make nine monthly payments of $21,207, including interest starting on April 18, 2019. At July 31, 2020, the outstandingbalance related to this finance agreement was paid in full.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        OnApril 27, 2020, the Company was granted a loan (the “Loan”) from the Banc of California in the aggregate amount of$952,744, pursuant to the Paycheck Protection Program (the “PPP”) under the CARES Act, which was enacted March 27,2020. The term of the loan is two years, with monthly payments due the first day of each month, beginning seven months from thedate of initial disbursement, or December 1, 2020. Interest accrues at 1% per year, effective on the date of initial disbursement.The outstanding principal balance on the loan as of July 31, 2020 was $952,744.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Pursuantto the terms of the CARES Act and any implementing rules and regulations, the Company may apply for the Loan to be forgiven bythe SBA in whole or in part beginning no sooner than seven weeks from the date of initial disbursement. The Company intends touse the proceeds for purposes consistent with the PPP. While the Company currently believes that its use of the Loan proceedswill meet the conditions for forgiveness of the Loan, the Company cannot assure that it will be eligible for forgiveness of theLoan, in whole or in part. Any Loan balance remaining following forgiveness by the SBA will be fully re-amortized over the remainingterm of the Loan. The entire principal balance remaining unpaid, along with all accrued and unpaid interest, shall be due andpayable on the Maturity Date.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        OnJune 18, 2020, the Company entered into a finance agreement with AFCO Premium Credit LLC (“AFCO”). Pursuant to theterms of the agreement, AFCO loaned the Company the principal amount of $551,803, which would accrue interest at 3.381% per annum,to partially fund the payment of the premium of the Company’s Director &amp; Officer insurance. The agreement requires theCompany to make ten monthly payments of $56,039, including interest starting on July 18, 2020. At July 31, 2020, the outstandingbalance related to this finance agreement was $497,319.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Futureminimum payments under note payable liabilities as of July 31, 2020 are as follows:       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">       <font style="font: 10pt Times New Roman, Times, Serif">       </font>      </p>      <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">       <tbody>        <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">         <td style="font-size: 10pt; font-weight: bold">          Years ending July 31,         </td>         <td>         </td>         <td colspan="2" style="text-align: right">         </td>         <td>         </td>        </tr>        <tr style="vertical-align: bottom; background-color: White">         <td style="width: 80%; font-size: 10pt; text-align: left">          2021         </td>         <td style="width: 2%; font-size: 10pt">         </td>         <td style="width: 1%; font-size: 10pt; text-align: left">          $         </td>         <td style="width: 16%; font-size: 10pt; text-align: right">          969,509         </td>         <td style="width: 1%; font-size: 10pt; text-align: left">         </td>        </tr>        <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">         <td style="font-size: 10pt; text-align: justify; padding-bottom: 1.5pt">          2022         </td>         <td style="font-size: 10pt; padding-bottom: 1.5pt">         </td>         <td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: left">         </td>         <td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: right">          480,554         </td>         <td style="padding-bottom: 1.5pt; font-size: 10pt; text-align: left">         </td>        </tr>        <tr style="vertical-align: bottom; background-color: White">         <td style="font-size: 10pt; padding-bottom: 2.5pt">          Total         </td>         <td style="font-size: 10pt; padding-bottom: 2.5pt">         </td>         <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">          $         </td>         <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">          1,450,063         </td>         <td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">         </td>        </tr>       </tbody>      </table>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <b>         Note7—Stockholders’ Equity        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <i>         ReverseStock Split        </i>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        OnMay 20, 2019, the Company effected a one-for-ten reverse stock split of its authorized and outstanding common stock. Under Nevadalaw, and in accordance with Nevada Revised Statutes (“NRS”) Section 78.207, the split was approved by the Board ofDirectors of the Company and shareholder approval was not required. Pursuant to this reverse stock split, the total number ofauthorized common shares was reduced from 160,000,000 to 16,000,000 shares and the number of common shares outstanding was reducedfrom 71,216,082 shares to 7,121,594 shares (which reflects adjustments for fractional share settlements). The par value was notadjusted as a result of the reverse stock split. All applicable share and per share information contained in these consolidatedfinancial statements has been retroactively adjusted to reflect the reverse stock split.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <!-- Field: Page; Sequence: 82; Value: 13 -->      <div style="margin-bottom: 6pt; border-bottom: Black 1.5pt solid">       <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">        <tbody>         <tr style="vertical-align: top; text-align: left">          <td style="width: 33%">          </td>          <td style="text-align: center; width: 34%">           F-           <!-- Field: Sequence; Type: Arabic; Name: PageNo -->           17           <!-- Field: /Sequence -->          </td>          <td style="width: 33%">          </td>         </tr>        </tbody>       </table>      </div>      <div style="page-break-before: always; margin-top: 6pt">       <p style="margin: 0pt">       </p>      </div>      <!-- Field: /Page -->      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <i>        </i>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <i>         Amendmentto Articles of Incorporation        </i>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        OnSeptember 6, 2019, the Company filed with the Secretary of State of Nevada an amendment to its Certificate of Incorporation increasingthe number of shares of common stock that the Company is authorized to issue from 16,000,000 shares of common stock, par value$0.0001 per share, to 26,000,000 shares of common stock, par value $0.0001 per share.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        OnMay 29, 2020, the Company filed with the Secretary of State of Nevada an amendment to its Certificate of Incorporation increasingthe number of shares of common stock that the Company is authorized to issue from 26,000,000 shares of common stock, par value$0.0001 per share, to 100,000,000 shares of common stock, par value $0.0001 per share.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <i>        </i>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <i>         ChinaGrand Pharmaceutical and Healthcare Holdings Limited and Sirtex Medical US Holdings, Inc.        </i>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        OnFebruary 7, 2020, the Company closed (the “Closing”) a strategic transaction (the “Transaction”) withGrand Decade Developments Limited, a direct, wholly-owned subsidiary of China Grand Pharmaceutical and Healthcare Holdings Limited,a company formed under the laws of the British Virgin Islands (“CGP”), and its affiliate, Sirtex Medical US Holdings,Inc., a Delaware corporation (“Sirtex” and, together with CGP, the “Buyers”). On October 10, 2019, theCompany and the Buyers entered into Stock Purchase Agreements (as amended, the “Purchase Agreements”) pursuant towhich the Company agreed to sell and issue to CGP and Sirtex 10,000,000 shares and 2,000,000 shares, respectively, of the Company’scommon stock for a total purchase price of $30 million. The net proceeds, after deducting offering fees and expenses paid by theCompany, were approximately $28.0 million. The Company evaluated whether any proceeds received in the Stock Purchase Agreementsshould be allocated to other agreements entered into at the same time and concluded that there should not be any allocation dueto the de minimis value of the other agreements. Upon Closing, CGP and Sirtex owned 43.95% and 8.79%, respectively, of the outstandingshares of common stock of the Company.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <u>         PurchaseAgreements        </u>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        ThePurchase Agreements include customary covenants that obligate the Company to use commercially reasonable efforts to cause thepurchased shares to be approved for listing on The Nasdaq Capital Market, and a contractual anti-dilution mechanism that accountsfor the Company’s outstanding options and warrants, as well as other customary covenants. In addition, the Company, CGP,and Sirtex each shall pay their respective fees and expenses in connection with the transactions contemplated by the PurchaseAgreements. On the date of the Closing the Company reimbursed legal fees and expenses incurred by each of CGP and Sirtex in anaggregate amount of $600,000, which are part of the offering fees and expenses noted above.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <u>         Stockholders        </u>       </font>       <font style="font: 10pt Times New Roman, Times, Serif">        <u>         Agreements        </u>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Concurrentlywith the execution and delivery of the Purchase Agreements, the Company, CGP, and Sirtex entered into Stockholders Agreements(the “Stockholders Agreements”), to be effective upon the Closing, pursuant to which, among other things, CGP andSirtex received and exercised the option to nominate a combined total of three (3) members to the Board of Directors, initiallyat the Closing, and thereafter at every annual meeting of the stockholders of the Company in which directors are generally elected,including at every adjournment or postponement thereof. If either CGP or Sirtex beneficially owns less than 40% of the sharesacquired pursuant to the Purchase Agreements, either (as applicable) shall have the right to nominate members to the Board ofDirectors in proportion with their ownership of the issued and outstanding common stock.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Inaddition, CGP and Sirtex will have certain rights of participation in future financings as well as a right of first refusal relatedto future potential transactions. The Stockholder Agreements implement a 70% supermajority approval by the Board of Directorsfor certain actions, as well as stockholder consent rights for CGP, all of which are conditioned upon CGP and Sirtex maintainingcertain ownership thresholds.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <!-- Field: Page; Sequence: 83; Value: 13 -->      <div style="margin-bottom: 6pt; border-bottom: Black 1.5pt solid">       <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">        <tbody>         <tr style="vertical-align: top; text-align: left">          <td style="width: 33%">          </td>          <td style="text-align: center; width: 34%">           F-           <!-- Field: Sequence; Type: Arabic; Name: PageNo -->           18           <!-- Field: /Sequence -->          </td>          <td style="width: 33%">          </td>         </tr>        </tbody>       </table>      </div>      <div style="page-break-before: always; margin-top: 6pt">       <p style="margin: 0pt">       </p>      </div>      <!-- Field: /Page -->      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <u>         FirstAmendment to the Purchase Agreements and Stockholder Agreement        </u>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        OnNovember 26, 2019, the Company entered into an amendment (the “First Amendment”) to the Purchase Agreements with CGPand Sirtex and to the Stockholder Agreement with CGP. The First Amendment provided that following the Closing, the Company would,at its next annual meeting of stockholders (instead of at the Special Meeting, as previously required by the Purchase Agreements),seek, among other things, the requisite stockholder approval for the Company to amend its Articles of Incorporation to (i) increasethe Company’s authorized shares of common stock by 4,000,000 shares from 26,000,000 shares to 30,000,000 shares and (ii)add the corporate opportunity waiver (described below). In addition, the First Amendment (a) amended the Purchase Agreements toprovide that a material breach of the Purchase Agreements shall be deemed to have occurred if the Closing does not occur within10 business days of the satisfaction of the conditions to the Company’s obligations, including the approval of the ProposedTransactions by the Company’s shareholders and (b) amended the Stockholder Agreement with CGP to provide that rescissionof the corporate opportunity waiver is subject to the enhanced voting requirements described below.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Inconnection with approving the First Amendment, to the extent permitted by applicable law, the Board has (i) renounced any interestor expectancy of the Company in, or in being offered an opportunity to participate in, business opportunities that are presentedto CGP and certain related parties, the directors on the Board which have been nominated by CGP or Sirtex pursuant to the StockholderAgreements, any other person or persons who are, at the time, associated with or nominated by, or serving as representatives ofeither CGP or Sirtex, or the respective affiliates of the foregoing parties (including their officers or directors who are employees,officers, directors, managers, stockholders or members) (the “Covered Persons”), (ii) resolved that none of such CoveredPersons shall have any obligation to refrain from (a) engaging in similar activities or lines of business as the Company or developingor marketing any products or services that compete, directly or indirectly, with those of the Company, (b) investing or owningany interest publicly or privately in, serving as a director or officer of or developing a business relationship with, any personengaged in similar activities or lines of business as, or otherwise in competition with, the Company, (c) doing business withany client or customer of the Company or (d) employing or otherwise engaging a former officer or employee of the Company, and(iii) resolved that neither the Company nor any of its subsidiaries shall have any right to be offered any opportunity to participateor invest in any venture engaged or to be engaged in by any Covered Person.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        OnMay 29, 2020, the Company’s shareholders approved amendments to its Articles of Incorporation to, among other things, increasethe Company’s authorized shares of common stock by 74,000,000 shares from 26,000,000 shares to 100,000,000 sharesand include a waiver of the duty of certain directors to present corporate opportunities to the Company.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <i>         May2019 Offering        </i>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        OnMay 24, 2019, the Company completed the offer and sale of an aggregate of 3,492,063 shares of its common stock, together with3,492,063 accompanying warrants to purchase an aggregate of 2,619,047 shares of its common stock, at a combined purchase priceof $3.15 per share of common stock and warrant. The warrants have an exercise price of $3.45 per full share, became exercisableon May 24, 2019 and expire on May 24, 2024. The gross proceeds of the offering were approximately $11.0 million, and the net proceeds,after deducting the placement agent’s fee and other offering fees and expenses paid by the Company, were approximately $10.0million. In connection with the offering, the Company paid the placement agent a cash fee equal to 6.5% of the gross proceedsof the offering, as well as legal and other expenses equal to $90,000. In addition, pursuant to the underwriting agreement, theCompany granted the underwriters an option, exercisable for 45 days, to purchase up to an additional 523,809 shares of its commonstock (the “Option Shares”) and/or warrants to purchase up to 392,857 shares of common stock (the “Option Warrants”).On May 24, 2019, the underwriters partially exercised their option and purchased 238,095 Option Warrants to purchase an aggregateof 178,571 shares of the Company’s common stock, at a purchase price of $0.01 per warrant before underwriting discounts,or $2,381. The Option Warrants have an exercise price of $3.45 per share, became exercisable on May 24, 2019 and expire on May24, 2024.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <!-- Field: Page; Sequence: 84; Value: 13 -->      <div style="margin-bottom: 6pt; border-bottom: Black 1.5pt solid">       <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">        <tbody>         <tr style="vertical-align: top; text-align: left">          <td style="width: 33%">          </td>          <td style="text-align: center; width: 34%">           F-           <!-- Field: Sequence; Type: Arabic; Name: PageNo -->           19           <!-- Field: /Sequence -->          </td>          <td style="width: 33%">          </td>         </tr>        </tbody>       </table>      </div>      <div style="page-break-before: always; margin-top: 6pt">       <p style="margin: 0pt">       </p>      </div>      <!-- Field: /Page -->      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Thefair value of the warrants issued to the purchasers in the offering, based on their fair value relative to the common stock issued,was approximately $3.6 million (based on the Black-Scholes option valuation model assuming no dividend yield, a 5.0 year life,volatility of 82.99% and a risk-free interest rate of 2.12%). The Company completed an evaluation of these warrants and determinedthey should be classified as equity within the accompanying consolidated balance sheets.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <i>        </i>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <i>         AspireCapital        </i>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        OnMarch 29, 2019, the Company entered into a common stock purchase agreement (the “Purchase Agreement”) with AspireCapital Fund, LLC, (“Aspire Capital”) pursuant to which the Company agreed to issue and sell to Aspire Capital sharesof its common stock equal to an aggregate amount of up to $20.0 million at the Company’s request from time to time duringa 30-month period. The Company had filed with the Securities and Exchange Commission a prospectus supplement to the Company’seffective shelf registration statement on Form S-3 registering all the shares of common stock that may be offered to Aspire Capitalfrom time to time. In consideration for entering into the Purchase Agreement the Company issued to Aspire Capital 120,201 sharesof the Company’s common stock which represented 3% of the aggregate commitment.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Underthe Purchase Agreement, on any trading day selected by the Company, the Company had the right, in its sole discretion, to presentAspire Capital with a purchase notice, directing Aspire Capital to purchase up to 30,000 shares of the Company’s commonstock per business day, up to $20.0 million of the Company’s common stock in the aggregate at a per share price equal tothe lesser of:       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">       <tbody>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           ●          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           the    lowest sale price of the Company’s common stock on the purchase date; or          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           ●          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           the    arithmetic average of the three (3) lowest closing sale prices for the Company’s common stock during the ten (10) consecutive    trading days ending on the trading day immediately preceding the purchase date          </font>         </td>        </tr>       </tbody>      </table>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.25in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Uponexecution of the Purchase Agreement, the Company agreed to sell to Aspire Capital 400,674 shares of common stock for total proceeds,before expenses, of $2,000,000. Additionally, in April 2019, the Company sold a total of 90,000 shares of its common stock toAspire Capital resulting in the Company receiving total proceeds, before expenses, of approximately $520,000 in cash. There wereno underwriting or placement agent fees associated with the offering.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        OnMay 27, 2019, the Company terminated the Purchase Agreement.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <i>         AlphaHoldings        </i>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        OnAugust 31, 2018, the Company entered into a stock purchase agreement with Alpha Holdings, Inc. (“Alpha Holdings”),pursuant to which the Company agreed to issue and sell to Alpha Holdings shares of its common stock equal to an aggregate amountof up to $15.0 million at a market purchase price of $15.00 per share, which was the closing price of the Company’s commonstock the day immediately before the agreement was executed by the parties.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        OnOctober 9, 2018, the Company received total proceeds, before expenses, of $8.0 million in cash from the offering and issued AlphaHoldings 533,333 shares of common stock. There were no underwriting or placement agent fees associated with the offering.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        OnDecember 6, 2018, the Company received total proceeds, before expenses, of $7.0 million in cash from the offering and issued AlphaHoldings 466,666 shares of common stock. There were no underwriting or placement agent fees associated with the offering.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <i>         CommonStock Option Exercise        </i>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Duringthe year ended July 31, 2019, shares of common stock issued related to option exercises totaled 43,029. The Company realized proceedsof $0.6 million from the stock option exercises. There were no stock options exercised during the year ended July 31, 2020.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <!-- Field: Page; Sequence: 85; Value: 13 -->      <div style="margin-bottom: 6pt; border-bottom: Black 1.5pt solid">       <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">        <tbody>         <tr style="vertical-align: top; text-align: left">          <td style="width: 33%">          </td>          <td style="text-align: center; width: 34%">           F-           <!-- Field: Sequence; Type: Arabic; Name: PageNo -->           20           <!-- Field: /Sequence -->          </td>          <td style="width: 33%">          </td>         </tr>        </tbody>       </table>      </div>      <div style="page-break-before: always; margin-top: 6pt">       <p style="margin: 0pt">       </p>      </div>      <!-- Field: /Page -->      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <i>         OutstandingWarrants        </i>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Duringthe year ended July 31, 2020, the Company repurchased an aggregate of 266,098 warrants from certain warrant holders for an aggregateof approximately $0.2 million. The repurchase price was paid in cash, and upon repurchase, all the warrants were cancelled andof no further force and effect.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        AtJuly 31, 2020, the Company had outstanding warrants to purchase 3,114,288 shares of its common stock, with exercise prices rangingfrom $3.45 to $43.75, all of which were classified as equity instruments. These warrants expire at various dates between November2020 and May 2024.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <b>        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <b>         Note8—Stock-Based Compensation        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        TheOncoSec Medical Incorporated 2011 Stock Incentive Plan (as amended and approved by the Company’s stockholders (the “2011Plan”)), authorizes the Company’s Board of Directors to grant equity awards, including stock options and restrictedstock units, to employees, directors and consultants. The 2011 Plan authorizes a total of 750,000 shares for issuance thereunder,and includes an automatic increase of the number of shares of common stock reserved thereunder on the first business day of eachcalendar year by the lesser of: (i) 3% of the shares of the Company’s common stock outstanding as of the last day of theimmediately preceding calendar year; (ii) 100,000 shares; or (iii) such lesser number of shares as determined by the Company’sBoard of Directors. As of July 31, 2020, there were an aggregate of 3,350,000 shares of the Company’s common stock authorizedfor issuance under the 2011 Plan. Under the 2011 Plan, incentive stock options are to be granted at a price that is no less than100% of the fair value of the Company’s common stock at the date of grant. Stock options vest over a period specified inthe individual option agreements entered into with grantees, and are exercisable for a maximum period of 10 years after the dateof grant. Stock options granted to stockholders who own more than 10% of the outstanding stock of the Company at the time of grantmust be issued at an exercise price of no less than 110% of the fair value of the Company’s common stock on the date ofgrant.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        OnApril 14, 2020, the Board approved, subject to and contingent on stockholder approval at the Company’s Annual Meeting, amendmentsto the 2011 Plan to (i) increase the number of shares authorized under the 2011 Plan by 2,300,000 shares, and (ii) delete theprovision in the 2011 Plan that provides for certain annual and automatic increases in the shares of our common stock reservedfor issuance thereunder. On May 29, 2020, the Company’s shareholders approved the amendments to the 2011 Plan.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <i>        </i>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <i>         Modificationof Stock Option Awards        </i>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Duringthe year ended July 31, 2020, the Company cancelled 878,534 outstanding common stock option awards under the following terms:       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">       <tbody>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           ●          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           The    Company entered into Stock Option Cancellation Agreements (the “Cancellation Agreements”) with certain executive    officers, directors and other senior level employees of the Company, pursuant to which such individuals (the “Senior    Level Option holder”) agreed to the voluntary surrender and cancellation of certain previously granted stock options    (the “Cancelled Options”) to purchase in the aggregate 699,140 shares of the Company’s common stock. Under    the terms of the Cancellation Agreements, each Senior Level Option holder and the Company acknowledged and agreed that the    surrender and cancellation of the Cancelled Options was without any expectation on the part of the Senior Level Option holder    to receive, and without any obligation on the Company to pay or grant, any cash, equity awards or other consideration presently    or in the future with respect to the Cancelled Options.          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           ●          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           The    Company cancelled outstanding common stock options held by employees and consultants other than Senior Level Option holders    of the Company, pursuant to which such individuals previously granted stock options to purchase in the aggregate 179,394 shares    of the Company’s common stock were cancelled for cash consideration of approximately $26,000.          </font>         </td>        </tr>       </tbody>      </table>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <!-- Field: Page; Sequence: 86; Value: 13 -->      <div style="margin-bottom: 6pt; border-bottom: Black 1.5pt solid">       <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">        <tbody>         <tr style="vertical-align: top; text-align: left">          <td style="width: 33%">          </td>          <td style="text-align: center; width: 34%">           F-           <!-- Field: Sequence; Type: Arabic; Name: PageNo -->           21           <!-- Field: /Sequence -->          </td>          <td style="width: 33%">          </td>         </tr>        </tbody>       </table>      </div>      <div style="page-break-before: always; margin-top: 6pt">       <p style="margin: 0pt">       </p>      </div>      <!-- Field: /Page -->      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        TheCompany accounted for the effects of the stock option modifications described above under the guidance of ASC 718 as follows:       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">       <tbody>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           ●          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           A    cancellation of an award that is not accompanied by the concurrent grant of (or offer to grant) a replacement award or other    valuable consideration shall be accounted for as a repurchase for no consideration. Accordingly, any previously unrecognized    compensation expense is recognized at the cancellation date.          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           ●          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           The    amount of cash paid to settle an equity-classified award is charged directly to equity as long as that amount is equal to    or less than the fair-value-based measure of the award on the settlement date. To the extent that the settlement consideration    exceeds the fair-value-based measure of the equity-classified award on the settlement date, that difference is recognized    as additional compensation cost. The cash paid to settle employee and consultant equity-classified awards, other than Senior    Level Option holders, was less than the fair-value-based measure of the award on the settlement date. The approximately $26,000    in cash paid to settle the equity-classified awards was charged directly to additional paid in capital.          </font>         </td>        </tr>       </tbody>      </table>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Followingthe cancellation of the outstanding option awards described above, there were 15,000 stock option awards outstanding under the2011 Plan. The Company recorded the previously unrecognized compensation cost related to the cancelled outstanding stock optionawards of approximately $1.2 million on the date of cancellation.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        OnOctober 23, 2018, the Company entered into stock option cancellation agreements with two consultants. As per the terms of theagreements, an aggregate of 53,500 stock options were cancelled. The consultants were not issued replacement awards under thecancellation agreements. Under ASC 718, a cancellation of an award that is not accompanied by the concurrent grant of (or offerto grant) a replacement award or other valuable consideration shall be accounted for as a repurchase for no consideration. Accordingly,any previously unrecognized compensation cost shall be recognized at the cancellation date. The Company recorded unrecognizedcompensation of the cancelled awards, or $377,278, to compensation costs with an offsetting entry to additional paid in capitalon the date of the cancellation.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        OnAugust 22, 2018, the Company entered into a stock option cancellation agreement with an individual. As per the terms of the agreement,30,000 fully vested stock options were cancelled. On August 22, 2018, the Company issued 17,500 shares of restricted common stock.Upon modification, it is required under ASC 718 to analyze the fair value of the instruments, before and after the modification,recognizing the increase as a charge to the statement of operations. The Company computed the fair value of the cancelled awardand compared the fair value to that of the restricted stock award. The Company recorded the excess of the fair value of the restrictedstock award over the fair value of the cancelled award, or $135,425, to compensation costs with an offsetting entry to commonstock and additional paid in capital on the date of the modification.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <i>        </i>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <i>         Modificationof Award        </i>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        OnOctober 2, 2019, the Company entered into an amendment to a consulting agreement with a consulting firm. Prior to the amendmentthe Company was required to issue 3,000 restricted common shares monthly for services through July 2, 2020. As per the terms ofthe amended agreement, starting October 2, 2019, the Company will be required to issue 15,000 shares of restricted common stockmonthly for services through July 2, 2020. Upon modification, it is required under ASC 718 to analyze the fair value of the instruments,before and after the modification, recognizing additional compensation cost for any incremental value. The Company computed thefair value of the award prior to the amendment and compared the fair value to that of the modified award. The incremental compensationcost of approximately $0.2 million resulting from the modification will be recognized ratably over the remaining term of the consultingagreement.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <i>         BonusesPaid in Common Stock        </i>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <i>        </i>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        OnMarch 11, 2020, the Compensation Committee of the Board of Directors approved the payment of discretionary bonuses to our ChiefExecutive Officer and seven other officers in an aggregate amount equal to $836,250 (the “2019 Incentive Bonuses”),in recognition of the Company’s achievement of certain operational and strategic objectives in 2019 and each individual’songoing contributions to the success of the Company.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <!-- Field: Page; Sequence: 87; Value: 13 -->      <div style="margin-bottom: 6pt; border-bottom: Black 1.5pt solid">       <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">        <tbody>         <tr style="vertical-align: top; text-align: left">          <td style="width: 33%">          </td>          <td style="text-align: center; width: 34%">           F-           <!-- Field: Sequence; Type: Arabic; Name: PageNo -->           22           <!-- Field: /Sequence -->          </td>          <td style="width: 33%">          </td>         </tr>        </tbody>       </table>      </div>      <div style="page-break-before: always; margin-top: 6pt">       <p style="margin: 0pt">       </p>      </div>      <!-- Field: /Page -->      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Inorder to conserve cash and improve cash flow, the Compensation Committee determined that it would be in the Company’s bestinterests to pay one-half of the 2019 Incentive Bonuses, or $418,125, in cash, and one-half of the 2019 Incentive Bonuses in sharesof our common stock (“Contingent Bonus Shares”), subject to approval by the Board of Directors and contingent on stockholderapproval of the issuance of the Contingent Bonus Shares at the Company’s annual shareholder meeting (the “Annual Meeting”).On April 14, 2020, the Board of Directors approved the issuance of the Contingent Bonus Shares to the officers, contingent onstockholder approval at the Annual Meeting, and determined that the aggregate number of Contingent Bonus Shares would be 302,989shares (the “Bonus Share Pool”), which was determined by dividing $418,125 by $1.38, the closing price of our commonstock on March 11, 2020.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        OnMay 29, 2020, the Company’s stockholders approved the Bonus Share Pool and the Contingent Bonus Shares were granted to theofficers following the Annual Meeting. The Contingent Bonus Shares are subject to a six-month holding period requirement. TheCompany, using the net shares method, issued an aggregate of 185,003 shares of Company common stock to pay one-half of the discretionarybonuses. 117,986 shares of Company common stock were withheld at vesting to cover individual tax withholding obligations. TheCompany recorded compensation expense related to the Contingent Bonus Shares of $0.7 million during the year ended July 31, 2020,which was determined by multiplying the Bonus Share Pool, or 302,989, by $2.23, the closing price of our common stock on May 29,2020.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <i>        </i>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <i>         StockOptions        </i>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <i>        </i>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Duringthe year ended July 31, 2020, the Company granted options to purchase 1,158,982, 225,000 and 80,000 shares of its common stockto employees, directors and consultants under the 2011 Plan, respectively. The stock options issued to employees have a ten-yearterm, vest over a period ranging from two to three years and have exercise prices ranging from $1.56 to $3.30. The stock optionsissued to directors have a 10-year term, vest over three years and have an exercise price of $1.56. The stock options issued toconsultants have ten-year terms, vest in accordance with the terms of the applicable consulting agreement and have an exerciseprice of $1.56. 5,050 options granted during the year ended July 31, 2020 were cancelled during the second quarter of fiscal year2020 as part of the stock option cancellation transaction discussed previously.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Duringthe year ended July 31, 2019, the Company granted options to purchase 154,249, 77,500 and 1,000 shares of its common stock toemployees, directors and consultants under the 2011 Plan, respectively. The stock options issued to employees have a ten-yearterm, vest over three years, and have exercise prices ranging from $2.57 to $15.80. The stock options issued to directors havea 10-year term, vest over a period ranging from one to three years and have exercise prices ranging from $5.80 and $8.41. Thestock options issued to consultants have ten-year terms, vest in accordance with the terms of the applicable consulting agreementand have an exercise price of $6.25.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Duringthe year ended July 31, 2019, the Company granted options to purchase 20,000 and 50,000 shares of its common stock to employeesand consultants outside the 2011 Plan. The stock options issued to employees have a ten-year term, vest over three years, andhave an exercise price of $16.40. The stock options issued to consultants have ten-year terms, vest in accordance with the termsof the applicable consulting agreement and have exercise prices ranging from $8.46 and $14.30.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        TheCompany accounts for stock-based compensation based on the fair value of the stock-based awards granted and records forfeituresas they occur. As such, the Company recognizes stock-based compensation cost only for those stock-based awards that vest overtheir requisite service period, based on the vesting provisions of the individual grants. The service period is generally thevesting period, with the exception of stock options granted pursuant to a consulting agreement, in which case the stock optionvesting period and the service period are defined pursuant to the terms of the consulting agreement.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <!-- Field: Page; Sequence: 88; Value: 13 -->      <div style="margin-bottom: 6pt; border-bottom: Black 1.5pt solid">       <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">        <tbody>         <tr style="vertical-align: top; text-align: left">          <td style="width: 33%">          </td>          <td style="text-align: center; width: 34%">           F-           <!-- Field: Sequence; Type: Arabic; Name: PageNo -->           23           <!-- Field: /Sequence -->          </td>          <td style="width: 33%">          </td>         </tr>        </tbody>       </table>      </div>      <div style="page-break-before: always; margin-top: 6pt">       <p style="margin: 0pt">       </p>      </div>      <!-- Field: /Page -->      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Thefollowing assumptions were used for the Black-Scholes calculation of the fair value of stock-based compensation related to stockoptions granted during the periods presented:       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 93%; border-collapse: collapse; margin-left: 0.25in">       <tbody>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           <b>           </b>          </font>         </td>         <td colspan="2" style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif">          <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            <b>             Year                                         Ended            </b>           </font>          </p>          <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            <b>             July        31, 2020            </b>           </font>          </p>         </td>         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           <b>           </b>          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           <b>           </b>          </font>         </td>         <td colspan="2" style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif">          <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            <b>             Year                                         Ended            </b>           </font>          </p>          <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            <b>             July        31, 2019            </b>           </font>          </p>         </td>         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           <b>           </b>          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF">         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           Expected    term (years)          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           5.00–6.50    years          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           5.00–6.50    years          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white">         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           Risk-free    interest rate          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           0.30    -1.70          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           %          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           1.74    – 3.09          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           %          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF">         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           Volatility          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           80.93    – 87.95          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           %          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           72.88    –83.87          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           %          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white">         <td style="font: 10pt Times New Roman, Times, Serif; width: 60%">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           Dividend    yield          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; width: 2%">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; width: 1%">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           0          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; width: 1%">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           %          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; width: 1%">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; width: 2%">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           0          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; width: 1%">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           %          </font>         </td>        </tr>       </tbody>      </table>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        TheCompany’s expected volatility is derived from the historical daily change in the market price of its common stock. The Companyuses the simplified method to calculate the expected term of options issued to employees, non-employees and directors. The risk-freeinterest rate used in the Black-Scholes calculation is based on the prevailing U.S. Treasury yield in effect at the time of grant,commensurate with the expected term. For the expected dividend yield used in the Black-Scholes calculation, the Company has neverpaid any dividends on its common stock and does not anticipate paying dividends on its common stock in the foreseeable future.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Thefollowing is a summary of the Company’s 2011 Plan and non-Plan stock option activity for the years ended July 31, 2020 and2019:       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font: 10pt Times New Roman, Times, Serif">       </font>      </p>      <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 95%; font: 10pt Times New Roman, Times, Serif; margin-left: 0.25in">       <tbody>        <tr style="vertical-align: bottom">         <td style="text-align: right">         </td>         <td>         </td>         <td colspan="2">         </td>         <td>         </td>         <td style="font-size: 10pt; font-weight: bold">         </td>         <td colspan="2" style="font-size: 10pt; font-weight: bold; text-align: center">          Weighted         </td>         <td style="font-size: 10pt; font-weight: bold">         </td>        </tr>        <tr style="vertical-align: bottom">         <td style="text-align: right">         </td>         <td>         </td>         <td colspan="2" style="text-align: center">         </td>         <td>         </td>         <td style="font-size: 10pt; font-weight: bold">         </td>         <td colspan="2" style="font-size: 10pt; font-weight: bold; text-align: center">          Average         </td>         <td style="font-size: 10pt; font-weight: bold">         </td>        </tr>        <tr style="vertical-align: bottom">         <td style="text-align: right">         </td>         <td>         </td>         <td colspan="2" style="text-align: center">         </td>         <td>         </td>         <td style="font-size: 10pt; font-weight: bold">         </td>         <td colspan="2" style="font-size: 10pt; font-weight: bold; text-align: center">          Exercise         </td>         <td style="font-size: 10pt; font-weight: bold">         </td>        </tr>        <tr style="vertical-align: bottom">         <td style="text-align: right">         </td>         <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1.5pt">         </td>         <td colspan="2" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">          Options         </td>         <td style="padding-bottom: 1.5pt; font-size: 10pt; font-weight: bold">         </td>         <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1.5pt">         </td>         <td colspan="2" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">          Price         </td>         <td style="padding-bottom: 1.5pt; font-size: 10pt; font-weight: bold">         </td>        </tr>        <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">         <td style="width: 60%; font-size: 10pt; font-weight: bold; text-align: justify">          Outstanding - July 31, 2018         </td>         <td style="width: 2%; font-size: 10pt">         </td>         <td style="width: 1%; font-size: 10pt; text-align: left">         </td>         <td style="width: 16%; font-size: 10pt; text-align: right">          891,252         </td>         <td style="width: 1%; font-size: 10pt; text-align: left">         </td>         <td style="width: 2%; font-size: 10pt">         </td>         <td style="width: 1%; font-size: 10pt; text-align: left">          $         </td>         <td style="width: 16%; font-size: 10pt; text-align: right">          15.00         </td>         <td style="width: 1%; font-size: 10pt; text-align: left">         </td>        </tr>        <tr style="vertical-align: bottom; background-color: White">         <td style="font-size: 10pt; text-align: justify">          Granted         </td>         <td style="font-size: 10pt">         </td>         <td style="font-size: 10pt; text-align: left">         </td>         <td style="font-size: 10pt; text-align: right">          302,749         </td>         <td style="font-size: 10pt; text-align: left">         </td>         <td style="font-size: 10pt">         </td>         <td style="font-size: 10pt; text-align: left">          $         </td>         <td style="font-size: 10pt; text-align: right">          7.88         </td>         <td style="font-size: 10pt; text-align: left">         </td>        </tr>        <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">         <td style="font-size: 10pt; text-align: justify">          Exercised         </td>         <td style="font-size: 10pt">         </td>         <td style="font-size: 10pt; text-align: left">         </td>         <td style="font-size: 10pt; text-align: right">          (43,029         </td>         <td style="font-size: 10pt; text-align: left">          )         </td>         <td style="font-size: 10pt">         </td>         <td style="font-size: 10pt; text-align: left">          $         </td>         <td style="font-size: 10pt; text-align: right">          13.16         </td>         <td style="font-size: 10pt; text-align: left">         </td>        </tr>        <tr style="vertical-align: bottom; background-color: White">         <td style="font-size: 10pt; text-align: justify">          Forfeited/Cancelled         </td>         <td style="font-size: 10pt">         </td>         <td style="font-size: 10pt; text-align: left">         </td>         <td style="font-size: 10pt; text-align: right">          (228,700         </td>         <td style="font-size: 10pt; text-align: left">          )         </td>         <td style="font-size: 10pt">         </td>         <td style="font-size: 10pt; text-align: left">          $         </td>         <td style="font-size: 10pt; text-align: right">          15.32         </td>         <td style="font-size: 10pt; text-align: left">         </td>        </tr>        <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">         <td style="font-size: 10pt; text-align: justify; padding-bottom: 1.5pt">          Expired         </td>         <td style="font-size: 10pt; padding-bottom: 1.5pt">         </td>         <td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: left">         </td>         <td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: right">          (700         </td>         <td style="padding-bottom: 1.5pt; font-size: 10pt; text-align: left">          )         </td>         <td style="font-size: 10pt; padding-bottom: 1.5pt">         </td>         <td style="padding-bottom: 1.5pt; font-size: 10pt; text-align: left">          $         </td>         <td style="padding-bottom: 1.5pt; font-size: 10pt; text-align: right">          57.60         </td>         <td style="padding-bottom: 1.5pt; font-size: 10pt; text-align: left">         </td>        </tr>        <tr style="vertical-align: bottom; background-color: White">         <td style="font-size: 10pt; font-weight: bold; text-align: justify">          Outstanding - July 31, 2019         </td>         <td style="font-size: 10pt">         </td>         <td style="font-size: 10pt; text-align: left">         </td>         <td style="font-size: 10pt; text-align: right">          921,572         </td>         <td style="font-size: 10pt; text-align: left">         </td>         <td style="font-size: 10pt">         </td>         <td style="font-size: 10pt; text-align: left">          $         </td>         <td style="font-size: 10pt; text-align: right">          12.63         </td>         <td style="font-size: 10pt; text-align: left">         </td>        </tr>        <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">         <td style="font-size: 10pt; text-align: justify">          Granted         </td>         <td style="font-size: 10pt">         </td>         <td style="font-size: 10pt; text-align: left">         </td>         <td style="font-size: 10pt; text-align: right">          1,463,982         </td>         <td style="font-size: 10pt; text-align: left">         </td>         <td style="font-size: 10pt">         </td>         <td style="font-size: 10pt; text-align: left">          $         </td>         <td style="font-size: 10pt; text-align: right">          1.60         </td>         <td style="font-size: 10pt; text-align: left">         </td>        </tr>        <tr style="vertical-align: bottom; background-color: White">         <td style="font-size: 10pt; text-align: justify">          Exercised         </td>         <td style="font-size: 10pt">         </td>         <td style="font-size: 10pt; text-align: left">         </td>         <td style="font-size: 10pt; text-align: right">          -         </td>         <td style="font-size: 10pt; text-align: left">         </td>         <td style="font-size: 10pt">         </td>         <td style="font-size: 10pt; text-align: left">          $         </td>         <td style="font-size: 10pt; text-align: right">          -         </td>         <td style="font-size: 10pt; text-align: left">         </td>        </tr>        <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">         <td style="font-size: 10pt; text-align: justify; padding-bottom: 1.5pt">          Forfeited/Cancelled         </td>         <td style="font-size: 10pt; padding-bottom: 1.5pt">         </td>         <td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: left">         </td>         <td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: right">          (942,698         </td>         <td style="padding-bottom: 1.5pt; font-size: 10pt; text-align: left">          )         </td>         <td style="font-size: 10pt; padding-bottom: 1.5pt">         </td>         <td style="padding-bottom: 1.5pt; font-size: 10pt; text-align: left">          $         </td>         <td style="padding-bottom: 1.5pt; font-size: 10pt; text-align: right">          12.31         </td>         <td style="padding-bottom: 1.5pt; font-size: 10pt; text-align: left">         </td>        </tr>        <tr style="vertical-align: bottom; background-color: White">         <td style="font-size: 10pt; font-weight: bold; text-align: justify; padding-bottom: 2.5pt">          Outstanding and expected to vest – July 31, 2020         </td>         <td style="font-size: 10pt; padding-bottom: 2.5pt">         </td>         <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">         </td>         <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">          1,442,856         </td>         <td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">         </td>         <td style="font-size: 10pt; padding-bottom: 2.5pt">         </td>         <td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">          $         </td>         <td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: right">          1.65         </td>         <td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">         </td>        </tr>        <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">         <td style="font-size: 10pt; font-weight: bold; text-align: justify; padding-bottom: 2.5pt">          Exercisable – July 31, 2020         </td>         <td style="font-size: 10pt; padding-bottom: 2.5pt">         </td>         <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">         </td>         <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">          474,933         </td>         <td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">         </td>         <td style="font-size: 10pt; padding-bottom: 2.5pt">         </td>         <td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">          $         </td>         <td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: right">          1.72         </td>         <td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">         </td>        </tr>       </tbody>      </table>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Asof July 31, 2020, the total intrinsic value of options outstanding and exercisable was $3.7 million and $1.2 million, respectively.As of July 31, 2020, the Company has approximately $1.6 million in unrecognized stock-based compensation expense attributableto the outstanding options, which will be amortized over a period of approximately 2.61 years.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Stock-basedcompensation expense recorded in the Company’s consolidated statements of operations for the year ended July 31, 2020 resultingfrom stock options awarded to the Company’s employees, directors and consultants was approximately $2.6 million, which includedapproximately $1.2 million related to the cancellation of certain stock option awards. Of the total expense, $1.3 million wasrecorded to research and development and $1.3 million was recorded in general and administrative in the Company’s consolidatedstatements of operations for the year ended July 31, 2020.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Stock-basedcompensation expense recorded in the Company’s consolidated statements of operations for year ended July 31, 2019 resultingfrom stock options awarded to the Company’s employees, directors and consultants was approximately $2.9 million, respectively.Of this balance, $1.2 million was recorded to research and development and $1.7 million was recorded in general and administrativein the Company’s consolidated statements of operations for year ended July 31, 2019.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <!-- Field: Page; Sequence: 89; Value: 13 -->      <div style="margin-bottom: 6pt; border-bottom: Black 1.5pt solid">       <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">        <tbody>         <tr style="vertical-align: top; text-align: left">          <td style="width: 33%">          </td>          <td style="text-align: center; width: 34%">           F-           <!-- Field: Sequence; Type: Arabic; Name: PageNo -->           24           <!-- Field: /Sequence -->          </td>          <td style="width: 33%">          </td>         </tr>        </tbody>       </table>      </div>      <div style="page-break-before: always; margin-top: 6pt">       <p style="margin: 0pt">       </p>      </div>      <!-- Field: /Page -->      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Theweighted-average grant date fair value of stock options granted during the year ended July 31, 2020 was $1.67. The weighted-averagegrant date fair value of stock options granted during the year ended July 31, 2019 was $5.29.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <i>         RestrictedStock Units (“RSUs”)        </i>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Forthe year ended July 31, 2020, the Company recorded $0.3 million, in stock-based compensation related to RSUs, which is reflectedin the consolidated statements of operations.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Asof July 31, 2020, there were 34,914 restricted stock units (“RSUs”) outstanding. During the year ended July 31, 2020,35,230 RSU’s vested.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        InDecember 2018, the Company granted its President and Chief Executive Officer 75,000 restricted stock unit awards (“RSUs”).The units vest as follows: 6,250 units vested on January 31, 2019, and the remaining 68,750 units vest in equal quarterly installmentsof 6,250 units beginning on April 30, 2019 and ending on October 31, 2021. The closing price of the Company’s common stockon the date of grant was $6.00 per share, which is the fair market value per unit of the RSUs.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        InOctober 2018, the Company granted 5,000 RSUs to an employee. The units vest as follows: 1,250 units vested on October 29, 2018,and the remaining 3,750 units vest according to the following vesting schedule: 1,250 units on October 29, 2019, 1,250 units onOctober 29, 2020 and 1,250 units on October 29, 2021. The closing price of the Company’s common stock on the date of grantwas $16.40 per share, which is the fair market value per unit of the RSUs.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        OnOctober 26, 2018, in accordance with a severance agreement with an employee, the Company’s Board of Directors approved theaccelerated vesting of 25% of the outstanding RSUs held by the employee. The RSUs, which originally vest on the third anniversaryof the grant date, or March 29, 2020, were accelerated to vest on October 26, 2018. As per ASC 718, on the date of the modificationthe Company reversed the previously accrued expense on the unvested RSUs of $63,278 and recognized the fair value of the modifiedgrant of $44,250 on the date of the modification.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Forthe year ended July 31, 2019, the Company recorded approximately $0.4 million in stock-based compensation related to RSUs, whichis reflected in the consolidated statements of operations. As of July 31, 2019, there were 77,956 RSU’s outstanding.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <i>         SharesIssued to Directors        </i>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        InApril 2020, the Company granted a director 12,500 shares of common stock under the 2011 Plan for services rendered. The sharesvested immediately and the closing price of the Company’s common stock on the date of grant was $1.55 per share. The Companyrecorded compensation expense relating to the share issuance of approximately $19,000 during the year ended July 31, 2020.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <i>         SharesIssued to Consultants        </i>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Duringthe year ended July 31, 2020, 184,499 shares of common stock valued at approximately $0.9 million, were issued to consultantsfor services. The common stock share values were based on the dates the shares were granted. The Company recorded compensationexpense relating to the share issuances of approximately $0.9 million, during the year ended July 31, 2020.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Duringthe year ended July 31, 2019, 60,300 shares of common stock valued at approximately $0.9 million were issued to consultants forservices. The common stock share values were based on the dates the shares were granted. The Company recorded compensation expenserelating to the share issuances of approximately $0.9 million during the year ended July 31, 2019.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <!-- Field: Page; Sequence: 90; Value: 13 -->      <div style="margin-bottom: 6pt; border-bottom: Black 1.5pt solid">       <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">        <tbody>         <tr style="vertical-align: top; text-align: left">          <td style="width: 33%">          </td>          <td style="text-align: center; width: 34%">           F-           <!-- Field: Sequence; Type: Arabic; Name: PageNo -->           25           <!-- Field: /Sequence -->          </td>          <td style="width: 33%">          </td>         </tr>        </tbody>       </table>      </div>      <div style="page-break-before: always; margin-top: 6pt">       <p style="margin: 0pt">       </p>      </div>      <!-- Field: /Page -->      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <i>        </i>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <i>         2015Employee Stock Purchase Plan        </i>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Underthe Company’s 2015 Employee Stock Purchase Plan (“ESPP”), the Company is authorized to issue 50,000 shares ofthe Company’s common stock. The sixth offering period under the ESPP ended on January 31, 2019, with 1,428 shares purchasedand distributed to employees, the seventh offering period under the ESPP ended on July 31, 2019, with 2,053 shares purchased anddistributed to employees, the eighth offering period under the ESPP ended on January 31, 2020, with 2,841 shares purchased anddistributed to employees, and the ninth offering period under the ESPP ended on July 31, 2020, with 1,358 shares purchased anddistributed to employees. At July 31, 2020, there were 33,409 shares remaining available for issuance under the ESPP.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        TheESPP is considered a Type B plan under FASB ASC Topic 718 because the number of shares a participant is permitted to purchaseis not fixed based on the stock price at the beginning of the offering period and the expected withholdings. The ESPP enablesthe participant to “buy-up” to the plan’s share limit, if the stock price is lower on the purchase date. Asa result, the fair value of the awards granted under the ESPP is calculated at the beginning of each offering period as the sumof:       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">       <tbody>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           ●          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           15%    of the share price of an unvested share at the beginning of the offering period,          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           ●          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           85%    of the fair market value of a six-month call on the unvested share aforementioned, and          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           ●          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           15%    of the fair market value of a six-month put on the unvested share aforementioned.          </font>         </td>        </tr>       </tbody>      </table>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Thefair market value of the six-month call and six-month put are based on the Black-Scholes option valuation model. For the six-monthoffering period ended January 31, 2020, the following assumptions were used: six-month maturity, 2.04% risk free interest, 90.64%volatility, 0% forfeitures and $0 dividends. For the six-month offering period ended July 31, 2020, the following assumptionswere used: six-month maturity, 1.54% risk free interest, 76.59% volatility, 0% forfeitures and $0 dividends.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Forthe six-month offering period ended January 31, 2019, the following assumptions were used: six-month maturity, 2.22% risk freeinterest, 61.83% volatility, 0% forfeitures and $0 dividends. For the six-month offering period ended July 31, 2019, the followingassumptions were used: six-month maturity, 2.46% risk free interest, 126.35% volatility, 0% forfeitures and $0 dividends.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Approximately$3,800 and $12,000 was recorded as stock-based compensation during the years ended July 31, 2020 and 2019, respectively.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <i>         CommonStock Reserved for Future Issuance        </i>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Thefollowing table summarizes all common stock reserved for future issuance at July 31, 2020:       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 75%; margin-left: 0.5in">       <tbody>        <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">         <td style="width: 80%; text-align: left">          <font style="font-family: Times New Roman, Times, Serif">           Common Stock options    outstanding (within the 2011 Plan and outside of the terms of the 2011 Plan)          </font>         </td>         <td style="width: 2%">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td style="width: 1%; text-align: left">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td style="width: 16%; text-align: right">          <font style="font-family: Times New Roman, Times, Serif">           1,442,856          </font>         </td>         <td style="width: 1%; text-align: left">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>        </tr>        <tr style="vertical-align: bottom; background-color: White">         <td style="text-align: justify">          <font style="font-family: Times New Roman, Times, Serif">           Common Stock reserved for restricted    stock unit release          </font>         </td>         <td>          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td style="text-align: left">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td style="text-align: right">          <font style="font-family: Times New Roman, Times, Serif">           34,914          </font>         </td>         <td style="text-align: left">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>        </tr>        <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">         <td style="text-align: justify">          <font style="font-family: Times New Roman, Times, Serif">           Common Stock authorized for future    grant under the 2011 Plan          </font>         </td>         <td>          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td style="text-align: left">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td style="text-align: right">          <font style="font-family: Times New Roman, Times, Serif">           1,616,901          </font>         </td>         <td style="text-align: left">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>        </tr>        <tr style="vertical-align: bottom; background-color: White">         <td style="text-align: justify">          <font style="font-family: Times New Roman, Times, Serif">           Common Stock reserved for warrant    exercise          </font>         </td>         <td>          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td style="text-align: left">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td style="text-align: right">          <font style="font-family: Times New Roman, Times, Serif">           3,114,288          </font>         </td>         <td style="text-align: left">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>        </tr>        <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">         <td style="text-align: justify; padding-bottom: 1.5pt">          <font style="font-family: Times New Roman, Times, Serif">           Commons Stock    reserved for future ESPP issuance          </font>         </td>         <td style="padding-bottom: 1.5pt">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td style="border-bottom: Black 1.5pt solid; text-align: left">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td style="border-bottom: Black 1.5pt solid; text-align: right">          <font style="font-family: Times New Roman, Times, Serif">           33,409          </font>         </td>         <td style="padding-bottom: 1.5pt; text-align: left">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>        </tr>        <tr style="vertical-align: bottom; background-color: White">         <td style="text-align: justify; padding-bottom: 2.5pt">          <font style="font-family: Times New Roman, Times, Serif">           Total common    stock reserved for future issuance          </font>         </td>         <td style="padding-bottom: 2.5pt">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td style="border-bottom: Black 2.5pt double; text-align: left">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td style="border-bottom: Black 2.5pt double; text-align: right">          <font style="font-family: Times New Roman, Times, Serif">           6,242,368          </font>         </td>         <td style="padding-bottom: 2.5pt; text-align: left">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>        </tr>       </tbody>      </table>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <b>         Note9—Income Taxes        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        TheFASB Topic on Income Taxes prescribes a recognition threshold and measurement attribute criteria for the financial statement recognitionand measurement of tax positions taken or expected to be taken in a tax return. For benefits to be recognized, a tax positionmust be more-likely-than-not to be sustained upon examination by taxing authorities. An uncertain income tax position will notbe recognized if it has less than a 50% likelihood of being sustained. The Company has had no unrecognized tax benefits.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <!-- Field: Page; Sequence: 91; Value: 13 -->      <div style="margin-bottom: 6pt; border-bottom: Black 1.5pt solid">       <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">        <tbody>         <tr style="vertical-align: top; text-align: left">          <td style="width: 33%">          </td>          <td style="text-align: center; width: 34%">           F-           <!-- Field: Sequence; Type: Arabic; Name: PageNo -->           26           <!-- Field: /Sequence -->          </td>          <td style="width: 33%">          </td>         </tr>        </tbody>       </table>      </div>      <div style="page-break-before: always; margin-top: 6pt">       <p style="margin: 0pt">       </p>      </div>      <!-- Field: /Page -->      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        TheCompany recognizes interest and/or penalties related to income tax matters in income tax expense. The Company has not recognizedany interest and/or penalties in the accompanying consolidated statements of operations for the year ended July 31, 2020 and 2019.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        TheCompany is subject to taxation in the United States, various states and in Australia. The Company’s tax years for 2007 andforward, 2010 and forward and 2017 and forward are subject to examination by the United States federal tax authorities, Californiatax authorities and New Jersey tax authorities, respectively, due to the carry forward of unutilized net operating losses andresearch and development credits.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        AtJuly 31, 2020, the Company had federal, New Jersey and California net operating loss carryforwards of approximately $170 million,$67 million and $87 million, respectively. In addition, the Company has federal, California and New Jersey research and developmenttax credit carryforwards of approximately $2.4 million, $2.0 million and $0.3 million, respectively. The Company also has CaliforniaHiring Credits of approximately $9,300.       </font>       <font style="font-family: Times New Roman, Times, Serif">        The federal net operatinglosses incurred in years beginning after January 1, 2018 in the amount of $67 million can be carried forward indefinitely. Theremaining $103 million of federal net operating loss, research tax credit carryforwards and New Jersey and California net operatingloss carryforwards will begin to expire in 2029 unless previously utilized. The California research and development credit carryforwardswill carry forward indefinitely until utilized. The Company has foreign net operating loss carryforwards in Australia of $1.0million.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        TheCompany has not completed a study to assess whether one or more ownership changes, as defined by IRC Section 382/383 of the InternalRevenue Code of 1986, as amended (the “Code”), have occurred since the Company’s formation, due to the complexityand cost associated with such a study, and the fact that there may be additional such ownership changes in the future. Based ona preliminary assessment, the Company believes that ownership changes have occurred. The Company estimates that if such an ownershipchange had occurred, the federal and state net operating loss carry-forwards and research and development tax credits that canbe utilized in the future will be significantly limited. The Company may never be able to realize the benefit of some or all ofthe federal and state net loss carryforwards or research and development tax credit carryforwards, either due to ongoing operatinglosses or due to ownership changes, which limits the usefulness of the loss carryforwards.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font: 10pt Times New Roman, Times, Serif">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif">        Setforth below is the (benefit) provision for income taxes for continuing operations for the years ended July,31:       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif">       </font>      </p>      <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 75%; font: 10pt Times New Roman, Times, Serif; margin-left: 0.5in">       <tbody>        <tr style="vertical-align: bottom">         <td style="padding-bottom: 1.5pt; font-size: 12pt">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="padding-bottom: 1.5pt; font-weight: bold">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           2020          </font>         </td>         <td style="padding-bottom: 1.5pt; font-weight: bold">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="padding-bottom: 1.5pt; font-weight: bold">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           2019          </font>         </td>         <td style="padding-bottom: 1.5pt; font-weight: bold">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">         <td>          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           Current:          </font>         </td>         <td style="font-size: 12pt">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font-size: 12pt; text-align: left">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           $          </font>         </td>         <td style="font-size: 12pt; text-align: right">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font-size: 12pt; text-align: left">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font-size: 12pt">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font-size: 12pt; text-align: left">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           $          </font>         </td>         <td style="font-size: 12pt; text-align: right">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font-size: 12pt; text-align: left">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="vertical-align: bottom; background-color: White">         <td style="padding-left: 10pt">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           Federal          </font>         </td>         <td>          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="text-align: left">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="text-align: right">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           -          </font>         </td>         <td style="text-align: left">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td>          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="text-align: left">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="text-align: right">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           -          </font>         </td>         <td style="text-align: left">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">         <td style="padding-left: 10pt; width: 60%">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           State          </font>         </td>         <td style="width: 2%">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="width: 1%; text-align: left">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="width: 16%; text-align: right">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           (872,000          </font>         </td>         <td style="width: 1%; text-align: left">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           )          </font>         </td>         <td style="width: 2%">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="width: 1%; text-align: left">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="width: 16%; text-align: right">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           1,300          </font>         </td>         <td style="width: 1%; text-align: left">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="vertical-align: bottom; background-color: White">         <td style="padding-bottom: 1.5pt; padding-left: 10pt">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           Foreign          </font>         </td>         <td style="padding-bottom: 1.5pt">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="border-bottom: Black 1.5pt solid; text-align: left">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="border-bottom: Black 1.5pt solid; text-align: right">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           -          </font>         </td>         <td style="padding-bottom: 1.5pt; text-align: left">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="padding-bottom: 1.5pt">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="border-bottom: Black 1.5pt solid; text-align: left">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="border-bottom: Black 1.5pt solid; text-align: right">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           -          </font>         </td>         <td style="padding-bottom: 1.5pt; text-align: left">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">         <td style="padding-bottom: 2.5pt; text-align: left">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           Total    (benefit from) provision for income taxes          </font>         </td>         <td style="padding-bottom: 2.5pt">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="border-bottom: Black 2.5pt double; text-align: left">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           $          </font>         </td>         <td style="border-bottom: Black 2.5pt double; text-align: right">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           (872,000          </font>         </td>         <td style="padding-bottom: 2.5pt; text-align: left">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           )          </font>         </td>         <td style="padding-bottom: 2.5pt">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="border-bottom: Black 2.5pt double; text-align: left">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           $          </font>         </td>         <td style="border-bottom: Black 2.5pt double; text-align: right">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           1,300          </font>         </td>         <td style="padding-bottom: 2.5pt; text-align: left">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>        </tr>       </tbody>      </table>      <p style="font: 12pt Times New Roman, Times, Serif; margin: 0">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Significantcomponents of the Company’s deferred tax assets as of July 31, 2020 and 2019 are listed below:       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 75%; font: 10pt Times New Roman, Times, Serif; margin-left: 0.5in">       <tbody>        <tr style="vertical-align: bottom">         <td style="text-align: center">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td style="font-weight: bold; padding-bottom: 1.5pt">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">          <font style="font-family: Times New Roman, Times, Serif">           2020          </font>         </td>         <td style="padding-bottom: 1.5pt; font-weight: bold">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td style="font-weight: bold; padding-bottom: 1.5pt">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">          <font style="font-family: Times New Roman, Times, Serif">           2019          </font>         </td>         <td style="padding-bottom: 1.5pt; font-weight: bold">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>        </tr>        <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">         <td style="width: 60%; text-align: left">          <font style="font-family: Times New Roman, Times, Serif">           Net operating loss carryforwards          </font>         </td>         <td style="width: 2%">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td style="width: 1%; text-align: left">          <font style="font-family: Times New Roman, Times, Serif">           $          </font>         </td>         <td style="width: 16%; text-align: right">          <font style="font-family: Times New Roman, Times, Serif">           46,623,000          </font>         </td>         <td style="width: 1%; text-align: left">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td style="width: 2%">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td style="width: 1%; text-align: left">          <font style="font-family: Times New Roman, Times, Serif">           $          </font>         </td>         <td style="width: 16%; text-align: right">          <font style="font-family: Times New Roman, Times, Serif">           35,361,000          </font>         </td>         <td style="width: 1%; text-align: left">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>        </tr>        <tr style="vertical-align: bottom; background-color: White">         <td>          <font style="font-family: Times New Roman, Times, Serif">           Credits          </font>         </td>         <td>          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td style="text-align: left">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td style="text-align: right">          <font style="font-family: Times New Roman, Times, Serif">           4,311,000          </font>         </td>         <td style="text-align: left">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td>          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td style="text-align: left">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td style="text-align: right">          <font style="font-family: Times New Roman, Times, Serif">           3,257,000          </font>         </td>         <td style="text-align: left">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>        </tr>        <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">         <td style="text-align: left">          <font style="font-family: Times New Roman, Times, Serif">           Start-up costs          </font>         </td>         <td>          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td style="text-align: left">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td style="text-align: right">          <font style="font-family: Times New Roman, Times, Serif">           21,000          </font>         </td>         <td style="text-align: left">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td>          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td style="text-align: left">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td style="text-align: right">          <font style="font-family: Times New Roman, Times, Serif">           23,000          </font>         </td>         <td style="text-align: left">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>        </tr>        <tr style="vertical-align: bottom; background-color: White">         <td style="text-align: left">          <font style="font-family: Times New Roman, Times, Serif">           Accumulated depreciation          </font>         </td>         <td>          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td style="text-align: left">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td style="text-align: right">          <font style="font-family: Times New Roman, Times, Serif">           98,000          </font>         </td>         <td style="text-align: left">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td>          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td style="text-align: left">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td style="text-align: right">          <font style="font-family: Times New Roman, Times, Serif">           122,000          </font>         </td>         <td style="text-align: left">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>        </tr>        <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">         <td style="text-align: left">          <font style="font-family: Times New Roman, Times, Serif">           Option and stock awards          </font>         </td>         <td>          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td style="text-align: left">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td style="text-align: right">          <font style="font-family: Times New Roman, Times, Serif">           386,000          </font>         </td>         <td style="text-align: left">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td>          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td style="text-align: left">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td style="text-align: right">          <font style="font-family: Times New Roman, Times, Serif">           4,825,000          </font>         </td>         <td style="text-align: left">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>        </tr>        <tr style="vertical-align: bottom; background-color: White">         <td style="padding-bottom: 1.5pt">          <font style="font-family: Times New Roman, Times, Serif">           Other          </font>         </td>         <td style="padding-bottom: 1.5pt">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td style="border-bottom: Black 1.5pt solid; text-align: left">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td style="border-bottom: Black 1.5pt solid; text-align: right">          <font style="font-family: Times New Roman, Times, Serif">           122,000          </font>         </td>         <td style="padding-bottom: 1.5pt; text-align: left">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td style="padding-bottom: 1.5pt">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td style="border-bottom: Black 1.5pt solid; text-align: left">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td style="border-bottom: Black 1.5pt solid; text-align: right">          <font style="font-family: Times New Roman, Times, Serif">           241,000          </font>         </td>         <td style="padding-bottom: 1.5pt; text-align: left">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>        </tr>        <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">         <td style="text-align: left">          <font style="font-family: Times New Roman, Times, Serif">           Net deferred tax assets          </font>         </td>         <td>          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td style="text-align: left">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td style="text-align: right">          <font style="font-family: Times New Roman, Times, Serif">           51,561,000          </font>         </td>         <td style="text-align: left">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td>          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td style="text-align: left">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td style="text-align: right">          <font style="font-family: Times New Roman, Times, Serif">           43,829,000          </font>         </td>         <td style="text-align: left">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>        </tr>        <tr style="vertical-align: bottom; background-color: White">         <td style="text-align: left; padding-bottom: 1.5pt">          <font style="font-family: Times New Roman, Times, Serif">           Valuation allowance    for deferred tax assets          </font>         </td>         <td style="padding-bottom: 1.5pt">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td style="border-bottom: Black 1.5pt solid; text-align: left">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td style="border-bottom: Black 1.5pt solid; text-align: right">          <font style="font-family: Times New Roman, Times, Serif">           (51,561,000          </font>         </td>         <td style="padding-bottom: 1.5pt; text-align: left">          <font style="font-family: Times New Roman, Times, Serif">           )          </font>         </td>         <td style="padding-bottom: 1.5pt">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td style="border-bottom: Black 1.5pt solid; text-align: left">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td style="border-bottom: Black 1.5pt solid; text-align: right">          <font style="font-family: Times New Roman, Times, Serif">           (43,829,000          </font>         </td>         <td style="padding-bottom: 1.5pt; text-align: left">          <font style="font-family: Times New Roman, Times, Serif">           )          </font>         </td>        </tr>        <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">         <td style="text-align: left; padding-bottom: 2.5pt">          <font style="font-family: Times New Roman, Times, Serif">           Net deferred    taxes          </font>         </td>         <td style="padding-bottom: 2.5pt">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td style="border-bottom: Black 2.5pt double; text-align: left">          <font style="font-family: Times New Roman, Times, Serif">           $          </font>         </td>         <td style="border-bottom: Black 2.5pt double; text-align: right">          <font style="font-family: Times New Roman, Times, Serif">           -          </font>         </td>         <td style="padding-bottom: 2.5pt; text-align: left">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td style="padding-bottom: 2.5pt">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td style="border-bottom: Black 2.5pt double; text-align: left">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td style="border-bottom: Black 2.5pt double; text-align: right">          <font style="font-family: Times New Roman, Times, Serif">           -          </font>         </td>         <td style="padding-bottom: 2.5pt; text-align: left">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>        </tr>       </tbody>      </table>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Avaluation allowance of $51.6 million and $43.8 million at July 31, 2020 and 2019, respectively, has been recognized to offsetthe net deferred tax assets as realization of such assets is uncertain. The valuation allowance increased by $7.8 millionand increased by $6.6 million for the years ended July 31, 2020 and 2019, respectively.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Areconciliation of income taxes using the statutory income tax rate, compared to the effective rate, is as follows:       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 75%; margin-left: 0.5in">       <tbody>        <tr style="vertical-align: bottom">         <td>          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td style="font-weight: bold; padding-bottom: 1.5pt">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">          <font style="font-family: Times New Roman, Times, Serif">           2020          </font>         </td>         <td style="padding-bottom: 1.5pt; font-weight: bold">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td style="font-weight: bold; padding-bottom: 1.5pt">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">          <font style="font-family: Times New Roman, Times, Serif">           2019          </font>         </td>         <td style="padding-bottom: 1.5pt; font-weight: bold">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>        </tr>        <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">         <td style="width: 60%; text-align: left">          <font style="font-family: Times New Roman, Times, Serif">           Federal tax benefit at the    expected statutory rate          </font>         </td>         <td style="width: 2%">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td style="width: 1%; text-align: left">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td style="width: 16%; text-align: right">          <font style="font-family: Times New Roman, Times, Serif">           21.00          </font>         </td>         <td style="width: 1%; text-align: left">          <font style="font-family: Times New Roman, Times, Serif">           %          </font>         </td>         <td style="width: 2%">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td style="width: 1%; text-align: left">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td style="width: 16%; text-align: right">          <font style="font-family: Times New Roman, Times, Serif">           21.00          </font>         </td>         <td style="width: 1%; text-align: left">          <font style="font-family: Times New Roman, Times, Serif">           %          </font>         </td>        </tr>        <tr style="vertical-align: bottom; background-color: White">         <td style="text-align: left">          <font style="font-family: Times New Roman, Times, Serif">           State income tax, net of federal tax    benefit          </font>         </td>         <td>          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td style="text-align: left">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td style="text-align: right">          <font style="font-family: Times New Roman, Times, Serif">           1.60          </font>         </td>         <td style="text-align: left">          <font style="font-family: Times New Roman, Times, Serif">           %          </font>         </td>         <td>          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td style="text-align: left">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td style="text-align: right">          <font style="font-family: Times New Roman, Times, Serif">           (0.01          </font>         </td>         <td style="text-align: left">          <font style="font-family: Times New Roman, Times, Serif">           )%          </font>         </td>        </tr>        <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">         <td style="text-align: left">          <font style="font-family: Times New Roman, Times, Serif">           Non-deductible expenses          </font>         </td>         <td>          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td style="text-align: left">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td style="text-align: right">          <font style="font-family: Times New Roman, Times, Serif">           (0.76          </font>         </td>         <td style="text-align: left">          <font style="font-family: Times New Roman, Times, Serif">           )%          </font>         </td>         <td>          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td style="text-align: left">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td style="text-align: right">          <font style="font-family: Times New Roman, Times, Serif">           (0.46          </font>         </td>         <td style="text-align: left">          <font style="font-family: Times New Roman, Times, Serif">           )%          </font>         </td>        </tr>        <tr style="vertical-align: bottom; background-color: White">         <td style="text-align: left">          <p style="margin: 0; font: 10pt Times New Roman, Times, Serif">           <font style="font-family: Times New Roman, Times, Serif">            Tax                                 impact of stock option cancellations           </font>          </p>         </td>         <td>          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td style="text-align: left">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td style="text-align: right">          <p style="margin: 0; font: 10pt Times New Roman, Times, Serif">           <font style="font-family: Times New Roman, Times, Serif">            (10.04           </font>          </p>         </td>         <td style="text-align: left">          <font style="font-family: Times New Roman, Times, Serif">           )          </font>          %         </td>         <td>          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td style="text-align: left">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td style="text-align: right">          <font style="font-family: Times New Roman, Times, Serif">           -          </font>         </td>         <td style="text-align: left">          <font style="font-family: Times New Roman, Times, Serif">           %          </font>         </td>        </tr>        <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">         <td style="text-align: left">          <font style="font-family: Times New Roman, Times, Serif">           Change in valuation allowance          </font>         </td>         <td>          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td style="text-align: left">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td style="text-align: right">          <font style="font-family: Times New Roman, Times, Serif">           (11.46          </font>         </td>         <td style="text-align: left">          <font style="font-family: Times New Roman, Times, Serif">           )%          </font>         </td>         <td>          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td style="text-align: left">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td style="text-align: right">          <font style="font-family: Times New Roman, Times, Serif">           (21.32          </font>         </td>         <td style="text-align: left">          <font style="font-family: Times New Roman, Times, Serif">           )%          </font>         </td>        </tr>        <tr style="vertical-align: bottom; background-color: White">         <td style="padding-bottom: 1.5pt">          <font style="font-family: Times New Roman, Times, Serif">           Other          </font>         </td>         <td style="padding-bottom: 1.5pt">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td style="border-bottom: Black 1.5pt solid; text-align: left">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td style="border-bottom: Black 1.5pt solid; text-align: right">          <font style="font-family: Times New Roman, Times, Serif">           1.68          </font>         </td>         <td style="padding-bottom: 1.5pt; text-align: left">          <font style="font-family: Times New Roman, Times, Serif">           %          </font>         </td>         <td style="padding-bottom: 1.5pt">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td style="border-bottom: Black 1.5pt solid; text-align: left">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td style="border-bottom: Black 1.5pt solid; text-align: right">          <font style="font-family: Times New Roman, Times, Serif">           0.79          </font>         </td>         <td style="padding-bottom: 1.5pt; text-align: left">          <font style="font-family: Times New Roman, Times, Serif">           %          </font>         </td>        </tr>        <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">         <td style="text-align: left; padding-bottom: 2.5pt">          <font style="font-family: Times New Roman, Times, Serif">           Income tax benefit    - effective rate          </font>         </td>         <td style="padding-bottom: 2.5pt">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td style="border-bottom: Black 2.5pt double; text-align: left">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td style="border-bottom: Black 2.5pt double; text-align: right">          <font style="font-family: Times New Roman, Times, Serif">           2.02          </font>         </td>         <td style="padding-bottom: 2.5pt; text-align: left">          <font style="font-family: Times New Roman, Times, Serif">           %          </font>         </td>         <td style="padding-bottom: 2.5pt">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td style="border-bottom: Black 2.5pt double; text-align: left">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td style="border-bottom: Black 2.5pt double; text-align: right">          <font style="font-family: Times New Roman, Times, Serif">           (0.00          </font>         </td>         <td style="padding-bottom: 2.5pt; text-align: left">          <font style="font-family: Times New Roman, Times, Serif">           )%          </font>         </td>        </tr>       </tbody>      </table>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <!-- Field: Page; Sequence: 92; Value: 13 -->      <div style="margin-bottom: 6pt; border-bottom: Black 1.5pt solid">       <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">        <tbody>         <tr style="vertical-align: top; text-align: left">          <td style="width: 33%">          </td>          <td style="text-align: center; width: 34%">           F-           <!-- Field: Sequence; Type: Arabic; Name: PageNo -->           27           <!-- Field: /Sequence -->          </td>          <td style="width: 33%">          </td>         </tr>        </tbody>       </table>      </div>      <div style="page-break-before: always; margin-top: 6pt">       <p style="margin: 0pt">       </p>      </div>      <!-- Field: /Page -->      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <i>        </i>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <i>         Saleof New Jersey Net Operating Losses        </i>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <b>        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        InMay 2020, the Company received $0.9 million in net proceeds from the sale of its New Jersey Net Operating Losses under the Stateof New Jersey NOL Transfer Program.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <b>        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <b>         Note10—Commitments and Contingencies        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <i>         Contingencies        </i>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        OnOctober 29, 2019, the Company’s stockholder, Alpha Holdings, Inc. (“Alpha”) filed two civil actions in the districtcourt, Clark County, Nevada (the “District Court”), related to the proposed equity investment in the Company (the“Proposed Transaction”) by (i) Grand Decade Developments Limited (“Grand Decade”), a British Virgin Islandslimited company and a wholly-owned subsidiary of China Grand Pharmaceutical and Healthcare Holdings Limited (“CGP”)and (ii) Sirtex Medical US Holdings, Inc., an affiliate of CGP (“Sirtex”). The first action, asserted against theCompany only, sought to compel the Company to make its books and records available for inspection, so that Alpha could solicitproxies from other stockholders in connection with the vote to approve the Proposed Transaction. The second action, a putativeclass action asserted against the Company, certain directors on the OncoSec Board (the “Director Defendants”), Sirtexand Grand Decade, sought, among other things, a preliminary injunction to enjoin the Proposed Transaction and a special meetingof OncoSec’s shareholders seeking approval of the Proposed Transaction, based on claims that the Director Defendants breachedtheir fiduciary duties by (i) failing to make complete and accurate disclosures concerning the Proposed Transaction, (ii) adoptingimproper defensive measures to preclude the Company from pursuing or receiving alternatives to the Proposed Transaction, and (iii)running an inadequate “sales process” that failed to obtain the highest value reasonably available. This second actionalso asserted a claim against Sirtex and CGP for aiding and abetting the Director Defendants’ alleged breaches of fiduciaryduties. On November 13, 2019, the two actions were consolidated into a single proceeding, when the court so-ordered a joint stipulationfiled by the parties. On February 6, 2020, the District Court judge denied Alpha’s motion for preliminary injunction inits entirety and allowed the special meeting of shareholders to take place on February 7, 2020. The Nevada Supreme Court thendenied Alpha’s request for an emergency appeal. Alpha subsequently filed a stipulation dismissing the action with prejudice,which the District Court entered on March 5, 2020. Since Alpha’s cases were dismissed with prejudice, they cannot be relitigatedand the Company has no liability to Alpha with matters addressed in these lawsuits.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        The Company is not a party to any other legal proceeding or aware of any other threatened action as of the date of thisannual report.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <i>         EmploymentAgreements        </i>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        TheCompany has entered into employment agreements with certain executive officers and certain other key employees. Generally, theterms of these agreements provide that, if the Company terminates the officer or employee other than for cause, death or disability,or if the officer terminates his or her employment with the Company for good cause, the officer shall be entitled to receive certainseverance compensation and benefits as described in each such agreement.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        OnJuly 16, 2018, the Company and the Company’s former Chief Financial Officer entered into a separation and release agreementin connection with the former CFO’s termination of employment with the Company. Pursuant to the agreement, the Company willpay the former CFO severance compensation of $300,000, less applicable withholdings, in the form of salary continuation in accordancewith the Company’s customary payroll practices. On July 16, 2018, the Company recorded a liability of $300,000 on its consolidatedbalance sheet, and the offsetting charge was recorded in general and administrative expense as salary expense. As of July 31,2019, the Company accrued a liability under the agreement of $9,364 and as of July 31, 2020 the liability was paid in full.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <!-- Field: Page; Sequence: 93; Value: 13 -->      <div style="margin-bottom: 6pt; border-bottom: Black 1.5pt solid">       <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">        <tbody>         <tr style="vertical-align: top; text-align: left">          <td style="width: 33%">          </td>          <td style="text-align: center; width: 34%">           F-           <!-- Field: Sequence; Type: Arabic; Name: PageNo -->           28           <!-- Field: /Sequence -->          </td>          <td style="width: 33%">          </td>         </tr>        </tbody>       </table>      </div>      <div style="page-break-before: always; margin-top: 6pt">       <p style="margin: 0pt">       </p>      </div>      <!-- Field: /Page -->      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        OnOctober 26, 2018, the Company and an employee entered into a separation and release agreement in connection with the employee’stermination of employment with the Company. Pursuant to the agreement, the Company will pay the former employee severance compensationof $415,000, less applicable withholdings, in the form of salary and bonus continuation in accordance with the Company’scustomary payroll practices. In addition, the Company agreed to pay the cost of health insurance for 12 months from the date ofseparation and accelerate the vesting of 2,500 RSUs. On October 26, 2018, the Company recorded a liability of $451,112 on itsconsolidated balance sheet, and the offsetting charge was recorded in research and development expense as salary expense. As ofJuly 31, 2019, the Company accrued a liability under the agreement of $117,271 and as of July 31, 2020 the liability was paidin full.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <i>         CGPand Sirtex        </i>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <u>         LicenseAgreement and Services Agreement        </u>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Concurrentlywith the execution and delivery of the Purchase Agreements, the Company and CGP entered into a License Agreement (the “LicenseAgreement”), which became effective upon the Closing. Pursuant to the License Agreement, the Company, among other things,granted CGP and its affiliates an exclusive, sublicensable, royalty-bearing license to develop, manufacture, commercialize, orotherwise exploit the Company’s current and future products, including TAVO and the VLA in the following territories: ChinaMainland, Hong Kong, Macau, Taiwan, Armenia, Azerbaijan, Bahrain, Bangladesh, Bhutan, Brunei, Burma, Cambodia, East Timor, Georgia,India, Indonesia, Jordan, Kazakhstan, Kuwait, Kyrgyzstan, Laos, Malaysia, Mongolia, Nepal, Oman, Pakistan, Papua New Guinea, Philippines,Qatar, Saudi Arabia, Singapore, South Korea, Sri Lanka, Tajikistan, Thailand, Turkmenistan, United Arab Emirates, Uzbekistan andVietnam (the “Territory”). Under the terms of the License Agreement, CGP will pay the Company up to 20% royaltieson the net sales (as defined in the License Agreement) of such products in the Territory during the applicable Royalty Term (asdefined in the License Agreement) (such royalties, the “Royalties’).       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Duringthe Royalty Term for a Licensed Product and a Region in the Territory, under no circumstances will the Royalties payable to Licensorhereunder in respect of such Licensed Product and such Region for a calendar half be less than ten percent (10%) of Net Salesof such Licensed Product for such Region for such calendar half, provided that such percentage shall be pro-rated if such RoyaltyTerm ends in such calendar half.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Ifeither party believes that the other party has materially breached one or more of its material obligations under the License Agreement,then the non-breaching party may, following a cure period, terminate the License Agreement upon written notice to the breachingparty, subject to other conditions. Licensee may terminate the License Agreement in its entirety for any reason or no reason uponprior written notice to Licensor. Additionally, the License Agreement may be terminated upon certain events involving bankruptcyor insolvency. If CGP terminates the License Agreement for convenience or the Company terminates the License Agreement due toCGP’s breach or insolvency, then, subject to certain conditions, each party’s rights and licenses will terminate,and CGP will have certain obligations to assign to the Company, or grant a right of reference under, certain regulatory documentationor approvals. If CGP terminates the License Agreement due to the Company’s breach or insolvency, then CGP will have theoption either to keep the License Agreement in effect with the royalty rate owed by CGP to the Company reduced by 50% or to terminatethe License Agreement (in which case each party’s rights and licenses will terminate, except that CGP will have the rightto wind down certain clinical trials).       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Inaddition, the Company and Sirtex entered into a Services Agreement (the “Services Agreement”) which became effectiveupon the Closing. Pursuant to the Services Agreement, the Company agreed, among other things, to pay Sirtex low single-digit royaltieson the Net Sales (as defined in the Services Agreement) of all Products (defined as TAVO and VLA products and their accompanyinggenerators, and any products (including, for clarity, combination products) incorporating or including such products and theiraccompanying generators), in all countries other than those in the Territory. In exchange for the royalty fee, Sirtex will providethe Company with certain services for these products, including key opinion leader management and engagement services, voice ofcustomer (VOC) services, development of a go to market strategy, and pricing, reimbursement and market access services.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <!-- Field: Page; Sequence: 94; Value: 13 -->      <div style="margin-bottom: 6pt; border-bottom: Black 1.5pt solid">       <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">        <tbody>         <tr style="vertical-align: top; text-align: left">          <td style="width: 33%">          </td>          <td style="text-align: center; width: 34%">           F-           <!-- Field: Sequence; Type: Arabic; Name: PageNo -->           29           <!-- Field: /Sequence -->          </td>          <td style="width: 33%">          </td>         </tr>        </tbody>       </table>      </div>      <div style="page-break-before: always; margin-top: 6pt">       <p style="margin: 0pt">       </p>      </div>      <!-- Field: /Page -->      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Ifeither party believes that the other party has materially breached one or more of its material obligations under the ServicesAgreement, then the non-breaching party may, following a cure period, terminate the Services Agreement upon written notice tothe breaching party, subject to other conditions. Sirtex may terminate the Services Agreement in its entirety for any reason orno reason upon prior written notice to the Company. Additionally, the Services Agreement may be terminated upon certain eventsinvolving bankruptcy or insolvency.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <u>         RegistrationRights Agreements        </u>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Onthe date of the Closing, the Company, CGP, and Sirtex entered into Registration Rights Agreements (the “Registration RightsAgreements”), pursuant to which, among other things, CGP and Sirtex will each have the right to deliver to the Company awritten notice requiring the Company to prepare and file with the SEC, a registration statement with respect to resales of sharesof some or all the common stock of the Company held by CGP and Sirtex. The Registration Rights Agreements do not provide for anycash penalties or additional penalties associated with any delays in registering the securities.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <b>         Note11 – Leases        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <b>        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        InFebruary 2016, the FASB issued ASU 2016-02, which supersedes previous lease accounting guidance (Topic 840) and establishes aright-of-use model that requires a lessee to record an asset and liability on the balance sheet for all leases with terms longerthan 12 months. The Company does not have any material variable payments, residual value guarantees or restrictive covenants forits leases and does not have any leases with terms of 12 months or less.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        OnAugust 1, 2019, upon adoption of ASC Topic 842, the Company recorded right-of-use assets of approximately $1.4 million, leaseliabilities of approximately $2.1 million and a reduction in deferred rent liabilities of $0.6 million for operating leases. Also,the adoption of ASC 842 did not have an impact on the Company’s beginning accumulated deficit balance.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <i>         LeaseAgreements        </i>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        OnFebruary 14, 2018, the Company entered into a lease agreement with MawIt Inc., for approximately 3,100 rentable square feet locatedat 24 N. Main Street, Pennington, New Jersey, which serves as the Company’s New Jersey corporate headquarters. The termof the lease commenced on March 1, 2018 and was to expire on April 30, 2020. In November 2018, the Company entered into an amendedlease agreement for the addition of approximately 2,800 rentable square feet. The term of the amended lease commenced on January15, 2019 and expires on December 31, 2020. Base rent under the amended lease agreement is $11,686 per month for each of the firsttwo months, $11,929 per month for each of the third through fifteenth months and $12,173 per month for each of the sixteenth throughtwenty-three months. The Company prepaid rent of approximately $60,000 as per the terms of the amended agreement. The lease agreementalso requires the Company to share in certain monthly operating expenses of the premises and required the Company to pay a securitydeposit of $23,372.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        InMarch 2018, the Company entered into a Lease Assignment Agreement (the “Lease Assignment Agreement”) with VividionTherapeutics, Inc. (“Vividion”) for the Company’s 34,054 square foot location at 5820 Nancy Ridge Drive, SanDiego, California, 92121 (“NR Premises”), whereby the Company assigned its Lease Agreement with ARE-SD Region No.18, LLC (the “Landlord”) to Vividion. Under the Lease Assignment Agreement, Vividion pays directly to Landlord thebase rent of $101,500 per month (based upon $2.98 per rentable square foot of the NR Premises) plus operating expenses and propertymanagement fees attributable to the NR Premises currently estimated at $46,500 per month (including an estimate for utilities)during the term of the Lease Assignment Agreement, which was the remaining term of the lease through October 2025.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Whilethe lease and all of the related obligations were assigned to Vividion, prior to November 2019 the Company could ultimately havean obligation on the Lease Assignment Agreement if Vividion defaulted on their obligation to the Landlord after all remedies wereexhausted by the Landlord with regard to Vividion’s obligations. Such an event was not considered probable and no obligationwas recorded as of July 31, 2019. In connection with the Company entering into a new lease in November 2019 (See below), the landlordreleased the Company from any obligations and liabilities arising under the Lease Assignment Agreement.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <!-- Field: Page; Sequence: 95; Value: 13 -->      <div style="margin-bottom: 6pt; border-bottom: Black 1.5pt solid">       <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">        <tbody>         <tr style="vertical-align: top; text-align: left">          <td style="width: 33%">          </td>          <td style="text-align: center; width: 34%">           F-           <!-- Field: Sequence; Type: Arabic; Name: PageNo -->           30           <!-- Field: /Sequence -->          </td>          <td style="width: 33%">          </td>         </tr>        </tbody>       </table>      </div>      <div style="page-break-before: always; margin-top: 6pt">       <p style="margin: 0pt">       </p>      </div>      <!-- Field: /Page -->      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Inconjunction with the Lease Assignment Agreement, the Company and Vividion also entered into a sublease (the “Sublease”),with respect to the 12,442 square-foot location at 3565 General Atomics Court, Suite 100, San Diego, CA, 92121 leased by Vividionfrom Landlord which serves as the Company’s California office (the “Sublease Premise”). Under the Sublease,the Company shall pay to Vividion base rent of $49,768 per month subject to an annual 3% increase, (based upon $4.00 per rentablesquare foot of the Sublease Premises) plus operating expenses and property management fees attributable to the Sublease Premisescurrently estimated at $30,400 per month during the term of the Sublease, which extends through September 2020. The Company movedto the new location in April 2018.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Atthe time of the lease agreements noted above, the Company had a deferred rent liability recorded on the consolidated balance sheetof $1.1 million, of which $0.6 million is remaining as of July 31, 2019. The deferred rent liability associated with the lease/subleasewas reduced to $0 on August 1, 2019 upon adoption of ASC Topic 842.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        InNovember 2019, the Company entered into a lease agreement for its office space in California directly with the landlord, ARE-SDRegion No. 18, LLC (“ARE”), with an effective date being the earlier of: (a) October 1, 2020 or (b) the day afterthe termination of the Company’s existing sublease if it ends prior to September 30, 2020. The lease is for a term of 36months, with one renewal option for an additional 36-month term. The minimum monthly payment is $55,989. The Company accountedfor the ARE lease as a contract modification, and accordingly, recorded an additional right-of-use asset for approximately $5.3million and lease liabilities of approximately $5.2 million for this operating lease.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        TheCompany has operating leases for corporate offices and lab space. These leases have remaining lease terms of approximately oneyear to seven years, some of which include options to extend the lease. For any lease where the Company is reasonably certainthat a renewal option will be exercised, the lease payments associated with the renewal option period are included in the ROUasset and lease liability as of July 31, 2020.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Supplementalbalance sheet information related to leases as of July 31, 2020 was as follows:       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">       <tbody>        <tr style="vertical-align: bottom; background-color: White">         <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">          <font style="font-family: Times New Roman, Times, Serif">           Operating    Leases:          </font>         </td>         <td>          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td style="text-align: left">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td style="text-align: right">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td style="text-align: left">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>        </tr>        <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">         <td style="width: 80%; text-align: left; padding-bottom: 2.5pt">          <font style="font-family: Times New Roman, Times, Serif">           Operating    lease right-of-use assets          </font>         </td>         <td style="width: 2%; padding-bottom: 2.5pt">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td style="width: 1%; border-bottom: Black 2.5pt double; text-align: left">          <font style="font-family: Times New Roman, Times, Serif">           $          </font>         </td>         <td style="width: 16%; border-bottom: Black 2.5pt double; text-align: right">          <font style="font-family: Times New Roman, Times, Serif">           5,948,224          </font>         </td>         <td style="width: 1%; padding-bottom: 2.5pt; text-align: left">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>        </tr>        <tr style="vertical-align: bottom; background-color: White">         <td style="font-weight: bold; text-align: left">          <font style="font-family: Times New Roman, Times, Serif">           Operating Leases:          </font>         </td>         <td>          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td style="text-align: left">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td style="text-align: right">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td style="text-align: left">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>        </tr>        <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">         <td style="text-align: left">          <font style="font-family: Times New Roman, Times, Serif">           Current portion included in current    liabilities          </font>         </td>         <td>          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td style="text-align: left">          <font style="font-family: Times New Roman, Times, Serif">           $          </font>         </td>         <td style="text-align: right">          <font style="font-family: Times New Roman, Times, Serif">           500,357          </font>         </td>         <td style="text-align: left">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>        </tr>        <tr style="vertical-align: bottom; background-color: White">         <td style="text-align: left; padding-bottom: 1.5pt">          <font style="font-family: Times New Roman, Times, Serif">           Long-term portion    included in non-current liabilities          </font>         </td>         <td style="padding-bottom: 1.5pt">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td style="border-bottom: Black 1.5pt solid; text-align: left">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td style="border-bottom: Black 1.5pt solid; text-align: right">          <font style="font-family: Times New Roman, Times, Serif">           5,874,442          </font>         </td>         <td style="padding-bottom: 1.5pt; text-align: left">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>        </tr>        <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">         <td style="text-align: left; padding-bottom: 2.5pt; padding-left: 10pt">          <font style="font-family: Times New Roman, Times, Serif">           Total    operating lease liabilities          </font>         </td>         <td style="padding-bottom: 2.5pt">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td style="border-bottom: Black 2.5pt double; text-align: left">          <font style="font-family: Times New Roman, Times, Serif">           $          </font>         </td>         <td style="border-bottom: Black 2.5pt double; text-align: right">          <font style="font-family: Times New Roman, Times, Serif">           6,374,799          </font>         </td>         <td style="padding-bottom: 2.5pt; text-align: left">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>        </tr>       </tbody>      </table>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Supplementallease expense related to leases was as follows:       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">       <tbody>        <tr style="vertical-align: bottom">         <td style="text-align: justify">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td style="padding-bottom: 1.5pt">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">          <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            <b>             For                                         the Year            </b>           </font>          </p>          <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            <b>             Ended            </b>           </font>          </p>          <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            <b>             July                                         31, 2020            </b>           </font>          </p>         </td>         <td style="padding-bottom: 1.5pt">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>        </tr>        <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">         <td style="width: 80%; text-align: justify; padding-bottom: 1.5pt">          <font style="font-family: Times New Roman, Times, Serif">           Operating    lease cost          </font>         </td>         <td style="width: 2%; padding-bottom: 1.5pt">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left">          <font style="font-family: Times New Roman, Times, Serif">           $          </font>         </td>         <td style="width: 16%; border-bottom: Black 1.5pt solid; text-align: right">          <font style="font-family: Times New Roman, Times, Serif">           1,273,616          </font>         </td>         <td style="width: 1%; padding-bottom: 1.5pt; text-align: left">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>        </tr>        <tr style="vertical-align: bottom; background-color: White">         <td style="padding-left: 10pt; text-align: justify; padding-bottom: 2.5pt">          <font style="font-family: Times New Roman, Times, Serif">           Total    lease expense          </font>         </td>         <td style="padding-bottom: 2.5pt">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td style="border-bottom: Black 2.5pt double; text-align: left">          <font style="font-family: Times New Roman, Times, Serif">           $          </font>         </td>         <td style="border-bottom: Black 2.5pt double; text-align: right">          <font style="font-family: Times New Roman, Times, Serif">           1,273,616          </font>         </td>         <td style="padding-bottom: 2.5pt; text-align: left">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>        </tr>       </tbody>      </table>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Otherinformation related to leases where the Company is the lessee is as follows:       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">       <tbody>        <tr style="vertical-align: bottom">         <td style="text-align: justify">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td style="padding-bottom: 1.5pt">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">          <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            <b>             As                                         of            </b>           </font>          </p>          <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            <b>             July                                         31, 2020            </b>           </font>          </p>         </td>         <td style="padding-bottom: 1.5pt">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>        </tr>        <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">         <td style="width: 80%; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif">           Weighted-average remaining    lease term          </font>         </td>         <td style="width: 2%">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td style="width: 1%; text-align: left">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td style="width: 16%; text-align: right">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           6.1                                         years          </font>         </td>         <td style="width: 1%; text-align: left">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>        </tr>        <tr style="vertical-align: bottom; background-color: White">         <td style="text-align: justify">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td>          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td style="text-align: left">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td style="text-align: right">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td style="text-align: left">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>        </tr>        <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">         <td style="text-align: justify">          <font style="font-family: Times New Roman, Times, Serif">           Weighted-average discount rate          </font>         </td>         <td>          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td style="text-align: left">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td style="text-align: right">          <font style="font-family: Times New Roman, Times, Serif">           10.00          </font>         </td>         <td style="text-align: left">          <font style="font-family: Times New Roman, Times, Serif">           %          </font>         </td>        </tr>       </tbody>      </table>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <!-- Field: Page; Sequence: 96; Value: 13 -->      <div style="margin-bottom: 6pt; border-bottom: Black 1.5pt solid">       <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">        <tbody>         <tr style="vertical-align: top; text-align: left">          <td style="width: 33%">          </td>          <td style="text-align: center; width: 34%">           F-           <!-- Field: Sequence; Type: Arabic; Name: PageNo -->           31           <!-- Field: /Sequence -->          </td>          <td style="width: 33%">          </td>         </tr>        </tbody>       </table>      </div>      <div style="page-break-before: always; margin-top: 6pt">       <p style="margin: 0pt">       </p>      </div>      <!-- Field: /Page -->      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Supplementalcash flow information related to operating leases was as follows:       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">       <tbody>        <tr style="vertical-align: bottom">         <td style="text-align: justify">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td style="padding-bottom: 1.5pt">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">          <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            <b>             For                                         the Year Ended            </b>           </font>          </p>          <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            <b>             July                                         31, 2020            </b>           </font>          </p>         </td>         <td style="padding-bottom: 1.5pt">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>        </tr>        <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">         <td style="width: 80%; text-align: justify; padding-bottom: 1.5pt">          <font style="font-family: Times New Roman, Times, Serif">           Cash    paid for operating lease liabilities          </font>         </td>         <td style="width: 2%; padding-bottom: 1.5pt">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left">          <font style="font-family: Times New Roman, Times, Serif">           $          </font>         </td>         <td style="width: 16%; border-bottom: Black 1.5pt solid; text-align: right">          <font style="font-family: Times New Roman, Times, Serif">           1,406,167          </font>         </td>         <td style="width: 1%; padding-bottom: 1.5pt; text-align: left">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>        </tr>        <tr style="vertical-align: bottom; background-color: White">         <td style="padding-left: 10pt; text-align: justify; padding-bottom: 2.5pt">          <font style="font-family: Times New Roman, Times, Serif">           Total    cash flows related to operating lease liabilities          </font>         </td>         <td style="padding-bottom: 2.5pt">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td style="border-bottom: Black 2.5pt double; text-align: left">          <font style="font-family: Times New Roman, Times, Serif">           $          </font>         </td>         <td style="border-bottom: Black 2.5pt double; text-align: right">          <font style="font-family: Times New Roman, Times, Serif">           1,406,167          </font>         </td>         <td style="padding-bottom: 2.5pt; text-align: left">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>        </tr>       </tbody>      </table>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Futureminimum lease payments under non-cancellable leases as of July 31, 2020 were as follows:       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">       <tbody>        <tr style="vertical-align: bottom">         <td style="border-bottom: Black 1.5pt solid; font-weight: bold">          <font style="font-family: Times New Roman, Times, Serif">           Years    ending July 31,          </font>         </td>         <td>          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td colspan="2" style="text-align: right">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td>          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>        </tr>        <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">         <td style="width: 80%; text-align: left">          <font style="font-family: Times New Roman, Times, Serif">           2021          </font>         </td>         <td style="width: 2%">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td style="width: 1%; text-align: left">          <font style="font-family: Times New Roman, Times, Serif">           $          </font>         </td>         <td style="width: 16%; text-align: right">          <font style="font-family: Times New Roman, Times, Serif">           1,116,946          </font>         </td>         <td style="width: 1%; text-align: left">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>        </tr>        <tr style="vertical-align: bottom; background-color: White">         <td style="text-align: justify">          <font style="font-family: Times New Roman, Times, Serif">           2022          </font>         </td>         <td>          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td style="text-align: left">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td style="text-align: right">          <font style="font-family: Times New Roman, Times, Serif">           1,392,265          </font>         </td>         <td style="text-align: left">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>        </tr>        <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">         <td style="text-align: justify">          <font style="font-family: Times New Roman, Times, Serif">           2023          </font>         </td>         <td>          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td style="text-align: left">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td style="text-align: right">          <font style="font-family: Times New Roman, Times, Serif">           1,431,473          </font>         </td>         <td style="text-align: left">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>        </tr>        <tr style="vertical-align: bottom; background-color: White">         <td style="text-align: justify">          <font style="font-family: Times New Roman, Times, Serif">           2024          </font>         </td>         <td>          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td style="text-align: left">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td style="text-align: right">          <font style="font-family: Times New Roman, Times, Serif">           1,474,552          </font>         </td>         <td style="text-align: left">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>        </tr>        <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">         <td style="text-align: justify">          <font style="font-family: Times New Roman, Times, Serif">           2025          </font>         </td>         <td>          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td style="text-align: left">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td style="text-align: right">          <font style="font-family: Times New Roman, Times, Serif">           1,516,126          </font>         </td>         <td style="text-align: left">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>        </tr>        <tr style="vertical-align: bottom; background-color: White">         <td style="padding-bottom: 1.5pt">          <font style="font-family: Times New Roman, Times, Serif">           Thereafter          </font>         </td>         <td style="padding-bottom: 1.5pt">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td style="border-bottom: Black 1.5pt solid; text-align: left">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td style="border-bottom: Black 1.5pt solid; text-align: right">          <font style="font-family: Times New Roman, Times, Serif">           1,774,569          </font>         </td>         <td style="padding-bottom: 1.5pt; text-align: left">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>        </tr>        <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">         <td style="text-align: left; padding-left: 10pt">          <font style="font-family: Times New Roman, Times, Serif">           Total minimum lease    payments          </font>         </td>         <td>          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td style="text-align: left">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td style="text-align: right">          <font style="font-family: Times New Roman, Times, Serif">           8,705,931          </font>         </td>         <td style="text-align: left">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>        </tr>        <tr style="vertical-align: bottom; background-color: White">         <td style="text-align: left; padding-bottom: 1.5pt">          <font style="font-family: Times New Roman, Times, Serif">           Less: Imputed    interest          </font>         </td>         <td style="padding-bottom: 1.5pt">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td style="border-bottom: Black 1.5pt solid; text-align: left">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td style="border-bottom: Black 1.5pt solid; text-align: right">          <font style="font-family: Times New Roman, Times, Serif">           (2,331,132          </font>         </td>         <td style="padding-bottom: 1.5pt; text-align: left">          <font style="font-family: Times New Roman, Times, Serif">           )          </font>         </td>        </tr>        <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">         <td style="padding-bottom: 2.5pt">          <font style="font-family: Times New Roman, Times, Serif">           Total          </font>         </td>         <td style="padding-bottom: 2.5pt">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td style="border-bottom: Black 2.5pt double; text-align: left">          <font style="font-family: Times New Roman, Times, Serif">           $          </font>         </td>         <td style="border-bottom: Black 2.5pt double; text-align: right">          <font style="font-family: Times New Roman, Times, Serif">           6,374,799          </font>         </td>         <td style="padding-bottom: 2.5pt; text-align: left">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>        </tr>       </tbody>      </table>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <b>         <i>          Disclosuresrelated to periods prior to adoption of ASC 842         </i>        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Thefuture minimum obligations under leases in effect as of July 31, 2019 having a noncancelable term in excess of one year as determinedprior to the adoption of ASC 842 are as follows:       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">       <tbody>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">         <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           <b>            Years    ending July 31,           </b>          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">         <td style="font: 10pt Times New Roman, Times, Serif; width: 82%">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           2020          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; width: 1%">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; width: 1%">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           $          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; width: 15%; text-align: right">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           1,356,000          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; width: 1%">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           2021          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           308,000          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">         <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           Total    minimum lease payments          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           $          </font>         </td>         <td style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           1,664,000          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>       </tbody>      </table>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <b>        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <b>         Note12—401(k) Plan        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        EffectiveMay 15, 2012, the Company adopted a defined contribution savings plan pursuant to Section 401(k) of the Code. The plan is forthe benefit of all qualifying employees and permits voluntary contributions by employees of up to 100% of eligible compensation,subject to the maximum limits imposed by Internal Revenue Service. The terms of the plan allow for discretionary employer contributionsand the Company currently matches 100% of its employees’ contributions, up to 3% of their annual compensation. The Company’scontributions are recorded as expense in the accompanying consolidated statements of operations and totaled approximately $136,342and $94,000 for the years ended July 31, 2020 and 2019, respectively.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <b>         Note13—Related Party Transactions        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <b>        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        OnFebruary 12, 2020, the Company entered into a consulting agreement with the spouse of the Company’s Chief Scientific Officer.The term of the agreement is four months and can be extended by written agreement. The agreement provides for an hourly basedfee structure for assisting the Company with matters related to oncology and device development related to the Company’splatform. In addition to an hourly based fee structure, the consultant will be eligible to receive stock option awards. On June12, 2020 the Company amended the consulting agreement, extending the term of the existing agreement until December 12, 2020. Theconsultant was paid consulting fees of approximately $0.1 million during the year ended July 31, 2020. In addition, the consultantwas granted 30,000 non-qualified stock option valued at approximately $48,000 on the date of grant. The non-qualified stock optionshave a 10-year term, vest immediately and have an exercise prices of $1.56. As of July 31, 2020, the Company accrued consultingfees of approximately $0.1 million, under the consulting agreement and is included in accounts payable and accrued liabilitiesat July 31, 2020 in the accompanying consolidated balance sheets.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <b>        </b>       </font>      </p>      <!-- Field: Page; Sequence: 97; Options: NewSection; Value: 32 -->      <div style="margin-bottom: 6pt; border-bottom: Black 1.5pt solid">       <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">        <tbody>         <tr style="vertical-align: top; text-align: left">          <td style="width: 33%">          </td>          <td style="text-align: center; width: 34%">           F-           <!-- Field: Sequence; Type: Arabic; Name: PageNo -->           32           <!-- Field: /Sequence -->          </td>          <td style="width: 33%">          </td>         </tr>        </tbody>       </table>      </div>      <div style="page-break-before: always; margin-top: 6pt">       <p style="margin: 0pt">       </p>      </div>      <!-- Field: /Page -->      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <b>        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <b>         Note14—Subsequent Events        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <b>        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Exceptas disclosed elsewhere herein, below are the Company’s subsequent events.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        OnAugust 19, 2020, the Company completed the offer and sale of an aggregate of 4,608,589 shares of its common stock at a purchaseprice of $3.25 per share in a registered direct offering. The gross proceeds of the offering were approximately $15.0 million,and the net proceeds, after deducting the placement agent’s fee and other offering fees and expenses paid by the Company,were approximately $13.7 million. In connection with the offering, the Company paid the placement agent and other financial advisorsan aggregate cash fee equal to 8.0% of the gross proceeds of the offering, as well as legal and other expenses equal to $75,000.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        OnAugust 25, 2020, the Company entered into an amended lease agreement for the Company’s Pennington, New Jersey office. Thelease was to expire on December 31, 2020. The amendment extends the lease term through December 31, 2021 and the lease term automaticallyrenews for up to two additional one-year terms. Base rent under the amended lease agreement escalates 2% per year over the termbeginning January 1, 2021.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Subsequentto July 31, 2020, the Company issued an aggregate of 1,176,576 stock options to certain individuals, including executive officers,non-executive employees, non-employee directors and consultants. The stock options issued have a ten-year term, vest over a periodranging from one to three years and have an exercise price ranging from $3.43 to $3.82. In addition, the compensation committeeapproved the accelerated vesting of 1,206,102 previously granted time-vesting stock options.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">      </p>      <!-- Field: Page; Sequence: 98; Value: 32 -->      <div style="margin-bottom: 6pt; border-bottom: Black 1.5pt solid">       <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">        <tbody>         <tr style="vertical-align: top; text-align: left">          <td style="width: 33%">          </td>          <td style="text-align: center; width: 34%">           F-           <!-- Field: Sequence; Type: Arabic; Name: PageNo -->           33           <!-- Field: /Sequence -->          </td>          <td style="width: 33%">          </td>         </tr>        </tbody>       </table>      </div>      <div style="page-break-before: always; margin-top: 6pt">       <p style="margin: 0pt">       </p>      </div>      <!-- Field: /Page -->      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif">        <a name="v_01">        </a>        <font style="font-size: 10pt; text-transform: uppercase">         <b>          ITEM16. FORM 10-K SUMMARY         </b>        </font>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        TheCompany has elected not to provide summary information.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">      </p>      <!-- Field: Page; Sequence: 99; Options: NewSection; Value: 64 -->      <div style="margin-bottom: 6pt; border-bottom: Black 1.5pt solid">       <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">        <tbody>         <tr style="vertical-align: top; text-align: left">          <td style="text-align: center; width: 100%">           <!-- Field: Sequence; Type: Arabic; Name: PageNo -->           64           <!-- Field: /Sequence -->          </td>         </tr>        </tbody>       </table>      </div>      <div style="page-break-before: always; margin-top: 6pt">       <p style="margin: 0pt">       </p>      </div>      <!-- Field: /Page -->      <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">        <b>         <a name="v_02">         </a>         SIGNATURES        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Pursuantto the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this reportto be signed on its behalf by the undersigned, thereunto duly authorized.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">       <tbody>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           ONCOSEC    MEDICAL INCORPORATED          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; width: 50%; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; width: 3%; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; width: 47%; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           By:          </font>         </td>         <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           <i>            /s/    Daniel J. O’Connor           </i>          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           Date:    October 28, 2020          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           Daniel    J. O’Connor          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           <i>            President    and Chief Executive Officer           </i>          </font>         </td>        </tr>       </tbody>      </table>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Pursuantto the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalfof the registrant in the capacities and on the dates indicated.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">       <tbody>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">         <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 28%; text-align: center">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           <b>            SIGNATURE           </b>          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; width: 2%; text-align: center">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 50%; text-align: center">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           <b>            TITLE           </b>          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; width: 2%; text-align: center">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 18%; text-align: center">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           <b>            DATE           </b>          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif">         <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           <i>            /s/    Daniel J. O’Connor           </i>          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">          <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            President,                                         Chief Executive Officer and Director           </font>          </p>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           October    28, 2020          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           Daniel    J. O’Connor, J.D.          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           (           <i>            Principal    Executive Officer           </i>           )          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif">         <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           <i>            /s/    Robert J. DelAversano           </i>          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           Principal    Accounting Officer and Controller          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           October    28, 2020          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           Robert    J. DelAversano          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           (           <i>            Interim    Principal Financial Officer and Principal Accounting Officer           </i>           )          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           <i>            /s/    Margaret Dalesandro           </i>          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           Chair    of the Board          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           October    28, 2020          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           Margaret    Dalesandro, PhD          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           <i>            /s/    James DeMesa           </i>          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           Director          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           October    28, 2020          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           Dr.    James DeMesa          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           <i>            /s/    Joon Kim           </i>          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           Director          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           October    28, 2020          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           Joon    Kim          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           <i>            /s/    Herbert Kim Lyerly           </i>          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           Director          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           October    28, 2020          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           Dr.    Herbert Kim Lyerly          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           <i>            /s/    Kevin R. Smith           </i>          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           Director          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           October    28, 2020          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           Kevin    R. Smith          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           <i>            /s/    Robert Ward           </i>          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           Director          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           October    28, 2020          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           Robert    Ward          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           <i>            /s/    Yuhang Zhao           </i>          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           Director          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           October    28, 2020          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           Yuhang    Zhao          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           <i>            /s/    Chao Zhou           </i>          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           Director          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           October    28, 2020          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           Chao    Zhou          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>       </tbody>      </table>      <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <!-- Field: Page; Sequence: 100; Value: 64 -->      <div style="margin-bottom: 6pt; border-bottom: Black 1.5pt solid">       <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">        <tbody>         <tr style="vertical-align: top; text-align: left">          <td style="text-align: center; width: 100%">           <!-- Field: Sequence; Type: Arabic; Name: PageNo -->           65           <!-- Field: /Sequence -->          </td>         </tr>        </tbody>       </table>      </div>      <div style="page-break-before: always; margin-top: 6pt">       <p style="margin: 0pt">       </p>      </div>      <!-- Field: /Page -->      <p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">        <b>        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">        <b>         EXHIBITINDEX        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">       <font style="font-family: Times New Roman, Times, Serif">       </font>      </p>      <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">       <tbody>        <tr style="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">         <td style="width: 0.75in; border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           <b>            Exhibit    Number           </b>          </font>         </td>         <td style="width: 0.15in; text-align: justify; font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           <b>            Description    of Exhibit           </b>          </font>         </td>        </tr>        <tr style="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">         <td style="text-align: right; font: 10pt Times New Roman, Times, Serif; vertical-align: top">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif">         <td style="vertical-align: top; text-align: right; font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           3.1          </font>         </td>         <td style="vertical-align: bottom; text-align: justify; font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="vertical-align: top; text-align: justify; font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif">           <a href="http://www.sec.gov/Archives/edgar/data/1444307/000149315217012058/ex3-1.htm" style="-sec-extract: exhibit">            <font style="font-size: 10pt">             Articles    of Incorporation of OncoSec Medical Incorporated, as amended (incorporated by reference to our Annual Report on Form 10-K,    filed on October 25, 2017.)            </font>           </a>          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif">         <td style="vertical-align: top; text-align: right; font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="vertical-align: bottom; text-align: justify; font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="vertical-align: top; text-align: justify; font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif">         <td style="vertical-align: top; text-align: right; font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           3.2          </font>         </td>         <td style="vertical-align: bottom; text-align: justify; font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="vertical-align: top; text-align: justify; font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif">           <a href="http://www.sec.gov/Archives/edgar/data/1444307/000110465912015899/a12-6565_1ex3d6.htm" style="-sec-extract: exhibit">            <font style="font-size: 10pt">             Amended    and Restated Bylaws (incorporated by reference to our Current Report on Form 8-K, filed on March 6, 2012)            </font>           </a>          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif">         <td style="vertical-align: top; text-align: right; font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="vertical-align: bottom; text-align: justify; font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="vertical-align: top; text-align: justify; font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">         <td style="text-align: right; font: 10pt Times New Roman, Times, Serif; vertical-align: top">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           3.3          </font>         </td>         <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif">           <a href="http://www.sec.gov/Archives/edgar/data/1444307/000149315219007911/ex3-1.htm" style="-sec-extract: exhibit">            <font style="font-size: 10pt">             Certificate    of Change to amend the Articles of Incorporation of OncoSec Medical Incorporated, as filed with the Nevada Secretary of State    on May 20, 2019 (incorporated by reference to Exhibit 3.1 on our Current Report on Form 8-K, filed on May 20, 2019)            </font>           </a>          </font>         </td>        </tr>        <tr style="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">         <td style="text-align: right; font: 10pt Times New Roman, Times, Serif; vertical-align: top">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">         <td style="text-align: right; font: 10pt Times New Roman, Times, Serif; vertical-align: top">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           3.4          </font>         </td>         <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif">           <a href="https://www.sec.gov/Archives/edgar/data/1444307/000149315219016036/ex3-4.htm" style="-sec-extract: exhibit">            <font style="font-size: 10pt">             Certificate    of Change to amend the Articles of Incorporation of OncoSec Medical Incorporated, as filed with the Nevada Secretary of State    on September 6, 2019 (incorporated by reference to Exhibit 3.4 on our Form 10-K filed on October 25, 2019)            </font>           </a>          </font>         </td>        </tr>        <tr style="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">         <td style="text-align: right; font: 10pt Times New Roman, Times, Serif; vertical-align: top">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>        </tr>       </tbody>      </table>      <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">       <tbody>        <tr>         <td style="vertical-align: top; text-align: right; width: 0.75in">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           3.5          </font>         </td>         <td style="vertical-align: bottom; text-align: justify; width: 0.15in">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td style="vertical-align: bottom; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif">           <a href="https://www.sec.gov/Archives/edgar/data/1444307/000149315220001841/ex3-1.htm" style="-sec-extract: exhibit">            <font style="font-size: 10pt">             Amended    and Restated Bylaws of OncoSec Medical Incorporated (incorporated by reference to Exhibit 3.1 on Form 8-K filed with the SEC    on February 10, 2020).            </font>           </a>          </font>         </td>        </tr>        <tr>         <td style="vertical-align: top; text-align: right">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td style="vertical-align: bottom; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td style="vertical-align: bottom; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>        </tr>        <tr>         <td style="vertical-align: top; text-align: right">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           3.6          </font>         </td>         <td style="vertical-align: bottom; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td style="vertical-align: bottom; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif">           <a href="https://www.sec.gov/Archives/edgar/data/1444307/000149315220010178/ex3-1.htm" style="-sec-extract: exhibit">            <font style="font-size: 10pt">             Certificate    of Amendment of Amended and Restated Articles of Incorporation of OncoSec Medical Incorporated (incorporated by reference    to Exhibit 3.1 on Form 8-K filed with the SEC on May 29, 2020).            </font>           </a>          </font>         </td>        </tr>       </tbody>      </table>      <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">       <tbody>        <tr style="font: 10pt Times New Roman, Times, Serif">         <td style="vertical-align: top; text-align: right; font: 10pt Times New Roman, Times, Serif; width: 0.75in">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td style="vertical-align: bottom; text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 0.15in">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td style="vertical-align: top; text-align: justify; font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif">         <td style="vertical-align: top; text-align: right; font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           4.1          </font>         </td>         <td style="vertical-align: bottom; text-align: justify; font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="vertical-align: top; text-align: justify; font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif">           <a href="http://www.sec.gov/Archives/edgar/data/1444307/000110465912085256/a12-29771_1ex10d2.htm" style="-sec-extract: exhibit">            <font style="font-size: 10pt">             Form    of Common Stock Purchase Warrant (incorporated by reference to our Current Report on Form 8-K, filed on December 19, 2012)            </font>           </a>          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif">         <td style="vertical-align: top; text-align: right; font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="vertical-align: bottom; text-align: justify; font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="vertical-align: top; text-align: justify; font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif">         <td style="vertical-align: top; text-align: right; font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           4.2          </font>         </td>         <td style="vertical-align: bottom; text-align: justify; font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="vertical-align: top; text-align: justify; font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif">           <a href="http://www.sec.gov/Archives/edgar/data/1444307/000110465913070965/a13-14798_6ex10d2.htm" style="-sec-extract: exhibit">            <font style="font-size: 10pt">             Form    of Common Stock Purchase Warrant (incorporated by reference to our Current Report on Form 8-K, filed on September 19, 2013)            </font>           </a>          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif">         <td style="vertical-align: top; text-align: right; font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="vertical-align: bottom; text-align: justify; font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="vertical-align: top; text-align: justify; font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif">         <td style="vertical-align: top; text-align: right; font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           4.3          </font>         </td>         <td style="vertical-align: bottom; text-align: justify; font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="vertical-align: top; text-align: justify; font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif">           <a href="http://www.sec.gov/Archives/edgar/data/1444307/000110465914044244/a14-14875_1ex4d1.htm" style="-sec-extract: exhibit">            <font style="font-size: 10pt">             Form    of Common Stock Purchase Warrant (incorporated by reference to our Current Report on Form 8-K, filed on June 5, 2014)            </font>           </a>          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif">         <td style="vertical-align: top; text-align: right; font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="vertical-align: bottom; text-align: justify; font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="vertical-align: top; text-align: justify; font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif">         <td style="vertical-align: top; text-align: right; font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           4.4          </font>         </td>         <td style="vertical-align: bottom; text-align: justify; font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="vertical-align: top; text-align: justify; font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif">           <a href="http://www.sec.gov/Archives/edgar/data/1444307/000110465915076329/a15-22519_1ex4d1.htm" style="-sec-extract: exhibit">            <font style="font-size: 10pt">             Form    of Common Stock Purchase Warrant (incorporated by reference to Exhibit 4.1 of our Current Report on Form 8-K, filed on November    5, 2015)            </font>           </a>          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif">         <td style="vertical-align: top; text-align: right; font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="vertical-align: bottom; text-align: justify; font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="vertical-align: top; text-align: justify; font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif">         <td style="vertical-align: top; text-align: right; font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           4.5          </font>         </td>         <td style="vertical-align: bottom; text-align: justify; font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="vertical-align: top; text-align: justify; font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif">           <a href="http://www.sec.gov/Archives/edgar/data/1444307/000149315216010270/ex4-1.htm" style="-sec-extract: exhibit">            <font style="font-size: 10pt">             Form    of Series A Common Stock Purchase Warrant (incorporated by reference to Exhibit 4.1 of our Current Report on Form 8-K, filed    on May 24, 2016)            </font>           </a>          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif">         <td style="vertical-align: top; text-align: right; font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="vertical-align: bottom; text-align: justify; font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="vertical-align: top; text-align: justify; font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif">         <td style="vertical-align: top; text-align: right; font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           4.6          </font>         </td>         <td style="vertical-align: bottom; text-align: justify; font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="vertical-align: top; text-align: justify; font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif">           <a href="http://www.sec.gov/Archives/edgar/data/1444307/000149315216010270/ex4-2.htm" style="-sec-extract: exhibit">            <font style="font-size: 10pt">             Form    of Series B Common Stock Purchase Warrant (incorporated by reference to Exhibit 4.2 of our Current Report on Form 8-K, filed    on May 24, 2016)            </font>           </a>          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif">         <td style="vertical-align: top; text-align: right; font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="vertical-align: bottom; text-align: justify; font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="vertical-align: top; text-align: justify; font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif">         <td style="vertical-align: top; text-align: right; font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           4.7          </font>         </td>         <td style="vertical-align: bottom; text-align: justify; font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="vertical-align: top; text-align: justify; font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif">           <a href="http://www.sec.gov/Archives/edgar/data/1444307/000149315217011943/ex4-1.htm" style="-sec-extract: exhibit">            <font style="font-size: 10pt">             Form    of Common Stock Purchase Warrant (incorporated by reference to Exhibit 4.1 of our Current Report on Form 8-K, filed on October    24, 2017)            </font>           </a>          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif">         <td style="vertical-align: top; text-align: right; font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="vertical-align: bottom; text-align: justify; font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="vertical-align: top; text-align: justify; font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif">         <td style="vertical-align: top; text-align: right; font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           4.8          </font>         </td>         <td style="vertical-align: bottom; text-align: justify; font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="vertical-align: top; text-align: justify; font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif">           <a href="http://www.sec.gov/Archives/edgar/data/1444307/000149315217012071/ex4-1.htm" style="-sec-extract: exhibit">            <font style="font-size: 10pt">             Form    of Common Stock Purchase Warrant (incorporated by reference to Exhibit 4.1 of our Current Report on Form 8-K, filed on October    26, 2017)            </font>           </a>          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif">         <td style="vertical-align: top; text-align: right; font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="vertical-align: bottom; text-align: justify; font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="vertical-align: top; text-align: justify; font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif">         <td style="vertical-align: top; text-align: right; font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           4.9          </font>         </td>         <td style="vertical-align: bottom; text-align: justify; font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="vertical-align: top; text-align: justify; font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif">           <a href="http://www.sec.gov/Archives/edgar/data/1444307/000149315217012880/ex4-1.htm" style="-sec-extract: exhibit">            <font style="font-size: 10pt">             Form    of Common Stock Purchase Warrant (incorporated by reference to Exhibit 4.1 of our Current Report on Form 8-K, filed on November    13, 2017)            </font>           </a>          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif">         <td style="vertical-align: top; text-align: right; font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="vertical-align: bottom; text-align: justify; font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="vertical-align: top; text-align: justify; font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif">         <td style="vertical-align: top; text-align: right; font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           4.10          </font>         </td>         <td style="vertical-align: bottom; text-align: justify; font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="vertical-align: top; text-align: justify; font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif">           <a href="http://www.sec.gov/Archives/edgar/data/1444307/000149315217012880/ex4-2.htm" style="-sec-extract: exhibit">            <font style="font-size: 10pt">             Form    of Common Stock Purchase Warrant (incorporated by reference to Exhibit 4.2 of our Current Report on Form 8-K, filed on November    13, 2017)            </font>           </a>          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif">         <td style="vertical-align: top; text-align: right; font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="vertical-align: bottom; text-align: justify; font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="vertical-align: top; text-align: justify; font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">         <td style="text-align: right; font: 10pt Times New Roman, Times, Serif; vertical-align: top">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           4.11          </font>         </td>         <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif">           <a href="http://www.sec.gov/Archives/edgar/data/1444307/000149315219008118/ex4-1.htm" style="-sec-extract: exhibit">            <font style="font-size: 10pt">             Form    of Common Stock Purchase Warrant (incorporated by reference to Exhibit 4.1 of our Current Report on Form 8-K, filed on May    23, 2019)            </font>           </a>          </font>         </td>        </tr>        <tr style="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">         <td style="text-align: right; font: 10pt Times New Roman, Times, Serif; vertical-align: top">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">         <td style="text-align: right; font: 10pt Times New Roman, Times, Serif; vertical-align: top">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           4.12          </font>         </td>         <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif">           <a href="http://www.sec.gov/Archives/edgar/data/1444307/000149315219013326/ex4-1.htm" style="-sec-extract: exhibit">            <font style="font-size: 10pt">             Form    of Indenture (incorporated by reference to Exhibit 4.1 of Form S-3, filed on August 23, 2019)            </font>           </a>          </font>         </td>        </tr>        <tr style="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">         <td style="text-align: right; font: 10pt Times New Roman, Times, Serif; vertical-align: top">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: right; vertical-align: top">          <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            4.13           </font>          </p>         </td>         <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif">           <a href="https://www.sec.gov/Archives/edgar/data/1444307/000149315220001841/ex4-1.htm" style="-sec-extract: exhibit">            <font style="font-size: 10pt">             Registration    Rights Agreement, dated as of February 7, 2020, by and between OncoSec Medical Incorporated and Grand Decade Developments    Limited (incorporated by reference to Exhibit 4.1 on Form 8-K filed with the SEC on February 10, 2020).            </font>           </a>          </font>         </td>        </tr>        <tr style="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">         <td style="text-align: right; font: 10pt Times New Roman, Times, Serif; vertical-align: top">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">         <td style="text-align: right; font: 10pt Times New Roman, Times, Serif; vertical-align: top">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           4.14          </font>         </td>         <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif">           <a href="https://www.sec.gov/Archives/edgar/data/1444307/000149315220001841/ex4-2.htm" style="-sec-extract: exhibit">            <font style="font-size: 10pt">             Registration    Rights Agreement, dated as of February 7, 2020, by and between OncoSec Medical Incorporated and Sirtex Medical US Holdings,    Inc. (incorporated by reference to Exhibit 4.2 on Form 8-K filed with the SEC on February 10, 2020).            </font>           </a>          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif">         <td style="vertical-align: top; text-align: right; font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="vertical-align: bottom; text-align: justify; font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="vertical-align: top; text-align: justify; font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif">         <td style="vertical-align: top; text-align: right; font: 10pt Times New Roman, Times, Serif">          <p style="margin: 0">           <font style="font-family: Times New Roman, Times, Serif">            4.15           </font>          </p>         </td>         <td style="vertical-align: bottom; text-align: justify; font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td style="vertical-align: top; text-align: justify; font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif">           <a href="ex4-15.htm">            Description    of Securities of OncoSec Medical Incorporated.           </a>          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif">         <td style="vertical-align: top; text-align: right; font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td style="vertical-align: bottom; text-align: justify; font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td style="vertical-align: top; text-align: justify; font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif">         <td style="vertical-align: top; text-align: right; font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           10.1†          </font>         </td>         <td style="vertical-align: bottom; text-align: justify; font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="vertical-align: top; text-align: justify; font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif">           <a href="http://www.sec.gov/Archives/edgar/data/1444307/000110465911034591/a11-14788_1ex10d2.htm" style="-sec-extract: exhibit">            <font style="font-size: 10pt">             Cross-License    Agreement, dated March 24, 2011 by and between OncoSec Medical Incorporated and Inovio Pharmaceuticals, Inc. (incorporated    by reference to our Quarterly Report on Form 10-Q, filed on June 14, 2011)            </font>           </a>          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif">         <td style="vertical-align: top; text-align: right; font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="vertical-align: bottom; text-align: justify; font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="vertical-align: top; text-align: justify; font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif">         <td style="vertical-align: top; text-align: right; font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           10.2#          </font>         </td>         <td style="vertical-align: bottom; text-align: justify; font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="vertical-align: top; text-align: justify; font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif">           <a href="http://www.sec.gov/Archives/edgar/data/1444307/000110465911034591/a11-14788_1ex10d3.htm" style="-sec-extract: exhibit">            <font style="font-size: 10pt">             Employment    Agreement with Punit Dhillon dated May 18, 2011 (incorporated by reference to our Quarterly Report on Form 10-Q, filed on    June 14, 2011)            </font>           </a>          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif">         <td style="vertical-align: top; text-align: right; font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="vertical-align: bottom; text-align: justify; font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="vertical-align: top; text-align: justify; font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif">         <td style="vertical-align: top; text-align: right; font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           10.3#          </font>         </td>         <td style="vertical-align: bottom; text-align: justify; font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="vertical-align: top; text-align: justify; font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif">           <a href="http://www.sec.gov/Archives/edgar/data/1444307/000110465915074513/a15-22033_2ex10d1.htm" style="-sec-extract: exhibit">            <font style="font-size: 10pt">             Form    of Indemnification Agreement (incorporated by reference to our Current Report on Form 8-K, filed on October 29, 2015)            </font>           </a>          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif">         <td style="vertical-align: top; text-align: right; font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="vertical-align: bottom; text-align: justify; font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="vertical-align: top; text-align: justify; font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif">         <td style="vertical-align: top; text-align: right; font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           10.4#          </font>         </td>         <td style="vertical-align: bottom; text-align: justify; font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="vertical-align: top; text-align: justify; font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif">           <a href="http://www.sec.gov/Archives/edgar/data/1444307/000110465915083603/a15-21201_1ex10d2.htm" style="-sec-extract: exhibit">            <font style="font-size: 10pt">             Executive    Employment Agreement, effective July 6, 2015, by and between the Company and Richard Slansky (incorporated by reference to    our Quarterly Report on Form 10-Q, filed on December 8, 2015)            </font>           </a>          </font>         </td>        </tr>       </tbody>      </table>      <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <!-- Field: Page; Sequence: 101; Value: 64 -->      <div style="margin-bottom: 6pt; border-bottom: Black 1.5pt solid">       <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">        <tbody>         <tr style="vertical-align: top; text-align: left">          <td style="text-align: center; width: 100%">           <!-- Field: Sequence; Type: Arabic; Name: PageNo -->           66           <!-- Field: /Sequence -->          </td>         </tr>        </tbody>       </table>      </div>      <div style="page-break-before: always; margin-top: 6pt">       <p style="margin: 0pt">       </p>      </div>      <!-- Field: /Page -->      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">       <tbody>        <tr style="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">         <td style="width: 0.75in; border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           <b>            Exhibit    Number           </b>          </font>         </td>         <td style="width: 0.15in; text-align: justify; font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           <b>            Description    of Exhibit           </b>          </font>         </td>        </tr>        <tr style="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">         <td style="text-align: right; font: 10pt Times New Roman, Times, Serif; vertical-align: top">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="text-align: center; font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif">         <td style="vertical-align: top; text-align: right; font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           10.5          </font>         </td>         <td style="vertical-align: bottom; text-align: justify; font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="vertical-align: top; text-align: justify; font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif">           <a href="http://www.sec.gov/Archives/edgar/data/1444307/000110465915000148/a14-26939_1ex10d1.htm" style="-sec-extract: exhibit">            <font style="font-size: 10pt">             Lease    Agreement, dated December 31, 2014, by and between the Company and ARE-SD Region No. 18, LLC (incorporated by reference to    Exhibit 10.1 of our Current Report on Form 8-K, filed on January 2, 2015)            </font>           </a>          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif">         <td style="vertical-align: top; text-align: right; font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="vertical-align: bottom; text-align: justify; font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="vertical-align: top; text-align: justify; font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif">         <td style="vertical-align: top; text-align: right; font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           10.6          </font>         </td>         <td style="vertical-align: bottom; text-align: justify; font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="vertical-align: top; text-align: justify; font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif">           <a href="http://www.sec.gov/Archives/edgar/data/1444307/000110465915076329/a15-22519_1ex10d1.htm" style="-sec-extract: exhibit">            <font style="font-size: 10pt">             Securities    Purchase Agreement, dated as of November 3, 2015, by and among the Company and signatories thereto (incorporated by reference    to Exhibit 10.1 of our Current Report on Form 8-K, filed on November 5, 2015)            </font>           </a>          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif">         <td style="vertical-align: top; text-align: right; font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="vertical-align: bottom; text-align: justify; font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="vertical-align: top; text-align: justify; font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif">         <td style="vertical-align: top; text-align: right; font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           10.7          </font>         </td>         <td style="vertical-align: bottom; text-align: justify; font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="vertical-align: top; text-align: justify; font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif">           <a href="http://www.sec.gov/Archives/edgar/data/1444307/000110465915076329/a15-22519_1ex10d2.htm" style="-sec-extract: exhibit">            <font style="font-size: 10pt">             Placement    Agency Agreement, dated as of November 3, 2015, by and between the Company and H.C. Wainright &amp; Co., LLC (incorporated    by reference to Exhibit 10.2 of our Current Report on Form 8-K, filed on November 5, 2015)            </font>           </a>          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif">         <td style="vertical-align: top; text-align: right; font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="vertical-align: bottom; text-align: justify; font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="vertical-align: top; text-align: justify; font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif">         <td style="vertical-align: top; text-align: right; font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           10.8          </font>         </td>         <td style="vertical-align: bottom; text-align: justify; font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="vertical-align: top; text-align: justify; font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif">           <a href="http://www.sec.gov/Archives/edgar/data/1444307/000149315216010270/ex10-1.htm" style="-sec-extract: exhibit">            <font style="font-size: 10pt">             Securities    Purchase Agreement, dated as of May 22, 2016, by and among the Company and signatories thereto (incorporated by reference    to Exhibit 10.1 of our Current Report on Form 8-K, filed on May 24, 2016)            </font>           </a>          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif">         <td style="vertical-align: top; text-align: right; font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="vertical-align: bottom; text-align: justify; font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="vertical-align: top; text-align: justify; font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif">         <td style="vertical-align: top; text-align: right; font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           10.9          </font>         </td>         <td style="vertical-align: bottom; text-align: justify; font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="vertical-align: top; text-align: justify; font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif">           <a href="http://www.sec.gov/Archives/edgar/data/1444307/000149315216010270/ex10-2.htm" style="-sec-extract: exhibit">            <font style="font-size: 10pt">             Placement    Agency Agreement, dated as of May 22, 2016, by and between the Company and H.C. Wainwright &amp; Co., LLC (incorporated by    reference to Exhibit 10.2 our Current Report on Form 8-K, filed on May 24, 2016)            </font>           </a>          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif">         <td style="vertical-align: top; text-align: right; font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="vertical-align: bottom; text-align: justify; font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="vertical-align: top; text-align: justify; font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif">         <td style="vertical-align: top; text-align: right; font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           10.10†          </font>         </td>         <td style="vertical-align: bottom; text-align: justify; font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="vertical-align: top; text-align: justify; font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif">           <a href="http://www.sec.gov/Archives/edgar/data/1444307/000149315217013893/ex10-11.htm" style="-sec-extract: exhibit">            <font style="font-size: 10pt">             Clinical    Trial Collaboration and Supply Agreement, dated as of May 10, 2017, by and between the Company and MSD International GmbH    (incorporated by reference to Exhibit 10.11 of our Current Report on Form 10-Q, filed on June 13, 2018)            </font>           </a>          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif">         <td style="vertical-align: top; text-align: right; font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="vertical-align: bottom; text-align: justify; font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="vertical-align: top; text-align: justify; font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif">         <td style="vertical-align: top; text-align: right; font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           10.11          </font>         </td>         <td style="vertical-align: bottom; text-align: justify; font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="vertical-align: top; text-align: justify; font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif">           <a href="http://www.sec.gov/Archives/edgar/data/1444307/000149315217011943/ex10-1.htm" style="-sec-extract: exhibit">            <font style="font-size: 10pt">             Securities    Purchase Agreement, dated October 22, 2017, by and between the Company and each purchaser named therein (incorporated by reference    to Exhibit 10.1 of our Current Report on Form 8-K, filed on October 24, 2017)            </font>           </a>          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif">         <td style="vertical-align: top; text-align: right; font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="vertical-align: bottom; text-align: justify; font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="vertical-align: top; text-align: justify; font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif">         <td style="vertical-align: top; text-align: right; font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           10.12          </font>         </td>         <td style="vertical-align: bottom; text-align: justify; font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="vertical-align: top; text-align: justify; font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif">           <a href="http://www.sec.gov/Archives/edgar/data/1444307/000149315217011943/ex10-2.htm" style="-sec-extract: exhibit">            <font style="font-size: 10pt">             Engagement    Letter, dated October 20, 2017, by and between the Company and H.C. Wainwright &amp; Co., LLC (incorporated by reference to    Exhibit 10.2 of our Current Report on Form 8-K, filed on October 24, 2017)            </font>           </a>          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif">         <td style="vertical-align: top; text-align: right; font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="vertical-align: bottom; text-align: justify; font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="vertical-align: top; text-align: justify; font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif">         <td style="vertical-align: top; text-align: right; font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           10.13          </font>         </td>         <td style="vertical-align: bottom; text-align: justify; font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="vertical-align: top; text-align: justify; font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif">           <a href="http://www.sec.gov/Archives/edgar/data/1444307/000149315217012071/ex10-1.htm" style="-sec-extract: exhibit">            <font style="font-size: 10pt">             Securities    Purchase Agreement, dated October 25, 2017, by and between the Company and the purchaser named therein (incorporated by reference    to Exhibit 10.1 of our Current Report on Form 8-K, filed on October 26, 2017)            </font>           </a>          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif">         <td style="vertical-align: top; text-align: right; font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td style="vertical-align: bottom; text-align: justify; font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td style="vertical-align: top; text-align: justify; font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif">         <td style="vertical-align: top; text-align: right; font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           10.14#          </font>         </td>         <td style="vertical-align: bottom; text-align: justify; font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="vertical-align: top; text-align: justify; font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif">           <a href="http://www.sec.gov/Archives/edgar/data/1444307/000149315217012689/ex10-1.htm" style="-sec-extract: exhibit">            <font style="font-size: 10pt">             Executive    Employment Agreement, dated November 7, 2017, by and between the Company and Daniel J. O’Connor (incorporated by reference    to Exhibit 10.1 of our Current Report on Form 8-K, filed on November 9, 2017)            </font>           </a>          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif">         <td style="vertical-align: top; text-align: right; font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="vertical-align: bottom; text-align: justify; font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="vertical-align: top; text-align: justify; font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif">         <td style="vertical-align: top; text-align: right; font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           10.15#          </font>         </td>         <td style="vertical-align: bottom; text-align: justify; font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="vertical-align: top; text-align: justify; font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif">           <a href="http://www.sec.gov/Archives/edgar/data/1444307/000149315217012689/ex10-2.htm" style="-sec-extract: exhibit">            <font style="font-size: 10pt">             Amended    and Restated Executive Employment Agreement, dated November 7, 2017, by and between the Company and Punit Dhillon (incorporated    by reference to Exhibit 10.2 of our Current Report on Form 8-K, filed on November 9, 2017)            </font>           </a>          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif">         <td style="vertical-align: top; text-align: right; font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="vertical-align: bottom; text-align: justify; font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="vertical-align: top; text-align: justify; font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif">         <td style="vertical-align: top; text-align: right; font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           10.16#          </font>         </td>         <td style="vertical-align: bottom; text-align: justify; font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="vertical-align: top; text-align: justify; font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif">           <a href="http://www.sec.gov/Archives/edgar/data/1444307/000149315217012689/ex10-1.htm" style="-sec-extract: exhibit">            <font style="font-size: 10pt">             Stock    Option Award Agreement, dated November 7, 2017, by and between the Company and Daniel J. O’Connor (incorporated by reference    to Exhibit 10.3 of our Current Report on Form 8-K, filed on November 9, 2017)            </font>           </a>          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif">         <td style="vertical-align: top; text-align: right; font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="vertical-align: bottom; text-align: justify; font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="vertical-align: top; text-align: justify; font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif">         <td style="vertical-align: top; text-align: right; font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           10.17#          </font>         </td>         <td style="vertical-align: bottom; text-align: justify; font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="vertical-align: top; text-align: justify; font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif">           <a href="http://www.sec.gov/Archives/edgar/data/1444307/000149315217012689/ex10-1.htm" style="-sec-extract: exhibit">            <font style="font-size: 10pt">             Stock    Option Award Agreement, dated November 7, 2017, by and between the Company and Daniel J. O’Connor (incorporated by reference    to Exhibit 10.4 of our Current Report on Form 8-K, filed on November 9, 2017)            </font>           </a>          </font>         </td>        </tr>       </tbody>      </table>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <!-- Field: Page; Sequence: 102; Value: 64 -->      <div style="margin-bottom: 6pt; border-bottom: Black 1.5pt solid">       <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">        <tbody>         <tr style="vertical-align: top; text-align: left">          <td style="text-align: center; width: 100%">           <!-- Field: Sequence; Type: Arabic; Name: PageNo -->           67           <!-- Field: /Sequence -->          </td>         </tr>        </tbody>       </table>      </div>      <div style="page-break-before: always; margin-top: 6pt">       <p style="margin: 0pt">       </p>      </div>      <!-- Field: /Page -->      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">       <tbody>        <tr style="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">         <td style="width: 0.75in; border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           <b>            Exhibit    Number           </b>          </font>         </td>         <td style="width: 0.1in; text-align: justify; font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           <b>            Description    of Exhibit           </b>          </font>         </td>        </tr>        <tr style="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">         <td style="text-align: right; font: 10pt Times New Roman, Times, Serif; vertical-align: top">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="text-align: center; font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif">         <td style="vertical-align: top; text-align: right; font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           10.18          </font>         </td>         <td style="vertical-align: bottom; text-align: justify; font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="vertical-align: top; text-align: justify; font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif">           <a href="http://www.sec.gov/Archives/edgar/data/1444307/000149315217012880/ex10-1.htm" style="-sec-extract: exhibit">            <font style="font-size: 10pt">             Form    of Warrant Exercise Agreement, dated November 13, 2017, by and between the Company and such holder named therein (incorporated    by reference to Exhibit 10.1 of our Current Report on Form 8-K, filed on November 13, 2017)            </font>           </a>          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif">         <td style="vertical-align: top; text-align: right; font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="vertical-align: bottom; text-align: justify; font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="vertical-align: top; text-align: justify; font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif">         <td style="vertical-align: top; text-align: right; font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           10.19#          </font>         </td>         <td style="vertical-align: bottom; text-align: justify; font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="vertical-align: top; text-align: justify; font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif">           <a href="http://www.sec.gov/Archives/edgar/data/1444307/000149315218000522/ex10-1.htm" style="-sec-extract: exhibit">            <font style="font-size: 10pt">             OncoSec    Medical Incorporated 2011 Stock Incentive Plan, as amended and restated, dated January 12, 2018 (incorporated by reference    to Exhibit 10.1 of our Current Report on Form 8-K, filed on January 12, 2018)            </font>           </a>          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif">         <td style="vertical-align: top; text-align: right; font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="vertical-align: bottom; text-align: justify; font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="vertical-align: top; text-align: justify; font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif">         <td style="vertical-align: top; text-align: right; font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           10.20          </font>         </td>         <td style="vertical-align: bottom; text-align: justify; font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="vertical-align: top; text-align: justify; font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif">           <a href="http://www.sec.gov/Archives/edgar/data/1444307/000149315218003763/ex10-1.htm" style="-sec-extract: exhibit">            <font style="font-size: 10pt">             Assignment    of Lease, dated March 9, 2018, by and between OncoSec Medical Incorporated and Vividion Therapeutics, Inc. (incorporated by    reference to Exhibit 10.1 of our Current Report on Form 8-K, filed on March 22, 2018)            </font>           </a>          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif">         <td style="vertical-align: top; text-align: right; font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="vertical-align: bottom; text-align: justify; font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="vertical-align: top; text-align: justify; font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif">         <td style="vertical-align: top; text-align: right; font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           10.21          </font>         </td>         <td style="vertical-align: bottom; text-align: justify; font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="vertical-align: top; text-align: justify; font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif">           <a href="http://www.sec.gov/Archives/edgar/data/1444307/000149315218008598/ex10-3.htm" style="-sec-extract: exhibit">            <font style="font-size: 10pt">             Sublease,    dated March 9, 2018, by and between OncoSec Medical Incorporated and Vividion Therapeutics, Inc. (incorporated by reference    to Exhibit 10.3 of our Current Report on Form 10-Q, filed on June 13, 2018)            </font>           </a>          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif">         <td style="vertical-align: top; text-align: right; font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="vertical-align: bottom; text-align: justify; font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="vertical-align: top; text-align: justify; font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif">         <td style="vertical-align: top; text-align: right; font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           10.22#          </font>         </td>         <td style="vertical-align: bottom; text-align: justify; font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="vertical-align: top; text-align: justify; font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif">           <a href="http://www.sec.gov/Archives/edgar/data/1444307/000149315218008598/ex10-4.htm" style="-sec-extract: exhibit">            <font style="font-size: 10pt">             Confidential    Separation Agreement, dated May 2, 2018, by and between OncoSec Medical Incorporated and Punit S. Dhillon (incorporated by    reference to Exhibit 10.4 of our Current Report on Form 10-Q, filed on June 13, 2018)            </font>           </a>          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif">         <td style="vertical-align: top; text-align: right; font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="vertical-align: bottom; text-align: justify; font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="vertical-align: top; text-align: justify; font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif">         <td style="vertical-align: top; text-align: right; font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           10.23          </font>         </td>         <td style="vertical-align: bottom; text-align: justify; font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="vertical-align: top; text-align: justify; font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif">           <a href="http://www.sec.gov/Archives/edgar/data/1444307/000149315218008598/ex10-5.htm" style="-sec-extract: exhibit">            <font style="font-size: 10pt">             Clinical    Trial Collaboration and Supply Agreement between OncoSec Medical Incorporated and Merck dated May 8, 2018 (incorporated by    reference to Exhibit 10.5 of our Current Report on Form 10-Q, filed on June 13, 2018)            </font>           </a>          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif">         <td style="vertical-align: top; text-align: right; font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="vertical-align: bottom; text-align: justify; font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="vertical-align: top; text-align: justify; font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif">         <td style="vertical-align: top; text-align: right; font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           10.24#          </font>         </td>         <td style="vertical-align: bottom; text-align: justify; font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="vertical-align: top; text-align: justify; font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif">           <a href="http://www.sec.gov/Archives/edgar/data/1444307/000149315218010062/ex10-1.htm" style="-sec-extract: exhibit">            <font style="font-size: 10pt">             Executive    Employment Agreement, dated July 16, 2018, by and between the Company and Sara M. Bonstein (incorporated by reference to Exhibit    10.1 of our Current Report on Form 8-K, filed on July 16, 2018)            </font>           </a>          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif">         <td style="vertical-align: top; text-align: right; font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="vertical-align: bottom; text-align: justify; font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="vertical-align: top; text-align: justify; font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif">         <td style="vertical-align: top; text-align: right; font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           10.25          </font>         </td>         <td style="vertical-align: bottom; text-align: justify; font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="vertical-align: top; text-align: justify; font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif">           <a href="http://www.sec.gov/Archives/edgar/data/1444307/000149315218001431/ex1-1.htm" style="-sec-extract: exhibit">            <font style="font-size: 10pt">             Purchase    Agreement, dated February 1, 2018, between OncoSec Medical Incorporated and Piper Jaffray &amp; Co., as representatives of    the several underwriters named therein (incorporated by reference to Exhibit 1.1 of our Current Report on Form 8-K filed on    February 1, 2018)            </font>           </a>          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif">         <td style="vertical-align: top; text-align: right; font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="vertical-align: bottom; text-align: justify; font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="vertical-align: top; text-align: justify; font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif">         <td style="vertical-align: top; text-align: right; font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           10.26          </font>         </td>         <td style="vertical-align: bottom; text-align: justify; font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="vertical-align: top; text-align: justify; font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif">           <a href="http://www.sec.gov/Archives/edgar/data/1444307/000149315218012845/ex10-1.htm" style="-sec-extract: exhibit">            <font style="font-size: 10pt">             Stock    Purchase Agreement, dated as of August 31, 2018, between OncoSec Medical Incorporated and Alpha Holdings, Inc. (incorporate    by reference to Exhibit 10.1 on our Current Report on Form 8-K filed on August 31, 2018)            </font>           </a>          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif">         <td style="vertical-align: top; text-align: right; font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="vertical-align: bottom; text-align: justify; font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="vertical-align: top; text-align: justify; font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif">         <td style="vertical-align: top; text-align: right; font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           10.27          </font>         </td>         <td style="vertical-align: bottom; text-align: justify; font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="vertical-align: top; text-align: justify; font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif">           <a href="http://www.sec.gov/Archives/edgar/data/1444307/000149315218014674/ex10-27.htm" style="-sec-extract: exhibit">            <font style="font-size: 10pt">             Lease    Agreement, dated February 14, 2018, between OncoSec Medical Incorporated and Mawlt Incorporated (incorporated by reference    to Exhibit 10.27 on our Current Report on Form 10-K, filed on October 19, 2018)            </font>           </a>          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif">         <td style="vertical-align: top; text-align: right; font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="vertical-align: bottom; text-align: justify; font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="vertical-align: top; text-align: justify; font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">         <td style="text-align: right; font: 10pt Times New Roman, Times, Serif; vertical-align: top">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           10.28          </font>         </td>         <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif">           <a href="http://www.sec.gov/Archives/edgar/data/1444307/000149315219004246/ex10-1.htm" style="-sec-extract: exhibit">            <font style="font-size: 10pt">             Common    Stock Purchase Agreement, dated March 29, 2019, between OncoSec Medical Incorporated and Aspire Capital Fund, LLC (incorporated    by reference to Exhibit 10.1 of our Current Report on Form 8-K, filed on March 29, 2019)            </font>           </a>          </font>         </td>        </tr>        <tr style="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">         <td style="text-align: right; font: 10pt Times New Roman, Times, Serif; vertical-align: top">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">         <td style="text-align: right; font: 10pt Times New Roman, Times, Serif; vertical-align: top">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           10.29          </font>         </td>         <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif">           <a href="http://www.sec.gov/Archives/edgar/data/1444307/000149315219008906/ex10-1.htm" style="-sec-extract: exhibit">            <font style="font-size: 10pt">             OncoSec    Medical Incorporated Change in Control Plan, effective as of June 7, 2019 (incorporated by reference to Exhibit 10.1 of our    Current Report on Form 8-K, filed on June 10, 2019)            </font>           </a>          </font>         </td>        </tr>        <tr style="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">         <td style="text-align: right; font: 10pt Times New Roman, Times, Serif; vertical-align: top">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>        </tr>        <tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif">         <td style="vertical-align: top; text-align: right; font: 10pt Times New Roman, Times, Serif; width: 0.75in">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           10.30          </font>         </td>         <td style="width: 0.15in; text-align: justify; font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif">           <a href="http://www.sec.gov/Archives/edgar/data/1444307/000149315219015370/ex10-1.htm" style="-sec-extract: exhibit">            <font style="font-size: 10pt">             Stock    Purchase Agreement, dated as of October 10, 2019 (incorporated by reference to Exhibit 10.1 of our Current Report on Form    8-K, filed on October 11, 2019            </font>           </a>          </font>         </td>        </tr>        <tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif">         <td style="text-align: right; font: 10pt Times New Roman, Times, Serif; vertical-align: top">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif">         <td style="text-align: right; font: 10pt Times New Roman, Times, Serif; vertical-align: top">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           10.31          </font>         </td>         <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif">           <a href="http://www.sec.gov/Archives/edgar/data/1444307/000149315219015370/ex10-2.htm" style="-sec-extract: exhibit">            <font style="font-size: 10pt">             Stock    Purchase Agreement, dated as of October 10, 2019 (incorporated by reference to Exhibit 10.2 of our Current Report on Form    8-K, filed on October 11, 2019            </font>           </a>          </font>         </td>        </tr>        <tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif">         <td style="text-align: right; font: 10pt Times New Roman, Times, Serif; vertical-align: top">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif">         <td style="text-align: right; font: 10pt Times New Roman, Times, Serif; vertical-align: top">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           10.32+          </font>         </td>         <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif">           <a href="http://www.sec.gov/Archives/edgar/data/1444307/000149315219015370/ex10-3.htm" style="-sec-extract: exhibit">            <font style="font-size: 10pt">             License    Agreement, dated as of October 10, 2019 (incorporated by reference to Exhibit 10.3 of our Current Report on Form 8-K, filed    on October 11, 2019)            </font>           </a>          </font>         </td>        </tr>        <tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif">         <td style="text-align: right; font: 10pt Times New Roman, Times, Serif; vertical-align: top">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif">         <td style="text-align: right; font: 10pt Times New Roman, Times, Serif; vertical-align: top">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           10.33+          </font>         </td>         <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif">           <a href="http://www.sec.gov/Archives/edgar/data/1444307/000149315219015370/ex10-4.htm" style="-sec-extract: exhibit">            <font style="font-size: 10pt">             Service    Agreement, dated as of October 10, 2019 (incorporated by reference to Exhibit 10.4 of our Current Report on Form 8-K, filed    on October 11, 2019)            </font>           </a>          </font>         </td>        </tr>        <tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif">         <td style="text-align: right; font: 10pt Times New Roman, Times, Serif; vertical-align: top">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif">         <td style="text-align: right; font: 10pt Times New Roman, Times, Serif; vertical-align: top">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           10.34          </font>         </td>         <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif">           <a href="http://www.sec.gov/Archives/edgar/data/1444307/000149315219015370/ex10-5.htm" style="-sec-extract: exhibit">            <font style="font-size: 10pt">             Stockholder    Agreement, dated as of October 10, 2019 (incorporated by reference to Exhibit 10.5 of our Current Report on Form 8-K, filed    on October 11, 2019)            </font>           </a>          </font>         </td>        </tr>        <tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif">         <td style="text-align: right; font: 10pt Times New Roman, Times, Serif; vertical-align: top">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif">         <td style="text-align: right; font: 10pt Times New Roman, Times, Serif; vertical-align: top">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           10.35          </font>         </td>         <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif">           <a href="http://www.sec.gov/Archives/edgar/data/1444307/000149315219015370/ex10-6.htm" style="-sec-extract: exhibit">            <font style="font-size: 10pt">             Stockholder    Agreement, dated as of October 10, 2019 (incorporated by reference to Exhibit 10.6 of our Current Report on Form 8-K, filed    on October 11, 2019)            </font>           </a>          </font>         </td>        </tr>        <tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif">         <td style="text-align: right; font: 10pt Times New Roman, Times, Serif; vertical-align: top">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>        </tr>        <tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif">         <td style="text-align: right; font: 10pt Times New Roman, Times, Serif; vertical-align: top">          <font style="font-family: Times New Roman, Times, Serif">           10.36          </font>         </td>         <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif">           <a href="https://www.sec.gov/Archives/edgar/data/1444307/000149315219019194/ex10-1.htm" style="-sec-extract: exhibit">            Lease    Agreement, dated November 20, 2019, between OncoSec Medical Incorporated and 3535/3565 General Atomics Court, LLC (incorporated    by reference to Exhibit 10.1 of our form 10-Q, filed on December 13, 2019).           </a>          </font>         </td>        </tr>        <tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif">         <td style="text-align: right; font: 10pt Times New Roman, Times, Serif; vertical-align: top">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>        </tr>        <tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif">         <td style="text-align: right; font: 10pt Times New Roman, Times, Serif; vertical-align: top">          <font style="font-family: Times New Roman, Times, Serif">           10.37          </font>         </td>         <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif">           <a href="https://www.sec.gov/Archives/edgar/data/1444307/000149315219018403/ex10-1.htm" style="-sec-extract: exhibit">            Amendment    Agreement, dated as of November 26, 2019, by and between OncoSec Medical Incorporated and Grand Decade Developments Limited,    (incorporated by refence to Exhibit 10.1 of our Current Report on Form 8-K, filed with the SEC on November 26, 2019).           </a>          </font>         </td>        </tr>        <tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif">         <td style="text-align: right; font: 10pt Times New Roman, Times, Serif; vertical-align: top">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>        </tr>        <tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif">         <td style="text-align: right; font: 10pt Times New Roman, Times, Serif; vertical-align: top">          <font style="font-family: Times New Roman, Times, Serif">           10.38          </font>         </td>         <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif">           <a href="https://www.sec.gov/Archives/edgar/data/1444307/000149315219018403/ex10-2.htm" style="-sec-extract: exhibit">            Amendment    Agreement, dated as of November 26, 2019, by and between OncoSec Medical Incorporated and Sirtex Medical US Holdings, Inc.,    (incorporated by refence to Exhibit 10.2 of our Current Report on Form 8-K, filed with the SEC on November 26, 2019).           </a>          </font>         </td>        </tr>        <tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif">         <td style="text-align: right; font: 10pt Times New Roman, Times, Serif; vertical-align: top">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>        </tr>        <tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif">         <td style="text-align: right; font: 10pt Times New Roman, Times, Serif; vertical-align: top">          <font style="font-family: Times New Roman, Times, Serif">           10.39          </font>         </td>         <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif">           <a href="https://www.sec.gov/Archives/edgar/data/1444307/000149315220006753/ex10-1.htm" style="-sec-extract: exhibit">            First    Amendment to the Executive Employment Agreement entered into between the Company and Daniel J. O’Connor, dated November    7, 2017, as filed with the Securities and Exchange Commission on November 9, 2017, as Exhibit 10.1 on Form 8-K, executed on    April 15, 2020 (incorporated by reference to Exhibit 10.1 on Form 8-K filed with the SEC on April 20, 2020).           </a>          </font>         </td>        </tr>        <tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif">         <td style="text-align: right; font: 10pt Times New Roman, Times, Serif; vertical-align: top">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif">         <td style="vertical-align: top; text-align: right; font: 10pt Times New Roman, Times, Serif; width: 0.75in">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           21.1          </font>         </td>         <td style="vertical-align: bottom; text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 0.1in">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="vertical-align: top; text-align: justify; font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif">           <a href="http://www.sec.gov/Archives/edgar/data/1444307/000149315217013893/ex21-1.htm" style="-sec-extract: exhibit">            <font style="font-size: 10pt">             Subsidiaries    of the registrant (incorporated by reference to Exhibit 21.1 of our Annual Report on Form 10-K/A, filed on November 28, 2017)            </font>           </a>          </font>         </td>        </tr>        <tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif">         <td style="text-align: right; font: 10pt Times New Roman, Times, Serif; vertical-align: top">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>         <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif">          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif">         <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: right; width: 0.75in">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           23.1*          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify; width: 0.15in">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           <a href="ex23-1.htm">            Consent    of Independent Registered Public Accounting Firm, Mayer Hoffman McCann P.C.           </a>          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif">         <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: right">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif">         <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: right">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           31.1*          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           <a href="ex31-1.htm">            Certification    of Chief Executive Officer pursuant to Rules 13a-14 and 15d-14 promulgated under the Securities Exchange Act of 1934           </a>          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif">         <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: right">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif">         <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: right">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           31.2*          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           <a href="ex31-2.htm">            Certification    of Chief Financial Officer pursuant to Rules 13a-14 and 15d-14 promulgated under the Securities Exchange Act of 1934           </a>          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif">         <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: right">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif">         <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: right">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           32.1*          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           <a href="ex32-1.htm">            Certification    of Chief Executive Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act    of 2002           </a>          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif">         <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: right">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif">         <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: right">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           32.2*          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           <a href="ex32-2.htm">            Certification    of Chief Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act    of 2002           </a>          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif">         <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: right">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif">         <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: right">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           101.INS*          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           XBRL    Instant Document          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif">         <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: right">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif">         <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: right">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           101.SCH*          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           XBRL    Taxonomy Extension Schema Document          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif">         <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: right">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif">         <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: right">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           101.CAL*          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           XBRL    Taxonomy Extension Calculation Linkbase Document          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif">         <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: right">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif">         <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: right">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           101.DEF*          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           XBRL    Taxonomy Extension Definition Linkbase Document          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif">         <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: right">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif">         <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: right">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           101.LAB*          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           XBRL    Taxonomy Extension Label Linkbase Document          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif">         <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: right">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif">         <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: right">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           101.PRE          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           XBRL    Taxonomy Extension Presentation Linkbase Document          </font>         </td>        </tr>       </tbody>      </table>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        *Filed herewith.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        **Furnished herewith.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        #Management contract or compensatory plan or arrangement.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        †Confidential treatment has been granted or requested with respect to portions of this exhibit pursuant to Rule 24b-2 of the SecuritiesExchange Act of 1934 and these confidential portions have been redacted from the filing that is incorporated by reference. A completecopy of this exhibit, including the redacted terms, has been separately filed with the Securities and Exchange Commission.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        +Certain confidential portions of this exhibit have been omitted pursuant to Item 601(b) of Regulation S-K.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <!-- Field: Page; Sequence: 103; Options: Last -->      <div style="margin-bottom: 6pt; border-bottom: Black 1.5pt solid">       <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">        <tbody>         <tr style="vertical-align: top; text-align: left">          <td style="text-align: center; width: 100%">           <!-- Field: Sequence; Type: Arabic; Name: PageNo -->           68           <!-- Field: /Sequence -->          </td>         </tr>        </tbody>       </table>      </div>      <!-- Field: /Page -->      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">      </p>     </text>    </filename>   </sequence>  </type> </document></body>